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Abstract 
Cytomegalovirus (CMV)-based vectors are a promising vaccine platform with an ability to 
induce high levels of durable, immediate, effector memory T (TEM) cell responses against 
their heterologous encoded pathogen target antigen. The primary focus of this thesis is 
centered on a hypothesis that targeting of essential CMV tegument proteins by using 
regulatable protein-destabilization is suitable as a conditional vaccine attenuation strategy. 
CMVs are generally benign, however in individuals whose immune systems are immature or 
weakened, CMV can be a significant pathogen causing substantial morbidity and mortality. 
Previous studies have shown that replication-defective versions of CMV made by 
conventional permanent deletion of essential genes are not compromised in terms of their 
immunogenicity. However, such non-conditional attenuation requirs parallel development of 
complementing cell lines, which is technically difficult, expensive and not suitable for use in 
many situations and environments, in particular low and middle-income countries (LMICs). 
Recently, protein destabilizing domain (DD) technology has been developed that has the 
potential to be brought against this issue. DDs are conditionally unstable protein domains that 
can provide regulatable degradation of a desired protein by genetic fusion to the targeted 
protein. Addition of a small-molecule binding ligand stabilizes the DD, thereby increasing 
levels of the targeted protein in a rapid and dose-dependent manner. Using the murine CMV 
(MCMV) system, we hypothesized that fusion of a DD to essential tegument proteins of 
MCMV would be capable of regulating the stability of the tegument proteins resulting in 
generation of conditionally-attenuated MCMV vectors. Part one of this thesis details 
construction and in vitro characterization of recombinant MCMVs using this DD-based 
destabilization strategy, and identifies this approach as able to provide a means for production 
of CMV-based vaccines that differ in their levels of attenuation based on the specific 
tegument protein targeted.  
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The second part of the thesis is concerned with initial development of CMV as a vaccine 
vector against pandemic influenza A (IA) virus infection. IA virus is a respiratory pathogen 
that despite the availability of vaccines continues to have an enormous impact on population 
health and world economy. Standard seasonal (epidemic) IA vaccines provide only 
‘homosubtypic’ immunity. The omnipresent potential for emergence of pandemic IA 
subtypes, for which the human population possesses no immunity, makes IA a major global 
health concern. The hypothesis being tested in these studies is that targeting of more 
conserved IA virus proteins with CD8
+  
TEM cell-based immunity by using CMV-based 
vectors as a quintessential inducer of such ‘effector’ memory responses, will provide the 
desired heterotypic immunity capable of preventing pandemic IA. This initial study 
determined the capacity of a MCMV-based vaccine expressing the conserved IA proteins 
nucleoprotein (NP), polymerase (PA) and non-structural protein 2 (NS2) to induce immunity 
in mice as a strategy to prevent pandemic IA emergence.    
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1.1 General Background 
 
1.1.1 Herpesviridae  
Herpesviruses are a significant cause of human disease worldwide and are among the most 
widespread and successful viral microbes across the entire animal kingdom. The herpesvirus 
family is a group of over 100 viruses that infect a variety of animal species including birds, 
mammals, fish and reptiles. It is believed that mammalian herpesviruses arose from a 
common ancestral virus at least 80 million years ago (McGeoch et al., 1995) with non-
mammalian herpesviruses having diverged from this common lineage 120 million years 
earlier (Davison, 1993). 
Herpesviruses are large DNA viruses, ranging in size from approximately 130 to 250 nm in 
diameter. They possess a large linear double-stranded DNA genome (127-290 kb) enclosed 
within a T=16 icosahedral capsid, which is then surrounded by an amorphous tegument layer. 
The tegument layer is proteinaceous in nature, being comprised of over fourteen different 
virus-derived proteins as well as a number of cellular proteins (Varnum et al., 2004). The 
tegumented capsid is then surrounded by a lipid envelope containing membrane-associated 
proteins (Varnum et al., 2004; Figure 1.1).  
Herpesvirus family members share additional common features. These include host range 
restriction, nuclear-localized replication (both in terms of DNA replication and genome 
encapsulation) and establishment of persistent life-long infection within their respective host 
(Pellet & Roizman, 2007). Following an initial lytic acute replication, life-long infection is 
characterized by the virus entering a latent phase with minimal virus gene transcriptional 
activity (Davison, 2002). Sites of latency vary depending on the particular mammalian 
herpesvirus subfamily (see below). In healthy, immunocompetent individuals herpesvirus 
infection may remain asymptomatic for long periods, even for life. However, reactivation of 
29 
 
latent virus can occur during periods of stress and immunosuppression, leading to conditions 
ranging in severity from recurrent cold-sores to herpes stromal keratitis, the leading cause of 
herpes simplex virus (HSV) blindness in the western world (Crough & Khanna, 2009). 
Herpesviruses are divided into three subfamilies: alpha-, beta-, and gamma-herpesviruses. 
Alpha-herpesviruses are neurotropic (Slater et al., 1994). They demonstrate variability in host 
range, have a short reproductive cycle in infected hosts, and grow rapidly in cell culture. 
They also have the ability to establish latent infection in sensory ganglia. There are 3 human 
alpha-herpesviruses. HSV-1 and -2 are responsible for cold-sores and genital herpes, 
respectively. Varicella zoster virus (VZV) is the causative agent of chickenpox and shingles 
(Arbuckle et al., 2010; Kondo & Mocarski, 1994; Wang et al., 2005; Young & Murray, 
2003).   
Beta-herpesviruses have more a highly restricted host range, longer reproductive cycles, and 
grow more slowly in cell culture than alpha-herpesviruses. Members of the beta-herpesvirus 
subfamily include human cytomegalovirus (CMV; HCMV), human herpesvirus-6A and -6B 
and human herpesvirus-7. CMV derives its name from the enlargement of infected cells 
(cytomegaly) observed during infection. During latency, main sites of virus persistence are 
myeloid-derived cells (i.e., CD34
+
 stem cells), salivary glands and kidney cells. Gamma-
herpesvirus subfamily members have a similarly restricted host range and establish latency in 
lymphoid tissue. Viral replication is generally restricted to either T or B cells and includes 
well known human pathogens such as Kaposi’s sarcoma-associated herpes virus (KSHV) and 
Epstein-Barr virus (EBV).  
This thesis focuses on the CMV beta-herpesvirus, which is discussed in more detail below. 
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Figure 1.1 Structure of CMV virion. The double-stranded (ds) DNA viral genome is 
contained within an icosahedral viral capsid surrounded by a proteinaceous tegument layer. 
The tegumented capsid is in turn surrounded by a lipid bilayer membrane envelope studded 
with virally encoded glycoproteins. Reprinted from (Streblow et al., 2006). 
 
 
1.1.2 Cytomegalovirus (CMV) 
CMVs are present in a wide range of mammalian hosts, including human, primate, and 
rodents (Roizman & Pellett, 2001). However, CMVs are highly species-restricted, with no 
cross-species infection having been identified even between closely evolutionarily related 
mammalian species. A typical consequence of CMV infection in vitro as well as in vivo is 
enlargment of the infected cell (cytomegaly) and the presence of inclusions in the nucleus 
called owls eyes (Wallace et al., 1956). The CMV genome encodes more than 200 proteins, 
many of which are of unknown function. Many of these proteins are not essential for the viral 
growth in vitro, but are believed to have an important role in vivo by modulation of the host 
environment (Mocarski, 2002). HCMV is the best studied of the CMVs in terms of 
pathogenesis, and is a major human pathogen that infects a large proportion of the human 
population. Generally HCMV produces subclinical infection in healthy people with normal 
immune systems.  
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1.1.2.1 Virion structure 
The CMV virion consists of a highly ordered icosahedral nucleocapsid of about 130 nm in 
diameter containing a linear viral ds-DNA genome of approximately 230 kilobases (kb). This 
genome size is on the larger end of herpesviruses, with genomes of alpha- and gamma- 
herpesviruses generally being smaller in size (>120 kb). The CMV capsid is surrounded by a 
lipid bilayer envelope carrying various viral glycoproteins that are responsible for viral 
attachment and entry into host cells. Similar to all herpesviruses, CMVs also have a large 
amorphous proteinaceous layer between the capsid and the envelope called the tegument. 
Currently at least 30 viral tegument proteins are known to be present within the CMV virion 
(Kalejta, 2008). Upon viral entry, tegument protein are introduced into the cell and perform 
critical functions during the viral life cycle. The following sections will look at each virus 
structural element in detail.  
 
1.1.2.1.1 Genome 
The HCMV DNA genome is 230 kb in size. Although early studies suggested a protein 
coding capacity in the order of 100 to 200 proteins, more recent ribosome profiling studies 
have identified over 750 translated open reading frames (ORFs). This makes HCMV one of 
the most complex viral pathogens known to infect humans (Stern-Ginossar et al., 2012). The 
HCMV genome, like those of other members of the primate beta-herpesvirus subfamily is 
organised into two unique regions: the unique long (UL) and unique short (US) regions 
(Figure 1.2; Mocarski et al., 2013). Each unique region is flanked by terminal repeat 
components (TRL or TRS) of approximately 300 to 600 bp. This terminal component is 
repeated in an inverted orientation at the other end of the unique region (called IRL or IRS), 
and gives rise to general organization of the HCMV genome as TRL-UL- IRL-IRS-US-TRS 
(Cha et al., 1996; Tamashiro & Spector, 1986). CMV replication generates equimolar 
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populations of four isomers of the genome (Kilpatrick & Huang, 1977). These isomers have 
the same DNA sequence but differ in orientation and position of the UL and US segments 
(Kilpatrick & Huang, 1977). Within the virion the ds-DNA genome is maintained as a linear 
molecule, which then undergoes circularization within the nucleus shortly after infection. 
Studies have shown that the circular isomeric form of the HCMV genome even in the form of 
a bacterial artificial chromosome (BAC) (discussed in detail below) is infectious (Borst et al., 
1999).  
Genomes of other CMVs show some variation on the theme of unique regions flanked by 
repeats. Chimpanzee CMV (CCMV), being the only other CMV from apes to have been fully 
sequenced, is comparable to HCMV with two unique regions (UL and US) flanked by direct 
repeats (Davison et al., 2003). Rat CMV (RCMV) (Maastricht strain) has a small terminal 
repeat of 504 bp that lacks the internal repeat sequence (Vink, Beuken & Bruggeman, 1996). 
The laboratory-passaged MCMV (Smith strain) was the first complete MCMV genome to be 
sequenced. Using whole-genome shotgun sub-cloning followed by Sanger sequencing of 
virion-associated DNA, the MCMV Smith strain genome was shown to consist of 230,278 bp 
arranged with a small terminal repeat (31 bp) and several short internal repeats (Rawlinson, 
Farrell & Barrell, 1996). It was indicated that the MCMV genome encodes approximately 
170 ORFs, but based on the recent study of HCMV by Stern-Ginossar et al. (2012), it would 
appear that this number may be increased substantially upwards.  
Comparison of HCMV and MCMV DNA content show similarities in both distribution and 
level of G+C (58% and 58.7%, respectively); (Rawlinson, Farrell & Barrell, 1996). 
Substantial sequence variation has been observed between different strains of HCMV. 
However, genomic sequencing of an additional laboratory strain of MCMV (strain K181) 
identified relatively high MCMV genome conservation. More recently, Smith et al. (2008) 
showed that there were also no major deletions or insertions in the genome of multiple recent 
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MCMV field strain isolates with genome size being similarly highly conserved (Smith et al., 
2008). More subtle differences in sequence, particularly at the genomic termini were 
observed, however, which did impact in vivo replication of the viruses. 
 
 
Figure 1.2  Schematic of CMV genome organization. (A) The HCMV genome consists of 
the unique long sequence (UL), flanked by terminal repeat long (TRL) and inverted repeat 
long (IRL). The unique short sequence (US) is flanked by terminal repeat short (TRS) and 
inverted repeat short (IRS). (B) The MCMV genome consists of a single unique sequence 
with two terminal direct repeats (DR); (Mocarski et al., 2013; Rawlinson, Farrell & Barrell, 
1996). 
 
1.1.2.1.2 Capsid  
The capsid (also called nucleocapsid) packages and protects the viral genome. Cryo-electron 
microscopy (EM) and image reconstruction has been used to determine the structure of the 
CMV capsid (Dai et al., 2008; Yu et al., 2011). These studies show the CMV capsid to have 
an icosahedral lattice geometry structure with each icosahedron consisting of hexamer-
pentamer clusters (Butcher et al., 1998). The major structural subunit of the capsid is the 
caposomere, which is comprised of hexons at the faces and pentons at the vertices organised 
with a triangulation number of 16 (T = 16). The hexon capsomeres form the 150 subunits of 
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each icosahedral face, and the penton capsomeres form the 12 icosahedral face vertices. The 
CMV capsid is composed of four structural proteins: major capsid protein (MCP, encoded by 
UL86 and M86 in HCMV and MCMV, respectively), minor capsid protein (mCP, encoded by 
UL85 and M85), minor capsid-binding protein (mC-BP encoded by UL46 and M46) and 
smallest capsid protein (SCP, encoded by UL48A and M48.2); (Gibson et al., 1996; Sedarati 
& Rosenthal, 1988). All 150 hexon capsomeres are composed of MCP and SCP, while the 
majority of the penton capsomeres consist of pentamers of MCP. Both types of capsomeres 
are linked together by mC-BP and mCP triplexes that are required for the stabilization of the 
capsid structure (Dai et al., 2013; Trus et al., 2001). 
 
1.1.2.1.3 Envelope  
CMV virions have a phospholipid bilayer envelope that contains viral glycoproteins as well 
as cellular proteins derived from the host. In the current ‘Envelopment, De-envelopment, Re-
envelopment’ model initial herpesvirus envelopment takes place at the inner nuclear 
membrane. Following de-envelopment from the cisternae of endoplasmic reticulum (ER) to 
release the capsid into the cytosol, final envelopment and acquisition of the mature virion 
envelope occurs in endosomal trans-Golgi network (TGN) regions (Eggers et al., 1992; 
Gibson et al., 1996). The role of lipid components acquired during envelopment in stabilizing 
virion structure and maintaining the integrity of the viral envelope has not been determined. 
CMV also acquires host cellular proteins during envelopment. These proteins include CD55 
and CD59, β-microglobumin and annexin II (Grundy, McKEATING & Griffiths, 1987; 
Grundy et al., 1987; Wright et al., 1995). It has been suggested that these proteins may play a 
role in modulating virus attachment or host cellular responses (Boehme et al., 2004; Compton 
et al., 2003).   
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The virus-encoded glycoproteins present within the HCMV envelope are generally conserved 
between different CMVs. These glycoproteins are essential for initiation of virus-host 
attachment, virus entry and cell-to-cell virus transmission. Over 50 distinct virion encoded 
glycoproteins are thought to be present within the HCMV particle, although the majority have 
not been studied in any detail. Three major glycoprotein complexes have been identified: 
homodimers of glycoprotein B (gB, encoded by UL55); heterodimers of glycoprotein M (gM, 
UL100) and glycoprotein N (gN, UL73); and heterotrimers of glycoprotein H (gH, UL75), 
glycoprotein L (gL, UL15) and either glycoprotein O (gO, UL74) or glycoproteins encoded 
by UL128, UL130 and UL131A (Huber & Compton, 1998; Huber & Compton, 1999; Jarvis 
& Nelson, 2007; Mach et al., 2000).  
The gB is a type I integral membrane protein that forms a homodimeric glycoprotein complex 
termed gCI. This gCI complex binds to heparan sulfate proteoglycans facilitating both entry 
into host cells and cell-to-cell spread of infection. The gM/gN complex is the most abundant 
component of the viral envelope, and has a role in virus entry and membrane fusion through 
formation of a gM/gN disulphide-linked dimer which also exhibits heparin-binding activity 
(Kari & Gehrz, 1992; Mach et al., 2000). The gH/gL proteins together with gO are required 
for viral entry into fibroblasts through mediating fusion of viral and host cell membrane 
(Spaete et al., 1993). A gH/gL/pUL128/pUL130/pUL131A is required for viral entry into 
non-fibroblast cells, including endothelial, epithelial and dendritic cells (for review, see: 
(Jarvis & Nelson, 2007). The genes encoding these core glycoproteins (with the exception for 
the cell tropism related gO, pUL128/pUL130/pUL131A) are all essential for virus replication 
(Mach et al., 2000; Varnum et al., 2004).    
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1.1.2.1.4 Tegument  
The tegument layer of CMV occupies the space between the outer lipid membrane and the 
icosahedral protein capsid containing the viral genomic ds-DNA (Kalejta, 2008). The 
tegument layer is unique to herpesviruses. It contains approximately 30 virus-encoded 
proteins (Roizman & Sears, 2001), thereby accounting for more than half of the seventy-one 
viral proteins that are found in infectious HCMV virions (Kalejta, 2008; Varnum et al., 2004). 
Given a capsid size of 125 nm within a 220 nm virion, the tegument represents a significant 
aspect of the virion space-representing approximately 40% of the virion protein mass (Gibson, 
1996). The tegument layer appears largely unstructured by EM, although some structure is 
observed in regions associate with binding of tegument to the capsid. Tegument proteins are 
delivered to cells at the very start of the infection process following fusion of the virus 
envelope with cellular membranes, and thereby have the potential to modulate the cellular 
environment even prior to the onset of viral gene expression (Kalejta, 2008).  
Following release into the cytoplasm, tegument proteins play an important role in multiple 
stages of the viral life cycle, which starts by facilitating release of viral DNA from 
disassembling capsids. The capacity for tegument to function immediately after infection 
without requiring de novo gene expression has presumably evolved due to the significant 
advantage it provides to the virus. Other important functions associated with the tegument are 
modulation of gene expression, immune evasion, and assembly and egress. Most tegument 
protein are phosphorylated, but the physiological significance of this phosphorylation 
remains largely unexplored. The four most abundant tegument proteins are lower matrix 
protein, pp65 (UL83, M83), basic phosphoprotein pp150 (UL32, M32), upper matrix protein 
pp71 (UL82, M82) and membrane–associated myristylated protein pp28 (UL99, M99) 
(Baxter & Gibson, 2001; Gibson, 1996; Kalejta, 2008; Sanchez et al., 2000).   
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1.1.2.1.4.1 Lower matrix protein UL83 (pp65) 
The pp65 protein encoded by UL83 is the most abundant of the tegument proteins accounting 
for >15% of the virion protein mass (Gibson, 1996; Varnum et al., 2004). The UL83 gene is 
expressed with L kinetics, however due to the presence within the incoming virion, pp65 
rapidly accumulates within the cell following infection. Early during infection, pp65 is 
localized within the nucleus of infected cells, but in the late phase the protein redistributes 
predominantly to the cytoplasm (Kalejta, 2008). UL83 is not essential for virus replication, as 
UL83 deletion does not significantly impair the growth of virus in fibroblasts (Schmolke et 
al., 1995). However, UL83 deleted HCMV is unable to make a virus-like particle called a 
‘dense body’, one of three viral particle types (virions and non-infectious enveloped particles 
being the other two) that are observed during normal HCMV infection (Irmiere & Gibson, 
1983).  
A number of studies have shown pp65 to play an important role in protecting HCMV-
infected cells from being destroyed by the immune system by inhibiting activation of 
multiple components of the host immune system (Arnon, Markel & Mandelboim, 2006). 
Pp65 has been shown to inhibit natural killer (NK) cell cytotoxic activity by binding to the 
activating receptor NKp30 and acting as an antagonistic ligand. In this capacity pp65 
interferes with the ability of NKp30 to cross-talk between other NK cells, as well as 
preventing NK cell-mediated killing of infected cells (Arnon et al., 2005; Arnon, Markel & 
Mandelboim, 2006). Pp65 has also been shown to inhibit the induction of host interferon 
responses (Abate, Watanabe & Mocarski, 2004) based on the observation of elevated level of 
expression of interferon-stimulated genes in cells infected with a recombinant virus lacking 
the pp65 protein (Abate, Watanabe & Mocarski, 2004). In regards to the adaptive immune 
response, pp65 was found to block the ability of MHC class I to present the viral immediate-
early (IE) protein by phosphorylation of the IE protein (Gilbert et al., 1996).  
38 
 
The kinase activity of pp65 is also involved in mediating degradation of the alpha chain in the 
HLA-DR MHC class II cell surface receptor by inducing the accumulation of HLA class II 
molecules within the lysosome (Odeberg et al., 2003).  
 
1.1.2.1.4.2 The basic phosphoprotein UL32 (pp150) 
The pp150 basic phosphoprotein is the product of the UL32 gene of HCMV and is expressed 
with L kinetics. Pp150 is the second most abundant tegument protein after pp65 comprising 
approximately 10% of the virion mass (Gibson, 1996; Varnum et al., 2004). Orthologues of 
UL32 are found in other beta-herpesviruses, including: MCMV, rat CMV, chimpanzee CMV, 
HHV-6, and HHV-7. However, UL32 orthologues are not found in either alpha- or gamma-
herpesviruses (Adler, Nigro & Pereira, 2007). The pp150 molecule undergoes substantial 
post-translational modification by glycosylation and phosphorylation, which increases the 
molecular mass from an estimated 113 kDa to a mass of 150 kDa for pp150 within the virion 
(Jahn et al., 1987; Roby & Gibson, 1986). Pp150 is found within non-infectious enveloped 
particles, cytoplasmic nucleocapsids and virions, but is not present in immature nuclear-
localized capsids (Gibson & Irmiere, 1983; Irmiere & Gibson, 1983).  
Protein sequence alignment of pp150 orthologues from other beta-herpesviruses shows an 
overall similarity of 17%, with the highest level of conservation occurring within the amino 
terminal 300 amino acids (aa), suggesting a functional conservation of this region (Baxter & 
Gibson, 2001). Conserved regions 1 and 2 (CR1 and CR2) (L52 to Y62 and N201-L209, 
respectively) are two highly conserved N-terminal motifs present with the N-terminal region. 
Pp150 contacts the capsids through the end of the capsomeres or the triplex subunits that 
interlink them (Chen et al., 1999; Trus et al., 1999). Pp150 is also known to bind to the 
HCMV capsids through the N-terminal one-third of the molecule. This interaction with the 
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capsid is consistent with a role of pp150 in virus assembly (see below) (Baxter & Gibson, 
2001). An additional cluster of four conserved cysteine (Cys-X7-Cys-X9-Cys-X7-Cys) are 
found in primate CMVs near the CR2 region (Baxter & Gibson, 2001). Pp150 is modified by 
the attachment of O-linked N-acetyl glucose amine (a unique posttranslational glycosylation 
of nuclear and cytosolic proteins) at two serine residues (Serine-921 and Serine- 952) near the 
carboxyl terminus. However, mutation of either of these serines individually does not inhibit 
pp150 function (AuCoin et al., 2006; Greis, Gibson & Hart, 1994).   
Pp150 is essential for production of infectious virus since deletion of the UL32 ORF leads to 
a complete loss of productive virus replication (Tandon & Mocarski, 2008). The critical role 
of the CR motifs has also been shown as mutational CR inactivation (N201A and G207A) 
similarly prevents virus replication. In the absence of pp150, nucleocapsids were shown to 
accumulate in a juxtanuclear structure called the viral assembly compartment (AC), but failed 
to proceed further to vesicular transport associated with virion release (Tandon & Mocarski, 
2008). These findings confirmed and expanded on results from earlier studies using a 
recombinant HCMV expressing pp150 tagged at its carboxyl terminus with enhanced green 
fluorescent protein (pp150-EGFP), which had similarly suggested a role for pp150 in late 
stages of virus assembly. In these earlier studies pp150 was shown to localize to the nucleus 
at early times of infection, but was then found primarily in the cytoplasm at later times. The 
pp150 protein was also shown to have near perfect co-localization with pUL86 (MCP), 
suggesting that viral particles in the nucleus acquired the tegument protein pp150 during 
budding at the nuclear membrane (Sampaio et al., 2005), although other researchers had 
reported exclusive localization of pp150 to the cytoplasm (Sanchez et al., 2000).  
Consistent with a cytoplasmic assembly role, pp150 co-localizes at the AC with other 
tegument proteins including pp65 and pp28 (see below), envelope glycoproteins gB, gH and 
gM/gN, and with markers of the distal secretory pathway (Sanchez et al., 2000).  
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Additional studies support this role for pp150 in late (cytoplasmic) stages of virus assembly 
(AuCoin et al., 2006; Meyer et al., 1997; Tandon & Mocarski, 2008; Yu, Silva & Shenk, 
2003; Zipeto et al., 1993); (Figure 1.3). Aside from its functional role, pp150 is a highly 
immunogenic protein eliciting a strong humoral immune response during both latent and 
reactivated viral infection in CMV positive individuals (Greijer et al., 1999; Landini et al., 
1991). It is an immune-dominant target of the host cellular response against HCMV ( Gyulai 
et al., 2000; Riddell et al., 1991) and represents a major target of human MHC-restricted 
cytotoxic T cells following HCMV infection (Elkington et al., 2003; Gyulai et al., 2000).  
 
 
 
Figure 1.3 Function of the tegument proteins (pp150 and pp28). For the detail of the 
tegument protein functions see (Section 1.1.1.4). Re-printed from (Kalejta, 2008).  
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1.1.2.1.4.3 Upper matrix protein UL82 (pp71) 
The pp71 tegument protein, encoded by the UL82 gene, is expressed with E-L kinetics 
(Kalejta, 2008). Pp71 localizes to the nucleus in both UL82 transfected and HCMV-infected 
cells (Smith, Kosuri & Kerry, 2014). It has been shown that transfection of pp71 into cultured 
cells lead to increased infectivity of the viral genomic DNA (Baldick et al., 1997). As 
reviewed in Kalejta (2008) rather being essential, pp71 is required for efficient virus 
replication. The main function of pp71 is as a transcriptional activator that enhances IE gene 
expression within infected cells (Liu & Stinski, 1992). Pp71 is also believed to be important 
for initiation of tegument assembly and interacts directly with newly assembled capsids (Trus 
et al., 1999).  Pp71 has been shown to possess an immune invasion function by preventing 
cell surface expression of MHC class I through a delay in transport from the ER (Trgovcich 
et al., 2006).  
 
1.1.2.1.4.4 The membrane–associated myristylated protein pp28 (UL99)  
The UL99 encoded tegument protein pp28 is 190 amino acids in length with a predicted 
molecular weight of 28 kDa. As a true late (L) gene (see below), the expression of UL99 is 
completely dependent on the onset of viral DNA replication and pp28 does not accumulate 
within infected cells until late times of infection (Phillips & Bresnahan, 2012; Silva et al., 
2003; Wing & Huang, 1995). Pp28 localizes in the cytoplasm in both transfected and HCMV 
infected cells. This localization is dependent on myristoylation of glycine 2 at the amino-
terminus of the pp28 protein (Sanchez, Sztul & Britt, 2000). Myristoylation mediates 
insertion of the pp28 protein into cytoplasmic membranes associated with the cellular 
secretory pathway. This association appears to be critical for virus morphogenesis as a 
HCMV recombinant encoding a mutation that blocked myristoylation (G2A) resulted in 
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localization of the mutant pp28 to the nucleus and a failure to produce infectious virus (Britt 
et al., 2004).  
During HCMV infection, pp28 co-localizes and accumulates with other tegument proteins 
(pp150, pp65) and envelope glycoproteins (gB, gH and gP65) at the AC, with its co-
localization appearing to be required for production of infectious virus (Seo & Britt, 2006) 
(Kalejta, 2008). Multiple studies have shown pp28 to be essential for virus replication, due to 
its role in late (cytoplasmic) steps of virus assembly (Britt et al., 2004; Silva et al., 2003). 
Consistent with this assembly function, phenotypic characterization of pp28-deleted viruses 
show that early events of viral replication including entry, gene expression and viral genome 
synthesis all appear to be normal. In contrast, in the absence of pp28 tegument proteins 
results in accumulation of non-enveloped capsids in the cytoplasm at late times of infection, 
which fail to associate with the AC (Silva et al., 2003).  
Fine-mapping studies showed the 61 N-terminal amino acids (aa) to be sufficient for wild 
type (WT) virus replication (Jones & Lee, 2004; Seo & Britt, 2006), with the first 50 amino 
acids also supporting viral replication, although with delayed kinetics and at decreased levels 
(Seo & Britt, 2006). Impaired replication corresponded to inefficient retention of pp28 
mutants at the AC consistent and a defect in virion envelopment (Seo & Britt, 2006; Seo & 
Britt, 2007). These studies also showed that an acidic region of pp28 located between aa 44 
and 59 and a region between aa 34 to 43 are required for normal localization of pp28 to the 
AC (Figure 1.3). The acidic region was shown to function in a context dependent manner, 
with pp28 accumulation at the AC being eliminated by relocalization of the acidic cluster to 
the carboxyl terminus of the pp28 protein (Seo & Britt, 2006). Together, these studies show 
pp28 to be essential for late (cytoplasmic) stages of CMV assembly. Interestingly, this is a 
similarity pp28 appears to share with pp150, wherein for both molecules the N-terminal 
region appears to play the more critical role.   
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Figure 1.4 Schematic diagram of HCMV pp28. The 190 aa pp28 protein contains a 
myristolyation sites at glycine 2 (G2), an acidic domain located between aa 44-59 at the 
amino terminus and region located between aa 34-43, which are essential for pp28 function 
and replication of the virus. 
 
 
1.1.2.2 Virus life cycle 
To initiate infection, all viruses must deliver their genome into host cell (Figure 1.5). As an 
enveloped virus, HCMV entry requires the use of virus envelope proteins to facilitate 
adherence to the cell surface and fusion between the cellular membrane and the virus 
envelope. Fusion results in the transport of virion components into the cytoplasm, which is 
followed by transport of the capsid to the nucleus. The viral genome is then delivered to the 
nucleus through the nuclear pore (Smith & de Harven, 1974). The viral genome is used as a 
template for viral gene transcription leading ultimately to production of viral proteins, many 
of which are responsible for co-opting the cellular machinery and inhibiting the host immune 
response. This is followed by production of proteins involved in virus DNA replication at E 
early times. Later times of infection are concerned with virion assembly and egress (for 
review see: (Mocarski et al., 2013). The entire replication process will be described in detail 
in the following sections.  
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1.1.2.2.1 Viral entry 
During infection of the human host, HCMV productively replicates in many different cell 
types, including: fibroblast, epithelial, endothelial, monocyte-derived macrophage, smooth 
muscle, hepatocyte, stromal, and neuronal cells (Plachter, Sinzger & Jahn, 1996; Sinzger et 
al., 2000). However, HCMV displays a relatively restricted cell tropism in vitro. Fibroblasts 
are the most commonly used cell type for CMV isolation and propagation in culture. HCMV 
appears able enter most cell types, with the restriction to full productive replication being 
associated with a post-penetration block in virus gene expression (Sinzger et al., 2000). 
HCMV attachment and entry into fibroblasts is rapid and efficient, and occurs at neutral pH 
through direct fusion of the viral envelope with the plasma membrane (Compton, 
Nepomuceno & Nowlin, 1992). In other cell types like epithelial and endothelial cells, the 
virus enters via receptor-mediated endocytosis requiring low pH (Ryckman et al., 2006). 
Although the complete repertoire of cellular receptors involved in mediating HCMV entry 
remain to be defined, the broad cellular tropism of the virus indicates that these receptor(s) 
are widely distributed across diverse cell types. The initial step in HCMV entry involves 
binding of gB to heparin sulphate proteoglycans present on the host cell surface, which is 
followed by subsequent interaction of gB with its non-heparin receptor resulting in a more 
stable binding state (Compton, Nowlin & Cooper, 1993). Platelet derived growth factor alpha 
(PDGFR-alpha) and epidermal growth factor (EGFR) receptors have been identified as two 
non-heparin gB binding receptors (Soroceanu, Akhavan & Cobbs, 2008).  
Fusion of the viral envelope with the host cell membrane results in entry of the tegumented 
nucleocapsid into the cytoplasm. Tegument proteins facilitate transport the capsid to the 
nuclear pore through utilization of the cytosolic organelle transport network involving 
microtubules (Sinzger et al., 2000). DNA is then released from the nucleocapsid and enters 
the nucleus through the nuclear pore complex. Tegument proteins pUL47 and pUL48, which 
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form a pUL47/pUL48 complex, appear to play a vital role in transporting capsids to the 
nucleus and possibly transporting the viral DNA into the nucleus. Mutant viruses lacking 
pUL47 have a delayed onset of IE gene expression and are less infectious compared to WT 
virus. Other studies suggest that the pp150 tegument protein may also be involved in this 
process. Nocodazole (a drug causing microtubule depolymerisation) is associated with 
diffuse cytoplasmic redistribution of pp150 throughout the cytoplasm, and was shown to 
prevent delivery of HCMV DNA to the nucleus and to block IE gene expression (Ogawa-
Goto et al., 2003). Once in the nucleus, DNA is circularized either by recombination between 
the repeat sequence at the terminal ends of the genome or by direct ligation of two ends of the 
genome (Mocarski et al., 2013). The circularized DNA is localized near nuclear structures 
called nuclear domain 10 (ND10), where virus gene transcription occurs (Ahn, Jang & 
Hayward, 1999). Residual empty capsids remain at the cytoplasmic side of nuclear pores for 
several hours before disintegrating (Peng et al., 2010). 
 
1.1.2.2.2 Viral gene expression 
Transcription of all herpesvirus genes, including those of CMV, occurs in the nucleus using 
host cell RNA-polymerase II and associated basal transcription machinery (Fortunato et al., 
2000). CMV gene expression can be classified into three major kinetic phases based on time 
of expression and sensitivity to inhibitors of protein translation and viral DNA synthesis. The 
three kinetic classes are: immediate-early (IE or α), early (E or β) and late (L or γ) genes 
(Fortunato et al., 2000). IE genes are expressed immediately following virus entry. IE gene 
products regulate viral and cellular gene expression in order to optimize the cellular 
environment for virus genome replication, and are required to initiate the regulatory cascade 
that leads to appropriate expression of E genes.  
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Expression of E genes is dependent on the expression and availability of IE gene products, 
but does not require viral DNA synthesis. E genes can be divided into two subclasses β1 
(true-E) and β2 (E-L) depending on time of expression. E gene products mostly encode non-
structural proteins (for example, proteins involved in virus DNA genome replication such as 
viral DNA polymerase; UL54). Proteins involved in immune evasion such as the MHC 
down-modulators, US2 and US11 are also expressed at this time (Jones & Sun, 1997; Wiertz 
et al., 1996).  
L genes (γ phase) genes are similarly divided into two classes: γ1 (partial-L) and γ2 (true-L), 
with expression of γ1 genes being amplified by viral DNA replication. The γ1 genes are 
transcribed at low levels before DNA replication, which are then stimulated several fold 
following DNA replication. Expression of γ2 genes is completely dependent on viral DNA 
replication. Examples of L genes include structural proteins and tegument proteins encoded 
by UL32 (PP150), UL94 (M94) and UL99 (pp28), which are all essential for late events of 
virion assembly and morphogenesis in the cytoplasm (see above) (AuCoin et al., 2006; Silva 
et al., 2003; Wing, Lee & Huang, 1996).      
 
1.1.2.2.3 DNA replication 
Replication of all herpesviruses occurs in the nucleus. Within 4 hours post-infection (hpi), the 
incoming linear HCMV DNA genome circularizes within the nucleus. For HCMV, DNA 
genome replication then occurs at between 14 to 24 hpi, and release of virus progeny starts 
from 36 hpi onwards. The peak of virus production occurs from between 60 to 80 hpi 
(yielding ~1000 copies of viral genome per infected cell); (Hertel & Mocarski, 2004). HCMV 
DNA synthesis requires a conserved set of six virus encoded replication fork proteins that 
together direct synthesis of the viral genome during productive lytic infection. The replication 
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fork proteins are as follows: DNA polymerase (encoded by UL54 and M54 for HCMV and 
MCMV, respectively), polymerase accessory enzyme (UL44/M44), single stranded (ss) 
DNA-binding protein (UL57/M57), and proteins of the heterodimeric helicase-primase (HP) 
complex (UL70/M70; UL120/M120) and the ATPase (helicase) subunit (UL105/M105) 
(McMahon & Anders, 2002; Rawlinson, Farrell & Barrell, 1996).  
The DNA polymerase enzyme consists of pUL44 and pUL54. The pUL44 protein increases 
the processivity of DNA polymerase, which is essential for DNA replication. In addition to a 
5’ to 3’ DNA synthesis function, DNA polymerase also contains a 3` to 5` endonuclease 
activity enabling ‘proof-reading’ of the large DNA genome. This HP complex has DNA-
dependent ATPase, primase and helicase activities. Following unwinding of the heteroduplex 
genome DNA, the HP complex produces RNA oligonucleotides to prime polymerase 
elongation on the lagging DNA strand. As HCMV does not encode the necessary biosynthetic 
machinery for nucleotide biosynthesis, all dNTPs required for replication of the viral genome 
must be supplied by the host cell (Chee et al., 1990). HCMV stimulates cellular transcription, 
translation and up-regulation of proteins involved in the biosynthesis of DNA precursors 
(Estes & Huang, 1977; Song & Stinski, 2002). At the same time, host cell DNA replication is 
prevented by a virus-induced block in progression of cell cycle (Fortunato et al., 2000). 
Together, this HCMV-mediated regulation of the cell produces an environment rich in the 
necessary precursors for replication of the viral genome, whilst reducing competition of the 
host DNA replication machinery for replication of its own cellular DNA – a perfect parasite. 
Within the nucleus, HCMV DNA replication occurs in a structure called the ‘replication 
compartment’. These structures are induced by the virus and then serve as sites for 
accumulation of proteins involved in viral genome replication (Wilkinson & Weller, 2003). 
Replication compartments initially form at the site of cellular ND10 nuclear bodies, which 
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are also the location at which the circular viral DNA genome localizes following release from 
the incoming nucleocapsid.  
Within the herpesvirus genome, lytic DNA replication initiates at a specific site called the 
origin of DNA/lytic replication (ori-Lyt). Some herpesviruses, including beta-herpesviruses 
such as CMV have a single ori-Lyt, whilst others have two (EBV and VZV) or even three ori-
Ly sites (HSV-1 and HSV-2) (Roizman & Pellett, 2001). Following initiation at the ori-Lyt site, 
most evidence supports viral DNA replication occurring through a rolling circle (theta θ-
based) mechanism similar to bacteriophage, with viral DNA synthesis resulting in the 
production of the large head-to-tail genome concatemers (Zhu et al., 1998). These 
concatamers are then believed to serve as the substrate for the cleavage/packaging into newly 
synthesized capsid with unit length genome. 
 
1.1.2.2.4 Virus assembly, maturation and egress 
Capsid assembly and viral DNA packaging takes place in the nucleus of infected cells, with 
the assembly pathway being highly conserved across all herpesviruses (Kalejta, 2008). 
Following their synthesis in the cytoplasm, nucleocapsid proteins in the form of 
preassembled intermediates (see below) are translocated into the nucleus and accumulate as 
nuclear inclusion bodies, which give rise to the characteristic ‘owl`s eye’ appearance of CMV 
infected cells. One preassembled capsid intermediate involves the viral major capsid protein 
(MC; pUL86) with the precursor of capsid assembly (scaffold) protein (pAP, pUL80.5) and 
proteinase precursor (pPR, pUL80a); (Fons et al., 1986). A second intermediate consists of 
minor capsid protein (mCP; pUL85) together with mCP-binding protein (mCBP; pUL46) 
interacting to form triplexes. Following their translocation into the nucleus, these two 
intermediates undergo assembly into procapsids.  
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Immature procapsids undergo maturation via proteolytic cleavage of an associated 
scaffolding protein resulting in formation of B capsids. B capsids are then ready for 
packaging of viral DNA through a capsid pore and maturation into infectious C capsid with 
concomitant removal of the scaffolding protein (Oien et al., 1997; Wood et al., 1997). 
Cleavage of the scaffolding protein uses ATP to provide the necessary energy for 
encapsulation of the DNA within B capsids. This is followed by cleavage of the genome 
concatamer, following packaging of exactly one genome unit length, resulting in formation of 
mature C capsid. The mechanism by which HCMV DNA achieves the packaging of precisely 
one full unit length of genome per capsid is not completely understood.  
Following C capsid formation, non-structural proteins, including those of the tegument 
control a complex two-stage Envelopment/De-envelopment/Re-envelopment process that 
precedes release of mature virions from the cell by exocytosis. Our understanding of this 
complex process is based primarily on studies using MCMV and HSV. The first step involves 
localization of C capsids to thickened concave patches in the inner nuclear membrane, which 
is then followed by budding of the capsid into the perinuclear cisternae of the ER (Gibson, 
1996; Gibson et al., 1996). The interaction of the virally encoded pUL53 with pUL50 
proteins (along with other viral proteins) is essential for this initial localization of C capsids 
to the nuclear membrane, and appears to occur concurrently with capsid maturation 
(Lötzerich, Ruzsics & Koszinowski, 2006).  
Following primary envelopment, de-envelopment delivers nucleocapsid into the cytoplasm 
for final assembly of the mature infectious enveloped virion at the assembly compartment 
(AC). The AC is a stable virus-induced structure composed of vesicles derived from the 
cellular secretory compartment. Virus proteins, including those present within the mature 
virion envelope, traffic to the AC and accumulate at the site. Most tegument proteins become 
associated with nucleocapsids during the final cytoplasmic phase of assembly at the AC. 
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However, some tegument proteins are also believed to become associate with the 
nucleocapsid during nuclear egress (Sanchez et al., 1998; Tooze et al., 1993). Host and viral 
kinases/phosphatases also contribute to the nuclear egress process (Steen et al., 2000).    
 
 
 
Figure 1.5 CMV life cycle. Virus enters host cells either through direct fusion or through the 
endocytic pathway depending on cell type. Virus attaches to cells through interaction of viral 
glycoproteins (including gB and gH) with heparin sulphate and other specific cell surface 
receptor(s). Fusion of the viral envelope with the cellular membrane releases nucleocapsid 
into the cytoplasm. The nucleocapsid is translocated to the nucleus, where viral DNA is 
released. Expression of IE gene triggers E expression, which is required for viral DNA 
replication. Virus DNA replication leads to the initiation of L gene transcription. Viral L 
genes encode proteins involved in DNA packaging and capsid assembly. Following its 
nuclear assembly, nucleocapsid enters the cytoplasm via a primary envelopment and then de-
envelopment at the nuclear and then ER membranes. This is followed by final envelopment at 
the AC in the cytoplasm. The mature virus particles are then released by exocytosis at the 
plasma membrane, reprinted from (Crough & Khanna, 2009). 
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1.1.2.3 Pathogenesis of CMV 
CMV is a widespread pathogen that infects between 40 to 100% of the population depending 
on age as well as location and socioeconomic status (Mocarski et al., 2013; Pass, 2001; 
Selinsky et al., 2005). After primary infection, virus is shed for weeks or months in bodily 
fluids including: tears, saliva, urine, semen and vertical secretions. HCMV is transmitted 
through direct contact with infected fluids and frequently occurs in the context of the 
childcare setting or during sexual contact. An additional route is through vertical transmission 
from mother to child during birth, via breast milk, or through the placenta during pregnancy 
(Pass, 2001). It is believed that these routes of vertical transmission play an important role in 
maintenance of CMV within the human population. Similar to all herpesviruses, HCMV has 
the ability to reactivate throughout the life of the host. 
HCMV infection in healthy (immunocompetent) individuals is generally asymptomic as the 
virus is controlled by the adaptive immune response. However, HCMV infection can cause 
life-threatening disease in immunocompromised individuals such as newborn infants, patients 
undergoing bone marrow or solid organ transplantation, and HIV infected individuals 
(Fowler et al., 1992; Patrone et al., 2003; Selik, Chu & Ward, 1995). In immunocompetent 
people symptoms are mild and include headache, malaise, fatigue, high fever, swollen lymph 
glands and rash. However, the clinical scenario is very different in the immunosuppressed. 
HCMV represents the most common viral cause of congenital infection and the leading viral 
cause of birth defects and brain damage in industrialized countries (Patrone et al., 2003). 
Birth defects range from deafness and mental retardation to fatal diease that includes 
pneumonia, encephalitis, hepatitis, and hydrops fetalis (a fatal congenital condition that 
eventually leads to heart failure) Table 1.1. HCMV has also been implicated in proliferative 
and inflammatory diseases, including cancer and atherosclerosis (Shen et al., 2004; 
Söderberg‐Nauclér, 2006). The severity of medical problems associated with HCMV in 
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these vulnerable populations underlies the necessity for developing means for attenuation of 
HCMV-based vaccines, such that the attractive immunological characteristics (see below) 
can be safely exploited in all populations regardless of immune status. 
 
Table 1.1 Human diseases caused by Herpesviridae members. 
Subfamily/ viruses                                                        Disease 
Alphaherpesviruses 
Herpes simplex virus type 1           Skin sores, labial ocular lesions, encephalitis and conjunctivitis 
Herpes simplex virus type 2           Genital lesions         
Varicella-zoster virus                     Chicken pox and Shingles 
 
Betaherpesviruses 
                                                                             I. In immunocompetent individuals 
                                                       Enteritis, Infectious mononucleosis, Thrombocytopenia,  severe anaemia      
                                                        and rarely encephalitis 
                                                                             II. Congenital CMV 
Human herpesvirus 5         Birth defects including mental retardation, vision & hearing loss                                     
v                                                                          III. In Immunocompromised individuals 
                                                       Lymphadenopathy, hepatitis, thrombocytopenia, nephritis, pneumonitis 
                                                       , gastrointestinal invasion and rarely encephalitis in transplant patients 
                                                         and vision loss and retinitis in AIDS patients   
        
Human herpesvirus 6                      Skin condition in infants called Exanthema subitum or Rosella infantum 
 
 
Human herpesvirus 7                      Skin condition in infants called Exanthema subitum or Rosella infantum 
 
Gammaherpesviruses 
Epstein-Bar virus                            Infectious mononucleosis associated with two rare forms of cancer: 
                                 Nasopharyngeal carcinoma and Burkitt’s lymphoma 
 
 
Kaposis sarcoma-                            Associated with Kaposi’s sarcoma 
associated herpesvirus 
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1.1.2.4 MCMV as a model for HCMV infection 
The strict host specificity of CMV means that HCMV can only be studied in humans. This 
has limited our understanding of many aspects of HCMV biology to extrapolation of findings 
from tissue culture using cells originated from humans. Empirical investigations of CMV in 
vivo are performed using related species-specific CMVs in their respective animal host. 
Murine CMV (MCMV) is a CMV of mice that provides a tractable in vivo model to 
investigate aspects of CMV biology, including persistence, latency and immunology with the 
hope of gaining insight into HCMV infection in humans. Many of the studies developing 
CMV as a vaccine vector platform have also been, at least initially for proof-of-concept, 
performed using recombinant MCMVs in mice (Morley, Ertl & Sweet, 2002; Tierney et al., 
2012; Tsuda et al., 2011). 
MCMV and HCMV share 80 conserved ORFs representing 45% sequence identity between 
the two viruses (Rawlinson, Farrell & Barrell, 1996). MCMV is also similar to HCMV in 
term of kinetics of gene expression, course of infection, and associated pathology and host 
immune response to CMV infection. Infection of mice with MCMV is also believed to be 
similar to HCMV infection of humans in terms of the different stages of infection, but this 
has been more clearly defined in the experimental MCMV model. In this model, CMV 
infection can be divided into three temporally distinct stages: i) acute infection of central 
visceral organs, ii) persistent infection of salivary glands for several weeks, and iii) 
establishment of virus latency stage for the life of the host (Lu et al., 2006).  
The pathological outcomes of MCMV infection in mice resemble those of HCMV in humans 
during acute and persistent infection and during reactivation from latency after immune 
suppression. MCMV can cause severe infections or lethality (Krmpotic et al., 2003) in 
immunologically immature or immunocompromised mice, whereas in immunocompetent 
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mice the virus can be re-activated from latency by immunosuppression (Sweet, 1999). 
However, a notable difference between the two viruses in their respective host species is that 
MCMV cannot be transmitted transplacentally to cause congenital defects in new born pups, 
which is due to differences in placental structure between rodents and primates. Nonetheless, 
the genetic and pathological similarities between these two viruses make the use of MCMV 
in mice an invaluable model for HCMV in humans, including for the development of CMV-
based vaccines. 
1.2 CMV Mutagenesis  
1.2.1 Generation of recombinant CMVs 
Functional characterization of viral genes by generating virus mutants has been important for 
the advance of many different areas of CMV research. The ability to construct recombinant 
CMVs expressing heterologous pathogen target antigens has similarly enabled translational 
studies towards the development of CMV-based vaccines. 
 
1.2.1.1 Methods of mutagenesis prior to BAC-based technology 
Mutagenesis of the herpesvirus genome has shown considerable technology-driven advances 
over the past 40 years. Compared to the relatively straightforward molecular manipulation of 
many viruses, the large genome combined with relatively slow growth of CMV in culture 
have been the main technological issues to be overcome for genetic manipulation of CMV. 
More than forty years ago a classical genetic approach using chemical-based mutagenesis 
was used to introduce random mutations into the herpesvirus genome for production of 
temperature-sensitive mutants, via point mutations, deletions or insertions (Brune, Messerle 
& Koszinowski, 2000). In spite of the large number of mutants generated by this technique, 
definitive identification of specific mutation(s) responsible for observed phenotypes and 
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exclusion of second site mutations were an inherent problem of such non-targeted mutagenic 
approaches (Sweet et al., 2007).  
Generation of the first recombinant  herpesvirus using site-directed mutagenesis was reported 
in the early 1980s, by using homologous recombination performed in permissive eukaryotic 
cells (Mocarski, Post & Roizman, 1980). Homologous recombination was initially used for 
introduction of mutations into individual genes of HSV, and then later adapted for other 
members of herpesvirus family, including CMV (Manning & Mocarski, 1988; Spaete & 
Mocarski, 1987). In this method, the mutation together with a selectable genetic marker is 
introduced into the target gene via the eukaryotic cellular recombination machinery. 
Homologous recombination utilizes a ubiquitous cellular pathway that is essential for many 
cellular processes, including maintenance of genomic integrity, segregation of chromosomes 
during meiosis, and rescue of stalled or collapsed replication forks as well as a function in 
telomere maintenance. Homologous recombination provides a means for repair of DNA 
double stranded breaks which occur either during DNA replication or following DNA 
damage by external factors such as irradiation (Heyer, 2006; Hunter, 2007; Muyrers et al., 
2000). 
The main disadvantage of this method is that selection procedures to purify recombinant 
viruses from WT virus are required. Since WT is over-represented in the resulting virus pool 
these procedures are generally laborious (especially for a slow growing virus such as CMV) 
requiring multiple rounds of selection. As selection is dependent on replication of the virus, 
isolation of recombinant viruses can be difficult if the mutation results in severe growth 
defects. Furthermore, completely replication-defective ‘null’ mutants of genes essential for 
viral growth can only be produced with parallel creation of complementing cell lines that 
provide the essential gene product in trans (DeLuca, McCarthy & Schaffer, 1985). Such cell 
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lines are notoriously difficult to produce, especially as many of the viral proteins will have 
cellular toxicity associated with their stable expression in cells. 
Almost a decade later a methodology based on use of overlapping cosmid clones was 
developed that overcame some of the problems associated with WT virus (Van Zijl et al., 
1988). In this system, viral genomes were sub cloned into E. coli and maintained as a set of 
overlapping cosmid clones. Genetic mutations were then introduced into the single respective 
cosmid clone containing the herpesvirus gene being targeted. Recombinant viruses are 
reconstituted by cotransfection of permissive eukaryotic cells with the mutated clone, 
together with the remaining cosmid set. The main advantage of this approach was that the 
introduction of markers and selection against non-recombinant WT virus was not required as 
only recombinant virus is reconstituted (Brune, Messerle & Koszinowski, 2000).  
However, the overlapping cosmid system still has several disadvantages including the 
difficulty of finding unique restriction sites within the large cosmids to use for genetic 
manipulation. Reconstitution of the viral genome in cell culture also required many 
recombination events to reassemble the entire full-length genome, which could lead to 
acquisition of unwanted ‘off-target’ mutations. Maintenance of the genetic stability of the 
cosmid clones also proved difficult, especially in those cosmids containing viral containing 
multiple repeat elements known to be susceptible to deletion or rearrangements. Finally, 
construction of the necessary reverting viruses needed to confirm that the observed phenotype 
in the recombinant virus is not due to an unwanted mutation elsewhere in the genome, was 
difficult with the cosmid-based technology.   
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1.2.1.2 Methods of mutagenesis using bacterial artificial chromosome (BAC)-based 
technology 
The development of BAC-based technology for genetic manipulation of herpesvirus genome 
in the late 1990s, whereby the viral genome is maintained as an infectious BAC within 
Escherichia coli (E.coli), was a watershed moment for the CMV field (Messerle et al., 1997) 
1997). BACs are DNA constructs based on the fertility (F) factor plasmid of E. coli (Shizuya 
et al., 1992). The size of herpesvirus genomes, which range in size from 125-240 kb exceeds 
the cloning capacity of an individual plasmid or cosmid which can incorporate up to 10 or 30 
kb of DNA, respectively (Warden, Tang & Zhu, 2010). Yeast artificial chromosomes (YACs) 
are able to carry larger regions of DNA (>2000 kb). However, YACs are not ideally suited to 
cloning of herpesvirus genomes as they are prone to undesired genomic rearrangements, 
especially between repetitive sequences as frequently occur in these viruses (Monaco & Larin, 
1994; Ramsay, 1994). In contrast, F plasmids were shown to be capable of propagating 
mammalian DNA inserts with significantly higher stability (Kim et al., 1992). Using the 
BAC technology, large DNA fragments from varied genomic sources can be maintained as a 
genetically stable F plasmid. This single foreign DNA source is then amenable to genetic 
manipulation by using bacterial-based genetic methodology (Shizuya et al., 1992). 
The demonstrated ability of F plasmids to stably maintain eukaryotic DNA fragments >300 
kilobases (kb) (Shizuya et al., 1992) led to the first adaptation of this system for the 
maintenance of herpesvirus genomes in the form of MCMV (Messerle et al., 1997). This 
novel technique has subsequently proved to be an invaluable tool for the manipulation of 
multiple different herpesvirus genomes (including HCMV and rhesus CMV) (Chang & Barry, 
2003; Messerle et al., 1997; Redwood et al., 2005). Infectious CMV virus is reconstituted by 
transfection of purified BAC DNA containing the entire herpesvirus genome sequence into 
permissive eukaryotic cells (Messerle et al., 1997). Since the CMV genome is maintained in 
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bacteria without the requirement for virus replication, a significant advantage of BAC-based 
technology over earlier systems was that mutations could be introduced into any viral gene, 
including null mutations into essential genes (Messerle et al., 1997; Wagner et al., 1999). 
 
1.2.1.2.1   The BAC vector 
Cloning the herpesvirus genome as a BAC requires the BAC cassette sequence to be inserted 
into the viral genome (using homologous recombination in eukaryotic cells; see above 
(Warden, Tang & Zhu, 2010). A typical BAC cassette is approximately 8 kb in size and 
contains all the genetic components required for maintenance of the BAC within bacteria, 
including an origin of replication (oriS) and replication gene (repE) involved in monitoring 
replication of the F plasmid. The BAC cassette also contains ParA and ParB genes that 
control the rate of replication so that the number of copies is limited to one or two copies in 
the bacterial cell (Shizuya et al., 1992). This ability to maintain the BAC at low copy appears 
critical for stability as it reduces the opportunity for recombination. The cassette also contains 
a selectable antibiotic resistance gene, most commonly chloramphenicol in order to select the 
bacterial colonies containing the BAC.  
For insertion of the BAC cassette into the viral genome the cassette is flanked by 0.5 to 1 kb 
of homologous sequence to the site of desired insertion within the CMV genome, which is 
generally a non-essential region of the virus which selected to avoid growth defects in the 
virus (Messerle et al., 1997; Warden, Tang & Zhu, 2010). Transfection of the homology-
flanked BAC cassette into CMV infected cells then results in formation of recombinant 
viruses containing the BAC cassette as a consequence of homologous recombination. 
F plasmids must be circularized in order to replicate and be stably maintained within bacteria 
as an artificial chromosome. This necessitates isolation of the herpesvirus genome containing 
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the BAC cassette only after circularization of the viral genome, which occurs for HCMV 
within approximately 4 hpi (see above). This procedure relies on adaptation of a protocol 
developed by Hirt (1967) for the isolation of small circular DNA molecules from eukaryotic 
cells (Eizuru, Inagawa & Minamishima, 1984). The isolated circular viral DNA is then 
transformed into a suitable E. coli strain (DH10B or DH5α) where the CMV BAC can be 
propagated and genetically modified. Bacterial genetic engineering can now be brought to 
bear against the generation of targeted mutations in the viral genome. 
Infectious recombinant virus is reconstituted by transfection of the genetically modified virus 
BAC DNA into a suitable permissive eukaryotic cell lines (Warden, Tang & Zhu, 2010). In 
the past years, multiple herpesviruses have been cloned as infectious herpesvirus BACs 
(Tables 1.2 and 1.3). Among those listed is MCMV (Smith strain; Messerle et al., 1997), 
which is relevant to the studies of this dissertation. The availability of herpesvirus genomes 
cloned as BACs allows modification of the viral genome and opens the way for myriad 
applications, such as using these cloned viruses as vehicles for development as vaccine and 
gene therapy platforms.  
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Table 1.2 BAC-cloned human herpesviruses 
BAC-based human herpesvirus name Representative studies 
Herpes Simplex Virus-1 (HSV-1) (Horsburgh et al., 1999) 
Herpes Simplex Virus-2 (HSV-2) 
 
(Meseda et al., 2004) 
Varicella Zoster Virus (VZV) 
 
(Nagaike et al., 2004) 
Epstein-Barr Virus (EBV) 
 
(Delecluse et al., 1998) 
Cytomegalovirus (CMV) 
 
(Borst et al., 1999; Hahn et al., 2003; 
Murphy et al., 2003) 
 
Human Herpesvirus 6 (HHV-6) (Borenstein & Frenkel, 2009) 
 
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) 
 
(Zhou et al., 2002) 
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Table 1.3 BAC-cloned animal herpesviruses 
BAC-based animal herpesvirus name Representative studies 
Bovine Herpesvirus Type I (BHV-1) (Mahony et al., 2002; Trapp et al., 2003) 
Bovine Herpesvirus Type 4 (BoHV-4) 
 
(Gillet et al., 2005)  
 
Equine Herpesvirus Type I (EHV-1) (Rudolph, O'CALLAGHAN & Osterrieder, 2002) 
Feline Herpesvirus Type I (FHV-1) (Tai et al., 2010) 
Guinea Pig Cytomegalovirus (GPCMV) (McGregor & Schleiss, 2001) 
Herpesvirus Saimiri (HVS) (White, Calderwood & Whitehouse, 2003) 
Koi Herpesvirus (KHV) (Costes et al., 2008) 
Marek’s Disease Virus (MDV) (Schumacher et al., 2000) 
Murine Cytomegalovirus (MCMV) (Bubeck et al., 2004; Messerle et al., 1997) 
(Brune et al., 1999) 
 
Murine Gammaherpesvirus 68 (MHV-68) (Adler et al., 2000) 
Pseudorabies Virus (PRV) 
 
(Smith & Enquist, 1999) 
Rhesus Cytomegalovirus (RhCMV) (Chang & Barry, 2003) 
Rhesus Rhadinovirus (RRV) (Estep et al., 2007) 
Herpesvirus of Turkeys (HVT) (Baigent et al., 2006) 
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1.2.1.2.2 BAC targeted mutagenesis by Red-mediated homologous recombination  
Although BAC cloning of herpesvirus genomes was a major technical advance, the genetic 
manipulation of these BACs still proved cumbersome. Initial methodologies were based on 
the RecA recombination system of bacteria and utilized sequential cycles of positive and 
negative selection with an antibiotic and the SacB marker, respectively.  Following selection 
of clones containing the desired mutation based on antibiotic resistance, the SacB gene was 
then used as a negative marker to remove both itself as well as the antibiotic gene, thereby 
leaving only the desired mutation in an otherwise WT genome. SacB encodes a protein called 
levansucrase, which catalyses the polymerization of fructosyl group in sucrose to form a 
lethal substance called levan which is toxic to E. coli (Bramucci & Nagarajan, 1996; 
Lepesant et al., 1972; Wagner, Ruzsics & Koszinowski, 2002). However, the propensity for 
SacB inactivation, which would confer on a clone the ability to grow in the presence of 
sucrose without removal of the antibiotic resistance marker or the (now inactivated) SacB 
gene, was a major problem with this system.    
In late 1990, a one-step mutagenesis strategy called E/T cloning was developed that was to 
revolutionize genetic manipulation of herpesvirus BACs (Zhang et al., 1998). This method 
uses the recombination functions of recombination proteins either recE and recT genes from 
prophage Rac or redα and redβ genes from bacteriophage λ (Muyrers et al., 1999; Zhang et 
al., 1998), or a defective lambda prophage (Lee et al., 2001; Yu et al., 2000). The γ Red-
encoded exo, bet, and gam are required for mediated recombination of short (>40 bp) 
homologous regions at both ends of the linear DNA fragment carrying the desired mutation, 
therefore allowing insertion of the linear DNA fragment at any site within the CMV BAC 
(Ruzsics & Koszinowski, 2008). The exo gene product encodes a 5’-3’ exonuclease activity 
which produces 3’ overhangs from introduced ds-DNA targeting cassettes. The bet gene 
product is a ss-DNA binding protein that binds to the 3’ overhang and promotes 
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recombination between the ds-DNA targeting cassette and regions of identical sequence 
within the BAC. At the same time, the gam gene function, prevents the degradation of linear 
DNA fragments by E.coli RecBCD exonuclease through inhibition of RecBCD. 
A notable advantage of E/T recombination over the earlier RecA-based system was the need 
for homologous sequences of only 40 bp compared to >1000 bp (of homology flanking the 
site targeted) for Rec A-based mutagenesis (Muyrers et al., 1999; Wagner, Ruzsics & 
Koszinowski, 2002). The homology sequences can also be freely selected, since the E/T 
recombination system does not require the presence of restriction enzyme recognition sites 
for cloning or excision of the targeted DNA sequence. Due to the short stretch of homology 
required for targeting, linear DNA fragments can also be generated by polymerase chain 
reaction (PCR) (Adler, Messerle & Koszinowski, 2003; Wagner, Ruzsics & Koszinowski, 
2002; Zhang et al., 1998). Following mutagenesis the marker gene can be removed by 
flanking the antibiotic resistance marker with short (34 bp) recombination sequence 
recognition sequences such as with FRT (FLP recognition target) or  LoxP (locus of crossing 
over P1 phage) sites (Zhang et al., 1998). 
 
1.2.2 Herpesviruses as a vaccine vector 
1.2.2.1 Viral vectors 
The basic aim of viral vaccines is to elicit a protective host immune response while avoiding 
disease from the vaccine itself. These delivery systems express the antigens within the cells 
of the vaccinated individual in situ thereby eliciting a strong immune response, but are 
removed from the deleterious effects of the pathogen. A number of different virus-based 
vaccine vector platforms are being developed. These platforms differ in a variety of 
characteristics, such as their level of persistence in the host, cellular tropism, carrying 
capacity for heterologous genetic material and quality and magnitude of associated immune 
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responses (Skenderi & Jonjić, 2012). Virus-based vaccines have advantages compared to 
other vaccine modalities in that they are able to activate both CD8
+
 and CD4
+ 
T cell 
responses, which are essential both for control of intracellular pathogens via direct killing of 
infected cells, but also for induction of robust antibody responses (Liu, 2010a). The ability of 
viral vectors to induce CD8
+
 T cells enables targeting of pathogen proteins or epitopes not 
normally exposed to antibodies, which are commonly more conserved regions. It is 
hypothesized that this capacity may be especially important for vaccination against highly 
divergent microbes like influenza A (IA) virus (Osterhaus, Fouchier & Rimmelzwaan, 2011). 
Traditionally, viral vaccine vectors are unable to establish a persistent infection within the 
vaccinated individual, being either completely replication defective or at most only able to 
establish an acute, limited infection cycle. These conventional vaccines, which still express 
their target antigen intracellularly, are able to stimulate cellular immune response (both CD4
+
 
and CD8
+
 T cells) and humoral immune responses without causing diseases. Although these 
classical vaccines have been successful for controlling some diseases (e.g. smallpox, yellow 
fever, measles, rubella and a number of other viral diseases), they have not been successful 
for more difficult to control pathogens such as HSV and human immunodeficiency virus.  
CMV has recently been developed as an innovative vaccine platform that may have 
considerable advantages over other existing virus-based vector vaccine systems. CMV is one 
of the most immunogenic viruses known (Sylwester et al., 2005) inducing a high immune 
response enriched for effector memory T- cells, TEM (Hansen et al., 2009), which commonly 
exceed 10% of the memory population for both CD4+ and CD8+ compartments (Sylwester et 
al., 2005). TEM cells are a subtype of memory CD8
+
 T cells, which tend to localize in 
peripheral and lymphoid tissue and are functionally primed for immediate defence at entry 
sites of the pathogen (Roberts, Ely & Woodland, 2005). This is because TEM are resident in 
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the lung airway and other similar effector tissue sites, so have the ability to mediate early 
control of a secondary virus infection (Roberts, Ely & Woodland, 2005). 
Several studies have shown CMV vectors to be effective at inducing protective immunity 
against different pathogens and pathogen associated toxins, including tetanus (Tierney et al., 
2012), highly virulent Ebola virus (Marzi et al., 2016; Tsuda et al., 2011) and simian 
immunodeficiency (SIV) virus (Hansen et al., 2011; Hansen et al., 2009). The efficacy of a 
CMV-based vaccine was initially demonstrated by the ability of RhCMV-based vectors 
expressing SIV target antigens to induce immunity against SIV in rhesus macaques (Hansen 
et al., 2009). Approximately half of vaccinated animals resisted establishment of chronic SIV 
systemic infection, and TEM  based CD8
+
 T cells appeared to play a primary role in mediating 
this protection (Hansen et al., 2011; Hansen et al., 2009) Comparison with rhesus macaques 
vaccinated with a conventional recombinant adenovirus (Ad5) vaccine, which induces a 
primarily central memory T cell (TCM) response, suggested that the ability of the 
RhCMV/SIV vaccine to maintain an SIV-specific TEM response in these sites corresponded 
with its ability to stringently control the highly pathogenic SIV infections early after mucosal 
challenge (Hansen et al., 2011). 
MCMV-based vaccines have also been shown to induce protective immunity against a variety 
of pathogens. In a series of studies, expression of a single CD8
+
 T cell epitope of the Ebola 
virus nucleoprotein was shown to protect against infection with this highly virulent human 
pathogen (Tsuda et al., 2011; Tsuda et al., 2015). These studies also reemphasized the unique 
characteristics of the immune response against the Ebola virus antigen, with the expansion 
(inflation) of the NP-specific CD8
+
 T cell response over time. Inflation is a unique 
characteristic of CMV-induced immune responses characterized by the continuous 
accumulation of a large number of virus-specific CD8
+
 T cells in the blood (Karrer et al., 
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2004), corresponding with maturation of a stable TEM (memory) response with immediate 
effector function at mucosal epithelial effector sites which persists for life.  
Most previous studies have focused on the T cell responses induced by CMV vectors.  
However, a number of studies indicate that CMV vectors may also be able to induce 
significant antibody responses against their encoded target antigen. A MCMV-based vaccine 
platform, encoding the tetanus toxin fragment C, induced sustained levels of protective 
antibodies essentially for the life of the mouse, following only a single dose of vaccination 
(Tierney et al., 2012). A more recent study demonstrated the ability of a RhCMV-based 
vaccine expressing the full-length Ebola virus GP to protect against a lethal Ebola virus 
challenge. Interestingly, vaccination induced high levels of GP-specific antibodies with no 
detectable GP-directed T cell response, which corresponded to control of GP expression by 
the endogenous RhCMV Rh112 promoter expressed with L kinetics (Marzi et al., 2016). In 
summary, CMV may be considered a unique vaccine vector platform due to its ability to 
elicit high levels of TEM CD8+ T cell responses. Recent studies also suggest that the vector 
can be genetically engineered towards production of antibodies as well as T cells.  
In this thesis, the MCMV mouse model is used for initial investigations into development of 
CMV as a vaccine platform. Studies detailed in Chapter 3 of this thesis use MCMV to 
examine the ability of a destabilization domain strategy to generate a conditionally 
replication-defective MCMV vaccine vector that can be produced in vitro, but will be 
attenuated in vivo. Chapter 4 is concerned with the initial development of a MCMV-based 
vector expressing internal conserved proteins of IA virus towards development of a universal 
IA vaccine.   
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1.3 CMV Attenuation    
1.3.1   CMVs as an attenuated vector platform 
Apart from their attractive immunological characteristics, fully replicating viral vectors such 
as CMV also have a number of potential disadvantages; a main one being the concern 
associated with in vivo gain-in virulence and diminished vaccine safety profile. Due to the 
pressure of selection on the replicating vector, stability of the heterologous target antigen may 
also be a concern if there is any selective disadvantage associated with expression of the 
target antigen gene. Viral vectors may also become virulence through recombination with 
endogenous viruses (Liu, 2010b)- albeit this is less of a concern for benign vectors like CMV. 
These concerns have led to the development of means of attenuating replicating viral vectors 
to improve their safety profile.    
Initial attenuation strategies relied on repeated passage under suboptimal conditions in either 
cultured cells or non-host animal species. These approaches have proven to be an effective 
means for attenuation of both virus as well as bacterial based vaccines. However, there are a 
number of safety concerns associated with the use of this approach, the main one being the 
inability to clearly define the mutation(s) responsible for the attenuation as well as the 
possibility for reversion of the vaccine to WT virulence-in large part because the nature of the 
attenuating mutation is not known (Lauring, Jones & Andino, 2010). 
Development of methodology for genetic manipulation of microbial genomes has enabled 
identification of many genes essential for viral replication and assembly through deletion or 
mutation of these genes. This knowledge has enabled targeted attenuation in which the 
attenuating mutation is clearly defined. Permanent inactivation of targeted genes requires 
propagation of the attenuated vector on a complementing cell line that expresses the missing 
viral gene(s) allowing viral replication. In the vaccine recipient, the virus is however unable 
to produce virus progeny, but viral genes are still expressed within the infected cells inducing 
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a strong immune response (Dudek & Knipe, 2006). The first use of a replication-defective 
virus as a vaccine was a HSV-1 strain with a deletion of a gene (ICP8; the major DNA-
binding protein) essential for genome replication, which was shown to protect mice from 
HSV-1 infection (Nguyen, Knipe & Finberg, 1992). This virus induced a protective immune 
response similar to its replication-competent parental virus (Morrison & Knipe, 1996). 
A main advantage of a replication-defective vaccine is the high level of safety that results 
from permanent genetic inactivation of the essential gene. However, the requirement for  
complementing cells to support growth of null mutants can be difficult to achieve, since the 
expression pattern of the essential gene is important for their function and because exogenous 
promoters often fail to reproduce the appropriate regulation observed with endogenous 
promoters (Pan et al., 2016). This is expected to be an even greater concern for vaccine 
platforms with complex gene expression profiles such as herpesviruses, which is reflected by 
the small number of complementing cell lines that have been established for herpesvirus null 
mutants. This is further complicated for the β- and γ- herpesvirus subfamilies, as many of 
these viruses can only be propagated on primary cell cultures (Borst et al., 2008; Mocarski et 
al., 1996; Silva et al., 2003).  
 
1.3.2   Conditional expression of essential genes and mutants of CMV 
An alternative strategy to deletion mutagenesis that avoids the need for trans-
complementation is conditional expression of the essential gene being targeted. Conditional 
gene expression was initially used for the study of virus gene function. The first generation of 
conditionally-attenuated herpesviruses were temperature sensitive (ts) mutants, where they 
were shown to be often superior to null mutants in identifying viral functions (Whitley, 
Kimberlin & Roizman, 1998). Most of the ts mutants described are alpha-herpesviruses 
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(Schaffer et al., 1973). Propagation of conditional beta-herpesvirus mutants by selection of a 
ts allele is technically more difficult, presumably due to the slower replication of the virus 
(Akel & Sweet, 1993), with generation of only a single HCMV ts mutant (UL122 gene) 
(Heider, Bresnahan & Shenk, 2002). More recent approaches have focused on conditional 
regulation of gene transcription. These have included tetracycline-regulated transactivation 
systems (Furth et al., 1994). These systems have proved invaluable for elucidation of CMV 
gene function particularly in the MCMV model (Rupp et al., 2005).  
Recently, a novel strategy was established for conditional regulation of proteins at the level 
of protein stability. This strategy is based on fusion of targeted essential virus proteins to a 
small metastable protein domain (called a destabilization domain, DD), which results in 
stability of the targeted protein becoming dependent on the presence of a small molecule 
ligand (Banaszynski et al., 2006). Two DD systems are currently in use, which are based on 
either rapamycin-binding protein (FKBP), or E. coli dihydrofolate reductase (ecDHFR). Both 
DD systems were engineered to be metabolically unstable in the absence of their high affinity, 
cell-permeable small ligands, Shield-1 or trimethoprim (TMP), respectively. The instability 
of the DD fused target protein results from degradation by the cellular proteasome. The 
addition of a ligand stabilizes the DD restoring their biological function in a rapid, reversible 
and ligand dose dependent manner (Figure 1.6; Banaszynski et al., 2006; Iwamoto et al., 
2010).    
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Figure 1.6 A general method of destabilization domain strategy. Destabilization domain 
(DD) protein fused genetically to a protein of interest (POI), the fusion results in degradation 
of the entire fusion protein. In the presence of a small synthetic ligand, the fusion protein is 
stabilized and protected from degradation, whereas the lack of ligand results in degradation of 
the fusion protein. Adopted from (Banaszynski et al., 2006). 
 
 
A 2009 study demonstrated the ability of a DD strategy to generate conditionally replicating 
CMV mutants using the dFKBP/Shield-1 system (Glaß et al., 2009). The dFKBP was fused 
to three essential CMV genes: major IE protein of MCMV and HCMV and two 
uncharacterized essential proteins of HCMV, pUL51 and pUL77. The dFKBP was added to 
the N-terminal of the respective proteins since it had been reported that N-terminus DD 
fusion resulted in better control of protein levels than fusion of the C-terminus (Banaszynski 
et al., 2006). Introduction by transfection of the recombinant MCMV BAC DNAs into 
permissive fibroblasts in the presence of shield-1 enabled virus reconstitution for all of the 
mutant viruses except the DD-destabilized pUL77 mutant. This suggested that fusion to the 
N-terminus may have interfered with an essential function of pUL77, which was supported 
by the ability to recover infectious virus in the presence of Shield-1 when the dFKBP DD 
domain was instead fused to the C-terminus of pUL77. For efficient complementation 
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concentrations of ligand were required that differed depending on the essential protein being 
targeted. Reversibility of this conditional attenuation system was also shown by withdrawal 
or addition of Shield-1 (Glaß et al., 2009). 
The ecDHFR-based system based on a mutant E. coli dihydrofolate reductase and its 
commercially available trimethoprim (TMP) as a stabilizing ligand was subsequently 
developed by the same laboratory as the FKBP/Shield-1 system (Iwamoto et al., 2010). A 
major advantage was one of cost of the DD stabilizing ligand (TMP), which had essentially 
limited the FKBP/Shield-1 system to in vitro and small animal studies. The ecDHFR is a 159 
aa-residue enzyme that reduces dihydrofolic acid to tetrahydrofolate acid, which is essential 
as a methyl group donor for several steps in prokaryotic primary metabolism (Schnell, Dyson 
& Wright, 2004).  
As a DD, ecDHFR possesses desired characteristics including, low protein level in the 
absence of TMP (i.e. low basal stability), robust and predictable dose-response behaviour, 
large dynamic range and rapid kinetics of degradation (Iwamoto et al., 2010). TMP is a well-
characterised drug that is commercially available, inexpensive and possesses good 
pharmacological characteristics. TMP is used mainly in the treatment of urinary tract 
infection through its effect on ecDHFR activity. TMP is one of the most widely used 
antibiotics since it binds with higher affinity (60,000 times) to bacterial rather than human 
DHFR and as a result inhibits bacterial DHFR far more potently than mammalian DHFR 
(Matthews et al., 1985). These attractive pharmacological properties of TMP and commercial 
availability coupled with the specificity of the ecDHFR-TMP interaction and low cost makes 
this destabilized protein-ligand pair ideal for development as a DD strategy. 
DD-based strategies have been shown to work successfully in multiple in vivo studies in mice 
(Banaszynski et al., 2008). DD system have also been used in other organisms, including: 
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Plasmodium falciparum (Dvorin et al., 2010; Muralidharan et al., 2011; Russo et al., 2009), 
Toxoplasma gondii (Herm-Götz et al., 2007) and also applied to conditionally regulate 
protein expression levels in Caenorhabditis elegans (Cho et al., 2013). Although, the DD-
ligand system has successfully been applied to regulate many proteins of CMV (Table 1.4), it 
has been shown in (at least one study) that the strategy may not be applicable to all virus 
proteins (Fehr & Yu, 2011). In the current study, we analysed the applicability of the 
replication defective technology to generate conditionally replicating MCMV mutants, whose 
growth is dependent on the ligand TMP, by fusing the ecDHFR domain protein to two 
essential tegument proteins of MCMV: pp150 and pp28.     
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ORF                                      Gene properties                                               Reference 
IE1/IE2                                   Multifunctional  essential proteins                             (Glaß et al., 2009) 
IE1/IE3                                   Multifunctional essential proteins                              (Glaß et al., 2009) 
pUL77                Participate in CMV genome cleavage and packaging                    (Glaß et al., 2009) 
pUL117                  Is required to block host DNA synthesis                                     (Qian et al., 2010) 
                                           during HCMV infection 
UL96                   Preserves the integrity of PP150-associated                 (Tandon & Mocarski, 2011) 
                             nucleocapsids during translocation from the  
                                         nucleous to the cytoplasm 
pUL79                  Promote the accumulation of late viral transcripts                      (Perng et al., 2011) 
                                           following HCMV DNA replication                                                                                                       
pUL51                       Essential for viral genome cleavage-packaging                     (Borst et al., 2013) 
                                                                                                                                   (Glaß et al., 2009) 
UL48                            Has role in intracellular capsid transport                               (Das et al., 2014) 
                                         and has deubiquiting enzyme activity                              
                                   
UL94                           Essential for cytoplasmic egress and                                       (Das et al., 2014) 
                                                 binds to ss-DNA  
UL103                         May have a role in viral replication,                                         (Das et al., 2014) 
                                  controls virions and dense body egress 
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1.4 Influenza A Virus  
1.4.1 Influenza and influenza viruses 
Influenza (flu) in humans is an acute, highly contagious respiratory illness that mainly affects 
the respiratory tract (i.e. the bronchi, throat and nose; (Kreijtz, Fouchier & Rimmelzwaan, 
2011). Flu is characterised by muscle pain, sudden onset of fever, headache, severe malaise 
with a sore throat, nasal inflammation and non-productive cough (Lamb, Krug & Knipe, 
2001). Influenza is caused primarily by the influenza A (IA) virus. During seasonal 
epidemics, IA viruses are responsible for 3-5 million cases of severe infections worldwide 
(Subbarao, Murphy & Fauci, 2006). Although most people recover from IA virus infection 
within 1-2 weeks without requiring medical treatment, infection can result in pneumonia, 
hospitalisation and death in the elderly, very young or chronically ill people (Lamb, Krug & 
Knipe, 2001). 
IA virus continue to have a major worldwide impact on humans health, with seasonal IA 
viruses alone causing 250,000-500,000 deaths worldwide annually (Drape et al., 2006; 
Razuri et al., 2012).  
There are three genera of influenza virus: type A, B and C all belonging to the 
Orthomyxoviridae family, which is a group of enveloped negative-sense, ss-RNA viruses 
with a segmented genome (Palese & Shaw, 2007). Influenza viruses can be characterized 
based on morphological features, sequence variability in surface glycoproteins, antigenic 
differences, protein-encoding mechanisms and number of RNA segments (Lamb, Krug & 
Knipe, 2001; Zambon, 1999). IA virus has a broad host range and naturally infects a variety 
of birds and mammals including humans, horses, pigs and sea mammals. The natural 
reservoir for IA viruses is aquatic birds (Webster et al., 1992). Influenza B (IB) and C (IC) 
viruses in contrast are normally found only in humans (Lamb, Krug & Knipe, 2001). This 
difference in breadth of species tropism is the main reason for only IA viruses being able to 
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cause pandemic disease. As IB and IC only infect humans, and thus can never evolve outside 
of the human population, most humans will have some level of immunity against these 
viruses (Gioia et al., 2008). This is not the case for IA, which is maintained and can evolve 
remotely from the human population, only to be reintroduced without warning into a 
potentially immunologically naïve population.  
 
1.4.2 IA virus virion structure  
The IA virus particle has a typical diameter of 80-160 nm, surrounded by a lipid bilayer 
envelope that is derived from the host cell membrane during the budding process (Figure 1.7). 
The IA virus particle is coated with two surface glycoproteins: hemagglutinin (HA) and 
neuraminidase (NA) protruding from the lipid bilayer in an approximate ratio of 4:1. Laver & 
Valentine, 1969 were first to describe that the surface spikes visible by EM were the HA and 
NA proteins (Figure 1.8). Also embedded within the viral envelope is the integral membrane 
matrix 2 protein (M2). M2 overlays matrix 1 (M1) protein that encloses the virion core and 
structurally supports the particle.  
The virion particle is pleomorphic in shape, ranging from spherical to filamentous depending 
on the viral strain and cell-type used for propagation (Lee & Saif, 2009; Noda & Kawaoka, 
2010). The filamentous form was first described in 1949 (Chu, Dawson & Elford, 1949). EM 
analysis of lung tissue from a patient who died as a result of 2009 H1N1 pandemic flu, 
(Swine-Origin strain) revealed a similar filamentous shape of virus particles (Rossman & 
Lamb, 2011).  
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Figure1.7. Schematic showing the structure of the IA virion. The genome of the IA virus 
consists of eight ss-RNA segments. The virion envelope contains two surface glycoproteins: 
HA and NA. The integral M2 protein is also located within the envelope, where the protein 
functions as an ion channel. The M1 protein is located immediately underneath the virus 
envelope and interacts with both the surface proteins and the ribonucleoprotein (RNP) 
complex. The RNP complex comprised of PB1, PB2 and PA, together form the RNA 
polymerase. The non-structural NEP/NS2 protein is also localized within the virion, whereas 
NS1 is found only in infected cells. Adapted from (Lee & Saif, 2009). 
 
Figure 1.8 EM of purified IA virions. Virions are covered with spikes composed of HA and 
NA (Bar; 100 nm). Printed from (Noda & Kawaoka, 2010). 
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1.4.2.1 IA virus genome 
The 13,600 nt genome of influenza virus is organised into eight segments of negative-sense 
ss-RNA. Segments are numbered based in order of decreasing length. Each RNA segment is 
surrounded by nucleoprotein (NP) forming a flexible rod-shaped ribonucleoprotein (RNP) 
that contains one copy of the trimeric polymerase (PB1, PB2, and PA) complex, which is 
essential for IA virus replication (Digard et al., 1999). The eight genome segments of IA 
virus are known to encode at least 12 proteins: segment 1 (PB2), segment 2 (PB1 and PB1-
F2), segment 3 (PA), segment 4 (HA), segment 5 (NP), segment 6 (NA), segment 7 (M1 and 
M2) and segment 8 (NS1 and NS2; Chen et al., 2001; Samji, 2009; Wise et al., 2009). 
Recently, two more new proteins (PA-X and M42) were discovered being translated from 
segments 3 and 7, respectively (Jagger et al., 2012; Wise et al., 2012).  Table 1.5 summarises 
the function of protein (s) encoded by each segment.  
  
1.4.1.1.3 IA virus classification 
Influenza A viruses are classified antigenically based on antigenic distinct HA and NA 
serotypes found on the virion surface. Currently, 18 different HA serotypes (H1-H18) and 11 
different NA serotypes (N1-N11) have been identified (Hampson & Mackenzie, 2006). 
Among these serotypes, 16 HA (H1-H16) and 9 NA (N1-N9) have been shown to circulate in 
waterfowl, with the remaining two (H17 and 18; and N10 and N11) having been isolated 
from bats (Tong et al., 2012). Human IA viruses have been limited to only H1, H2 and H3, 
and N1 and N2 (Gioia et al., 2008). Individual IA virus strains are classified by using a 
systematic nomenclature based on genus, animal species of isolation (except for humans), 
geographic location of isolation, isolate number, year of isolation, and HA and NA serotype. 
For example, A/Duck/Ukraine/1/63 (H3N8) is the first of a strain of a H3N8 type A influenza 
virus isolated from a duck in the Ukraine in 1963.  
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AI viruses can also be classified phylogenetically into two groups of viruses: Group 1 and 
Group 2 (Chen & Deng, 2009). Group 1 includes H1, H2, H5, H6, H8, H9, H11, H12, H13 
and H16; whereas group 2 includes H3, H4, H7, H10, H14 and H15 (Ellebedy & Ahmed, 
2012). Each group shares a region of sequence conservation in the stem region of the HA 
protein (see below) which contains the antibody binding site and is conserved amongst many 
IA viruses. As a consequence of genetic (segmental) reassortment (called antigenic shift; see 
below), IA viruses with new combinations of HA and NA serotypes have been generated 
over time. In recent years, avian influenza strains H5N1, H7N7 and H9N2 have been 
transmitted to humans, with disease but only limited human-to-human spread.  
 
Table 1.5 IA virus genome segments and encoded proteins (Bouvier & Palese, 2008; 
Wise et al., 2009). 
RNA Segment Encoded Protein(s) Protein Function 
1 PB2 Polymerase Subunit, mRNA cap recognition 
2 PB1 
PB1-F2 
PB1-N40 
Polymerase Subunit, RNA elongation 
Pro-apoptotic activity 
Polymerase complex interaction 
3 PA 
PA-X 
Polymerase Subunit, Endonuclease activity 
Modulates the host response &viral virulence 
4 HA Major surface glycoprotein, receptor binding & fusion 
activity 
5 NP RNA binding protein, nuclear import regulation 
6 NA Minor surface glycoprotein, sialidase activity, virus release 
7 M1 
M2 
M42 
RNA nuclear export regulation, viral budding & assembly 
Ion channel for controlling pH, virus uncoating & assembly 
Replaces M2 function in M2-null viruses 
8 NS1                           
 
NEP/NS2 
Interferon antagonist protein & regulation of host gene 
expression 
Nuclear Export of RNP 
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1.4.1.1.3.1 Hemagglutinin (HA) 
HA represents the major surface antigen of the IA virus (McHardy & Adams, 2009). The HA 
glycoprotein is assembled as a homo-trimeric spike of non-covalently linked monomers in the 
ER (Bosch et al., 1981). HA is initially produced as a single polypeptide (HA0) that is 
cleaved into two disulphide-linked subunits (HA1 and HA2). Depending on the IA virus 
strain (and HA proteolytic cleavage motif), cleavage of HA0 is carried out either by trypsin (a 
tissue-specific protease) or by the ubiquitously distributed furin protease (Bosch et al., 1979). 
The capacity for furin cleavage is responsible for the highly pathogenic (HPAI) phenotype in 
domestic fowl since it enables proteolytic activation of HA systemically (Horimoto & 
Kawaoka, 1994).  
HA is essential for the virus entry of the host cell. HA mediates virus attachment to the host 
cell by binding to sialic acid containing receptors on the host cell membrane. HA then 
mediates fusion between the virus membrane and endocytic vesicles following a major pH-
dependent conformational change of HA associated with exposure of the HA fusion peptide. 
This fusion event results in release of the viral RNP with its associated genome into the host 
cell cytoplasm. HA also serves as the main target of the host immune system. As a surface 
antigen, HA is under constant immune selection pressure from neutralizing antibodies 
following exposure to the influenza virus, either by natural infection or by seasonal epidemic 
vaccination (Both et al., 1983). 
 
1.4.1.1.3.2 Neuraminidase (NA) 
NA is the second major surface glycoprotein of the IA virus (Webster et al., 1992). The NA 
protein is folded in the ER followed by oligomerization to form almost mushroom-shaped 
trimeric protein molecules. As a type II protein, the N-terminal stalk of NA protein is 
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embedded in the viral envelope, whilst the box-shaped head contains enzymatic activity to 
catalyse the cleavage of sialic acid from cellular proteins within the secretory pathway 
(Gottschalk, 1957). This function is critical for the release of virus progeny during the viral 
replication cycle, as it enables virion escape from the host cell, which would otherwise be 
retained by the binding of HA to sialic residues of the host membrane proteins (Lee et al., 
2014). NA also prevents virus self-aggregation, and although the NA does not have any direct 
role in the attachment of viruses to host cells, it facilitates virus access to the epithelial cells 
by removing mucins (Liu et al., 1995; Palese et al., 1974).  
 
1.4.1.1.3.3 Polymerase proteins 
The PB1, PB2 and PA proteins together form the RNA polymerase complex of the IA virus, 
which is essential for virus replication as it provides the RNA-dependent RNA polymerase 
(RdRp) activity (Akkina, 1990; Ghanem et al., 2007). The proteins within this complex are 
named on the basis of the isoelectric properties of each protein. PB1 and PB2 are basic 
proteins while PA is an acidic protein. PB1 is the first basic subunit of the polymerase 
complex. It serves as a scaffold for binding of the other two polymerase complex subunits as 
well as the NP protein (Ghanem et al., 2007; Liu et al., 1995). As a catalytically active 
subunit of the RdRp complex, PB1 plays a key role in the initiation and elongation of mRNA, 
complementary RNA (cRNA) and genomic RNA (Nakagawa, Oda & Nakada, 1996; 
Ulmanen, Broni & Krug, 1981). For initiation of viral mRNA synthesis PB1, together with 
PB2 and PA (see below), generate capped RNA primers by endonucleolytic cleavage ‘cap-
stealing’ using cellular mRNA as the substrate. These host cell derived primers are then used 
to prime viral RNA synthesis (Li, Rao & Krug, 2001). 
PB2 is the second basic subunit of polymerase complex. The main function of the PB2 is to 
recognise and bind to the 5`-cap structure of host cell pre-mRNA, which in then later cleaved 
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during ‘cap-stealing’. PA is the third and only acidic subunit of the RdRp complex. The PA 
endonuclease cleaves 10-13 nucleotides from the PB2-bound host pre-mRNA (Cheung & 
Poon, 2007; Dias et al., 2009; Li, Rao & Krug, 2001). PA is also essential for efficient 
accumulation of PB1 in the nucleus (Fodor & Smith, 2004). PA has also been shown to be 
involved in various aspects of viral transcription and replication. However, its exact roles in 
viral transcription and replication are still poorly defined (Digard, Blok & Inglis, 1989; Fodor 
et al., 2002; Sanz-Ezquerro et al., 1995). 
        
1.4.1.1.3.4 Matrix proteins (M1 and M2) 
Segment 7 encodes two viral structural proteins: M1 and M2. M1 is the most abundant 
protein in the virion. M1 lies beneath the virion envelope forming a shell around the virion 
nucleocapsid. M1 binds to the RNP complex to facilitate its nuclear to cytoplasmic transport 
(Bui et al., 2000; Ye et al., 1987). It has been suggested that M1 also interacts with HA and 
NA through their cytoplasmic tails (Enami & Enami, 1996). M2 is a tetrameric 
transmembrane protein that functions as an ion channel to regulate pH (Lamb, Zebedee & 
Richardson, 1985). Following virus entry into the host cell, M2 allows acidification of the 
interior of the virus from the acidified endosomes, which leads to critical conformational 
changes necessary for virus uncoating (Holsinger et al., 1994). M2 also plays an essential 
role in facilitating virus egress in later stages of the replication cycle (Roberts et al., 2013). 
 
1.4.1.1.3.5 Non-structural proteins 
Segment 8 is the smallest gene segment and encodes for two non-structural proteins NS1 and 
NS2. Although NS1 is not incorporated into the virion, the protein is abundantly present in 
the nucleus of infected cells (Paterson & Fodor, 2012). NS1 interacts with a variety of 
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cellular proteins and plays an essential role in the pathogenesis and replication of the IA virus. 
NS1 possesses regulatory functions controlling both mRNA splicing and translation (Fortes, 
Beloso & Ortin, 1994; Qiu, Nemeroff & Krug, 1995), as well as promoting translation of 
viral mRNA (Garfinkel & Katze, 1993). It is also involved in inhibition of cellular innate 
antiviral pathways (Min & Krug, 2006; Wang et al., 2002), and has been shown to inhibit 
maturation and migration of dendritic cells leading to dysfunctional T cell stimulation and 
cytokine production (Fouchier et al., 2005). NS1 can be divided into two distinct functional 
domains. Consistent with its function in modulating innate immune pathways, the N-terminal 
of NS1 is an RNA binding domain consisting of aa residues 1-73 that has been shown to bind 
with low affinity to RNA molecules in vitro in a sequence independent manner (Chien et al., 
2004; Qian et al., 1995). C-terminal residues 74-230 bind cellular host proteins, which also 
aids in stabilization of the RNA-binding domain (Wang et al., 2002).  
NS2 (nuclear export protein; NEP), is expressed from an alternatively spliced mRNA. The 
NS2 protein is incorporated in a phosphorylated form into the IA virion (Richardson & 
Akkina, 1991). NS2 protein has been shown to perform many important biological functions 
during IA virus replication. In association with M1, NS2 facilitates the transport of the viral 
RNA complex from the nucleus to the cytoplasm (Robb et al., 2009). The N-terminus of the 
NS2 contains an HIV-1Rev-like nuclear export signal (NES) that interacts with cellular 
nucleoproteins, and can mediate nuclear export (Paragas et al., 2001). In addition to nuclear 
export function, NS2 also plays a critical role in the regulation of viral RNA transcription and 
replication (Robb et al., 2009). NS2 is involved in the viral budding process via an interaction 
with cellular ATPase (Gorai et al., 2012). 
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1.4.1.1.3.6   Nucleoprotein (NP) 
NP is the highly conserved and the second most abundant protein of virion (Webster et al., 
1992). Following synthesis and post-translational phosphorylation, NP is transported into the 
nucleus to where it binds to newly synthesised viral RNA to provide structural organization 
to the RNA complex (Portela & Digard, 2002; Wu, Sun & Panté, 2007). NP interacts with 
cellular proteins such as: importin-α, F-actin and CRM1, consistent with a role in nuclear to 
cytoplasmic transport of RNP complexes (Digard et al., 1999; Elton et al., 2001; O'Neill & 
Palese, 1995). Genetic and biochemical studies have shown that NP also plays a critical role 
in switching RNA synthesis from the transcription mode to the replication mode. In both in 
vitro and in vivo studies NP was shown to be essential for the switch to the replication mode 
(Krug et al., 1989). NP also interacts with other cellular (BAT/UAP56 and MX) (Momose et 
al., 2001; Turan et al., 2004) and viral (PB1, PB2 and M1 proteins) (Biswas, Boutz & Nayak, 
1998; Elton et al., 1999). The interaction between NP and M1 was suggested to play an 
important role in the budding process of the IA virus particle (Avalos, Yu & Nayak, 1997).  
Interestingly, NP-specific antibodies were recently shown to provide protection in mice 
(Carragher et al., 2008; LaMere et al., 2011b). Interestingly, vaccination with NP protein in 
adjuvant provided broad protection against diverse IA viruses by a mechanism involving NP-
specific IgG, FcR and CD8
+
 T cells (LaMere et al., 2011b). Due to the longevity of the NP-
specific antibodies the cross-protective immunity provided was shown to persist over several 
months (LaMere et al., 2011a). Since NP is a conserved influenza virus antigen and a major 
target for immune response especially cytotoxic T lymphocyte responses, it has been 
considered as a prime candidate for universal vaccines that generate cross-protective T cell 
responses (Berkhoff et al., 2007) (see below). 
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1.4.2 Antigenic diversity of IA virus     
Antigenic variation is a hallmark of the IA virus (Subbarao, Murphy & Fauci, 2006). This 
variation is due to both the segmented structure of the influenza virus genome enabling 
genomic reassortment, as well as the absence of a proof-reading mechanism leading to the 
accumulation of genetic errors incurred during genome replication (Zambon, 1999). These 
two sources of genetic variation, however, have markedly different outcomes: termed 
‘antigenic shift’ and ‘antigenic drift’, respectively. 
 
1.4.2.1 Antigenic Drift 
IA viruses in their natural host reservoir (aquatic birds) appear to be in evolutionary stasis. 
However, in other hosts virus develops rapidly in response to the immune selection 
(Sandbulte et al., 2011). As influenza strains develop continuously to avoid detection by host 
antibodies directed against the surface glycoproteins, frequent non-synonomous changes of 
amino acids occur as a result of mutation within HA, NA or both (Adams & Sandrock, 2010). 
The accumulation of these mutations is known as ‘antigenic drift’ as the original HA and NH 
serotypes are maintained (Figure 1.9). These mutations occur due to the absence of proof-
reading ability in the influenza’s RNA polymerase complexes leading to replication errors on 
the order of 1 × 10
–4
 per replication cycle (Holland et al., 1982). Mutations including deletion, 
insertion, and substitutions are the most important mechanisms for producing variation in IA 
viruses (Webster et al., 1992). Accumulation of mutations at the antigenic sites of HA can 
result in these sites no longer being recognised and neutralised by the host immune system. 
This can cause transition of the virus from low to higher pathogenic forms (Adams & 
Sandrock, 2010). As a result of antigenic drift, IA viruses can escape from immune control 
and cause seasonal epidemic flu on an annual basis. Due to immune selection through the flu 
season, the original ‘matched’ seasonal vaccine may no longer be able to control the virus. 
84 
 
Hence, flu vaccines must be reformulated annually to achieve the best match possible 
between the circulating virus strains and the strains that use in the vaccine generation (Chen 
& Deng, 2009; Neumann, Noda & Kawaoka, 2009).    
 
Figure 1.9 Schematic of antigenic drift. The antigenic drift process occurs when non-
synonymous mutation occurs in the genes encoding HA. These changes enable escape from 
the host immune system due to the neutralizing antibodies being able to recognize the new 
mutant form of the HA protein. 
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1.4.2.2 Antigenic Shift 
The second form of antigenic variation is antigenic shift. This is a major change in 
antigenicity of the virus associated with the introduction of novel viruses into an 
immunologically naïve population (Zambon, 1999). The segmented nature of the IA genome 
means that reassortment between two different IA viruses can occur, which is the driver of 
antigenic shift. Pandemic flu can arise when such reassortment results in the acquisition by an 
IA virus of new HA subtype (with or without NA) for which the existing human population 
has no immunity (Figure 1.10; Subbarao, Murphy & Fauci, 2006). In contrast to antigenic 
drift, antigenic shift can produce new IA virus subtypes suddenly at unpredictable and 
irregular intervals (Roose, Fiers & Saelens, 2009; Webster et al., 1992). Historically, such 
pandemic events have been shown to be rare, but are essentially guaranteed. The emerging 
pandemic IA virus can cause millions of flu related deaths (Zambon, 1999).  
Pandemic IA viruses can arise by several different mechanisms. The first mechanism 
involves direct transmission of an avian or swine IA virus with a capacity for efficient 
human-to-human transmission into the human population. It is believed that the 1918 H1N1 
‘Spanish flu’ arose through such a mechanism involving the introduction of an avian IA virus 
into an immunologically naive human population (Yuen et al., 1998). A second mechanism 
involves reassortment of co-circulating human and animal IA viruses due to simultaneous 
infection of cells followed by emergence of a novel IA virus reassortant that still possesses 
substantial human adaptation. Both the 1957 and the 1968 pandemic outbreaks arose from 
reassortment between human and avian viruses (Kasowski, Garten & Bridges, 2011; Webster 
et al., 1992). 
Sialic acid chemistry has a significant impact on IA virus transmission and thereby pandemic 
flu potential. IA viruses have different affinities for the α2,3 or α2,6 sialic acid linkage. 
Human IA viruses have greater affinity for the α2,6 linkage, which is found in the epithelial 
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cells of respiratory tissue of humans; whereas avian viruses preferentially bind through α2,3 
linkages found on the surface of avian epithelial cells (Peiris, De Jong & Guan, 2007). The 
α2,3-linkages are also present in human epithelial cells, especially in the lower respiratory 
tract, although they are much less common than the α2,6-linkages. This means that avian 
influenza virus can infect humans and cause disease. However, since they are only found in 
the lower respiratory tract, such α2,3-linkage utilizing avian viruses will transmit poorly 
through the human population (Lee & Saif, 2009; Matrosovich et al., 2004). In addition, Ito 
et al. (1998) proved that the respiratory tract of pigs contained both α 2, 3 and α 2, 6 linked 
sialic acids, indicating that pigs could be infected by both human and avian influenza virus 
strains potentially resulting in reassortant pandemics virus (Ito et al., 1998). 
Pigs have an important role in IA virus reassortment due to their ability to become infected 
with different types of IA virus (both humans and avian viruses). They can thereby serve as a 
“mixing vessel” or an intermediate host. The reason that pigs are a susceptible host for both 
human and avian influenza virus is due to the presence of both α2,3- and α2,6-linked 
receptors on epithelial cells lining the pig trachea, which allows reassortment and productive 
replication of IA viruses (Brown, 2000; Figure 1.11). Such an event is believed to have 
occurred in 2009, where a swine origin (H1N1) virus strain originated from a triple 
reassortment, containing genes originated from avian, porcine and human viruses (Michaelis, 
Doerr & Cinatl Jr, 2009). 
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Figure 1.10 Schematic diagram of antigenic shift. Human and avian IA subtypes have 
ability to co-infect the pigs respiratory tract cells facilitating segmental reassortment and 
emergence of novel viruses with pandemic potential.  
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Figure 1.11 Pigs act as a mixing vessel for IA viruses. Wild aquatic birds are the natural 
reservoir for all influenza A viruses. IA viruses are frequently infect the domestic fowl from 
the natural reservoir of wild aquatic birds, and also infect pigs through frequent transmission 
from domestic fowl. Pigs can be frequently infected from domestic fowl and human. In pigs, 
the virus reassortment can occur between humans, avian and swine influenza A viruses. 
Influenza A virus from pigs can frequently infect humans. Transmission of influenza A 
viruses can be either occasional (dotted line), or frequent (solid lines). Adapted from (Ma, 
Kahn & Richt, 2009).  
 
 
 
 
 
 
89 
 
1.4.3 IA virus pandemics 
Pandemics are defined as infectious outbreaks that affect large populations in a large 
geographic area, in a short period of time (Goldrick & Goetz, 2007). Pandemics can have a 
dramatic impact on world health and economy. The emergence of pandemic IA virus has 
been associated with the introduction and spread of an entirely new subtype with a new 
subset of genes, especially those coding for HA and NA, or re-emergence of a subtype that 
has not been in circulation for many years; in both cases the entire population is naïve and 
susceptible to infection (Roose, Fiers & Saelens, 2009). In general, the immune status and the 
exposure history of the human population will affect the severity and size of pandemics 
(Kreijtz et al., 2008). A virus bearing a novel HA or NA has the ability to cause a pandemic if 
a number of criteria are met: (i) a large proportion of population lacks immunity (naïve) to 
the emerging IA virus, (ii) the IA virus is associated with significant human disease, (iii) the 
IA virus has the capacity to spread efficiently from person-to-person (Subbarao, Murphy & 
Fauci, 2006).  
Based on phylogenetic studies of previous pandemic IA viruses, pathways to pandemic IA 
virus emergence are many and diverse. Pandemic AI viruses can emerge either by direct 
transfer from animal or avian sources to humans or following their reassortment with current 
circulating human strains. Alternatively, old pandemic strains may reappear as a new 
pandemic virus following their reintroduction years later into a now naïve human population 
(Kilbourne, 2006; Webster et al., 1992). Seven IA pandemics have been reported during the 
past 200 years (Oxford, 2000). These are summarized in Table 1.6 and then discussed 
individually in more detail below.       
 
                                    
90 
 
 Table 1.6 Pandemic outbreaks and mortality associated with IA virus. Adapted from   
(Morens, Taubenberger & Fauci, 2009; Oxford, 2000).   
  
 
 
 1.4.3.1 1918 ‘Spanish Influenza’ pandemic (H1N1) 
The largest pandemic was the H1N1 “Spanish flu” in 1918-1919. This strain caused the most 
destructive pandemic of the twentieth century, killing as many as 20 to 50 million people 
(Medina et al., 2010; Taubenberger & Morens, 2010). All eight RNA segments of the IA 
virus associated with the Spanish flu were avian in origin (Taubenberger & Morens, 2010). 
HA, NA and PB1 proteins are in particular thought to have participated to the high 
pathogenicity the virus (Pappas et al., 2008). Mortality was associated with an inversion of 
the normal ‘U’ shaped, being increased among young adults with 99% of deaths occurring in 
persons < 65 years of age (Kasowski, Garten & Bridges, 2011). This abnormal mortality 
distribution is thought to be a consequence of the cytokine storm induced by the 1918 
pandemic virus strain, which would be greater in individuals with more competent immune 
responses. Consistent with this, recombinant IA virus expressing HA of pandemic Spanish 
H1N1 strain, was shown to induce a strong, macrophage-derived cytokine inflammatory 
response and was associated with severe haemorrhaging (Kobasa et al., 2004). Secondary 
pneumonia is also believed to have played a critical role in the high mortality of pandemic 
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Spanish H1N1, as the virus encodes a PB1-F2 protein that promotes bacterial infection 
(McAuley et al., 2007). The absence of antibiotics would also have been a further obvious 
complicating factor in promoting secondary bacterial complications.  
 
1.4.3.2 1957 ‘Asian Influenza’ pandemic (H2N2)  
The 1957-1958 pandemic 
“
Asian flu
”
 originated in the Southern Chinese Provence of 
Guizhou in 1957. The virus originated by genetic reassortment between a human and avian 
IA virus (Oxford, 2000). HA (H2), NA (N2) and PB1 genes were of the avian virus origin, 
with the remaining genes coming from the circulating human H1N1 IA virus. Although the 
virus was not particularly pathogenic, the lack of any immunity in the human population to 
the HA2 and NA2 subtypes present in the emerging virus contributed to severity of the 
pandemic. The pandemic was associated with widespread illness and approximately two-
million deaths with infection rates highest in 5 to 19 year-olds (Goldrick & Goetz, 2007). 
Interestingly, a large-scale study showed 26% of elderly people (>75 years) to have pre-
existing cross-reactive antibodies to the 1957 H2N2 pandemic virus. Although this was not 
associated with any protective effect in this age population, it has been suggested to result 
from the 1890 (H2) pandemic (Kasowski, Garten & Bridges, 2011). 
 
1.4.3.3. 1968 ‘Hong Kong’ pandemic (H3N2) 
The H3N2 strain was isolated in Hong Kong in 1968. Like the previous pandemic, this strain 
was derived from a genetic reassortment between human and avian viruses (Webster, 1998). 
The pandemic Hong Kong IA virus obtained its HA (H3) and PB1 genes from an avian (duck) 
virus while NA (N2) and remaining genes came from the H2N2 circulating in the human 
population (Oxford, 2000). Although the virus spread globally and caused a significant 
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number of deaths, it was not as severe as Asian influenza pandemic (H2N2). This was 
presumably due to the presence of pre-existing N2 antibodies in the human population as a 
result of exposure to the previously circulating H2N2 (Kasowski, Garten & Bridges, 2011).  
 
1.4.3.4 1977 ‘Russian’ pandemic (H1N1) – re-emergence of a H1N1 strain  
The last IA pandemic of the 20
th
 century was a ‘Russian’ influenza and was caused by a 
H1N1 strain. Mortality was exclusively limited to persons younger than 25 years-old born 
after 1957 with 50% of cases among children of school age (Goldrick & Goetz, 2007). This 
unusual age distribution was due to pre-existing immunity in older individuals from exposure 
to H1N1 circulating before 1957. The lack of any apparent genetic drift in the ‘Russian’ 
strain led to the conclusion that this virus was a previous H1N1 strain that had been 
reintroduced into the human population by an accidental release from a laboratory freezer 
(Neumann, Noda & Kawaoka, 2009). A characteristic of pandemic IA virus infection is that 
when a new pandemic strain emerges, it tends to replace the previously circulating subtype. 
The Russian pandemic H1N1 was an exception, which superimposed itself on the pre-
existing H3N2, such that both virus subtypes have co-circulated in the human population 
causing predictable seasonal influenza outbreaks since 1977 (Kasowski, Garten & Bridges, 
2011). 
 
1.4.3.5 2009 pandemic (H1N1) 
All influenza pandemics of the 20
th
 century were associated with the emergence of influenza 
serotypes that differed from the IA virus already circulating in the human population at the 
time (Xu et al., 2010). In 2009, the new IA pandemic was triggered by a distant variety of an 
already circulating HA subtype (H1N1) (van de Sandt, Kreijtz & Rimmelzwaan, 2012).  
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This novel strain originated from swine and was generated by reassortment between (i) North 
American H3N2 and H1N2 swine viruses with (ii) Eurasian avian-like viruses. The American 
H3N2 and H1N2 swine viruses themselves were already triple reassortments between avian, 
human, and swine IA viruses. Together, this means that the 2009 H1N1 pandemic strain was 
the result of a quadruple reassortment (Girard et al., 2010; Neumann, Noda & Kawaoka, 
2009; Taubenberger & Morens, 2010).  
The 2009 pandemic H1N1 strain possesses PB2 and PA from North American virus origin, 
PB1 from human H3N2 virus origin, HA (H1), NP and NS proteins from classical swine 
virus and NA (N1) and M genes from Eurasian avian-like swine virus origin (Girard et al., 
2010; Neumann, Noda & Kawaoka, 2009; Smith et al., 2009). Recent studies have 
demonstrated that both the 1918 and the 2009 H1N1 have a high level of antigenic similarity, 
especially in the hemagglutinin (HA) protein where amino acid sequence is near identical 
between the two viruses (Krause et al., 2010). This high level of similarity is believed to be a 
result of the common pig origin of HA (H1) in both viruses, such that HA of the 2009 strain 
is a direct descendent of HA from the Spanish pandemic IA virus that has since been 
circulating in pigs. The remarkable antigenic stability of the HA is thought to be a result of 
the short life span of pigs. This provided an explanation for why older individuals had 
immunity to the H1N1 pandemic strain (see below) (Peiris, Tu & Yen, 2009). In addition, 
serological tests showed that individuals born prior to 1918, and who likely experienced the 
1918 Spanish IA pandemic, had the highest titres of serum neutralizing antibodies against the 
2009 H1N1 viruses (Krause et al., 2010). 
Young children, young adults and pregnant women were at highest risk from 2009 H1N1 
infection and disease; whereas older adults were relatively protected due to pre-existing 
immunity from previously circulating H1N1 viruses (Kasowski, Garten & Bridges, 2011). 
Clinical symptoms ranged from being largely asymptomatic or causing a mild, self-limiting 
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upper respiratory infection to more rare cases of pneumonia, multi-organ failure and death, 
especially among younger people (Girard et al., 2010; Peiris, Tu & Yen, 2009). Pulmonary 
symptoms in some patients were severe, which is believed to be associated with the ability of 
HA to bind both α2,6- and α2,3 -linked sialic acid receptors in the upper respiratory tract and 
deep in the lungs, respectively (Childs et al., 2009; Girard et al., 2010). The 2009 pandemic 
H1N1 strain continues to co-circulate with seasonal IA virus strains, and has been since 
incorporated into the seasonal vaccine (Leung & Nicoll, 2010).  
IA virus is spread mainly by virus-laden droplets produced through sneezing or coughing. 
After inhalation, the viral particle primarily targets epithelial cells lining the respiratory tract, 
which are an important first line of defence against IA virus (Samji, 2009). The host mounts a 
robust antiviral response to limit viral replication. Within a week, both innate and adaptive 
immune systems participate in containment and clearance of IA virus infection (Tamura & 
Kurata, 2004). 
 
1.4.4.1 Innate immune responses 
The first barrier of defence against IA virus infection is the innate immune system, which is 
activated within a few hours of infection (van de Sandt, Kreijtz & Rimmelzwaan, 2012). The 
first line of innate immunity against infection is a physical barrier, including the intact 
epithelial cell layer itself, as well as secreted effector molecules. Mucin (primarily MUC5AC 
and MUC5AB) is secreted from goblet cells in the respiratory epithelium where it serves to 
trap virus, which can then be expelled by broncho-pulmonary ciliary action (Pittet et al., 2010; 
Rubin, 2014). Virus that has compromised this barrier can be neutralized by soluble 
antimicrobial factors such as lysozymes, defensins and lactoferrin. In humans, replication of 
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IA virus has shown to be inhibited by alpha-defensins and neutrophils that produce cationic 
peptides (Salvatore et al., 2007).  
Pathogen-associated molecular patterns (PAMPs) of IA viruses such as viral RNA are 
recognized by pattern recognition receptors (PRRs), including: toll-like receptors (TLRs), 
retinoic acid inducible gene-1 (RIG-1) receptors, melanoma differentiation-associated gene 5 
(MDA5) and NOD-like receptors (NLR). These specific receptors recognize virus-associated 
PAMPs, whilst NLR also has the ability to recognize the activity of the virus replication 
strategy (Pang & Iwasaki, 2011). Among the 11 known TLRs known, TLR-3 and TLR-7 play 
an essential role in recognition of ds- and ss-RNA, respectively. In addition, it has been 
shown that both RIG-1 and MDA5 bind to ds-RNA virus. This recognition leads to the 
secretion of inflammatory cytokines from infected host cells such as interferon (IFN), tumor 
necrosis factor (TNF) and macrophage inflammatory protein (MIP), which is released by 
natural killer cells (NK cells) (Alexopoulou et al., 2001; Lund et al., 2004; McGill, Heusel & 
Legge, 2009). These cytokines have strong antiviral activity, limiting viral replication and 
killing virus infected cells (Achdout et al., 2003). 
Virus infection also induces chemokines that recruit immune cells such as neutrophils, NK 
cells and monocytes to aid in viral clearance from the lung (Hashimoto et al., 2007). Many 
studies have revealed the importance of NK cells for control of IA virus infection. NK cells 
have been shown to lyse IA virus-infected cells through recognition of the Fc portion of IA 
virus-specific antibodies bound to these cells through a process called antibody-dependent 
cell cytotoxicity (ADCC) (Ma et al., 2013; Sun, 2003). NK cells can also target IA virus-
infected cells for killing by binding of NK-expressed cytotoxic receptors NKp44 and NKp46 
to HA on the surface of infected cells (Arnon et al., 2001). The critical role of NK activity for 
IA virus control is shown in mice lacking the NKp46 receptor, where IA virus infection was 
associated with increased morbidity and mortality (Gazit et al., 2006). 
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The importance of the innate immune response for IA virus control is also seen by the myriad 
mechanisms by which the virus subverts these pathways. For example, both PB1 and PB2 
limit the production of IFN-β through the association with MAVS (mitochondrial antiviral 
signalling protein). NS1 can also block interferon production through inhibiting recognition 
of viral ss-RNA by the RIG-I receptor (van de Sandt, Kreijtz & Rimmelzwaan, 2012). 
Interestingly, a recent study has shown IA virus can also inhibit autophagy by interaction of 
M2 with the essential autophagy protein, microtubule-associated protein 1A/1B-light chain 
(LC3), which promotes re-localization of LC3 to the plasma membrane of virus infected cells 
(Beale et al., 2014). Autophagy has been identified as an important aspect of both the innate 
and adaptive immune response (Ma et al., 2013), and this recent study identifies a further 
means by which IA virus attempts to subvert host immunity.  
 
1.4.4.2   Adaptive immune responses to IA virus infection  
The adaptive immune response represents the second line of host defence against IA virus 
infection. Hallmarks of the adaptive immune response are antigen specificity and memory. IA 
virus infection induces both virus-specific humoral (represented by virus-specific antibodies 
produced by B lymphocytes), and cellular (represented by virus-specific T lymphocytes; 
CD4
+
 and CD8
+
) immunity (Cox, Brokstad & Ogra, 2004). Both of these arms of the 
adaptive immune response are important in host defence against IA virus infection 
(Staneková & Vareckova, 2010). 
Dendritic cells (DCs) are an important bridge between the innate and adaptive immune 
system. Following their activation at the site of IA virus infection, DCs migrate to lymph 
nodes draining the site of infection where they present viral antigens to activate naïve T 
lymphocytes (Tamura & Kurata, 2004; van de Sandt, Kreijtz & Rimmelzwaan, 2012). DCs 
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activate both CD4
+
 and CD8
+
 T cells, by supplying both antigen-specific signals through 
activation of T cells through the T cell receptor (TCR) together with the necessary co-
stimulatory signals. For activation of CD8
+
 T cells, IA virus-derived peptides must be 
presented in the context of MHC-I. DCs can acquire viral peptides for MHC-I loading either 
through the canonical pathway with peptides derived from IA virus within the cytoplasm, or 
through cross-presentation of viral peptides acquired by endocytosis of extracellular viral 
antigens (discussed in more detail below). The MHC-I: peptide complexes are then 
transported to the cell membrane where they stimulate CD8
+
 cytotoxic T cells possessing the 
appropriate virus-specific TCR (Banchereau & Steinman, 1998; Joffre et al., 2012). In the 
case of MHC-II molecules, extracellularly acquired viral proteins are degraded in endosomes 
in a fashion believed to be similar to cross-presentation, but peptides are then loaded onto 
MHC-II molecules. These MHC-II: peptide complexes are transported to the cell membrane 
to stimulate CD4
+
 T cells (Braciale, Sun & Kim, 2012). 
 
1.4.4.2.1 Antibody-mediated protection against IA infection 
Antibodies play an important role in resistance to IA infection and recovery from disease 
(Hampson & Mackenzie, 2006). Standard seasonal (epidemic) IA virus vaccines provide 
protection primarily by inducing antibodies against surface glycoproteins of homologous IA 
viruses circulating within the human population. Upon exposure to the IA virus, whether 
through vaccination or infection, specific antibodies are induced that have the ability to 
neutralize infection (Potter & Oxford, 1979). Neutralizing antibodies are primarily directed 
against the two surface proteins HA and NA, blocking the function of these molecules. This 
is the standard mechanism of action of current inactivated or subunit seasonal IA virus 
vaccines (Belshe et al., 2004).  
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Studies using recombinant vaccinia virus encoding different IA virus proteins have shown the 
prime importance of antibodies against HA and NA for protection. Antibodies against HA 
bind to the trimeric globular head of HA and provide protection by inhibiting binding of the 
virus to cellular receptors (Virelizier, 1975). These antibodies can also neutralize the virus by 
facilitating phagocytosis and ADCC (Brown & Kelso, 2009; Kreijtz, Fouchier & 
Rimmelzwaan, 2011). Antibodies against NA have been shown to inhibit release of influenza 
virus from cells restricting the spread of the virus within the respiratory tract. This 
aggregation of the virus particles leads to a decrease in the effective number of infectious 
units (Kreijtz, Fouchier & Rimmelzwaan, 2011). Antibodies against NA are therefore not 
protective, but rather limit the spread of virus by inhibiting NA enzymatic activity (Hampson 
& Mackenzie, 2006; Webster & Laver, 1967).  
Due to the high level of sequence variation between different serotypes of HA and NA, 
protection provided by antibodies is highly IA virus serotype-specific and limited to 
antigenically closely related viral strains and serotypes. As standard seasonal IA virus 
vaccines provide protection primarily by inducing antibodies against surface proteins of 
homologous IA viruses circulating within the human population, these vaccines do not create 
cross-protective (heterosubtypic) immunity (Boon et al., 2004; Brown & Kelso, 2009). This 
is the reason that IA vaccines need to be updated annually and ‘matched’ against IA viruses 
currently circulating within the human population.  
 
1.4.4.2.2 Cell-mediated protection against IA infection 
IA virus infection also induces a cellular immune response involving CD4
+
, CD8
+
 and 
regulatory T cells. The cellular immune response to IA virus infection is thought important 
for clearance of virus-infected cells and for preventing IA-associated complications (Karzon, 
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1996; (Cox, Brokstad & Ogra, 2004; Karzon, 1996). In humans, virus specific T-cell 
responses are first detected within 3 to 6 days of infection and then return approaching 
baseline levels by day 21 to 28 (Dolin, Murphy & Caplan, 1978; Ennis et al., 1981). 
Following primary infection, naïve T-cells expand and differentiated into cytotoxic effector T 
cells that are capable of eliminating virus infected cells. When the virus has been cleared 
from the body, a small residual component of cytotoxic effector CD8
+
 T cell population will 
develop into a virus-specific memory T cells pool. This memory CD8
+
 T cell are long lived 
and constantly circulate through the body primed to undergo rapid reactivation in the event of 
a secondary virus infection.  
The main task of CD4
+
 T cells (also called T ‘helper’ (Th) cells) is to orchestrate 
development of an appropriate antibody and cytotoxic CD8
+
 T cell response against the IA 
virus. CD4
+
 Th cells are divided into several subgroups including Th1 cells and Th2 cells. 
CD4
+
 T cells are activated in response to their cognate recall peptide in the context of MHC-
II. In humans, a broad range of peptides can be presented by MHC-II molecules encoded by 
three different MHC class II genes: HLA-DR, HLA-DQ and HLA-DP, with MHC-II 
molecules encoded by each of these genes binding to a distinct range of peptides. Activated 
CD4
+
 T cells perform their function, in large part, based on the cytokines that they express. 
For example, Th1 cells express IFN-γ that biases immunity towards enhancing CD8
+
 T cell 
cytotoxicity, whereas Th2 cells secrete IL-4 promoting B cell responses and production of 
IgG, IgA, and IgE antibodies.  
CD4
+
 T cells capable of cytotoxicity function have also been described. These cells express 
effector cytokines such IFN-γ, but also have an ability to destroy IA virus infected cells by a 
perforin/granzyme-mediated pathway (Brown, 2010). Another recent study by Wilkinson et 
al. (2012)  explored the importance of CD4
+
 T cells in protective immunity against IA virus 
infection in a unique human challenge study. Healthy volunteers were challenged with IA 
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virus, and IA virus-specific T cell and antibody responses were then monitored during the 
course of infection. The results showed a strong correlation between levels of pre-existing IA 
virus specific CD4
+
 T cells and reduced virus shedding and disease severity. Further 
characterization of these CD4
+
 T cells showed that they possessed cytotoxic function 
(Wilkinson et al., 2012). 
CD8
+
 T cell responses are crucial for clearance of virus from the host cells. These cells 
recognize virus peptides presented in the context of MHC-I on the surface of either 
professional APCs (during T cell priming; see above) or infected cells (prior to activation of 
effector killing mechanisms) through an antigen-specific interaction with the T cell TCR. 
During the canonical MHC-I presentation pathway, replication of viruses within cells leads to 
the degradation of virus proteins by the cellular proteasome. These virus peptides are then 
transported into the ER by transporter associated protein (TAP), where they are loaded onto 
MHC-I molecules. The MHC-I peptide binding groove contains two pockets that restrict the 
length of binding peptides to 8-12 amino acids. Following peptide binding, the MHC-
I:peptide complexes are transported to the cell surface through the Golgi network where they 
are presented to the TCR of CD8
+
 T cells (Kim et al., 2008). 
Humans have three major classes of MHC-I molecules: HLA-A, HLA-B, and HLA-C. 
Within the human population the major MHC-I classes exist as >16,000 multiple alleles, each 
binding its own distinct family of peptides. During priming, professional APCs (primarily 
DCs) present the MHC-I: peptide complex (derived by either the canonical pathway or via 
cross-priming; see above) to naïve CD8
+
 T cells, which recognise the MHC-I presented 
peptide via their unique TCR. This antigen-specific selection of naïve T cells, together with 
additional co-stimulatory signals provided by the activated APC via CD80/86 and CD28, 
results in clonal selection of the naïve CD8
+
 T cell for proliferation and differentiation. The 
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activated virus-specific ‘effector’ CD8
+
 T cells then migrate to the site of infection and target 
the infected cells expressing the cognate MHC-I: peptide complex on their cell surface.  
Virus-infected cells are killed by CTLs through two distinct pathways called the ‘intrinsic’ 
(granzyme (Gzm)/perforin-dependent) and ‘extrinsic’ (Fas: FasL-dependent) pathway; both 
pathways kill infected target cells by apoptosis. Intrinsic killing is mediated by 
permeabilization of the plasma membrane of infected cells through the action of perforin, 
which enables entry of GzmA/B to gain access to the cytoplasm inducing apoptosis (Andrade, 
2010). GzmA also has non-cytotoxic inhibitory activity through its effect on viral protein 
synthesis and induction of pro-inflammatory cytokines. Extrinsic killing can occur in the 
absence of GzmA/B, and involves a receptor: ligand interaction between Fas and FasL that 
results in induction of apoptosis in the Fas-expressing infected target cell (Regner et al., 2009; 
Topham, Tripp & Doherty, 1997; Waring & Müllbacher, 1999). CD8
+
 T cells also have the 
ability to enhance anti-viral activity through expression of different cytokines (La Gruta, 
Turner & Doherty, 2004).  
Multiple studies have shown that CD8
+
 T cells play a critical role in protective immunity 
against IA virus. In humans, data from several sources have shown decreased morbidity and 
virus replication in the lungs being associated with CTL levels (Boon et al., 2004; 
McElhaney et al., 2006), while in mice CTLs have been shown to be involved in protective 
immunity against multiple IA serotypes (Bender et al., 1992). The ability of T cell responses 
to target more conserved internal structural proteins appears important for cross-protective 
immunity (Braciale, Sun & Kim, 2012; Yewdell et al., 1985). The presence of cross-reactive 
IA virus specific CD8
+ 
T cells has been well-documented in humans (Boon et al., 2004; 
Jameson et al., 1999). Archival data from the Cleveland Family Study that captured data 
from the Asian influenza (H2N2) pandemic in 1957 as it swept through a monitored cohort of 
~ 60 families has been recently re-analysed (Epstein, 2006). Despite the absence of 
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antibodies to the newly emerging H2N2 pandemic serotype, adults who reported symptomic 
IA infection during 1950-1957 (H1N1) experienced a clinical attack rate with H2N2 IA three 
times lower than individuals with no documented prior H1N1 infection (Epstein, 2006). Since 
the H2N2 pandemic virus was a reassortant containing internal proteins from the previously 
circulating H1N1 strain, this strongly implicates immunity (presumably cell-mediated) 
against the common internal proteins of the viruses providing heterosubtypic control. A study 
by Sridhar et al. (2013) during emergence of the 2009 pandemic (H1N1) showed a similar 
effect. In this study, individuals with higher numbers of pre-existing CD8
+
 T cells against 
internal conserved CD8
+
 T cell epitopes developed less severe illness during infection with 
the emerging pandemic H1N1 virus (Sridhar et al., 2013). 
The importance of CTL responses for protection against different IA virus serotypes has also 
been shown in experimental human studies, where the presence of cross-reactive CD8
+
 CTLs  
was shown to correlate with the efficiency of recovery from IA infection in the absence of 
antibodies (McMichael et al., 1983). Similarly, Kreijtz et al. (2008) showed that IA virus-
specific CTLs that had developed in individuals in response to previous exposure to seasonal 
IA virus (H1N1 and H3N2) had significant cross-reactivity with H5N1 avian IA virus. 
Results from mouse studies corroborate these findings. Vaccination with a recombinant Ad5 
expressing NP and M2 induced heterosubtypic immunity against H1N1, H3N2, and H5N1 IA 
viruses following intranasal administration, that corresponded to the IA-specific CTLs (Price 
et al., 2010). Breadth of T cell immunity also appears to be important for broad 
heterosubtypic immunity (Gianfrani et al., 2000). Vaccination of mice with recombinant a 
vaccinia virus-based IA vaccine expressing multiple internal proteins (NP, PA, M1, PB1, and 
PB2) increased the breadth of the IA-specific T cell response and as a consequence the level 
of heterosubtypic protection against both closely and distantly related IA virus strains (Kwon 
et al., 2014). T cell responses in humans are most often directed to the epitopes of the internal 
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viral proteins NP, PA, and M1, which are conserved across IA subtypes (Chen et al., 2014; 
Grant et al., 2013; Liu et al., 2013; Wang et al., 2007). IA virus infections have been studied 
extensively in inbred strains of mice. CTLs are primarily targeted against internal virus 
proteins, and are conserved among different strains compared to surface glycoproteins 
(Townsend & Skehel, 1984). The primary T cells response to IA virus infection establishe an 
immunodominance hierarchy that becomes even more pronounced following secondary 
infection (Doherty et al., 2006). The primary IA virus-specific T cell response (using either 
H1N1 or H3N2 laboratory strains) is dominated by equivalent levels of CD8
+ 
T cells against 
NP and PA (Andreansky et al., 2005; Belz et al., 2000). During infection of C57/BL6 (H2b-
restricted) mice, the immunodominant epitope of NP has been defined as NP366-374, while in 
PA the equivalent epitope is PA 224-233 (Belz et al., 2000). In contrast, CTL levels against 
these two epitopes differ substantially during the secondary response. Following re-exposure 
to the IA virus, responses against PA224-233 are markedly diminished relative to those against 
NP366-374, with NP366-374-specific responses now accounting for 80% to 90% of all IA-
specific CD8
+
 T cells (Flynn et al., 1999).  
Together the studies above show the ability of vaccination and natural IA virus infection to 
induce virus-specific antibody and T cell responses (Boon et al., 2004; McElhaney et al., 
2006). The relative importance of these responses for control of IA virus infection will 
depend on the level of antigenic similarity of the challenging virus, with T cells being more 
important for protection against antigenically more distinct viruses (McElhaney et al., 2006). 
These studies also suggest that vaccination strategies focused on generating T cell responses 
directed towards the more conserved internal proteins of the IA virus may be an effective 
approach to generate an efficacious, broadly protective immune response against divergent 
IA virus subtypes. This strategy would be beneficial both for annual IA virus epidemics, but 
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even more importantly for pandemic IA, where the subtype and time of emergence are highly 
unpredictable but frequently devastating to human health at a global scale. 
1.5 Objectives of the thesis 
Objective 1: To test the hypothesis that targeting of essential CMV tegument proteins by 
using regulatable protein-destabilization is suitable for use as a conditional vaccine 
attenuation strategy. These studies detail construction and in vitro characterization of 
recombinant MCMVs targeting two distinct tegument proteins (pp28 and pp150) using this 
DD-based destabilization strategy. 
Objective 2: To test the hypothesis that targeting of more conserved IA virus proteins with 
CD8
+  
TEM cell-based immunity by using CMV-based vectors as a quintessential inducer of 
such ‘effector’ memory responses, will provide the desired heterotypic immunity capable of 
preventing  spread of emergent pandemic IA virus strains. This initial study determined the 
capacity of a MCMV-based vaccine expressing the epitopes from conserved IA proteins 
nucleoprotein (NP), polymerase (PA) and non-structural protein 2 (NS2) to induce immunity 
in mice as a strategy to prevent pandemic IA emergence.    
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2. Materials and methods  
2.1 Maintenance of eukaryotic cell lines 
All in vitro cell culture work was carried out under sterile conditions in a Class II biological 
safety cabinet (Holten LaminAir, UK). Cell lines were cultured at 37C using a Binder CO2 
incubator (Binder, Germany) under 95% humidity and 5% CO2. 
 
2.1.1 Murine embryonic fibroblast (MEF) cell line  
MEFs containing an inactivated p53 (MEF p53
–/–
) were used for these studies (kindly 
provided by Dr. Daniel Streblow, Oregon Health and Sciences University, OHSU, Portland, 
OR, USA). Throughout the thesis, these cells will be termed MEFs. MEF cultures were 
maintained at 37C under 5% CO2 in Dulbeccos modification of Eagles medium (DMEM; 
Gibco, Paisley, UK) supplemented with 5% (v/v) fetal bovine serum (FBS; heat-inactivated 
for 30 min at 56C), 1% (v/v) penicillin/streptomycin (100 unit/ml and 100 µg/ml) and 
glutamine (2 mM; Invitrogen, Paisley, UK).    
 
2.1.1.1 Sub-culturing of MEF cells 
MEFs were sub-cultured when monolayers reached 85-90% confluence. Prior to sub-
culturing, all reagents were brought to 37C. Culture medium was removed and the adherent 
monolayer was washed three times with 1× Dulbeccoʹs phosphate buffered saline (DPBS). 
Trypsin/EDTA (0.25% Gibco, Paisley, UK) was added to the cells, and was returned to the 
incubator until cells had detached from the surface of the flask. Detached cells were re-
suspended as a single cell suspension in fresh fully supplemented DMEM medium (Section 
2.1.1.) to neutralize trypsin. Cells were harvested by centrifugation at 1000 rpm (1500 × g) 
for 10 min at room temperature (RT), and then re-suspended in 5 ml DMEM. Cells were then 
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either transferred to a new flask using an appropriate volume for a split ratio between 1:3 or 
1:5 according to the experimental requirement or counted using a haemocytometer and 
seeded into dishes for use in experiments [Appendix 1]. 
 
2.1.1.2 Storage of MEF cells  
For long–term preservation frozen cell stocks were stored at -80C. Cells from one 175 cm
2 
flask were grown to 80% confluence, washed and trypsinized as described above. The single 
cell suspension was centrifuged at 1000 rpm (1500 × g) for 5 min at RT and the cell pellet 
was re-suspended to a density of  2 × 10
5
 – 5 × 10
6
 cells/ml in freezing medium containing 80% 
FBS and 20% (v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich, Dorset, UK). The suspension 
was aliquoted into 1.5 ml cryovials which were placed in a freezing pod; Mr. Frosty (Fisher 
Scientific, Leicestershire, UK) and subsequently stored at -80C or under LN2.  
 
2.1.1.3 Reviving frozen cell stocks 
DMSO is toxic to cells at temperatures above 4C, and its rapid removal is critical to 
maintain high cell viability. Cells (in cryovials) were rapidly thawed at 37C with gentle 
agitation. Cells were then transferred to pre-warmed fully supplemented DMEM followed by 
centrifuged at 1000 rpm (1500 × g) for 10 min at RT. Pelleted cells were re-suspended in 10 
ml fresh, pre-warmed DMEM by gentle pipetting and seeded into a 25 cm
2
 tissue culture 
flask. Cells were then incubated at 37C in a 5% CO2 as described above. 
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2.1.2 Visual monitoring of cell monolayers 
Microscopic observation and imaging of cell cultures were performed using an Olympus 
inverted microscope (MoTic AE2000, UK). 
 
2.1.3 Cell quantitation 
Cells were counted using a haemocytometer. The haemocytometer consists of nine 1 mm
2 
squares, each square representing a volume of 1x10
–4 
ml. Cells were counted in the four 
corner 1 mm
2 
squares using an inverted microscope and the total number of cells recorded 
was divided by four to give the average number of cells per 1 mm
2 
square. The concentration 
of the cells was calculated by applying the following formula:  
 
𝐶 =
𝑉
𝑁
 
𝐶: Cell concentration in cells/ml                             
𝑉: Volume counted = 1x10-4 ml.  
𝑁: Average number of cells per mm2        So:      𝐶 = 𝑁 × 10−4 cells/ml. 
Cells were then diluted to the appropriate seeding density and plated at the required density 
for use in experiments [Appendix I]. 
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2.2 Bacteriology methods 
2.2.1 Bacteria and plasmids 
BACs and plasmids were maintained in Escherichia coli (E. coli) strains. Bacteria and 
plasmids used in this study are shown in Table 2.1. EL250 and SW105 E. coli strains were 
kindly provided by Dr. Donald L. Court (Centre of Cancer Research, National Cancer 
Institute Frederick, MD, USA). The EL250 strain is based on DY380 (DH10B [λcl857 (cro-
bioA) < > araC-PBAD flpe]. EL250 cells express E/T recombinases under the control of a 
temperature-sensitive repressor (λcl857 repressor) providing the temperature regulatable 
expression. EL250s also contains a replication defective lambda prophage (Yu et al., 2000) 
coding for an arabinose-inducible FLP recombinase gene (Lee et al., 2001). The SW105 
strain is comparable to EL250, but also carries a functional gal operon except for deletion of 
galK enabling positive/negative using the GalK system (Warming et al., 2005). 
Culturing of EL250/SW105s under the permissive temperature at 32C maintains the λcl857 
repressor in an active state, resulting in repression of the E/T recombinase system. Shift to the 
permissive (de-repressive) temperature of 42C for 15 min inactivates the λcl857 repressor 
resulting in rapid induction of the E/T recombinase system, which then promotes efficient 
homologous recombination between linear ds-DNA recombination fragment introduced by 
transformation into the EL250/SW105s and the BAC DNA being targeted. The Exo gene 
encodes a 5` to 3` exonuclease that recognizes the end of the linear ds-DNA fragment 
containing the necessary region of homology to the region being targeted within the BAC 
thereby producing 3`-overhangs.  The Beta gene encodes a ss-DNA binding protein that binds 
to this 3`-overhang and promotes homologous recombination, whilst the Gam gene prevents 
degradation of the linear DNA cassette by inhibiting the E.coli RecBCD exonuclease.  
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EL250/SW105s contained the MCMV (Smith strain) BAC pSMfr3 as the genetic background 
for recombineering of MCMV recombinant vectors (kindly provided by Dr. Ulrich H. 
Koszinkowski, Max von Pettenkofer-Institute, Ludwing-Maximilians-University, Germany; 
(Messerle et al., 1997; Wagner et al., 1999). For all of these studies, the natural killer (NK) 
cell activating m157 gene of MCMV has been inactivated by deletion (pSMfr3m157), 
which is referred to as wild-type (WT) MCMV BAC throughout.   
All bacterial cultures were grown in Luria-Bertani (LB medium) or on plates containing LB 
and Bacto-Agar (Fisher Scientific, Leicestershire, UK; Appendix I). All media was 
autoclaved at 121C for 20 min, pressure 15 lbs/in
2
 and mixed with appropriate antibiotics 
(Table 2.1). LB plates were incubated overnight at 30C in a standard incubator. LB liquid 
cultures were incubated overnight at 30C in an orbital incubator at 230 rpm (VWR, West 
Sussex, UK). All bacterial strains were cultured at 30C, as growth at >32C will result in 
instability of the BAC genome due to inadvertent induction of the E/T recombination system 
(Paredes & Yu, 2012).    
 
2.2.2 Culture and long-term storage of bacteria 
A single colony was transferred from an agar plates into LB broth supplemented with 
appropriate antibiotics (Table 2.1) and cultured as above. For long-term storage of bacteria, 
overnight bacterial cultures were mixed at a 1:1 ratio with 80% (w/v) sterile glycerol (Fisher 
Scientific, Leicestershire, UK) using 800 µl of overnight culture. Glycerol stocks were then 
stored at -80C. Fresh cultures were revived from glycerol stocks on a regular basis by 
culturing of glycerol stock ‘scrapings’ in 5 to 50 ml LB with appropriate antibiotics as above. 
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2.2.3 Preparation of electrocompetent bacteria  
A single colony was transferred into 5 ml LB medium supplemented with appropriate 
antibiotics and cultured as above. The overnight culture was then added at a 1:50 dilution into 
50 ml of LB medium supplemented with antibiotics. Bacteria were then cultured at 30C with 
shaking for approximately 4 hours until reaching an optical density of 0.6 at 600 nm (OD600). 
Cells were harvested by centrifugation at 7,000 rpm for 10 min in a pre-cooled (4C) 
centrifuge. Excess LB was discarded and the pellet was washed in 250 ml of 10% (w/v) 
glycerol, followed by centrifugation at 7,000 rpm for 10 min at -4C. The supernatant was 
discarded and the washing step was repeated. Cells were pelleted and re-suspended in 
residual 10% glycerol and kept on ice until use. Electrocompetent bacteria were always 
prepared fresh immediately before use.  
 
2.2.4 Transformation of electrocompetent bacteria 
EL250/SW105 E.coli strains containing the WT MCMV BAC were used for construction of 
MCMV BAC recombinants. Electroporation of electrocompetent bacteria (see above) was 
performed using pre-cooled 0.2 cm
 
cuvettes in a Bio-Rad Gene Pulser (BIO-RAD, 
Hertfordshire, UK). Electrocompetent bacteria and recombination fragments were mixed 
gently in the cuvette by shaking followed by electroporation using pre-programmed ‘EC2’ 
conditions for E. coli in 0.2 cm
 
cuvettes. Immediately after electroporation, 800 µl of LB 
media (without antibiotics) was added to the cuvette and the entire mixture was transferred to 
a 5 ml centrifuge tube for recovery for 2 h at 30C with shaking. Following recovery, bacteria 
were plated on agar plates (supplemented with appropriate antibiotics) and incubated for 24-
48 h at 30C. Single colonies were isolated. Each colony was used to inoculate 5 ml LB broth 
(supplemented with appropriate antibiotics) and cultured overnight at 30C as above. 
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Table 2.1:  Plasmids, BACs and bacterial strains 
Plasmid/BAC                  Antibiotic            Growth Temp           Source or Reference 
                                          Selection                    (C)                                              
EL250                                      None
 
                        30                     Dr. Donald  L. Court 
                                                                                              Centre of Cancer Research, National 
                                                                                           Cancer Institute Frederick, USA 
 
pSMfr3 MCMVBAC          17 µg/ml Cam
1 
            30                   Dr U. Koszinowski 
                                                                                                     Ludwig-Maximilians-University,  
                                                                                           Germany 
                                                                                                                  (Messerle et al., 1997) 
pOri-WTFRT                        25 µg/ml Kan
2    
      30                   (Gustafsson et al., 1994) 
pOri-FRT5                               25 µg/ml Kan
2    
      30                    (Gustafsson et al., 1994) 
 pYD-C255                            25 µg/ml Kan
2
         30                     Dr. Donald  L. Court 
                                                                                              Centre of Cancer Research, National 
                                                                                           Cancer Institute Frederick, USA 
                                                                                                          (Warming et al., 2005) 
 SW105                           
 
         None                      30                      Dr. Donald  L. Court 
                                                                                                   Centre of Cancer Research, National 
                                                                                           Cancer Institute Frederick, USA 
                                                                                                          (Warming et al., 2005) 
AcGFP-DHFR-E134G           50 µg/ml Carb
3
          30                  Prof. Thomas J. Wandless 
                                                                                                            Stanford University, USA 
                                                                                                                (Cho et al., 2013) 
YFP-DHFR-Y100I                50 µg/ml Carb
3
         30                   Prof. Thomas J. Wandless 
                                                                                                           Stanford University, USA 
                                                                                                              (Iwamoto et al., 2010) 
AcGFP-DHFR-F140P            50 µg/ml Carb
3
     30                     Prof. Thomas J. Wandless 
                                                                                                          Stanford University, USA 
                                                                                                                (Not Published) 
 
 
113 
 
2.3 Molecular Biology methods 
2.3.1 Isolation and purification of nucleic acids 
2.3.1.1 Isolation of plasmid DNA (Mini preps) 
Bacteria containing plasmids of interest were grown in 5 ml LB broth supplemented with 
appropriate antibiotics as above. Overnight cultures were centrifuged (Denley BR401, 
Hamshire, UK) at 3,500 rpm (2,000 × g) for 15 min at RT and plasmid DNA was extracted 
using a plasmid Miniprep kit (Sigma-Aldrich, Dorset, UK) in accordance with 
Manufacturer
`
s instructions. Briefly, the pellet was re-suspended in 200 µl suspension buffer 
containing 100 µl/ml RNase. Bacteria were lysed by addition of 200 µl lysis buffer (200 mM 
NaOH, 1% SDS) and then mixed by gentle inversion six times. Neutralization buffer (3 M 
potassium acetate, pH 4.8) was added to neutralize the alkaline lysis reaction and to 
precipitate chromosomal DNA together with cellular debris and denatured proteins. Lysates 
were pelleted by centrifugation at 10,000 rpm (12,000 × g) for 10 min at RT and clarified 
supernatants were transferred to a DNA binding column followed by centrifugation at 10,000 
rpm for 1 min at RT. The flow through was discarded followed by two additional wash steps. 
Columns were then centrifuged for an additional 1 min to dry the membrane prior to elution 
of DNA by addition of 100 µl of Elution buffer (10 mM Tris-HCl, pH 8.5). After 1 min 
incubation at RT, plasmid DNA was eluted by centrifugation at 10,000 rpm (12,000 × g) for 
1 min at RT. The concentration of purified DNA was determined using a Nanodrop 
spectophotometer (see below). Purified plasmid DNA was analysed by restriction enzyme 
digestion and agarose gel electrophoresis as described below.    
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2.3.1.2. Isolation of BAC DNA from bacteria (BAC preps) using Alkaline Lysis 
BAC DNA was prepared from overnight bacterial cultures using the alkaline lysis method 
(Sambrook & Russell, 2001). Briefly, overnight bacterial cultures were pelleted at 3,500 rpm 
(12000 × g) for 15 min at RT to pellet bacteria. Supernatant was discarded and bacteria were 
re-suspended in 300 µl P1 buffer [50 mM Tris base, 10 mM EDTA, adjusted with HCL to pH 
8.0; containing 100 µg/ml RNAase Appendix III], followed by transfer to a 2 ml 
microcentrifuge tube (Greiner Bio-One Ltd, Stonehouse, UK). Three hundred microliters of 
P2 buffer [5 M NaOH, 10% SDS; Appendix III] was added and mixed by gentle inversion six 
times. Chromosomal DNA and protein were precipitated by addition of 300 µl P3 buffer [3 
M CH3CO2K adjusted with glacial acetic acid to pH 5.5; Appendix III], and mixing as before 
by gentle inversion. One millilitre of phenol/chloroform (CHCl3, Fisher Scientific 
Leicestershire, UK) was added and mixed by gentle rocking on a rotator for 10 min. To 
separate aqueous from organic phases the mixture was centrifuged at 14,000 rpm (12,000 × g) 
for 10 min at RT. Following centrifugation, the upper aqueous phase was transferred into a 
fresh 2 ml microcentrifuge tube. One hundred microliters of 3M sodium acetate [Appendix 
III] was added and mixed by inversion. One millilitre of isopropanol (Fisher Scientific, 
Leicestershire, UK) was then added followed by centrifugation at 14,000 rpm (12,000 × g) 
for 10 min at RT to precipitate the DNA. DNA pellets were washed to remove excess salt 
with 500 µl 75% ethanol (w/v in molecular grade water; both from Fisher Scientific, 
Leicestershire, UK), and centrifuged at 14,000 rpm (12,000 × g) for 10 min at RT. Ethanol 
was removed and pellets were air-dried at RT. DNA was gently resuspended in 50 µl of EB 
buffer (10 mM Tris-HCl, pH 8.5) to avoid shearing of BAC DNA. 
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2.3.1.3 Isolation of viral DNA from virus stocks 
Isolation of viral DNA from virus infected tissue culture cells was performed using a 
QIAampMinElute Virus Spin Kit (Qiagen, Manchester, UK), in accordance with 
Manufacturer’s instructions. Briefly, 40 µl of concentrated virus stock was brought upto a 
volume of 200 µl with DPBS. Twenty-five microliters of proteinase solution and 200 µl of 
buffer AL were added, vortexed to mix thoroughly and then incubated at 56C for 15 min. 
Two hundred and fifty microliters of 100% ethanol (Fisher Scientific, Leicestershire, UK) 
was added, mixed thoroughly by vortexing and then incubated for 5 min at RT. The mixture 
was transferred to a QIAamp MinElute column and centrifuged at 8,000 rpm (6,000 × g) for 
1 min at RT. Flow through was discarded and columns were washed with 500 µl of buffer 
AW1 followed by 500 µl volumes of buffer AW2 and then 100% ethanol. Residual ethanol 
was removed by centrifugation at 14,000 rpm (12,000 × g) for 3 min at RT, followed by 
incubation at 56C for 3 min to evaporate residual ethanol. Fifty microliters of AVE elution 
buffer (RNase-free water with 0.04% Sodium azide) was added to the column. Following 
incubation for 1 min at RT, DNA was eluted by centrifugation at 14,000 rpm (12,000 × g) for 
1 min at RT. Viral DNA was stored at 4C prior to further down-stream analysis. 
 
2.3.2 Quantitation of DNA  
Purified plasmid DNA or PCR product concentrations were determined using a NanoDrop 
ND-1000 Spectrophotometer (Labtech International Ltd, UK). Two microliters of DNA was 
required for determination of DNA concentration, which was based on OD260 readings. 
Readings at 260nm/280nm and 260nm/230nm were also evaluated to determine the quality of 
DNA. A ratio of 260nm/280nm ≥ 1.8 and 260nm/230nm ratios of between 1.8 and 2.2 indicate 
good quality DNA, free from contaminants such as salt or proteins. 
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2.3.3 Polymerase chain reaction (PCR)  
2.3.3.1 PCR primer design and preparation  
All primers were purchased from (Eurofins Genomics, Wolverhampton, UK). Primers were 
used for cloning, mutagenesis and sequencing. Primers used for amplification of recombinant 
DNA fragments for use in E/T recombination contained 60 bases homologous to the region 
flanking the site within the MCMV genome targeted for mutagenesis followed by 21 bases 
homologous to the template recombination plasmid. All primers other than those used for 
DNA sequencing were HPLC purified (Tables 2.2 to 2.6). 
 
2.3.3.2 Standard PCR 
PCR was performed towards a number of purposes. PCR was used to generate fragments for 
cloning and recombination. PCR in combination with DNA sequencing of recombinant 
MCMV BAC clones and reconstituted derivative viruses (see below) was also used to 
confirm the presence of desired mutations. Finally, PCR was used to confirm the absence of 
WT virus contamination in recombinant MCMV virus stocks. Reagents were kept on ice to 
minimize primer dimer formation and reactions were prepared as indicated [Appendix II]. 
Reagents were mixed thoroughly by pipetting and centrifuged briefly to collect the mixture at 
the bottom of the tubes. PCR controls using molecular grade water alone were always 
included. Specific thermo-cycling conditions are detailed in Appendix II. PCR products were 
separated and visualised on 1% agarose gel in 1 × TAE buffer (242 g Tris Base, 0.5 M EDTA, 
glacial acetic acid, ethidium bromide (EtBr) (0.5 µg/ml)) together with a 1 kb DNA 
molecular weight marker ladder. DNA bands were visualized and imaged under UV light 
using a gel documentation system (UVi Tech, UK). 
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Table 2.2: Primers for generating and sequencing MCMV influenza recombinants 
Primer name                                     Sequence                                                  Tm (C) 
IE2-NPF5-F        TTTCTCTTGACCAGAGACCTGGTGACCGTCAGGAAGAAGA              75 
                                TTCAGGGTGCCAGCAACGAGAACATGGAGACCATGTGA 
         AGCTTAGTACGTTAAA 
IE2-NPF5-R                                CACTTAACGGCTGACATGGG                                            75 
IE2-PAF5-F      TTTCTCTTGACCAGAGACCTGGTGACCGTCAGGAAGAAGA                 75 
                         TTCAGGTAGCAGCCTGGAGAACTTCAGGGCCTACGTGTGA 
                                                             AGCTTAGTACGTTAAA 
IE2-PAF5- R                            CACTTAACGGCTGACATGGG                                                75 
IE2-NS2F5-F        TTTCTCTTGACCAGAGACCTGGTGACCGTCAGGAAGA                      75 
                                AGATTCAGGGTAGGA CCTTCAGCTTCCAGCTGATCTG 
                                                            AAGCTTAGTACGTTAAA 
IE2-NS2F5-R                            CACTTAACGGCTGACATGGG                                               75 
IE2-NPFWT-F      TTTCTCTTGACCAGAGACCTGGTGACCGTCAGGAAGAA                  75 
                               GATTCAGGGTGCCAGCAACGAGAACATGGAGACCATG 
                                                      TGAACTTAACGGCTGACATG 
IE2-NPFWT-R      CTGTCCGATGAATAAAACCTCTTTATTTATTGATTAAAAA              75 
                                   CCATGACATACCTCGTGTCCTAGCTTAGTACGTTAAAC  
IE2-Flank-F                               ACACCGAGTACGAGGAGACC                                            61.4 
IE2-Flank-R                                CTGTCCGATGAATAAAACC                                               52.4 
BIE-Flank-F                               AGTCCCGACTACGATCCGGA                                             61.4 
BIE-Flank-R                                 CTGTCCGATGAATAAAACC                                              52.4 
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Table 2.3: Primers used for cloning and sequencing MCMV-ecDHFR recombinants 
using galK strategy 
Primer name                                     Sequence                                                     Tm (C) 
Pc255 galK-F                  GACATCTGTTGATGATAAAAAATTATATTTTTTTA                  71.3 
             GAGAGCCTGTTGACAATTAATCATCGGCA 
Pc255 galK-R                 CGGCGATCATGATCATGTTGCAACTGGGTGCGGC                    75 
                                                  GGGCTCCATTTAACCAATTCTGATTAGAA 
GalK-POS-F                   GACATCTGTTGATGATAAAAAATTATATTTTTTTAG                71.3 
               AGAGCCTGTTGACAATTAATCATCGGCA 
GalK-POS-R                  CGGCGATCATGATCATGTTGCAACTGGGTGCGGCG                  75 
                GGCTCCATTTAACCAATTCTGATTAGAA 
GalK-E134G-F               GACATCTGTTGATGATAAAAAATTATATTTTTTTAG                 73.2 
                  AGAGACCATGATCAGTCTGATTGCGGCG 
GalK-E134G-R               CGGCGATCATGATCATGTTGCAACTGGGTGCGGCG                  75 
                                          GGCTCCATCGTAGAATCGAGACCGAGGAGAGGGTT 
                                          AGGGATAGGCTTACCTCGCCGCTCCAGAATCTCAAA 
GalK-IE3 Inter-F                       CGGTTCTCATCCAAGTGACGG                                             61.8 
GalK-IE3 Inter-R                        TATATCAAAATGAGTGCACTG                                            52.0 
 
 
Table 2.4: Primers used for cloning and sequencing MCMV-ecDHFR recombinants  
Primer name                                     Sequence                                                     Tm (C) 
pOri E134G-F               GCGCCCCGGGGCCACCATGATCAGTCTGATTGCG           75 
pOri E134G-R              GCGCGAGCTCTTACGTAGAATCGAGACCGAGGAG           75 
                                     AGGGTTAGGGATAGGCTTACCTCGCCGCTCCAGAA 
                                                             TCTCAAA 
pOri Y100I-F                 GCGCCCCGGGGCCACCATGATCAGTCTGATTGCG            75 
pOri Y100I-R                  GCGCGAGCTCTTACGTAGAATCGAGACCGAGGAGAGG            75 
                                          GTTAGGGATAGGCTTACCTCGCCGCTCCAGAATCTCAAA 
pOri F140P-F                  GCGCCCCGGGGCCACCATGATCAGTCTGATTGCG                      75                                                
pOri F140P-R                  GCGCGAGCTCTTACGTAGAATCGAGACCGAGGAGAGG            75 
                            GTTAGGGATAGGCTTACCTCGCCGCTCCAGAATCTCAAA 
 
 
 
 
 
 
119 
 
Table 2.5: Primers used for generating and sequencing MCMV-IE recombinants 
Primer name                                     Sequence                                                     Tm (C) 
IE1 E134G-F        GTTGACGGATGCCTGATCGGCGATCATGATCATGTTGCAACT            75 
        GGGTGCGGCGGGCTCCATCGTAGAATCGAGACCGAGGAG 
IE1 E134G-R        GATATCTTCTGGTCTCTGTGGACATCTGTTGATGATAAAAAA            75 
                                TTATATTTTTTTAGAGAGACTTAACGGCTGACATGGGAA 
1E1 WT-F             GTTGACGGATGCCTGATCGGCGATCATGATCATGTTGCAACT            75  
                               GGGTGCGGCGGGCTCCATGGTGGCCCCGGGGATCTTGAA 
IE1 WT-R           GATATCTTCTGGTCTCTGTGGACATCTGTTGATGATAAAAA                75 
                               ATTATATTTTTTTAGAGAGACTTAACGGCTGACATGGGAA 
 
 
 
Table 2.6: Primers used for generating and sequencing MCMV-pp150 recombinants 
Primer name                                   Sequence                                                    Tm (C) 
 PP150 F140P-F      CCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCTGGTA             75 
                                  AAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCG 
 PP150 F140P-R     CTGTGATGATAATAAAAAAATAATAAAAACCAACCAGGAGC      75 
                                GAGCGATCATCGATCTTGTACTTAACGGCTGACATGGGAATTA 
 PP150 Short-F                    CCACTGCCAAACCCTCAA                                                         53.7 
 PP150 Short-R                   GGTCTGGAGGGTATAGAT                                                         51.4 
 
 
 
 
Table 2.7: Primers used for generating and sequencing MCMV-pp28 recombinants 
Primer name                                     Sequence                                                     Tm (C) 
PP28 F140P-F       ACGTCGTCTTTGAAATCCGCCAAGAACGGCGCCGGCGTGA               75 
                                AGAAAAAAGTCAGGGCCTTGATCAGTCTGATTGCGGCG 
PP28 F140P-R       TAAATCTCCTCCACTCTTTCTCCCTTTCTCCCCCCCTCACGGT           75 
                                CGATCGATAGATAGATAACTTAACGGCTGACATGGGAATTA 
PP28 Inter-F                                     TACGTTAGCCATGAGAGCTTA                                        55.9 
PP28 Inter-R                                     CCTCTAAGGTTTTAAGTTTTA                                         50.1 
PP28 Short-F                                     GACAAGAATAGCGCTATACCC                                      57.9 
PP28 Short-R                                     GAGAACATGTTGTTGTCACCA                                       55.9 
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2.3.4 Restriction enzyme analysis of BAC DNA 
Restriction enzyme analysis was used to confirm overall genomic integrity of MCMV BAC 
recombinants. BAC DNA was prepared as described above. Digestions were performed in a 
final volume of 50 µl using 41 µl of BAC DNA, 5 µl of (10 ×) Cut Smart restriction buffer 
(50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 100 µg/ml BSA, 
pH 7.9) and 4 µl of High-Fidelity (HF) restriction enzyme (EcoRI, HindIII or BamHI) 
(New England Bio lab, UK). Reactions were mixed thoroughly by vortexing, pulsed down 
and then incubated at 37C for 18 to 24 hours. Following digestion, samples were analysed 
by gel electrophoresis and resultant DNA bands were visualized under UV light as described 
above.  
 
2.3.5 Agarose gel electrophoresis  
PCR products and DNA digests (see above) were separated and visualised on 1% agarose 
(TAE) Tris acetate EDTA gels containing EtBr (0.5 µg/ml). Gels were run in horizontal tanks 
containing 1 × TAE running buffer [Appendix II]. DNA samples (5 to 40 µl) were mixed 
with 6 x loading dye (10 mM Tris-HCl, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 
60% glycerol, 6 mM EDTA) (to a final 1x concentration) before loading onto gels, and 
electrophoresis at 80 V for 50-60 min. 1kb DNA ladder [Invitrogen, UK; Appendix II] was 
included on every gel as a marker for DNA size. DNA was visualized under UV light using a 
gel documentation system (UVi Tech, Japan).  
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2.3.6. Agarose gel electrophoresis DNA purification 
When necessary, PCR products and cloning fragments generated by restriction digestion were 
purified by electrophoresis followed by excision from the gel. Briefly, DNA bands of interest 
were visualized under low intensity UV light and excised from the gel using a clean, single-
use, razor blade. A Quick Gel Extraction Kit (Invitrogen, Paisley, UK) was used to extract 
DNA from the agarose plug, in accordance with the Manufacturer’s instruction. Briefly, three 
volumes of a chaotropic solubilisation buffer (5.5M guanidine thiocyanate, 20 mM Tris-HCl, 
pH 6.6) were added to 1 volume of gel segment (based on gel fragment weight). Samples 
were then incubated using a 50C heat block until the gel slice had completely dissolved 
(approximately 10 min). After the gel slice was completely dissolved, the mixture was 
incubated for a further 5 min at 50C.  
One volume of isopropanol was then added and the mixture was transferred to a DNA 
binding column followed by centrifuged for 1 min at 8,000 rpm (6,000 × g) at RT.  The flow-
through was discarded and the column was washed with 500 µl of wash buffer (2 mM 
Tris.HCl pH 7.5, 20 ml NaCl in 80% EtOH). DNA was eluted from the column by addition 
of 50 µl of elution buffer (10 mM Tris-HCl, pH 8.5), incubation for 1 min at RT and 
centrifugation followed by collection of the eluted DNA. An aliquot of the purified sample (5 
µl) was then electrophoresed on a 1% TAE agarose gel to confirm isolation of a fragment of 
the desired size. The concentration of purified DNA was determined by Nanodrop, and 
purified DNA was stored at 4C for immediate use or at -20C for long-term storage. 
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2.3.7 Spin-column DNA purification  
PCR products and cloning fragment were also purified by using a QIA-Quick PCR 
Purification Kit (Invitrogen, Paisly, UK) in accordance with the Manufacturers instructions. 
Briefly, one volume of PCR sample was mixed with 5 volumes of HC B3 binding buffer. The 
mixture was then loaded on to a QIA-quick spin-column and centrifuged at 10,000 rpm 
(12,000 × g) for 30 s at RT. The flow-through was discarded and 650 µl of wash buffer (W1) 
buffer was added and the column was centrifuged at 10,000 rpm (12,000 × g) for 3 min at RT. 
The flow-through again was discarded, and the column was centrifuged for 1 minute. Fifty 
microliters of elution buffer (10 mM Tris-HCl, pH 8.5) was added to the column followed by 
incubation for 1 min at RT. Centrifugation at 14,000 rpm (12,000 × g) for 2 min at RT was 
used to elute the DNA, which was stored at 4C for immediate use or at -20C for long-term 
storage. 
 
2.3.8 Sequencing  
Sequencing was performed by a commercial vendor (Eurofin Genomic, UK), using primers 
listed in Tables 2.2- 2.7. Sequencing reactions were prepared in 20 µl reaction volumes, 
consisting of 10 pmol primer and 50-100 ng/µl of DNA. Sequence data obtained was 
analysed by using MacVector software (Version 15.1.5).  
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2.4 Cloning 
2.4.1 Preparation of insert and vector 
The ecDHFR domains used for destabilization of MCMV pp150 (M32) and MCMV pp28 
(M99) were prepared by PCR amplification from the following pBMN DHFR plasmids: 
AcGFP-DHFR-E134G (E134G), YFP-DHFR-Y100I (Y100I) and AcGFP-DHFR-F140P 
(F140P) using primers listed in Table 2.4. pBMN is a moloney leukemia virus (MMLV)-
based vector containing 5` and 3` LTR (retroviral long terminal repeats), which contains 
promoter, enhancer, and transcription elements. The plasmid also contains an internal 
ribosome entry site (IRES) and a fluorescent (YFP/AcGFP) gene as a florescent reporter for 
ecDHFR domains located immediately downstream of the IRES. This plasmid also contains a 
multiple cloning site (MCS) and a tandem-dimeric red flourescent protein (HcRed-t) behind 
the IRES as well as antibiotic selection marker (ampicillin resistance) [Appendix III]. The N-
terminal DHFR genes (E134G and Y100I) contain a Kozak translation initiation signal with a 
start codon while the C-terminal DHFR gene (F140P) contains a stop codon.  
PCR was performed using high-fidelity polymerase as detailed above, and PCR products 
were quantified by Nanodrop. PCR fragments were cloned into the pOri-FRT(WT) plasmid. 
This plasmid contains a kanamycin resistance marker for selection, two FRT sites, an R6K 
(suicide) origin of replication and an MCS for insertion of the PCR fragment. These plasmids 
were then used as PCR templates to generate the necessary recombinant fragments for 
targeting destabilization domain for genetic fusion to either the pp28 (M99) or pp150 (M32) 
genes in the WT MCMV BAC by using homologous recombination.  
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2.4.2 Digestion of DNA with restriction enzymes 
DNA (plasmid or PCR products) was digested with desired restriction enzymes at 37C for 2 
hr, as described above. Digests were generally performed in a final reaction volume of 50 µl 
using 40 µl of PCR product or plasmid, 4 µl of 10 × restriction buffer (50 mM Potassium 
acetate, 20 mM Tris-acetate, 10 mM Magnesium acetate, 100 µg/ml BSA, pH 7.9), 7 µl 
molecular distilled water and 4 µl of High-Fidelity (HF) restriction enzyme (New England 
Biolab, UK). The contents were mixed thoroughly and incubated at 37C for 2 h. If necessary 
the restriction enzymes were heat-inactivated according to Manufacturer’s instructions. 
Digested samples were then visualised by agarose gel electrophoresis.  
 
2.4.3 Ligation of DNA 
Purified restriction enzyme digested PCR products and pOri-FRT(WT) plasmids were ligated 
by using DNA ligase enzyme. Ligation was performed by mixing 2 µl (10 ×) ligation buffer, 
1 µl pOri- FRT(WT) plasmid (50 ng/µl), 1 µl of T4 DNA ligase (3 unit/µl; New England 
BioLab, UK) and 1µl of a PCR amplified DNA made to a final volume of 20 µl with distilled 
H2O. Ligation reactions were incubated at RT for 30 min. Reactions with no DNA insert 
served as negative controls. Ligation reactions were inactivated by incubation at 75C for 2 
min prior to either their immediate use for transformation competent bacteria or storage at 
20C. 
 
2.4.4 Transformation of E. coli with DNA plasmids 
Commercially available Pir1 competent bacteria (Invitrogen, Paisley, UK) were used for 
transformation. Pir1 bacteria encode the replication protein π that is required to enable 
replication of plasmids containing the R6Kγ (suicide) origin of replication present within the 
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pOriFRT(WT) plasmid. Four microliters of ligation reaction was added to pre-cooled 15 ml 
polypropylene tubes (Fisher Scientific, Leicestershire, UK). Non-digested pOriFRT(WT) 
plasmid was used as a positive transformation control to determine the efficiency of 
competent cells. Pir1 cells were thawed on ice and 50 µl were transferred into tubes 
containing the ligation mixture. The mixture was then gently mixed and incubated on ice for 
30 min. Cells were heat shocked at 42C for 40 s followed by 5 min recovery on ice. SOC 
medium [2.0 g Tryptane, 0.5 g yeast extract, 1M MgCl2, 1M MgSO4, 1M NaCl, 1M KCl, 20% 
Glucose; Appendix IV] was added up to 1ml and bacteria were incubated at 30C with 
shaking for 2 h. Bacteria were then plated on LB agar containing 25 µg/ml Kan (Table 2.1.) 
and incubated at 30C for 24 to 48 h. Colonies were screened by restriction enzyme analysis 
and agarose gel electrophoresis. Sequence integrity of the respective ecDHFR domains of 
selected clones were confirmed by using PCR and Sanger DNA sequencing. Glycerol stocks 
of selected recombinants were prepared and stored at -80C.  
 
2.5. Mutagenesis of MCMV BACs    
2.5.1 Mutagenesis of MCMV BACs by using E/T homologous recombination 
The large size of BACs makes standard cloning procedures unfeasible (Ruzsics & 
Koszinowski, 2008). Instead, homologous E/T (Red) recombination using small linear 
recombination fragments to target the BAC DNA for genetic manipulation are used. This 
technique, called Red E/T homologous recombination was established by Wagner and 
colleagues (Wagner & Koszinowski, 2004) and has been described in detail above (see 
Introduction). An overview of the process is shown in Figure 2.1. Recombinant PCR 
fragments being used to target the MCMV BAC genome contain short sequences of 
homology (approx. 60 bp) flanking the target site. Recombination fragments also contain an 
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antibiotic resistance marker to allow for selection of recombinants. The R6Kγ suicide origin 
of replication prevents replication of ‘carry-over’ PCR plasmid template from the PCR 
reaction used to produce the recombination fragment due to the absence of the π replication 
protein. In this study the linear PCR fragments carried the DNA sequence to be inserted 
(ecDHFR domains or IA virus epitopes), flanked by DNA sequence homologous to the 
targeted gene of MCMV (either M32 or M99) and a kanamycin resistance marker (Kan
R
) 
flanked by FRT sites for subsequent removal of Kan
R
 (Cox, 1988).  
 
2.5.1.1 Preparation of DNA recombinant fragment for recombineering 
Recombination fragments were generated by PCR using primers listed in Tables 2.2-2.7. 
Each primer contained 60 nucleotides of sequence homology flanking the targeted site of 
insertion within the MCMV BAC genome with additional sequence complementary to the 
template plasmids required for PCR amplification. PCR products were spin-column purified 
and characterized as described in above (Sections 2.3.6 to 2.3.8) prior to use for E/T 
recombination. 
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Figure 2.1 Schematic of E/T (Red) homologous recombination (‘recombineering) 
strategy used for construction of recombinant MCMV vaccine vectors. Recombinant 
fragments carrying a selectable marker (Kan
R
) flanked by FRT sites and desired mutation (M) 
(ecDHFR or IA virus epitope) are amplified by PCR. The recombination fragment also 
contains approx. 60 bp of sequence flanking the site targeted for insertion of the mutation 
within the MCMV BAC. Recombination fragments are electroporated into E.coli strains 
(either EL250 or SW105) expressing α , β , and γ  proteins of bacteriophage gamma 
required for homologous recombination. Following selection of recombinant BACs on the 
basis of kanamycin resistance, the FRT-flanked selectable marker is removed by FLP 
mediated-excision. The desired mutation and a single FRT ‘scar’ remain in the mutant 
MCMV genome. BAC, bacterial artificial chromosome (pink box); FRT, FLP-recombinase 
recognition site from Saccharomyces cerevisiae (grey box); Kan
R
; kanamycin resistance 
marker (yellow box); and M, desired mutation (red box).  
 
2.5.1.2 Recombineering of the MCMV BAC Genome 
Five millilitres LB cultures of EL250 bacteria containing the MCMV BAC were incubated 
overnight at 30C under chloramphenicol (Cam) selection (Cam, 17 µg/ml), which is 
required for maintenance of the MCMV BAC. One millilitre of the overnight culture was 
transferred to 50 ml LB broth (Cam, 17 µg/ml) and incubated at 30C for 4 h or until the 
OD600 reached 0.6.  After incubation, the recombination system was induced by incubating 
the culture at 42C for 17 min in a shaking water bath. Following temperature induction of 
the E/T recombination system, bacteria were rapidly cooled and then incubated on ice for 15 
min. Bacteria were then prepared made electrocompetent and electroporated with the 
respective recombination fragment as described above (see Section 2.2.4). Immediately after 
electroporation, bacteria were transferred into 800 µl LB medium (without any antibiotic) and 
incubated at 30C with shaking for 2 h at 30C to allow E/T recombination and recovery. 
Bacteria were then plated on LB agar plates with appropriate antibiotics (Table 2.1) and 
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incubated at 30C for two days until colonies became visible. Colonies were picked and the 
recombinant BAC DNA was isolated for further diagnostic analysis by restriction digest and 
PCR as described above. 
 
2.5.1.3 Removal of the FRT-flanked selection marker 
Following confirmation of genomic integrity of recombinant MCMV BACs by restriction 
enzyme digestion (see Section 2.3.4), FRT-flanked Kan
R
 markers were removed by arabinose 
induction of the FLP-recombinase present within the EL250 strain. Induction of FLP-
recombinase results in the removal of the entire Kan
R
 gene leaving a single FRT ‘scar’ 
(Wagner et al., 1999). One hundred microliters from an overnight starter culture was added to 
5 ml fresh LB broth (1:50 dilution) containing 17.5 µg/ml c and incubated for a 4 h or until 
the OD600 reached 0.6. One milliliter of 10% (w/v) arabinose solution (Fisher Scientific, 
Leicestershire, UK) was then added, and the culture was incubated for an additional 1 h to 
induce FLP recombinase expression. Five hundred microliters of the arabinose-induced 
culture was transferred into 4.5 ml LB (17.5 µg/ml Cam) and incubated at 30C shaking for 1 
hr. After performing a 10-fold dilution series, 50 µl of the 1x10
-4
 dilution was plated onto LB 
plates (17.5 µg/ml Cam) and incubated at 30C for two days until colonies became visible. 
Single colonies were picked and replica-plated overnight at 30C on fresh LB plates 
containing either Cam alone or Cam and Kan, to identify Kan-sensitive colonies (indicative 
of FRT-flanked Kan
R
 excision). Overnight cultures of Cam-resistant, Kan-sensitive colonies 
were prepared and BAC DNA was isolated and characterized by restriction digest analysis, 
and PCR and DNA Sanger sequencing as described above.  
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2.5.2 Mutagenesis of MCMV BAC plasmid using Galk recombination 
EL250-based E/T recombination leaves heterologous sequence as a residual FRT ‘scar’. To 
enable ‘seamless’ recombination that leaves no heterologous sequences, Warming and 
colleagues developed a two-step E/T-based strategy that uses a combination of positive 
(antibiotic-based) and negative (galK-based) markers for recombinant BAC selection 
(Warming et al., 2005). An outline of this strategy is shown in Figure 2.2. The SW105 
bacterial strain used is derived from EL250 and contains the same temperature induced E/T 
homologous recombination system. However, SW105s differ in the presence of a complete 
galactose operon with a precise deletion of the galactokinase K gene (galK), which is 
required for the galK-based negative selection.  
In the first step, a KanR/galK cassette is inserted by homologous recombination into the 
MCMV BAC genome as described above. The KanR/galK-containing recombination cassette 
is generated by PCR using pYD-C255 plasmid as the PCR template. Bacteria that have 
recombined the KanR/galK gene into the MCMV BAC are then selected for growth in the 
presence of Kan/Cam and on minimal plates that contain galactose as the only carbon source. 
A further round of purification of KanR/galK
+
 colonies is then achieved by streaking of 
single colonies on MacConkey galactose indicator plates and selection of bright red colonies. 
This colour change enables identification of KanR/galK
+
 colonies as a result of galactose 
metabolization by the galK
+
 bacteria acidifying the media and changing an indicator dye on 
the MacConkey plate to bright red. Bright red colonies are picked for the second 
recombination step.  
In the second recombination step, a PCR-derived recombination fragment containing the 
desired mutation flanked by the homologous targeting sequence is then used to replace the 
Kan/galK cassette. Bacteria are then grown on agar plates containing 2-deoxy-galactose 
(DOG) as the selection and glycerol as the carbon source. DOG is harmless in the absence of 
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galK. However, in the presence of galK, DOG serves as negative selection through its 
metabolization to a toxic intermediate (2-deoxy-galactose-1-phosphate) via phosphorylation 
by the product of the galK gene, galactokinase. Growth in the presence of DOG will therefore 
select for bacteria that have undergone recombination with the desired mutation fragment to 
replace the Kan/galK cassette. 
 
2.5.2.1 Insertion of MCMV BAC into SW105 bacterial strain 
The MCMV BAC was transformed into SW105 E. coli as described above (see Section 2.2.3 
and 2.2.4). Bacterial cultures were selected on LB agar plates containing (12.5 µg/ml Cam) 
and incubated at 30C for two days until colonies became visible. Colonies were picked and 
the recombinant BAC DNA was isolated for further diagnostic analysis by restriction digest 
as described in above. Glycerol stocks of MCMV transformed SW105 cells were then made 
for long-term permanent storage as described in Section 2.2.2. 
 
2.5.2.2 Preparation of galK cassette 
The KanR/galK cassettes were generated by PCR using 60 to 65 bp primers listed in Table 
2.3. Each primer contained 40 nucleotides of sequence homology flanking the targeted site of 
insertion within the MCMV genome. PCR was performed on pgalK-kan (pYD-C255) 
plasmid (Warming et al., 2005). PCR products were spin-column purified and characterised 
as above prior to use for recombination in SW105 bacteria containing the MCMV BAC 
genome.   
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Figure 2.2 Schematic representation of the galK recombination strategy used for 
construction of recombinant MCMV vaccine vectors.  Step 1: Recombinant fragments 
carrying the Kan
R
/galK gene flanked by 60 bp homologous sequence are produced by PCR 
and electroporated into E.coli (SW105) host harbouring MCMV BAC. Homologous E/T 
recombination is used to insert the Kan
R
/galK targeting cassette into the desired position 
targeted for mutagenesis within the MCMV BAC. Bacteria are then selected on M63 minimal 
medium containing Kan and Cam with galactose as the sole source of carbon. Step 2: After a 
round of purification on MacConkey agar plates, a second round of E/T recombination is 
used to replace the Kan
R
/galK marker with the a PCR recombination fragment containing the 
desired mutation. Bacteria then undergo negative selection by growth on minimal medium 
containing 2-deoxy-galactose (DOG) with glycerol as a sole carbon source to select for galK
–
 
bacteria that have replaced the Kan
R
/galK marker with the desired mutation. BAC, bacterial 
artificial chromosome; HOMO, homology arms; Mutate gene: desired mutation. SW105 is an 
E. coli strain; derived from EL250 containing the complete galactose operon except for 
targeted deletion of the galactokinase K gene (galK).  
 
 2.5.2.3 Electroporation of the galK cassette into electro-competent SW105 bacteria and 
positive selection 
Recombination PCR fragments were electroporated into SW105 bacteria harbouring MCMV 
BAC essentially as described for EL250s above. After recovery, bacterial cultures were 
transferred to an Eppendorf tube (Greiner Bio-One Ltd, Stonehouse, UK), pelleted at 14,000 
rpm (12,000 × g) for 30 sec at RT. Pellets were washed three times in 1 ml 1× M9 salt 
solution [Appendix IV] to remove any carbohydrate. Bacterial pellets were re-suspended in 1 
ml fresh M9 salt solution and then 10 µl, 50 µl and 100 µl were plated onto M63 minimal 
media plates [Appendix IV]. Plates were incubated at 30C for 4-5 days until colonies 
became visible. Colonies were selected based on the Kan resistant gene. Single colonies were 
picked and struck onto MacConkey plates and incubated at 30C overnight. Bright colonies 
were used for the second recombination step.  
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2.5.2.4 Electroporation of the DNA cassette into electrocompetent SW105 bacteria for 
reversion of galK followed by selection on DOG plates 
The DNA cassette containing the KanR/galK+ marker was replaced in a second round of E/T 
recombination by using a DNA recombination fragment containing the desired mutation and 
homologous sequence flanks. Electrocompetent KanR/galK+ bacteria were prepared as 
described and 1 μg of the DNA cassette (with desired mutation) was introduced by 
electroporation as before. Following electroporation, bacteria were transferred into 10 ml LB 
broth (without any supplements) and incubated with shaking for 4.5 h at 30C in a shaker for 
E/T recombination and recovery. Bacterial cultures were pelleted and washed as described in 
(Section 2.5.2.3) and then plated on DOG plates [Appendix IV]. DOG plates were incubated 
for three to five days at 30C until colonies became visible. 
 
2.6 Virology 
2.6.1 Virology Methods 
All eukaryotic tissue culture and virus work was carried out under sterile conditions in a 
biological safety cabinet Class II (Holten LaminAir, UK). Infected cells were incubated at 
37C using a Binder CO2 incubator (Binder, Germany) supplemented with 95% humidity and 
5% CO2. 
 
2.6.1.1 Reconstitution of viral progeny from recombinant MCMV BAC DNA in MEF 
cells 
Recombinant and WT viruses were reconstituted by electroporation of BAC DNA into MEF 
cells. MCMV BAC DNA was isolated and purified as described in (Section 2.3.1.2). MEFs 
were prepared, washed and trypsinized as described in (Section 2.1.1.1). MEFs were grown 
in 175 cm
2
 tissue culture flasks and were used for electroporation when monolayers were 85-
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90% confluent. Cells were counted and re-suspended at a concentration of 1x10
7
 cells/ml. 
Cells (250 µl) were used for each electroporation reaction. Five microliters of BAC DNA was 
transferred into 0.4 cm
2 
cuvettes (BIO-RAD Gene Pulser, UK) and 250 µl of the cell 
suspension was added and gently mixed immediately prior to electroporation using a Bio-Rad 
Gene Pulser (BIO RAD, Hertforshire, UK). Cells were pulsed at 0.25 KV, 950 uFD. 
Immediately following electroporation, 1 ml of DMEM medium was added to the cuvette and 
cells were transferred to a 10 cm
2
 dish containing 10 ml complete DMEM. Cells were 
incubated overnight at 37C / 5% CO2.  
One day post-transfection media was removed and cell monolayers were washed once with 3 
ml DPBS followed by being overlaid with a 1.2% seaplaque agar overlay (Lonza, Slough, 
UK) [Appendix I]. Prior to use, the 1.2% seaplaque agar was melted by microwaving and 
allowed to cool in a 37C water bath. The 1.2% seaplaque agar was mixed at a final ratio of 
1:1 with 2 × DMEM (500 ml sterile H2O, 13.38 g DMEM powder, 7.5% Sodium bicarbonate 
and 10% FBS; Life technology, Paisley, UK) and 10 ml was added to each plate. The plates 
were left at room temperature until the overlay agar solidified and were then returned to the 
37C incubator and monitored daily for plaque formation using an inverted microscope 
(Motic AE2000, UK). MCMV plaques were picked by gently stabbing a sterile 1000 µl 
pipette tip (Dutscher, Essex, UK) through the agar until the area of the plaque was reached. A 
small agar plug was then removed and transferred to a 2 ml microcentrifuge tube containing 
200 µl fresh medium and stored at -80C until required.  
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2.6.1.2 Reconstitution of viral progeny from recombinant MCMV BAC DNA in MEF 
cells in the presence of trimethoprim (TMP) 
The ecDHFR-tagged viruses (attenuated viruses) were reconstituted as described above, with 
the exception that the synthetic chemical ligand trimethoprim (TMP; Cat. No T7883, Sigma-
Aldrich, Dorset, UK) was added to the overlay to enable virus growth. After electroporation, 
cells were incubated overnight in 10 ml DMEM media supplemented with 50 or 100 µM 
TMP. The following day, the desired concentration of TMP was added to the seaplaque 
overlay. Plates were then incubated at 37C/5% CO2 as previously described, but fresh 
seaplaque overlay was added every 24 h to maintain the TMP concentration at the desired 
level. Plaque formation was monitored for up to 7 days using an inverted microscope (Motic 
AE2000, UK) and plaques were picked as described above. Seed and concentrated stocks of 
these recombinant viruses were always prepared in the presence of 50 or 100 µM TMP, 
which was replenished every 24 hours to maintain levels. 
 
2.6.1.3 Removal of the BAC cassette from reconstituted MCMV 
After reconstitution, viral progeny derived from recombinant MCMV BAC DNA still contain 
the BAC cassette. The presence of this BAC cassette has been shown to have a negative 
impact on virus replication in vivo (Wagner et al., 1999); (Section 1.2.1.2.1). To excise the 
BAC cassette from the reconstituted virus genome, MCMV virus was passaged five times on 
MEFs. Infected MEFs were incubated at 37C / 5% CO2 for 3-4 days until 100% CPE was 
observed in the culture. Cells were then harvested by scraping, centrifuged at 3800 rpm (4600 
× g) for 20 min at RT and the clarified supernatant was aliquoted and labelled as passage one 
(P1). The process was repeated until 5 passages were harvested. The passage 5 virus was then 
used as a starter virus stock from which to prepare MCMV seed stocks. 
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2.6.1.4 Preparation of virus seed stocks  
Seed stocks of MCMV were prepared in 175 cm
2
 tissue culture flask, in 20 ml volumes of 
DMEM as described in Section 2.1.1.1. The cells were infected with 120 µl of passage 5 
virus. Both cells and supernatant were harvested after 4 to 5 days when full CPE was 
observed. After centrifugation at 3,800 rpm (4,600 × g) for 20 min at RT to remove cellular 
debris, the clarified supernatant was stored at -80C in 1 ml aliquots. These aliquots were 
then used to make the concentrated viral stocks.  
 
2.6.1.5 Production of High Titre MCMV Virus Stocks 
Twelve 175 cm
2
 flasks of 80-90% confluent MEFs were infected at MOI of 0.01 in 20 ml of 
pre-warmed growth medium and incubated at 37C / 5% CO2 for 4 to 5 days until full CPE 
was observed. Cells and supernatant were harvested as described above and stored at -80C. 
Supernatant was rapidly thawed followed by centrifugation at 3,800 rpm (4,600 × g) for 20 
min at RT. The clarified supernatant (32 ml) was then added to Oakridge Nalgene-style tubes 
(Cat. No. 1053-8341, Fisher scientific, Leicestershire, UK), underlayed with a 4 ml 20% 
Sorbitol cushion [1mM MgCl2; 5mM Tris-HCl; pH7.4; Appendix I] and centrifuged at  
22,000 rpm (3,200 × g) for 80 min at RT to pellet the virus using a high speed centrifuge 
(Beckman Coulter, Fisher Scientific, UK). The supernatant was decanted and the viral pellet 
was re-suspended in 2 ml of 2% FCS in DPBS. Concentrated virus stocks were aliquoted and 
stored at - 80C. One aliquot was thawed and used to determine the titre of the stock and 
confirm sequence.  
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2.6.1.6 Titration of virus by TCID50 Limiting Dilution (median tissue culture infectious 
dose) assay  
Concentrated viral stocks were tittered on MEF cells using a TCID50 (defined as the dilution 
of virus required to infect 50% of the cells) assay. MEF cells were seeded at a density of 
1x10
5
 per well in 96 well plates in 100 μl volumes the day before the assay. Ten-fold serial 
dilutions of virus stocks were prepared and 100 μl of each dilution was added to replicate 
wells. The plate was incubated for four to five days at 37C, and wells with CPE were 
counted using a light microscope. Titres were expressed as TCID50/ml, and then plaque 
forming units per ml (PFU/cell) were calculated (Reed & Munech, 1938).  
 
2.6.1.7 Virus titration using a plaque assay 
MEF cells were seeded at a density of 1 X 10
5
 cells per well of a 24 well plate in 500 μl 
volumes and incubated overnight in a 37C incubator. 10-fold serial dilutions of samples 
were prepared in triplicate from 10 
-1
 to 10
-8
. Media was removed and 500 μl of each dilution 
was added to relevant wells. Plates were incubated overnight at 37C and the following day, 
media was removed, monolayers were washed with 1× DPBS, and overlaid with 1 ml of 
semi-solid methylcellulose [MTC; Appendix I]. MTC was used in order to prevent the spread 
of virus from infected cells to uninfected cells. On day three post-infection the monolayers 
were stained with Neutral Red [Appendix I] and returned to the incubator. Plaque 
development took 4-5 days at 37C/ 5% CO2. Five days post-infection plaques were counted 
using a light microscope and viral titres were expressed as PFU/cell, calculated using the 
following equation: 
𝑉𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑟𝑒 (𝑃𝐹𝑈/𝑚𝑙) =
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑤𝑒𝑙𝑙
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
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2.6.1.8 Virus growth curve kinetics 
To analyse the growth properties of the MCMV recombinants generated during this study, 
multi-step growth curves were performed. MEF cells were seeded at a density of 2 x10
5 
cells 
per well of 6 well plate or 4 × 10
5
 cells per T75 cm
2
 tissue culture flask. Cells were infected 
at a multiplicity of infection (MOI) of 0.01 or 0.1 plaque forming units (PFU/cell). After 2 h 
of incubation at 37C, the inoculum was removed, cells were washed twice with 1 × DPBS 
and fresh media was added. At selected times post infection, monolayers were scraped into 
supernatant, centrifuged at 14,000 rpm (12,000 × g) for 5 min at RT to pellet cells and 
clarified  supernatants were stored at -80C. Viral titres were determined by TCID50 or plaque 
assay (Section 2.6.1.6 and 2.6.1.7, respectively). 
 
2.7 Analysis of MCMV proteins 
2.7.1 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a widely used 
analytical technique for fractionation of protein samples and for estimation of molecule 
protein weight. In this study SDS-PAGE was performed using Laemmli’s discontinuous 
buffer system (Laemmli, 1970) and a BioRad mini gel apparatus (Bio-Rad, Leicestershire, 
UK). Glass plates (10 cm x 20 cm) were secured together using magnetic clips, the plate then 
transferred to the casting tray and secured in places with clamps. Glass plates were washed 
with distilled water, followed by 70% ethanol and then dried prior to use. A well-forming 
comb was inserted between the plates and the glass was marked 1 cm below the bottom of the 
comb, to mark the height of the resolving gel to be poured. The comb was removed and 
resolving gel prepared [Appendix V] and poured. To prevent atmospheric oxygen from 
interfering with gel polymerisation, 70% isopropanol was used to overlay the resolving gel. 
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The gel was left at RT for polymerisation. When polymerisation was complete, the 
isopropanol was removed and the gel interface was washed three times with distilled water. 
Filter paper (Whatman) was used to remove the excess water. A stacking gel [Appendix V] 
was then laid over the resolving gel followed by reinsertion of the comb was inserted. After 
polymerisation the magnetic clips were removed and the gel was transferred to the 
electrophoresis tank for electrophoresis. Running buffer (1×) [Appendix V] was added to the 
chamber unit. Wells were loaded with 25 µl of protein sample. Twenty-five microliters of 1× 
sample buffer [Appendix V] was added to empty wells. A protein molecular weight marker 
was always included to enable protein molecular weight determination. Electrophoresis was 
then performed at 90 V for 2 h. 
 
2.7.2 Western blotting analysis 
2.7.2.1 Transfer  
Proteins resolved by SDS-PAGE electrophoresis were transferred to PVDF membranes for 
western blot analysis by using a Criterion™ Blotter system (Bio-Rad, UK); (Towbin, 
Staehelin & Gordon, 1979). Two pieces of filter paper and foam, and one piece of PDVF 
membrane (Bio-Rad, Hertfordshire, UK) were cut to the same size as the gel (approximately 
7 cm × 8 cm). Two transfer pads were soaked in 1 × transfer buffer [Appendix V] for 10 min 
prior to use. Layers were then arranged within the transfer ‘sandwich’. The foam layer was 
placed on top of the filter paper followed by the gel. The PVDF membrane was placed 
directly on top of the gel using forceps, and then the remaining layers of filter paper were 
placed on top. Air bubbles were removed and the entire gel cassette sandwich was placed into 
the transfer gel tank containing TBST buffer [Appendix VII]. Transfer was performed at 100 
V for 1 h at 4C, with an ice pack to maintain temperature.   
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2.7.2.2 Immunodetection 
Following transfer, PVDF membranes were blocked in 25 ml of 5% non-fat milk (blocking 
buffer [2.5 g skimmed milk powder in 50 ml of 1× PBS-T or 1× TBS; Appendix VII] on an 
orbital shaker at 150 rpm for 1 h at RT or overnight at 4C. Membrane were then washed 
twice for 5 min with 1× TBST-T or 1× PBST-T [Appendix VII]. Membrane were then 
incubated with the primary antibody for 1 h, followed by washing three times with 1× TBST-
T or 1× PBST-T at RT with gentle shaking. The appropriate dilution of secondary antibody 
was added to the membrane and incubated for 1 h at RT with gentle shaking at 150 rpm. 
Secondary antibody was removed and the membrane was washed three times for 5 min with 
1× TBST-T or 1× PBST-T at RT before developing by chemiluminesence (Pierce, ECL, UK). 
 
2.7.2.3 Membrane Stripping 
PVDF membranes were stripped and re-probed up to three times. Thirty-five milliliters of 
stripping solution was added to the membrane and incubated on a shaker for 5 min. The 
membrane was then washed three times for 15 min with 1× TBST-T or 1× PBST-T at RT. 
The membrane was then ready to be probed again.  
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2.8 Animal models and vaccination 
To characterize the CD8
+
 T cell responses induced by recombinant MCMV/IA (NP, PA and 
NS2) strains, immunogenicity studies were performed in H2
b
-restricted mice. 6-8 week old 
C57BL/6 female mice were purchased from authorized vendors and allocated into four 
groups of 10 mice each (See Figure 2.3). All animal use complied with Guide for the Use and 
Care of Laboratory Animals, USDA Animal Welfare Regulations, PHS Policy on Humane 
Care and Use of Laboratory Animals and other relevant regulations. Studies were all 
performed only after obtaining necessary approval. Mice were inoculated intraperitonally 
(i.p.). Group 1 was the negative control group and received a mock inoculum. Group 2 and 
group 3 were inoculated with 3x10
5 
PFU/animal of wild type (MCMV-WT) and 1x10
5 
PFU/animal of inactivated H5N1. Group 4 was inoculated with a single dose of 1x10
5 
PFU of 
the three recombinant MCMV-IA (NP, PA, and NS2) vectors combined as a single bolus, 
giving a total of 3x10
5 
PFU/ animal (1x10
5 
PFU of each virus). At weeks 8 and 12 post-
inoculation, mice from each group were humanely euthanized to harvest splenocytes and 
additional organs (i.e. lung) for analysis of T cell responses.     
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Figure 2.3 Schematic showing MCMV/IA vaccinated mouse groups. Schematic showing 
MCMV-IA vaccinated mouse groups. C57BL/6 (H2b-restricted, 6-8 weeks old) female mice 
were immunized using a single ip dose of 1x10
5
 PFU of the indicated MCMV-IAV vector(s). 
Mice receiving the combination of the 3 MCMV IA vectors were inoculated with 1x10
5
 PFU 
of each vector as a single ip bolus for a total of 3x10
5
 PFU. Control groups received MCMV 
WT (3x10
5
 PFU), diluent (Mock) or formalin-inactivated H5N1. At weeks 8 and 12, 
splenocytes as well as other organs were harvested for analysis of T cell responses.  
 
  
2.8.1 T cell analysis by ICS 
Spleens isolated at times indicated were analysed for CD8
+ 
T cells directed against the 
MCMV-IA (NP, PA, and NS2) or MCMV-encoded M38 and M45 CTL epitopes by 
intracellular cytokine staining (ICS). Spleens were harvested into 5 ml RP-10 media on ice 
and were then homogenized on 100 micron pore-size cell strainers. Cell strainers were 
washed with an additional 5 ml RP-10, and splenocytes were centrifuged at 18,000 rpm (700 
× g) for 5 min at RT. Supernatants were discarded and pellets were resuspended in 20 ml RP-
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10 and re-centrifuged as above. Erythrocytes were removed from the samples by 
resuspension of the pellet in 2 ml 1 × RBC lysis buffer [See Appendix I for the recipe] and 
incubating for 4 min at RT. Lysis buffer was removed by washing twice with RP-10 media 
(20 ml, then 5 ml). Pellets were resuspended in 5 ml RP-10 media and cells were counted as 
described in (Section 2.1.3).       
Splenocytes at 1 × 10
6
 cells/ml were seeded into 96 well-plates and then centrifuged at 
18,000 rpm (700 × g) for 3 min at RT. Supernatants were discarded and cells were detached 
from the plate bottom by briefly vortexing the plate. One hundred microliter of RP-10 media 
was added to the cells and mixed thoroughly by pipetting. Cells were stimulated in the 
presence of brefeldin A (BFA; 10 μg/ ml) with peptides (1 μg/ ml); H2
b
-restricted epitopes IA 
virus proteins: (NP, PA, and NS2), PB or MCMV M38 or M45 (Munks et al., 2006). The 
H2
b
-restricted PB peptide was used as an AI virus-derived peptide not contained within the 
MCMV IA vaccine antigen. The well-characterised H2
b
- restricted epitopes (M38 and M45) 
from MCMV were used as an indicator of MCMV infection [Appendix X]. Cells were 
stimulated for 6 h at 37C, washed twice with 200 μl DPBS and centrifuged at 18,000 rpm 
(700 × g) for 3 min at 4C. Cells were then stained for surface markers by incubating with 
monoclonal antibodies [CD8, CD4 and CD3; Appendix X] in a total volume of 100 μl 
DPBS buffer and incubated overnight at 4C in the dark.  
After surface staining cellular markers (CD3, CD4 and CD8) cells were washed twice with 
200 μl of DPBS buffer and centrifuged at 18,000 rpm (700 × g) for 3 min at 4C.  Cells were 
then resuspended by vortexing and fixed by adding 100 μl of fixation buffer (eBioscience, 
Ireland), and incubating for 5 min at 4C. Cells were then permeabilized with 100 μl 1 × 
permeabilization buffer (eBioscience, Ireland). Cells were incubated for 3 min at 4C, 
followed by washing twice with 200 μl of 1 × permeabilization buffer and centrifugation at 
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18,000 rpm (700 × g) for 3 min at 4C. The supernatant was decanted and cells were 
resuspended by vortexing. The appropriate monoclonal antibodies (IFN-γ  and TNF-α; 
Appendix IV) were added in 100 μl /sample volumes of 1 × permeabilization buffer and then 
incubated for 1 hr at 4C. The stained cells were washed in cold 1 × permeabilization buffer 
twice, and then centrifuged at 18,000 rpm (700 × g) for 3 min at 4C and resuspended in 100 
μl of DPBS buffer for analysis by flow cytometry on a LSR II (BD Biosciences), and data 
was analysed by using FlowJo software (version 10.0.7; Tree Star, Inc.). Samples were 
performed in triplicate. Response frequencies were determined by subtracting background 
and then averaging background subtracted responses.   
 
2.9 Statistics 
Data are presented as mean +/- standard deviation. GraphPad Prism software program 
(Version 7) was used to assess statistical significances as well as to plot the graphs. Specific 
statistical test indicated in each experiment. P-values ≤ 0.05 were considered significant and 
displayed by (*) in the figures, (** =P- values ˂ 0.05, *** = P-values ˂ 0.005). In general, 
values corresponded to two experiments, each performed in triplicate.  
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Chapter Three: 
Development of a conditionally-attenuated cytomegalovirus 
(CMV) vaccine vector platform 
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3.1 Introduction 
As discussed in detail above, CMV- and other herpesvirus-based vaccines represent a 
promising vaccine vector platform, not only for humans but also for animals such as pigs that 
are involved in transmission of infectious pathogens like IA virus to humans. In this regard, 
CMV vectors are unique in the high level of immunity that they induce against their 
heterologous encoded pathogen target antigens, the long duration (even after a single dose) 
and immediate effector function associated with this immunity (Hansen et al., 2011; Hansen 
et al., 2009; Marzi et al., 2016; Redwood et al., 2007; Tierney et al., 2012; Tsuda et al., 2011; 
Tsuda et al., 2015).  Presumably due to the long period of coevolution and adaptation to their 
specific animal host, herpesviruses are largely benign in the presence of a normal healthy 
immune system. However, these viruses can cause severe and frequently fatal disease in the 
immunocompromised host (McCormick & Mocarski, 2015; Nassetta, Kimberlin & Whitley, 
2009). Environmental safety is an additional concern for any replicating genetically-modified 
organism (GMO), especially one so well adapted for spread. A considerable focus of our, as 
well as other, laboratories has therefore been the development of attenuation strategies for 
herpesvirus-based vectors.  
A number of studies indicate that herpesvirus replication may not be required for priming and 
maintenance of immune responses against herpesviruses. In these studies, completely 
replication-defective CMV (Mohr et al., 2010; Snyder et al., 2011) and HSV (Brockman & 
Knipe, 2002; Dudek & Knipe, 2006) have been shown to maintain levels of immunogenicity 
to those approaching and in many cases comparable to WT virus. Consistent with their 
inability to replicate, these replication-deficient viruses are completely non-pathogenic in 
vivo even in immune-compromised animals (Mohr et al., 2010). All of these studies have 
used permanent deletion of the gene encoding for an essential herpesvirus protein in order to 
achieve attenuation. This approach necessarily requires the production of replication-
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defective viruses on cell lines expressing the essential virus protein in trans for 
complementation of the virus replication deficiency. However, such cell lines can be difficult 
or impossible to create due to toxicity and stability issues, which are further complicated by 
kinetic requirements of gene expression due to the complexities of the herpesvirus replication 
cycle (Borst et al., 2008; Glaß et al., 2009; Mocarski et al., 1996).  
Conditional replication defective CMV based on genetic fusion of essential genes to DDs that 
can be modulated by a small binding molecule has been identified as one means to overcome 
the need for trans-complementation in CMV (Glaß et al., 2009) (see Section 1.3.2). In this 
earlier study the MCMV (IE1/3) or HCMV (UL51 and UL77) genes were targeted for 
regulation using the FKBP/shield DD system. In the present thesis two essential tegument 
proteins were selected based on a number of criteria. First, a recent study had suggested that 
T cell versus antibody bias of CMV-based vectors can be modulated by use of Early (E) 
versus Late (L) promoters to regulate the heterologous target antigen (Marzi et al., 2016). 
Therefore, any replication defective vector must be able to transit the virus replication cycle 
to the point where L gene expression can occur. This requirement necessarily limits 
attenuation to targeting of L genes. Second, tegument proteins, and pp28 and pp150 in 
particular, were targeted as they may be less structurally constrained functionally than other L 
proteins such as glycoproteins.  
Finally, selection of pp28 and pp150 was based on previous studies that had identified the 
ability of these proteins to maintain function and virus replication following their genetic 
fusion to heterologous domains. The ability of pp28 and pp150 to maintain function after 
fusion of heterologous protein domains to their carboxyl-terminus was consistent with this 
region being devoid of key functional information (AuCoin et al., 2006; Baxter & Gibson, 
2001; Seo & Britt, 2006; Silva et al., 2003). To align with their potential application to low 
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and middle-income countries (LMICs), where such conditional-replication strategies are most 
suited, an ecDHFR-based DD system was utilized that uses the inexpensive TMP stabilizing 
ligand compared to the far more costly Shield-1 molecule associated with the FKBP-based 
system. 
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3.2 Results 
As discussed in the Introduction (Section 3.1) a main hypothesis being examined in this 
thesis is whether targeting of essential tegument proteins is a suitable strategy for 
development of conditionally-replication defective MCMV vectors as a means for production 
of immunogenic, inexpensive attenuated vaccine vectors. Given the host species restriction of 
CMVs, MCMV infection in mice is an ideal small animal CMV model system in which this 
question can be explored. Although beyond the scope of this thesis (which is focused on in 
vitro studies to examine the practicality of this approach in a WT virus background before 
moving into defined pathogen challenge systems) the work performed in this present thesis 
has been used to support subsequent CMV-based vaccine studies in mouse pathogen systems 
such as Ebola virus.  
 
3.2.1 Cloning of MCMV recombinants conditionally attenuated by genetic fusion          
of ecDHFR to genes encoding pp150 or pp28 tegument proteins 
To construct the MCMV recombinants expressing destabilized essential tegument proteins, a 
number of factors need to be taken into account. DD domains differ in a number of important 
characteristics, including their dynamic range, basal expression level in the absence of the 
stabilizing TMP molecule and the requirement for their fusion to either the N or C-terminus 
of the protein being targeted for destabilization. It is also critical that fusion of the ecDHFR 
domain to the targeted protein does not affect the normal function of the essential virus 
protein when in the stabilized (TMP-bound) state. Although this can be predicted to a certain 
extent based on the effect of fusion of other domains to the proteins being targeted (when 
data is available), it can only be definitively determined by empirical analysis after 
construction of the respective recombinant viruses (Wang et al., 2016).  
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We therefore selected three ecDHFR versions for analysis in our studies for fusion to the N- 
or C-terminal regions: E134G and Y100I ecDHFR for N-terminal positioned destabilization, 
and F140P ecDHFR for destabilization through fusion to the C-terminus. Additionally, two 
N-terminal ecDHFR domains (E134G and Y100I) that differed in basal expression level and 
dynamic range were included to assess the effect of these parameters on tegument 
stabilization and virus attenuation (Table 3.1).  
Data from previous published studies clearly showed that the N-terminus of pp28 is 
absolutely essential for the virus replication. An acidic cluster (aa 44 to 57) in the N-terminus 
is required for the cytoplasmic localization of pp28 in virus infected cells and for replication 
of infectious virus (Jones & Lee, 2004; Seo & Britt, 2006). The N-terminus of pp28 was 
therefore not targeted destabilization, and ecDHFR was fused only to the C-terminus of pp28, 
which has been shown as non-essential for virus replication. A schematic of the entire 
cloning strategy is shown in Figure 3.2. 
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         Table 3.1 Characteristics of ec-DHFR DDs  
    ec-DHFR                Basal level of protein stability         Position                           
     Versions                                     -TMP     +TMP 
      E134G                                     400       5399                           N-terminus 
      Y100I                                      327       1871                           N-terminus 
      F140P                                      247       4757                           C-terminus 
       
 
 
 
 
 
Figure 3.1 Schematic showing the DD strategy. A destabilizing version of the E. coli 
dihydrofolate reductase (ecDHFR) is genetically fused to a protein of interest (POI). This 
fusion results in degradation of the entire fusion protein. Addition of the small synthetic 
ligand: TMP stabilizes the entire fusion protein, preventing degradation. Adapted from 
(Banaszynski et al., 2006; Iwamoto et al., 2010). 
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Figure 3.2 A flow-chart showing cloning ecDHFR into the pOriFRT(wt) vector. 
 
Overnight culture of pOri-FRT(wt) (vector) in LB medium with kanamycin 
Overnight culture of DD-plasmids in LB medium with Carbenicillin 
 
 Purification of both plasmids using QIAprep Spin Miniprep Kit 
 
 
pOri-FRT(wt): cutting with 
XmaI and SacI 
DD plasmid: amplify  
DD-ORF by PCR 
Digest PCR product by 
XmaI and SacI 
 
DD-ORF by PCR 
1% Agarose gel electrophoresis 
Cutting out from the gel 
DD- gene fragment: 523 bp 
pOri-FRT(wt): 1891 bp 
 
 
Purification using QIAam- 
Quick Gel Extraction Kit 
 
 
Ligation of DD gene into pOri-FRT(wt) 
Transformation of pOri-FRT(wt)-ecDHFR into 
Competent E.coli cells (Pir 1) 
 
Purification using QIAprep Spin Miniprep Kit 
kitKit 
 
 
Recombinant plasmid 
cutting with XmaI and SacI 
Amplification of the insert 
(-ecDHFR domain) by PCR 
To confirm that the cloning has been successful 
 
 
1% Agarose gel electrophoresis 
 
Sequencing to confirm successful cloning and making stocks 
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3.2.1.1 Cloning of ‘suicide’ plasmid containing ecDHFR for use as PCR template in 
construction of MCMV recombinants  
MCMV recombinant vectors were constructed using E/T linear homologous recombination, 
as described in (Sections 1.1.5.2.2). Figure 3.3 shows a flow-chart diagram of the 
construction process. The first step in E/T cloning is to generate the necessary recombination 
fragment encoding sequences of the destabilized protein together with the FRT flanked Kan
R
 
marker, which requires cloning of the individual ecDHFR variants into a ‘suicide’ vector 
called pOriFRT(wt). The pOriFRT(wt) plasmid contains a ‘suicide’ R6Kγ origin of 
replication, which prevents replication of the plasmid in bacteria other than those expressing 
the replication protein π. This prevents false-positive Kan-resistant clones due to template 
carry-over from the recombination fragment PCR, as the EL250 and SW105 cells lack the π 
protein. These ecDHFR containing plasmids are then used as templates to generate the 
necessary recombination fragments by PCR. Inclusion of homologous targeting sequences at 
the 5’ ends of the primers target the recombination cassette containing the ecDHFR for 
genetic fusion to the desired position of the pp150 or pp28 gene.  
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Figure 3.3 A flow-chart of construction of the recombinant MCMV vector vaccine. 
 
 
 
 
 
Amplification of recombinant fragments by PCR 
Linear homologous recombination using BAC technology 
Screening of recombinant clones 
Excision of kanamycin marker by FLP- mediated recombination  
Confirmation genomic integrity via PCR, restriction digestion and sequencing 
andesequencing 
Virus reconstitution from MCMV-BAC plasmid via transfection into eukaryotic cell  
Stocks preparation of recombinant MCMV  
Confirmation of insert stability by PCR and sequencing 
In vitro Growth analysis of recombinant MCMV compare to the wild-type MCMV 
I. Homologous Recombination 
II. Recombinant MCMV analysis 
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Figure 3.4 Schematic illustrating cloning of ecDHFR (E134G) domain to the 
pOriFRT(wt) vector. (A) The first step in the construction was amplification of ecDHFR-
(E134G) domain from ACGFP-DHFR-E134G plasmid by PCR, using synthetic 
oligonucleotide that contained restriction enzyme sites (XmaI and SacI) and a V5 tag. (B) In 
the second step, PCR products and pOriFRT(wt) (suicide-based vector) containing a KanR 
gene flanked by FRT sites as well as XmaI and SacI (for insertion of the E134 domain) were 
digested with XmaI and SacI followed by ligation. (C) Schematic of resulting plasmid 
pOriFRT(wt)-E134G. (D) PCR was then used to amplify recombination fragment containing 
the necessary flanking homology to pp150 for E/T based recombination within the MCMV 
genome.   
 
 
 
158 
 
159 
 
Figure 3.5 Schematic illustrating cloning of ecDHFR (Y100I) domain to the 
pOriFRT(wt) vector. (A) The first step in the construction was amplification of ecDHFR-
(Y100I) domain from YFP-DHFR-Y100I plasmid by PCR, using synthetic oligonucleotide 
that contained restriction enzyme sites (XmaI and SacI) and a V5 tag. (B) In the second step, 
PCR products and pOriFRT(wt) (suicide-based vector) containing KanR gene flanked by 
FRT sites as well as XmaI and SacI (for insertion of the Y100I domain) were digested with 
XmaI and SacI followed by ligation. (C) Schematic of resulting plasmid pOriFRT(wt)-Y100I. 
(D) PCR was used to amplify recombination fragment containing the necessary flanking 
homology to pp150 for E/T based recombination within the MCMV genome. 
   
3.2.1.1.1 Cloning of E134G and Y100I into pOriFRT(wt)--ecDHFR plasmid 
The aim was to clone the 540 bp ecDHFR gene domain into the pOriFRT(wt) vector in order 
to genetically fuse these domains to the N-terminus of the targeted pp28 and pp150 proteins. 
E134G or Y100I domains were amplified by PCR from parental plasmids (AcGFP-DHFR-
E134G and YFP-DHFR-Y100I (kindly provided by Dr. Thomas Wandless, University of 
Stanford, CA, USA) containing the ecDHFR (E134G) or ecDHFR (Y100I) domain fused 
in-frame to GFP or to the yellow fluorescent protein (YFP), respectively. PCR 
amplification was performed using synthetic pOri E134G or pOri Y100I primers (Table 2.4; 
Figures 3.4-3.5). After a GCGC anchor region, each primer contained restriction enzyme sites 
(SacI and XmaI) to enable insertion into the pOriFRT(wt) vector. PCR products were 
separated on a 1% agarose DNA gel for 1 h (Section 2.3.5) to confirm PCR amplification of 
the desired domain. The results shown in (Figure 3.6 A and B) indicate that the E134G and 
Y100I domain-fragments had been amplified, resulting in production of a single, well-
defined DNA band at the expected molecular size (540 bp; Figure 3.6 A and B lanes 2-5). 
The PCR products (Figure 3.6) were spin column purified (Section 2.3.7), digested with SacI 
and XmaI for 2 h at 37C and were then separated on a 1% agarose DNA gel, which yielded 
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a band of 1880 bp (Figure 3.7). The pOriFRT(wt) vector was also digested with SacI and 
XmaI. Single restriction digests of pOriFRT(wt) with SacI and XmaI alone were used to 
confirm digestion of the PCR products as a size shift would not be observable for the PCR 
products (Figure 3.7). Digested PCR products and vector were then gel extracted and purified 
using Quick Gel Extraction Kit (Section 2.3.6), and re-analysed on an agarose gel to ensure 
gel extraction was successful (Figure 3.7). The 1800 bp linearized vector and 540 bp PCR 
products show the presence of the desired gel-purified DNA of the correct size. The purified 
PCR product was then cloned into SacI and XmaI sites of pOriFRT(wt) plasmid. 
 
 
 
Figure 3.6 DNA gel showing PCR amplification of ecDHFR: (A) E134G domain from 
AcGFP-DHFR-E134G and (B) Y100I domain from YFP-DHFR-Y100I. PCR product were 
separated on a 1% agarose DNA gel and visualized by using EtBr (0.5 µg/ml). The single 
DNA band at 540 bp shows amplification of the desired ecDHFR E134G and Y100I domain.  
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The purified E134G or Y100I SacI/XmaI digested fragments were then ligated into the 
linearized pOriFRT(wt) vector (Figures 3.4 and 3.5), generating pOriFRT(wt)-E134G and 
pOriFRT(wt)-Y100I plasmids containing DD ecDHFR genes (E134G and Y100I), 
respectively. The ligated DNA was transformed into competent Pir 1 E.coli cells that express 
the necessary π protein for ‘suicide’ R6Kγ origin of replication complementation (as 
described in Section 2.4.4) and then plated onto agar with 25 µg/ml Kan. The following day 
20 single colonies were picked from the plates and grown overnight with 25 µg/ml Kan 
(Table 2.1). Plasmid DNA was extracted and purified using a plasmid Miniprep kit (Section 
2.3.1.1) and analysed by restriction enzyme digest and PCR to confirm presence the E134G 
or Y100I insert.  
(A)                                                                            (B) 
          
Figure 3.7 Gel electrophoresis showing SacI and XmaI digestion of PCR product and 
pOriFRT(wt) plasmid during cloning of pOriFRT(wt)-ecDHFR (E134G/Y100I). (A): the 
uncut vector (lane 1) was compared to single digested SacI (lane 2) and XmaI (lane 3) 
producing DNA fragment of approx. 1880 bp indicating digestion of the vector. Lanes 4, 5 
and 6, 7 show the restriction digestion of PCR product (E134G and Y100I) amplified from 
AcGFP-DHFR-E134G and YFP-DHFR-Y100I plasmids using SacI and XmaI digestion of 
fragments of the correct size (540 bp). (B): confirming the size bands following gel extraction 
and purification of pOriFRT(wt) vector (lane 1) and PCR amplified products: E134G lanes 2, 
3 and Y100I lanes 4, 5.  
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3.2.1.1.1.1   Restriction digestion analysis of recombinant plasmid pOriFRT(wt)-
E134G/Y100I 
To determine whether the E134G and Y100I domains had been inserted into the pOriFRT(wt) 
plasmid, plasmid DNA isolated from 25 individual Kan-resistant clones from each vector 
were analysed by SacI and XmaI restriction digestion. As shown in Figures 3.8 and 3.9, a 
subset of the clones yielded the expected 540 bp (insert) and 1880 bp (vector backbone) 
bands as expected for pOriFRT(wt)-ecDHFR(E134G) and pOriFRT(wt)-ecDHFR(Y100I). 
The results (Figures 3.8 and 3.9) show successful cloning and correct size insert in 5 colonies 
of E134G and 6 colonies of Y100I domain, respectively of total of 25 recombinant colonies 
subjected to screening. Other screened recombinant plasmids were parental pOriFRT(wt) and 
contained no inserts following restriction enzyme analysis; examples are shown in Figures 
3.8 and 3.9 lanes 2. Recombinant pOriFRT(wt)-ecDHFR(E134G) and pOriFRT(wt)-
ecDHFR(Y100I) clones are shown in lanes 3-7. In these lanes two bands were observed, the 
lower band indicated the inserted E134G/Y100I gene at the expected molecular size each 
(540 bp). While the upper band indicated the vector of the pOriFRT(wt)-E134G/Y100I 
without insert (1880 bp; Figures 3.8 and 3.9).  
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Figure 3.8 Restriction enzyme screening of pOriFRT(wt)-ecDHFR(E134G) clones. Lane 
1 shows uncut pOriFRT(wt)-control. Lane 2 shows control pOriFRT(wt) parental plasmid 
without insert, digested with SacI and XmaI. Lanes 3-7 show confirmed pOriFRT(wt)-
ecDHFR (E134G) clones following digestion with SacI and XmaI lanes (3-7). Two bands are 
observed; upper band of approximately 1880 bp indicated that the vectors are linearized and 
the lower bands indicated the insert (E134G) of approximately 540 bp.  
 
 
Figure 3.9 Restriction enzyme screening of pOriFRT(wt)-ecDHFR(Y100I) clones. Lane 
1 shows uncut pOriFRT(wt)-control. Lane 2 shows second control pOriFRT(wt) parental 
plasmid without insert, digested with SacI and XmaI. Lanes 3-6 show confirmed 
pOriFRT(wt)-ecDHFR (Y100I) clones following digestion with SacI and XmaI lanes (3-6). 
Two bands are observed; upper band of approximately 1880 bp indicated that the vectors are 
linearized and the lower bands indicated the insert (Y100I) of approximately 540 bp.  
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3.2.1.1.1.2 Sequence analysis of pOriFRT(wt)-ecDHFR(E134G) and (Y100I) 
template plasmids 
The colonies that screened positive for either the E134 or Y100I inserts by restriction digest 
(Figures 3.8-3.9) were analysed by PCR and Sanger sequencing to confirm the integrity of 
the ecDHFR domains. The E134G or Y100I domains were amplified using the same primers 
initially used to amplify the E134G/Y100I domains from the parental ecDHFR plasmids: 
AcGFP-DHFR-E134G and YFP-DHFR-Y100I. Consistent with the restriction digest analysis, 
PCR amplification produced a single band of the expected 540 bp size. Two clones (number 
1 and 3) of pOriFRT(wt)-ecDHFR(E134G) and pOriFRT(wt)-ecDHFR (Y100I) were 
selected for Sanger sequencing. The insert sequence from both clones of each plasmid 
showed 100% identity with the E134G or Y100I domains, followed by the sequence 
encoding the V5 epitope tag that had been fused in-frame during the PCR process (Figures 
3.10 and 3.11). Glycerol stocks of clones (1and 3) of the pOriFRT(wt)-ecDHFR (E134G) and 
(Y100I) plasmids were prepared and stored at -80C (Section 2.2.2). Following cloning of 
ecDHFR domain into the pOriFRT(wt) plasmid, the recombinant plasmids pOriFRT(wt)-
ecDHFR(E134G) and pOriFRT(wt)- ecDHFR(Y100I) were used to generate two versions of 
conditional replication-defective MCMV vaccine vectors destabilized by fusion of the DD to 
the N-terminus of the targeted tegument proteins. 
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CTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCGGGATAGGCTTACCTCGCCGC
TCCAGAATCTCAAAGCAATAGCTGTGAGAGTTCTGCGCATCAGCATCGTGGAATTCGCTGAA
TACCGATCCCCAGTCGTCCGGCTCGTAATCCGGGAAATGGGTGTCGCCTTCCACTTCTGCGTC
GATATGCGTCAGATACAGTTTTCGCGCTTTTGGCAAGAACTGTTCATAAACGCGACCGCCGCC
AATCACCATGATTTCTGGTACGTCACCACACGCCGCGATGGCTTCATCCACCGACTTCACCCA
CGTTACGCGATCGTCCGTACTCGGTTGACTGCTGAGGATAATATTTTTGCGTCCTGGCAACGG
ACGACCGATTGATTCCCAGGTATGGCGGCCCATAATCACGGGTTTATTTAAGGTGTTGTGTT
TAAACCAGGCGAGATCGGCAGGCAGGTTCCACGGCATGGCGTTTTCCATGCCGATAACGTGA
TCTACCGCTAACGCCGCAATCAGACTGATCATGGTGGCCCCGGGGATCTTGAAGTTCCTATTC
CGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGGGGTGGGCG
AAGAACTCCAGCATGAGATCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGATT
CCGAAGCCCAACCTTTCATAGAAGGCGGCGGTGGAATCGAAATCTCGTGATGGCAGGTTGGG
CGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAAGGCG
ATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAG 
Figure 3.10 Confirmation of ecDHFR (E13G) cloned into the pOriFRT(wt) plasmid via 
Sanger sequencing. PCR was performed on the recombinant plasmid expressing E134G 
domain. Two independent PCR products (A) clone 1 and (B) clone 2 were sequenced. Green 
sequence represents the ecDHFR (E134G) domain and black represent sequence homology to 
the pOriFRT(wt) plasmid.  
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AATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCGGGATAGGCTTACCTCGCCGCTCCA
GAATCTCAAAGCAATAGCTGTGAGAGTTCTGCGCATCAGCATCGTGGAATTCGCTGAATACC
GATTCCCAGTCATCCGGCTCGTAATCCGGGAAATGGGTGTCGCCTTCCACTTCTGCGTCGATA
TGCGTCAGATACAGTTTTTGCGCTTTTGGCAAGAACTGTTCAATAACGCGACCGCCGCCAATC
ACCATGATTTCTGGTACGTCACCACACGCCGCGATGGCTTCATCCACCGACTTCACCCACGTT
ACGCGATCGTCCGTACTCGGTTGACTGCTGAGGATAATATTTTTGCGTCCTGGCAACGGACG
ACCGATTGATTCCCAGGTATGGCGGCCCATAATCACGGGTTTATTTAAGGTGTTGCGTTTAA
ACCAGGCGAGATCGGCAGGCAGGTTCCACGGCATGGCGTTTTCCATGCCGATAACGTAATCT
ACCGCTAACGCCGCAATCAGACTGATCATGGTGGCCCCGGGGATCTTGAAGTTCCTATTCCGA
AGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGGGGTGGGCGAAG
AACTCCAGCATGAGATCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGATTCCG
AAGCCCAACCTTTCATAGAAGGCGGCGGTGGAATCGAAATCTCGTGATGGCAGGTTGGGCGT
CGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGATAG
AAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCCCA  
Figure 3.11 Confirmation of ecDHFR (Y100I) cloned into the pOriFRT(wt) plasmid via 
Sanger sequencing. PCR was performed on the recombinant plasmid expressing E134G 
domain. Two independent PCR products (A) clone 1 and (B) clone 2 were sequenced. Green 
sequence represents the ecDHFR (Y100I) domain and black represent sequence homology to 
the pOriFRT(wt) plasmid.  
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3.2.1.1.2 Cloning of F140P into pOriFRT(wt)-ecDHFR plasmid 
The F140P domain was cloned in a similar fashion to the N-terminal ecDHFR template 
constructs (Section 3.2.1.1). The ecDHFR (F140P) domain was amplified from AcGFP-
DHFR-F140P plasmid containing the ecDHFR domain fused in-frame to the yellow 
fluorescent protein (YFP) (kindly provided by Dr Thomas Wandless, University of Stanford, 
CA, USA) containing ecDHFR (F140P) domain by PCR using specific primers pOriF140P-
F/R (Table 2.4). As described in (Section 3.2.1.1), each primer contained restriction enzymes 
sites (SacI and XmaI see Figure 3.12) after a GCGC anchor region to enable insertion into the 
pOriFRT (wt) vector. PCR was performed and products were digested and separated on a 
agarose gel as described above (Section 3.2.1.1).  
The results shown in Figure 3.13 indicate that the ecDHFR (F140P)-fragment had been 
amplified, resulting in production of a single, well-defined DNA band at the expected 
molecular size (540 bp; Figure 3.13 lanes 2 and 3). As detailed in (Section 3.2.1.1.1), the 
PCR product and pOriFRT(wt) plasmid were digested with SacI and XmaI and then 
separated on a 1% agarose DNA gel. Results shown in Figure 3.14 indicate that digestion of 
pOriFRT(wt) plasmid yielded the expected 1800 bp band (lanes 2 and 3). The PCR product 
(F140P domain of approximately 540 bp) digested with the same restriction enzymes was gel 
extracted and purified using Quick Gel Extraction Kit (Section 2.3.6), followed by cloning 
into the SacI and XmaI sites of pOriFRT(wt) plasmid as described above. Single Kan-
resistant colonies were picked and characterized to confirm construction of the desired 
template plasmid (Figure 3.14) containing the ecDHFR (F140P) domain, which is designated 
as plasmid pOriFRT(wt)- ecDHFR (F140P).   
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Figure 3.12 Schematic illustrating cloning of ecDHFR (F140P) domain to the 
pOriFRT(wt) vector. (A) The first step in the construction was amplification of ecDHFR-
(Y100I) domain from ACGFP-DHFR-F140P plasmid by PCR, using synthetic 
oligonucleotide that contained restriction enzyme sites (XmaI and SacI) and V5 tag. (B) In 
the second step PCR products and pOriFRT(wt) (suicide-based vector) containing Kan
R
 gene 
flanked by FRT sites as well as XmaI and SacI (for insertion of the F140P domain) were 
digested with XmaI and SacI followed by ligation. (C) Schematic of resulting plasmid 
pOriFRT(wt)-F140P. (D) PCR was used to amplify recombination fragments containing the 
necessary flanking homology to pp150 or pp28 for E/T based recombination within the 
MCMV genome.   
 
 
Figure 3.13 DNA gel showing PCR amplification of ecDHFR (F140P) domain from 
AcGFP-DHFR-F140P. PCR products were separated on a 1% agarose DNA gel and 
visualized by using EtBr (0.5µg/ml). The single DNA band at 540 bp shows amplification of 
the desired ecDHFR (F140P) domain. 
 
 
 
170 
 
(A)                                                              (B) 
                                    
Figure 3.14  Gel electrophoresis showing SacI and XmaI digestion of PCR product and 
pOriFRT(wt) plasmid during cloning of pOriFRT(wt)-ecDHFR (F140P). (A): uncut 
vector (lane 1) was compared to single digested SacI (lane 2) and XmaI (lane 3) producing 
DNA fragment about 1880 bp indicating digestion of the vector. Lanes 4 and 5 show the 
restriction digestion of PCR product amplified from AcGFP-DHFR-F140P plasmid using 
SacI and XmaI producing fragments of the correct size (540 bp). (B) confirming the size 
bands following gel extraction and purification of pOriFRT (wt) vector (lane 1) and PCR 
amplified product (lane 2).     
 
3.2.1.1.2.1 Restriction digest analysis of recombinant pOriFRT(wt)-ecDHFR(F140P) 
plasmid   
The next step was to determine whether the ecDHFR-(F140P) domain had been correctly 
inserted within the pOriFRT(wt) plasmid by selection of recombinant clones and analysis by 
restriction enzyme digestion. As shown in Figure 3.15, a subset of clones showed the 
expected 540 bp (insert) and 1880 bp (vector backbone) bands as expected for pOriFRT(wt)-
ecDHFR(F140P). The result shows correct sized inserts in 5 of total of 25 recombinant 
colonies that were screened (Figure 3.15). Non-recombinant clones appeared to be parental 
pOriFRT(wt), which contained no inserts by restriction enzyme analysis; examples are shown 
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in Figure 3.15 lane 1. Recombinant pOriFRT(wt)-ecDHFR(F140P) clones are shown in lanes 
3-7. Two bands were observed, the lower band indicated the F140P domain insert at the 
expected molecular size (540 bp), while the upper band represented the pOriFRT(wt)-
ecDHFR(F140P) vector following excision of the insert (1880 bp) Figure 3.15. 
 
Figure 3.15 Restriction enzyme screening of pOriFRT(wt)-ecDHFR(F140P) clones. Lane 
1 shows uncut pOriFRT(wt) control. Lane 2 shows pOriFRT(wt) parental plasmid without 
insert digested with SacI and XmaI. Lanes 3-7 show confirmed pOriFRT(wt)-
ecDHFR(F140P) clones following digestion with SacI and XmaI. Two bands are observed: 
an upper band of approximately 1880 bp corresponds to linearized vector and the lower bands 
are the insert (F140P) of approximately 540 bp, lanes (3-7). 
 
3.2.1.1.2.2 Sequencing analysis of pOriFRT(wt)-ecDHFR(F140P) template plasmid 
The five plasmids that had screened positive for the 540 bp insert were PCR amplified to 
confirm presence of a insert representing the F140P domain by using the same primers used 
during initial amplification of the F140P domain from AcGFP-DHFR-F140P plasmid. 
Consistent with the restriction enzyme digestion results, PCR amplification produced a single 
band of the expected 540 bp size. Two clones (numbers 1 and 3) were selected for Sanger 
DNA sequencing. Sequence analysis showed sequence integrity of the 540 bp sequence 
F140P-V5 tag insert within the pOriFRT(wt)-ecDHFR(F140P) plasmids. The full length of 
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the insert sequence from both clone 1 and 3 showed 100% identity with the F140P from 
AcGFP-DHFR-F140P plasmid, followed by presence of sequence encoding the V5 epitope 
tag that had been fused in-frame during the PCR process (Figure 3.16). Following cloning of 
dDHFR-F140P domain into the pOriFRT (wt)-F140P plasmid, the recombinant 
pOriFRT(wt)-ecDHFR(F140P) plasmid was used to generate conditional replication-
defective MCMV vaccine vectors destabilized by fusion of the DD to the C-terminus of the 
targeted tegument proteins (see below). 
 
CATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACCCGT
GATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATTA
TCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAAGCC
ATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATGAACA
GTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAAGGCGACA
CCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGATGCTG
ATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTATCCCTA
ACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAAGTTCC
TATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGGGGTGGGCGAAGAACTCC
AGCATGAGATCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGATTCCGAAGCCC
AACCTTTCATAGAAGGCGGCGGTGGAATCGAAATCTCGTGATGGCAGGTTGGGCGTCGCTTG
GTCGGTCATTTCGAACCCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGATAGAAAGG
CGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCCCATTCG
CCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCT 
Figure 3.16 Confirmation of ecDHFR (F140P) cloned into the pOriFRT(wt) plasmid via 
Sanger sequencing. PCR was performed on the recombinant plasmid expressing E134G 
domain. Two independent PCR products (A) clone 1 and (B) clone 2 were sequenced. Green 
sequence represents the ecDHFR (F140P) domain and black represent sequence homology to 
the pOriFRT(wt) plasmid. 
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3.2.2 Construction of recombinant MCMV BAC clones carrying the ecDHFR-tagged to 
essential tegument protein M32 (pp150) or M99 (pp28) 
In the next section, the N-terminal (pOriFRT(wt)-E134G and pOriFRT(wt)-Y100I and C-
terminal pOriFRT(wt)-F140P ecDHFR template plasmids constructed above were used to 
derive the recombination PCR products required for construction of conditionally replication 
defective versions of the MCMV vector expressing either destabilized pp150 (M32) or pp28 
(M99). We targeted these essential tegument proteins of MCMV as they have been reported 
to support fusion of heterologous domains (i.e. GFP) without impacting functions necessary 
for virus replication (Sampaio et al., 2005). Based on these earlier studies as well as the 
observation that most of the critical information for function of these proteins appears to 
reside in the N-terminus (Baxter & Gibson, 2001; Chen et al., 1999;  Trus et al., 1999; Jones 
& Lee, 2004 & Seo & Britt, 2006), we hypothesized that the C-terminus DD fusion would 
have the least impact on tegument function. As BAC-based cloning removes functional 
constraints on the virus since the virus genome is maintained as a bacterial chromosome, N- 
and C-fused DD versions at the level of the BAC would be expected to be viable in terms of 
ability to E/T clone the respective BAC constructs. The lethality of the N-terminal fusions 
would only be seen during the attempt to reconstitute the viruses by transfection into the 
MCMV permissive MEFs (performed in the presence of TMP). 
We BAC cloned two N-terminal versions and one C-terminal version of both pp150 and pp28 
MCMV by fusion of ecDHFR to these tegument proteins individually. As we indicated above 
we decided to avoid ecDHFR domain fusion to the N-terminus of the pp28 protein, focusing 
on only the C-terminus, as the N-terminus has been shown essential for virus replication 
(Britt et al., 2004). Using E/T recombination, the two different versions of ecDHFR (E134G 
and Y100I) were fused in-frame to the N-terminus of pp150 (designated as MCMV-pp150-
E134G and MCMV-pp150-Y100I), respectively. Similarly ecDHFR (F140P) was fused in-
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frame to the carboxyl-terminus of pp150 and pp28 (designated MCMV-pp150-F140P and 
MCMV-pp28-F140P, respectively). We anticipated that fusion of ecDHFR domain to these 
essential tegument proteins would lead to rapid tegument protein degradation as a result of 
this genetic fusion. However, these tegument proteins should be stabilized in the presence of 
synthetic TMP ligand molecule and retain their function and activity (Figure 3.17). This 
strategy would result in replication of the MCMV vector being conditionally dependent on 
TMP, enabling production of vaccine stocks in vitro, but attenuation in vivo.  
 
 
Figure 3.17 Schematic illustration of the conditionally replication-defective MCMV 
vaccine using DD strategy. The attenuated MCMV vector was made by fusion of the 
ecDHFR domain to the essential tegument protein of MCMV. In the absence of the TMP, the 
ecDHFR directs the entire fusion protein for rapid degradation, preventing virus replication 
due to the absence of the essential protein. In the presence of TMP, the TMP molecule binds 
ecDHFR thereby stabilizing the fusion protein and enabling virus replication. The ecDHFR 
domain was epitope (V5) tagged as shown for ease of detection.  
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3.2.2.1 Construction of conditionally replication-defective MCMV-pp150-E134G/Y100I 
vector by E/T homologous recombination  
Two replication-defective vectors (MCMV-pp150) were constructed by fusion of E134G or 
Y100I in-frame to the N- terminus of pp150 (Figure 3.18). To construct the conditional 
recombinant MCMV-pp150-ecDHFR vaccines, linear DNA fragments encoding the sequence 
of the ecDHFR (E134G or Y100I) followed by the V5 tag and a Kan
R
 marker flanked on 
either end by sequence homologous to the targeted pp150 insertion site were generated by 
PCR, as described in (Section 2.3.3) using pOriFRT(wt)-ecDHFR(E134G/Y100I) templates 
(Figures 3.4 and 3.5). These recombinant PCR fragments were transformed by 
electroporation into electrocompetent recombinase-induced EL250 cells (see Section 2.2.4). 
Recombinant clones were then selected based on resistance to both Cam and Kan. The Kan
R
 
marker was then removed from selected recombinants by arabinose induction of the FLP 
recombinase system (Section 2.5.1.3).  
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Figure 3.18 Schematic illustrations of the conditionally replication-defective MCMV-
PP150-E134G/Y100I vectors using DD strategy. The attenuated MCMV vector was made 
by fusion of the ecDHFR domain to the N-terminus of pp150 protein. In the presence of TMP, 
the TMP molecule binds to ecDHFR thereby stabilizing the pp150 fusion protein and 
enabling virus replication. While in the absence of TMP, the ecDHFR directs the entire 
fusion protein for rapid degradation, preventing virus replication due to the absence of the 
essential pp150 protein. The ecDHFR domain was epitope tagged within the N-terminus of 
pp150 as shown for ease of detection.   
 
                       
3.2.2.1.1 Generation of PCR fragments with flanking viral homologies to pp150 (N-
terminus) 
The initial step in construction of the MCMV-pp150 BAC vectors was generation of linear 
PCR recombination fragments. Linear DNA fragments were amplified from pOriFRT(wt)-
ecDHFR(E134G) or pOriFRT(wt)-ecDHFR(Y100I) plasmids by PCR using 78 and 84nt 
synthetic oligonucleotides primers (pOri E134G-F/R and pOri Y100I-F/R primers; Table 2-4). 
The 5` end of each primer contained a 60 bp sequence with homology to the site of DD 
177 
 
fusion to pp150 followed by sequence required for annealing to the template plasmids (from 
which the Kan
R
 gene and ecDHFR were amplified; Section 2.3.3.1; Figures 3.19 and 3.20). 
The final recombination fragments therefore contain a Kan
R
 gene flanked by FRT sites with 
sequence of the 500 bp of ecDHFR (E134G or Y100I) domain and 60 nucleotides sequence 
homology flanking the site of insertion at the N-terminus of the pp150 gene locus of the 
MCMV BAC genome. Amplification of the PCR recombinant fragments was confirmed by 
electrophoresis on a 1% agarose DNA gels containing EtBr stain (Figures 3.19 and 3.20).  
Prior to gel extraction, purified fragments showed the expected 2 kb size (Figures 3.19 and 
3.20 C). 
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(A) 
 
(B)                                                       (C)    
 
Figure 3.19 Recombinogenic PCR fragments used for construction of the recombinant 
MCMV-pp150-E134G vaccine vector. (A): Schematic showing recombinant PCR 
generated linear fragments used for construction of recombinant MCMV-pp150-E134G 
attenuated vaccine vector. Kan
R
 flanked by FRT sites and sequences carrying the ecDHFR 
(E314G) domain with 60 bp of homologous sequences flanking at either end which is 
homologous to upstream and downstream coding sequences of the tegument protein pp150 of 
the MCMV virus were constructed by PCR, using pOriFRT(wt)- ecDHFR(E314G) plasmid 
as a template. (B): DNA gel showing recombinant PCR generated fragments containing 
E134G domain. The single DNA band at 2 kb shows amplification of the desired 
recombinogenic sequence. Two independent PCR reactions were prepared for each clone. (C) 
Gel purified PCR products confirming the extraction procedure was successful and the 
correct sized bands were purified. MW = 1kb molecular weight marker.  
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 (A)                                           
 
                                                  
(B)                                                       (C)                                                       
 
Figure 3.20 Recombinogenic PCR fragments used for construction of the recombinant 
MCMV-pp150-Y100I vaccine vector. (A): Schematic showing recombinant PCR generated 
linear fragments used for construction of recombinant MCMV-pp150-Y100I attenuated 
vaccine vector. Kan
R
 flanked by FRT sites and sequences carrying the ecDHFR (F140P) 
domain with 60 bp of homologous sequences flanking at either end which is homologous to 
upstream and downstream coding sequences of the tegument protein pp150 of the MCMV 
virus were constructed by PCR, using pOriFRT(wt)-ecDHFR(Y100I) plasmid as a template. 
(B): DNA gel showing recombinant PCR generated fragments containing Y100I domain. The 
single DNA band at 2 kb shows amplification of the desired recombinogenic sequence. Two 
independent PCR reactions were prepared for each clone. (C) Gel purification of PCR 
products confirming the extraction procedure was successful and the correct sized bands were 
purified. MW = 1kb molecular weight marker. 
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3.2.2.1.2 Construction of recombinant MCMV-pp150 based vector using E/T- based 
linear recombination strategy 
The recombination PCR products generated above were used to fuse the respective ecDHFR 
DD domain to the N-terminus of the pp150 locus of the MCMV BAC genome using red 
mediated homologous recombination (E/T recombination;Figure 3.21; Section 2.5.1) to 
generate MCMV vaccine vector. These recombinant PCR fragments were transformed by 
electroporation into electrocompetent, recombinase-induced EL250 cells as described in 
Section 2.2.4. Following recombination, bacteria were plated out onto Kan/Cam plates to 
select clones containing recombinant BACs. Colonies were counted (Table 3.2), and 4 clones 
from each recombinant were selected for further characterization. Overnight cultures were set 
up and recombinant BACs were isolated by alkaline lysis (Sambrook & Russell, 2001) as 
described in (Section 2.3.1.2).  
 
          Table 3.2 Numbers of recombinant MCMV-pp150-(E134G or Y100I)  
                                   BAC clones following E/T recombination 
MCMV Construct               PCR fragment        Number of colonies 
MCMV-pp150-E134G                      1                          100-200 
                                                           2                          150-200 
MCMV-pp150-Y100I                       1                           50-100 
                                                           2                          100-200 
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Figure 3.21 Schematic illustrating the construction of MCMV-pp150-ecDHFR 
(E134G/Y100I) vectors. The E/T- based linear recombination strategy used for construction 
of the two MCMV-pp150 vectors. Recombinant fragments carrying the Kan
R
 marker flanked 
by FRT sites and the sequence encoding the E134G/Y100I domain were amplified by PCR, 
and electroporated into E. coli expressing α, β and γ proteins of bacteriophage gamma 
recombinases. Following selection of recombinant BACs on the basis of the kan resistance, 
the Kan
R
 marker was removed using FLP mediated-recombination. The recombinant virus 
constructs were electroporated into MEFs to reconstitute recombinant MCMV-PP150-
ecDHFR virus. Frt, FLP-recombinase recognition site from the yeast Saccharomyces 
cerevisiae; Kan
R
, kan resistance gene; ecDHFR, destabilization domain protein (E134G or 
Y100I); V5 Tag was tagged to the ecDHFR proteins to facilitate detection of fused protein. 
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3.2.2.1.3 Restriction digestion of mutant BAC DNA to ensure intact genome 
During E/T based recombination, it is possible that elements of the BAC genome may be 
deleted or undergoes rearrangement. Restriction digest analysis was performed to ensure that 
all selected clones have maintained genomic integrity. A wild-type control (MCMV-WT) and 
four different recombinant MCMV-pp150-E134G/Y100I BAC clones were selected and 
digested by using restriction enzyme (EcoRI). The resulting restriction DNA digest was then 
separated on a 1% agarose DNA gel (Section 2.3.5). Banding patterns (size and number) 
generated by recombinant pp150 BACs were the compared with those of the MCMV-WT 
BAC control sample. As shown in Figure 3.22 there were no genomic rearrangement in 
recombinant MCMV-pp150-E134G (lanes 1-4) or Y100I (lanes 1-4) compared to the parental 
MCMV-WT BAC DNA.  
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Figure 3.22 Characterization of the recombinant MCMV-pp150-E134G/Y100I BAC 
genome using EcoRI restriction enzyme digestion. MCMV-WT and four independent 
clones from MCMV- pp150-E134G and MCMV-pp150-Y100I BACs were digested with 
EcoRI restriction enzyme and the resulting fragments were separated on a 1% agarose gel by 
electrophoreisis for 18-20 h at 45 V, and visualization with EtBr (0.5 μg/ml). Comparable 
restriction digestion pattern of MCMV-pp150-E134G and MCMV- pp150-E134G/Y100I 
clones with MCMV-WT BAC show the lack of any gross genomic rearrangements. 
Molecular size marker lane (MW) in kb is indicated. WT: wild type.  
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3.2.2.1.4 Kan
R
 cassette excision from recombinant MCMV-pp150-E134G/Y100I BACs 
In the next step the FRT-flanked Kan
R
 selectable marker was removed by arabinose induction 
of FLP recombinase (Section 2.5.3). In addition to removal of antibiotic resistance marker 
from the final BAC, removal of the Kan
R
 marker also prevents potential size issues with 
packaging of the genome into the viral capsid during replication in eukaryotic cells, which 
could lead to attenuation of the recombinant viruses. To confirm that Kan
R
 was removed 
from recombinant MCMV-pp150-E134G/Y100I BACs, 25 arabinose-induced colonies from 
each recombinant MCMV-pp150 BAC were screened by replica-plating on Cam/Kan versus 
Cam only plates (Section 2.5.1.3). Excision of Kan
R
 results in colonies growing only on 
plates containing Cam, with no growth on plates containing both Kan and Cam. However, 
results showed growth of bacterial colonies on both agar plates, indicating that Kan
R
 marker 
was still present within the BAC genome. Twenty-five more colonies from each recombinant 
BAC were selected to test for the excision of Kan
R
, but with the same result. A third attempt 
was made to remove the Kan
R
 by preparing new independently generated PCR fragments and 
repeating the entire homologous recombination to derive a second set of MCMV 
recombinants. However, again for both recombinant viruses, FLP recombinase induction 
using arabinose failed to remove the Kan
R
 marker (Table 3.3).   
Table 3.3 Analysis of MCMV BAC clones following excision of Kan cassette 
MCMV construct      Recombination      Clone     Selected colonies      Sensitive to Kan 
MCMV- pp150-E134G               1                         1                      25                                     Non 
                                                          1                            3                        25                                         Non 
                                                          2                            2                        25                                         Non 
                                                          2                            4                      25                                         Non 
MCMV- pp150-Y100I                1                         1                      25                                     Non 
                                                          1                            3                        25                                         Non 
                                                          2                            2                        25                                         Non 
                                                          2                            4                      25                                         Non 
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3.2.2.2 Construction of conditionally replication-defective MCMV-pp150/pp28-F140P 
vectors by Red E/T homologous recombination 
In the next section, a carboxyl targeted DD ecDHFR domain (F140P) was fused in-frame to 
the C terminus of pp150 and pp28 designated as MCMV-pp150-F140P and MCMV-pp28-
F140P, respectively (Figures 3.23 and 3.24) essentially as described above (Section 3.2.2.1).  
 
 
Figure 3.23 Schematic illustration of the conditionally replication-defective MCMV-
PP150-F140P vector using DD strategy. The attenuated MCMV vector was made by fusion 
of the ecDHFR domain to the C- terminus of pp150 protein. In the presence of TMP, the 
TMP molecule binds to ecDHFR thereby stabilizing the pp150 fusion protein and enabling 
virus replication. While in the absence of TMP, the ecDHFR directs the entire fusion protein 
for rapid degradation, preventing virus replication due to the absence of the essential pp150 
protein. The ecDHFR domain was epitope tagged within the C-terminus of pp150 as shown 
for ease of detection. 
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Figure 3.24 Schematic illustration of the conditionally replication-defective MCMV-
PP28-F140P vector using DD strategy. The attenuated MCMV vector was made by fusion 
of the ecDHFR domain to the C- terminus of pp28 protein. In the presence of TMP, the TMP 
molecule binds to ecDHFR thereby stabilizing the pp28 fusion protein and enabling virus 
replication. While in the absence of TMP, the ecDHFR directs the entire fusion protein for 
rapid degradation, preventing virus replication due to the absence of the essential pp28 
protein. The ecDHFR domain was epitope tagged within the N-terminus of pp28 as shown 
for ease of detection. 
 
 
3.2.2.2.1 Generation of PCR fragments with flanking viral homologies to pp150/pp28 
(C-terminus)  
Generation of linear recombinant fragments by PCR was the first step in the construction of 
recombinant MCMV-pp150-F140P and MCMV-pp28-F140P vectors. Linear DNA fragments 
were amplified by PCR using the pOriFRT(wt)-ecDHFR(F140P) plasmid template that was 
constructed above (Section 3.2.1.1.2) using synthetic oligonucleotides primers (pp150F140P 
F/R and pp28F140P F/R (Tables 2.6 and 2.7). The 5` end of each primer contained a 60 bp 
sequence with homology to the site of DD fusion to pp150 or pp28 followed by sequence 
required for annealing to the template plasmids (from which Kan
R
 gene and ecDHFR (F140P) 
was amplified; Section 2.3.3.1; Figures 3.25 and 3.26). The final recombination fragments 
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therefore contain a Kan
R
 gene flanked by FRT sites with sequence of the 500 bp of ecDHFR 
(F140P) domain and 60 nucleotides of homology to each end of the site of cassette insertion 
at the 3’ end of the pp150 or pp28 gene locus within the MCMV BAC genome. 
Electrophoresis of PCR products on a 1% agarose DNA gel (Figures 3.25 and 3.26 B) 
showed amplification of the desired 2 kb PCR product, which was the correct size for the 
anticipated PCR recombination fragment. An approximately 1.2 kb band was also present 
following amplification of the pp150 template. The 2 kb PCR recombination fragment was 
therefore purified by gel electrophoresis (Section 2.3.6) and gel extraction (Section 2.3.7). 
Electrophoresis confirmed isolation of only the expected 2 kb sized fragments (Figures 3.25 
and 3.26 C). 
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(A)                                           
 
    (B)                                                      (C)    
  
Figure 3.25 PCR recombination fragments used for construction of the recombinant 
MCMV-pp150-F140P vaccine vector. (A): Schematic showing PCR recombination 
fragments used for construction of recombinant MCMV-pp150-F140P attenuated vaccine 
vector. PCR using pOriFRT(wt)-ecDHFR(F140P) plasmid as a template was used to 
construct recombination fragments comprised of Kan
R
 flanked by FRT sites and sequences 
carrying the ecDHFR (F140P) domain with 60 bp of homologous sequences flanking at either 
end homologous to upstream and downstream coding sequences of the carboxyl terminus of 
pp150 (B): DNA gel showing recombinant PCR generated fragments containing F140P 
domain. The DNA band at 2 kb shows amplification of the desired recombinogenic sequence 
fragments. Two independent PCR reactions were prepared for each clone. (C) Gel 
purification of PCR products confirming purification of the correct sized bands. MW = 1kb 
molecular weight marker. 
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(A) 
 
(B)                                                           (C) 
                
Figure 3.26 PCR recombination fragments used for construction of the recombinant 
MCMV-pp28-F140 vaccine vector. (A): Schematic showing PCR recombination fragments 
used for construction of recombinant MCMV-pp28-F140P attenuated vaccine vector. PCR 
using pOriFRT(wt)-ecDHFR(F140P) plasmid as a template was used to construct 
recombination fragments comprised of Kan
R
 flanked by FRT sites and sequences carrying the 
ecDHFR (F140P) domain and 60 bp of homologous sequences flanking at either end 
homologous to the upstream and downstream site of insertion at the carboxyl terminus of 
pp28 (B): DNA gel showing recombinant PCR generated fragments containing F140P 
domain. The DNA band at 2 kb shows amplification of the desired recombinant fragments. 
Two independent PCR reactions were prepared for each clone. (C) Gel purification of PCR 
products confirming purification of the correct sized bands. MW = 1kb molecular weight 
marker. 
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3.2.2.2.2 Construction of recombinant MCMV-pp150/pp28 based vectors using E/T 
based linear recombination strategy 
The recombination PCR products generated above were used to fuse the ecDHFR(F140P)  
domain to the C-terminus of the pp150/pp28 locus within the MCMV BAC genome using 
E/T recombination (Figure 2.1; Section 2.5.1). Following recombination, bacteria were plated 
on Kan/Cam plates to select clones containing recombinant BACs. Bacterial colony number 
was quantified (Table 3.2), and 4 clones from each recombinant were selected for further 
characterization. Overnight cultures were set up and the recombinant BACs were isolated by 
alkaline lysis (Sambrook & Russell, 2001) as described in (Section 2.3.1.2). 
 
3.2.2.2.3 Restriction digestion of mutant BAC DNA to ensure intact genome 
To assess genome structure following recombination, restriction enzyme digest analysis of 
recombinant BACs was performed and compared to MCMV-WT. Eight independent 
recombinant MCMV-pp150-F140P and MCMV-pp28-F140P BAC clones were selected for 
analysis. The resulting DNA bands were then separated on a 1% agarose DNA gel (Section 
2.3.5). As shown in Figures 3.28 and 3.29, the banding patterns generated by digestion of 
recombinant pp150 and pp28 BACs were comparable with those of the digested MCMV-WT 
BAC control sample indicating absence of gross genomic rearrangement within recombinant 
MCMV-pp150 or pp28/F140P BACs. 
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Figure 3.27 Schematic illustrating the construction of MCMV-pp150/pp28-ecDHFR 
(F140P) vectors. The E/T- based linear recombination strategy used for construction of the 
two MCMV-pp150/pp28 vectors. Recombinant fragments carrying the Kan
R
 marker flanked 
by FRT sites and the sequence encoding the F140P domain was amplified by PCR, and 
electroporated into E. coli expressing α, β and γ proteins of bacteriophage gamma 
recombinases. Following selection of recombinant BACs on the basis of the kan resistance, 
the Kan
R
 marker was removed using FLP mediated-recombination. The recombinant virus 
constructs were electroporated into MEFs to reconstitute recombinant MCMV-PP150/pp28-
F140P virus. Frt, FLP-recombinase recognition site from the yeast Saccharomyces cerevisiae; 
Kan
R
, kan resistance gene; ecDHFR, destabilization domain protein (F140P); V5 Tag was 
tagged to the ecDHFR proteins to facilitate detection of fused protein. 
      
 
                   Table 3.4 Number of recombinant MCMV-pp150/pp28-F140P BAC clones  
                                   following E/T recombination. 
MCMV Constructs                  PCR fragment         Number of colonies 
MCMV-pp150-F140P                        PCR1                     100 -150 
                                                           PCR2                     150-200  
MCMV-pp28-F140P                          PCR1                      50-100 
                                                           PCR2                     100 -150 
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Figure 3.28 Characterization of recombinant MCMV-pp150-F140P BACs by using 
EcoRI restriction enzyme digestion. MCMV-WT and eight independent clones from 
MCMV-pp150-F140P BACs were digested with EcoRI restriction enzyme and the resulting 
fragments were separated on a 1% agarose gel by electrophoresis for 18-20 h at 45 V, 
followed by visualization with EtBr (0.5 μg/ml). Comparable restriction digestion pattern 
between MCMV-pp150-F140P recombinants and MCMV-WT BAC showed the absence of 
any gross genomic rearrangements. Molecular size marker lane (MW) in kb is indicated. 
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Figure 3.29 Characterization of recombinant MCMV-pp28-F140P BACs, by using 
EcoRI restriction enzyme digestion. MCMV-WT and eight independent clones from 
MCMV-pp28-F140P BACs were digested with EcoRI restriction enzyme and the resulting 
fragments were separated on a 1% agarose gel by electrophoresis for 18-20 h at 45 V, 
followed by visualization with EtBr (0.5 μg/ml). Comparable restriction digestion pattern 
between MCMV-pp28-F140P recombinant and MCMV-WT BAC showed the absence of any 
gross genomic rearrangements. Molecular size marker lane (MW) in kb is indicated. 
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3.2.2.2.4 Kan
R
 cassette excision from recombinant MCMV-pp150/pp28-F140P BACs 
In the next step, the FRT-flanked Kan
R
 selectable marker was removed from selected 
recombinant MCMV-pp150-F140P and MCMV-pp28-F140P BACs by arabinose induction 
of FLP recombinase as described previously (Section 3.2.2.1.4). Twenty-five arabinose-
induced colonies from each recombinant BAC were screened by replica-plating on Cam and 
Kan versus Cam only plates. Results show the FLPed clones were no longer able grow in the 
presence of Kan, but retained the ability to grow in the presence of Cam indicating that the 
Kan
R
 gene had indeed been removed as the bacterial colonies become sensitive to Kan. In 
contrast to the repeated inability to remove the Kan
R
 marker from the MCMV-pp150-
E134G/Y100I BACs (see above), these results confirmed excision of the KanR cassette 
from both recombinant MCMV-pp150-F140P and MCMV-pp28-F140P BACs (Table 3.5).  
To confirm the excision of the Kan
R
 cassette from BAC genomes, PCR analyses were 
performed using a pair of pp150 and pp28-specific primer (Tables 2.6 and 2.7). These 
primers were designed to flank the site of ecDHFR insertion within the respective 
recombinant MCMV genome. Primers were located at an adequate distance from the site of 
ecDHFR insertion to enable high quality DNA sequence reads over the ecDHFR insertion 
site. This was generally about 150 to 200 bps from the site of ecDHFR insertion (Tables 2.6 
and 2.7). PCR was performed on recombinant BAC DNA (pre- and post- FLP) (Figures 3.30 
and 3.31). The size of the amplified PCR products indicated excision of the Kan
R
 cassette, 
with pre-FLP BAC clones yielding PCR products of approximately 2 kb followed by a 
reduction in size by 1 kb after FLP-mediated removal of the Kan
R
 cassette (Figures 3.30 and 
3.31).  
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        Table 3.5 Analysis of recombinant MCMV BAC clones following excision of Kan
R
 
MCMV Construct    Recombination   Clone    Selected colonies    Sensitivity to Kan 
MCMV-pp150-F140P                 1               3                   25                                All 
                                                     2               6                   25                                All 
MCMV-pp28-F140P                   1                1                   25                                All 
                                                     2                5                   25                                All 
 
 
 
Figure 3.30 Confirmation of KanR marker removal from MCMV-pp150-F140P BAC 
genome by PCR. DNA from 4 clones of recombinant MCMV-pp150-F140P BACs (pre and 
post FLP) were screened by PCR using primers flanking the site of recombination. PCR 
products were separated on a 1% agarose gel for 60-90 min at 75 V, and visualized by 
staining with EtBr (0.5 μg/ml). PCR of pre- and post-FLP MCMV-pp150-F140P yielded 
PCR products of approximately 2 and 1 kb, respectively. Molecular size marker (MW) in kb 
is indicated. 
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Figure 3.31 Confirmation of KanR marker removal from MCMV-pp28-F140P BAC 
genome by PCR. DNA from 4 clones of recombinant MCMV-pp28-F140P BACs (pre and 
post FLP) were screened by PCR using primers flanking the site of recombination. PCR 
products were separated on a 1% agarose gel for 60-90 min at 75 V, and visualized by 
staining with EtBr (0.5 μg/ml). PCR of pre- and post-FLP MCMV-pp28-F140P yielded PCR 
products of approximately 2 and 1 kb, respectively. Molecular size marker (MW) in kb is 
indicated. 
 
To confirm the absence of genomic rearrangements in recombinant BACs following Kan
R
 
excision, BAC DNA was again analysed by restriction digests with EcoRI followed by 
electrophoresis on a 1% agarose gel (Figures 3.32 and 3.33) and sequencing (Figures 3.34 
and 3.35). MCMV-WT BAC DNA and MCMV-pp150/pp28-F140P recombinant BAC DNA 
(pre- and post-FLP) were compared side by side on the gel to confirm genomic integrity of 
the post-FLP recombinant clones. The banding patterns generated by restriction enzyme 
digestion of the recombinant MCMV-pp150/pp28 BACs were consistent with those of the 
MCMV-WT BAC control. Banding patterns were also comparable between the pre- and post- 
FLP samples, indicating the absence of genome rearrangement in the recombinant BAC DNA 
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following FLP recombinase mediated removal of the Kan
R
 marker. As a final level of 
characterization, the F140P domains from the recombinant MCMV BACs were amplified by 
PCR and sequenced by Sanger DNA sequencing (Section 2.3.8). Two recombinant BAC 
clones from each recombinant MCMV-PP150/PP28-F140P were selected for sequence 
characterization. The sequence data indicated that full-length sequence of the F140P domain 
was present in the recombinants with the absence of any mutations (Figure 3.34 and 3.35). 
Together, these results demonstrate excision of Kan
R
 cassette from recombinant MCMV-
pp150-F140P and MCMV-pp28-F140P BAC clones prior to virus reconstitution in MCMV 
permissive eukaryotic MEF cells. 
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Figure 3.32 Characterization of the recombinant (post-FLP) MCMV-pp150-F140P BAC 
genome using EcoRI restriction enzyme digestion. MCMV-WT and recombinant MCMV-
pp150-F140P pre-FLP (clones 2 and 4) and post-FLP (2-2, 2-4, 2-6, 2-8, 4-1, 4-4, 4-8, 4-16, 
and 4-18) BACs were digested with EcoRI restriction enzyme and the resulting fragments 
were separated on a 1% agarose gel for 18-20 hours at 45 V followed by visualization with 
EtBr (0.5 μg/ml). Comparable restriction digestion pattern between the MCMV-pp150-F140P 
clones pre- and post-FLP recombinase mediated removal of Kan
R
 demonstrates lack of any 
gross genomic rearrangements. Molecular size marker lane (MW) in kb is indicated.  
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Figure 3.33 Characterization of the recombinant (post-FLP) MCMV-pp28-F140P BAC 
genome using EcoRI restriction enzyme digestion. MCMV-WT and recombinant MCMV-
pp28-F140P pre-FLP (clones 5 and 6) and post-FLP (5-1, 5-2, 5-4, 5-6, 6-1, 6-3, 6-5, and 6-
10) BACs were digested with EcoRI restriction enzyme and the resulting fragments were 
separated on a 1% agarose gel for 18-20 hours at 45 V followed by visualization with EtBr (0.5 
μg/ml). Comparable restriction digestion pattern between the MCMV-pp28-F140P clones pre- 
and post-FLP recombinase mediated removal of Kan
R
 demonstrates lack of any gross 
genomic rearrangements. Molecular size marker lane (MW) in kb is indicated. 
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(A) 
GCCACACTCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCT
GGTAAAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTA
TCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACA
CCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAG
GACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAG
TCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGG
TCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAG
AAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGC
GAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGA
GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTT
CCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCG
GATATCGCTAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGG
TTTTTATTATTTTTTTATTATCATCACAGTAAAAAGAAAGACACTGTTCACACACTCTCTCG 
(B)  
 
CCACACTCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCTG
GTAAAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTAT
CGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACAC
CTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGG
ACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGT
CGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGT
CGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGA
AGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCG
AACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAG
GTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTC
CTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGG
ATATCGCTAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGGT
TTTTATTATTTTTTTATTATCATCACAGTAAAAAGAAAGACACTGTTCACACACTCTCTCGT 
Figure 3.34 Confirmation of MCMV-pp150-F140P BAC genome via Sanger DNA 
sequencing. PCR was performed on selected post-FLP MCMV-pp150-F140P BAC clones: 
(A) clone (2-6) and (B) clone (4-16) followed by DNA sequencing. Black sequence 
represents the pp150 protein and green represents sequence homology to the F140P domain. 
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(A) 
  
TCGGGGCGACAGGGAGGCGGAAAGCGGACGTCGTCTTTGAAATCCGCCAAGAACGGCGCCGG
CGTGAAGAAAAAAGTCAGGGCCTTGATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTA
TCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACA
CCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAG
GACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAG
TCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGG
TCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAG
AAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGC
GAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGA
GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTT
CCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCG
GATATCGCTAATTCCCATGTCAGCCGTTAAGTTATCTATCTATCGATCGACCGTGAGGGGGG
GAGAAAGGGAGAAAGAGTGGAGGAGATTTATTAAAAAAAACGACATGGTGACAACACCAT 
 
(B) 
 
GCTCGGGGCGACAGGGAGGCGGAAAGCGGACGTCGTCTTTGAAATCCGCCAAGAACGGCGCC
GGCGTGAAGAAAAAAGTCAGGGCCTTGATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGT
TATCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAA
CACCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCC
AGGACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGA
AGTCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGC
GGTCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGC
AGAAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCA
GCGAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGC
GAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAG
TTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTG
CGGATATC 
Figure 3.35 Confirmation of MCMV-pp28-F140P BAC genome via Sanger DNA 
sequencing. PCR was performed on selected post-FLP MCMV-pp28-F140P BAC clones: 
(A) clone (5-1) and (B) clone (6-10) followed by DNA sequencing. Black sequence 
represents the pp28protein and green represents sequence homology to the F140P domain. 
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3.2.3 Reconstitution of MCMV-pp150/pp28-F140P recombinant viruses 
CMV genomes are comprised of a single dsDNA molecule. As such production of infectious 
virus requires only introduction of the CMV DNA genome into CMV permissive cells for 
reconstitution of derivative CMV virus (Roizman & Pellett, 2001). Although labour-intensive, 
the impact of DD fusion to essential virus proteins on virus replication can only be 
ascertained empirically by construction and analysis of the respective recombinant viruses. 
To determine whether we were able to reconstitute recombinant CMVs expressing the pp150 
or pp28 ORFs fused to the ecDHFR destabilizing domain (F140P), BAC DNA was 
introduced into MEFs by electroporation. The use of MEFs is essential for MCMV 
reconstitution due to the high species-specificity of CMVs. MEF cells were electroporated 
with the recombinant MCMV-pp150-F140P or MCMV-pp28-F140P BACs. WT-MCMV 
BAC DNA was used as a positive control (Section 2.6.2.2). Two independent clones from 
each vector were selected for reconstitution (Table 3.6) to mitigate effects of any potential 
second site mutations.  
If the ecDHFR was destabilizing the targeted CMV tegument protein, then reconstitution of 
recombinant MCMVs was expected to require the presence of the stabilizing TMP molecule.  
To gain an initial insight into the conditionality of replication of the MCMV recombinants, 
the selected recombinant clones were grown in either the presence or absence of TMP. A 
TMP concentration of 50 μM was used, which was based on the amount previously shown to 
be able to afford stabilization in a study by (Glaß et al., 2009). Cell monolayers were 
monitored daily under the inverted microscope for signs of virus induced CPE ( swelling, 
rounding, aggregation, cell death and plaque development); (Kim & Carp, 1971). In the 
presence of TMP viral plaques from both pp28 and pp150 MCMV recombinants were 
detected 3-7 days post-transfection, which then spread through the entire monolayer by day 
10 at which point virus was harvested (Section 2.6.2.2). 
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 In the absence of TMP, reconstitution was far less efficient with only 2 (clone 2-6) and 3 
(clone 4-16) plaques resulting following reconstitution of the pp150 MCMV constructs, 
which were delayed until day 8 post-transfection. In the absence of TMP, neither of the pp28 
MCMV constructs resulted in any detectable plaques at least until day 14 post-transfection. 
These initial results suggest that fusion of the ecDHFR (F140P) domain to pp150 and pp28 
has resulted in TMP-dependent replication of the recombinant viruses that may be more 
stringent for the pp28 recombinant. Numbers of plaques were recorded in Table 3.6. MCMV-
pp150-F140P and pp28-F140P plaques were picked up and isolated as described in (Section 
2.6.2.1).  
 
 
Table 3.6. Reconstitution of recombinant MCMV-pp150/pp28-F140P BAC clones in the 
presence or absence of the TMP 
MCMV BAC construct                Clone                                 Plaque numbers 
                                                                           (+TMP)               (-TMP) 
MCMV-pp150-F140P                           (6-1)                                      12                    4                                      
                                                               (3-9)                                      10                    3                   
                                                                                                                                                                                                                                                                  
MCMV-pp28-F140P                             (1-2)                                      1                      0                                      
                                                               (5-1)                                      4                      0                                                                                                  
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3.2.3.1 Preparation of seed stock from recombinant MCMV-pp150/pp28-F140P viruses 
in the presence of TMP 
To enable further characterization of the different recombinant viruses following 
reconstitution of the MCMV BAC clones, seed stocks of MCMV-pp150-F140P and MCMV-
pp28-F140P were prepared using individual reconstituted plaque-derived viruses (clones (3-9) 
and (1-2), respectively; Section 2.6.2.4). A parental MCMV-WT seed stock was also 
prepared. Monolayers infected with MCMV-pp150-F140P or MCMV-pp28-F140P 
recombinant viruses were incubated for 5 or 7 days, in the presence of 100 μM TMP, until 
approximately 95% of cells demonstrated substantial CPE. The desired concentration of TMP 
was added to the media every 24 hr to maintain the TMP concentration at the desired level. 
Cells and supernatant were harvested, freeze thawed at -80C, clarified at 3800 rpm (4600 × 
g) for 20 min at RT, aliquoted and stored at -80C. 
 
3.2.3.2 Preparation of concentrated virus stocks in the presence of TMP 
High titre stocks of recombinant MCMV-pp150-F140P and MCMV-pp28-F140P viruses 
were prepared from the seed stocks generated above in the presence of TMP, as described in 
(Section 2.6.1.5). Stocks of parental MCMV-WT were also prepared.  Next, we assessed titre 
of recombinant and parental viruses by TCID50 assay in the presence or absence of TMP 
(Section 2.6.1.6). We hypothesized that if the recombinant viruses were conditionally 
attenuated as suggested by differences in virus reconstitution levels, then this would be 
observed as a decrease in replication in the absence of the stabilizing TMP molecule. As 
shown in (Figure 3.36), the relative titre of MCMV-WT was unaffected by the presence or 
absence of TMP as expected. Using two-tailed t-test, there was no significant difference (P= 
0.9333) relative to the appropriate control (without TMP) on day 4 post-infection. In contrast, 
the titre of the MCMV-pp150-F140P stock was 10-fold higher in the presence of TMP than 
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in the absence of TMP. At this further level of characterization, this difference suggested an 
intermediate level of TMP-dependency of replication of MCMV-pp150-F140P. Statistical 
analysis using two-tailed t-test indicated that although there was a trend towards lower 
replication, this 10-fold difference was not statistically significant (P= 0.5532). In 
comparison to only a trend towards TMP-dependent replication for MCMV-pp150-F140P, 
MCMV-pp28-FF140P replication was clearly dependent on the presence of TMP for 
replication. As shown in (Figure 3.37) statistical analysis using a two-tailed t-test indicated a 
statistically significant reduction in the level of the recombinant virus in the absence versus 
the presence of TMP (P˂0.0001). This result, suggests a level of destabilization of the pp28 
resulting from fusion to the F140P DD that results in a complete attenuated replication 
phenotype of the virus in the absence of the stabilizing TMP molecule.  
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Figure 3.36 Titration of Concentrated stocks in the present or absence of TMP by 
TCID50 assay. MEFs were infected with MCMV-WT or MCMV-pp150-F140P virus at a 
MOI of 0.01 PFU/cell and cultivated with (100 µM) or without (0 µM) TMP at 37C. Four 
days post infection the virus titres (log 10 PFU/cell) were determined in the cell monolayer.  
Error bars show the SE; N= 3 independent experiments. n.s.(not significant) P0.05 indicates 
there was not statistically significant differences relative to the infected cells in the absence of 
TMP, using two-tailed t-test.  
 
  
 
Figure 3.37 Titration of Concentrated stocks in the present or absence of TMP by 
TCID50 assay. MEFs were infected with MCMV-WT or MCMV-pp28-F140P virus at a 
MOI of 0.01 PFU/cell and cultivated with (100 µM) or without (0 µM) TMP at 37C. Four 
days post infection the virus titres (log 10 PFU/cell) were determined in the cell monolayer. 
Error bars show the SE; N= 3 independent experiments. n.s.(not significant) P0.05***, 
P˂0.05 indicates significant differences relative to the infected cells in the absence of TMP, 
using two-tailed t-test.  
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3.2.3.3 Confirmation of the absence of MCMV-WT from recombinant MCMV-
pp150/pp28-F140P  
Full characterization of recombinant virus stocks was critical prior to their use in subsequent 
experiments. Virus stocks were experimentally verified to ensure the F140P domain sequence 
was intact in all clones, and that we had not inadvertently selected virus clones that had 
acquired mutations during the reconstitution process. I was also necessary to exclude 
contamination with the wild-type MCMV.  
PCR amplification was performed using viral DNA extracted from concentrated stocks 
(Section 2.3.1.3). This was followed by direct DNA sequencing of the PCR products. Two 
independent PCR amplification reactions for each sample of viral DNA was performed using 
the same primer pair as was used previously to confirm excision of Kan
R
 from recombinant 
MCMV BAC (pp150Short-F/R and pp28Inter-F/R), (Section 2.3.3). Results showed that the 
bands of the expected sizes of 500 or 100 bp and 1000 bp were observed in the MCMV-WT 
lanes (1 & 2), and recombinant MCMV-pp150/pp28-F140P (lanes 3-6), respectively (Figures 
3.38-3.39). These results confirm the presence of the F140P domain, and demonstrate that 
there is no MCMV-WT contamination within the recombinant stocks.   
Two clones (number 1 and 4 of Figures 3.38 and 3.39) of each recombinant MCMV-
pp150/pp28-F140P virus were selected for Sanger sequencing using the primers pp150Short 
F/R and pp28Inter F/R (Tables 2.6 - 2.7). Sequence data demonstrated that the full length of 
the F140P domain was present, in the correct position, and did not have any deletions or 
mutations that might be impact the protein function (Figures 3.40 and 3.41).  
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Figure 3.38 Confirming presence of F140P domain in MCMV-pp150-F140P virus by 
PCR. DNA was isolated from MCMV-pp150-F140P concentrated stocks using a QIAamp kit 
and PCR was carried out using pp150Short F/R primers. PCR products were separated on a 1% 
agarose gel. The presence of a 1000 bp band in recombinant virus lanes (3-6) confirmed that 
the F140P domain was present, and the absence of the MCMV-WT sized band (500 bp) in 
the MCMV-pp150-F140P virus lanes confirmed the absence of WT contamination of 
recombinant.  
 
Figure 3.39 Confirming presence of F140P domain in MCMV-pp28-F140P virus by 
PCR. DNA was isolated from MCMV-pp28-F140P concentrated stocks using a QIAamp kit 
and PCR was carried out using pp28Inter-F/R primers. PCR products were separated on a 1% 
agarose gel. The presence of a 1000 bp band in recombinant virus lanes (3-6) confirmed that 
the F140P domain was present, and the absence of the MCMV-WT sized band (100 bp) in 
the MCMV-pp28-F140P virus lanes confirmed the absence of WT contamination of 
recombinant. 
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 (A) 
CCACACTCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCTG
GTAAAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTAT
CGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACAC
CTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGG
ACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGT
CGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGT
CGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGA
AGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCG
AACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAG
GTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTC
CTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGG
ATATCGCTAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGG 
 (B) 
CAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCTGGTAAAAAAATCG
TCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAAAA
CGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACC
CGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATA
TTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAA
GCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATGA
ACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAAGGCG
ACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGATG
CTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTATCC
CTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAAGT
TCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCGCTAATT
CCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGGTTTTTATTATTT 
Figure 3.40 Conformation of ecDHFR (F140P) within MCMV-pp150-F140P virus 
genome via Sanger sequencing. PCR was performed on the DNA extracted from 
concentrated virus stocks clone (5-1). Two independent PCR products (A and B) were 
sequenced. Black text represent pp28 genome sequence, green sequences represented 
homology to the F140P domain, orange sequences represented V5 tag and blue text 
represented downstream of MCMV genome sequence. 
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(A) 
 
CGATCAGCTCGGGGCGACAGGGAGGCGGAAGCGGACGTCGTCTTTGAAATCCGCCAAGAACG
GCGCCGGCGTGAAGAAAAAAGTCAGGGCCTTGATCAGTCTGATTGCGGCGTTAGCGGTAGAT
CACGTTATCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAA
CGCAACACCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCG
TTGCCAGGACGCAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGG
GTGAAGTCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGG
CGGCGGTCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCACATCG
ACGCACAAGTGGAACGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGGAATCGGT
ATTCAGCGAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATAGCTTTGAGATTCTGGA
GCGGCGAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCT
TGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAATGTATAGGAACTTCAGAGCGCTTTTGA 
 
(B) 
 
AGGCGGAAGCGGACGTCGTCTTTGAATCCGCCAAGAACGGCGCCGGCGTGAAGAAAAAAGTC
AGGGCCTTGATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAAAACGC
CATGCCGTGGAACCTGCCTGCCGATCTCGCCCGGTTTAAACGCAACACCTTAAATAAACCCGT
GATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATTA
TCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAAGCC
ATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATGAACA
GTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCACAATTGGAACGCGACA
CCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGATGCTG
ATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTATCCCTA
ACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAAGTTCC
TATTCTCTAGAATGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCGTTATCTCCC 
 
Figure 3.41 Conformation of ecDHFR (F140P) within MCMV-pp28-F140P virus 
genome via Sanger sequencing. PCR was performed on the DNA extracted from 
concentrated virus stocks clone (5-1). Two independent PCR products (A and B) were 
sequenced. Black text represent pp28 genome sequence, green sequences represented 
homology to the F140P domain, orange sequences represented V5 tag and blue text 
represented downstream of MCMV genome sequence. 
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3.2.4 Characterisation of recombinant MCMV-pp150/pp28-F140P virus in vitro 
3.2.4.1. Replication of MCMV-pp150/pp28-F140P at differing concentration of TMP 
The reduced titre of virus stocks produced in the absence compared to the presence of TMP 
(Figures 3.36 and 3.37) indicates that virus replication is to a certain extent being influenced 
by TMP stabilization. It is possible that visualization of CPE was not sensitive enough to 
identify more subtle differences in TMP-dependent growth. To obtain a more quantitative 
assessment and to confirm that viral growth was dependent on the presence of TMP, we 
examined the viral growth by titration of progeny virus at the different concentrations of 
TMP. For these studies the range of (0, 1, 5, 10, 50 and 100) µM of TMP were selected, 
which was based on earlier published study (Glaß et al., 2009). MEF cells were infected with 
recombinant MCMV-pp150-F140P or MCMV-pp28-F140P virus at MOI (0.01 PFU/cell) and 
then cultured under various concentrations of TMP. To maintain the concentration of the 
TMP in the culture as desired, we added TMP every 24 hr during the course of infection. 
Progression of infection was also visualized by CPE. Results presented in Figure 3.42 show 
the level of CPE at various TMP concentrations at day 4 post-infection (pi). The number of 
plaques at this time was also enumerated (Table 3.7). Consistent with the ability of the 
MCMV-pp150-F140P to be reconstituted in the absence of TMP, the virus grew in regardless 
presence or absence of TMP in the culture media. Results demonstrated that plaque numbers 
were increased with the increasing of TMP concentration, however at 100 µM of TMP e 
observed decrease of plaque number (Table 3.7). These result indicated that the presence of 
different concentration of TMP had little effect on the plaque numbers that formed by 
recombinant virus.  
In contrast, for cells infected with the MCMV-pp28-F140P virus (clone 1-2) and cultured 
with different concentration of TMP, the number of plaques increased and the size become 
larger with increasing of TMP concentration (Table 3.7; Figure 3.43). Subsequent 
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characterization of the viruses showed that the MCMV-pp28-F140P mutant virus was clearly 
attenuated in the absence of TMP. Upon cultivation without TMP only a few minifoci 
became detectable, which did not develop into plaques. When the virus was cultured at 100 
µM TMP the plaque number of the virus was indistinguishable from that of wild-type virus. 
Taken together, these results showed that fusion of the ecDHFR DD to essential tegument 
proteins of MCMV results in a conditional, TMP-dependent attenuated phenotype.  However, 
the specific tegument protein targeted affects the level of attenuation ranging from 
intermediate to complete. The amount of TMP needed for optimal stabilization of the viruses 
also differed for each fusion protein and can only be established empirically.   
   
Table 3.7 Number of MCMV-pp150/pp28-F140P plaques in representative sample from 
6.2 mm2 field of view   
Recombinant MCMV vector              Plaque number in different concentration of TMP (µM)  
                                                                   0             1             5            10            50           100 
MCMV-pp150-F140P                                13           15           18           20            25            18 
MCMV-pp28-F140P                                  1             3             6             6             10              12 
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Figure 3.42 Image of Dose-dependent regulation of the recombinant MCMV-pp150-
F140P replication and tunability of plaque formation by TMP. MEF cells were infected 
with the MCMV-pp150-F140P virus at a MOI of 0.01 PFU/cell and cultivated in the presence 
of various concentration of TMP as indicated. At day four post infection, images of infected 
cells were taken, depicting plaque formation by mutant MCMV under different concentration 
of TMP.  
 
Figure 3.43 Image of Dose-dependent regulation of the recombinant MCMV-pp28-
F140P replication and tunability of plaque formation by TMP. MEF cells were infected 
with the MCMV-pp28-F140P virus at a MOI of 0.01 PFU/cell and cultivated in the presence 
of various concentration of TMP as indicated. At day four post infection, images of infected 
cells were taken, depicting plaque formation by mutant MCMV under different concentration 
of TMP.  
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It is possible that visualization of CPE and counting plaque numbers were not sensitive 
enough to identify more subtle differences in TMP-dependent growth. Different 
concentrations of TMP were selected to obtain a more quantitative assessment and to provide 
additional evidence supporting the model of TMP, regulating MCMV-pp150/pp28-F140P 
virus replication by controlling the stability of the ecDHFR(F140P)-tagged pp150 or pp28 
protein. We determined the titre of cell-free virus by TCID50 assay in the presence of desired 
concentration of TMP (50µM or 100 µM TMP for culture of recombinant MCMV-pp150 or 
MCMV-pp28, respectively; Figures 3.44 & 3.45). 
 Results demonstrated that the stabilization of MCMV-pp150- F140P required higher amount 
of the ligand, which required as high as 50 µM TMP (Figure 3.44). Although the titre of the 
MCMV-pp150F140P virus were increased by increasing the TMP concentration, however 
statistical analysis using Tukey`s multiple comparison test revealed that there was no 
significant difference in the virus titre that grew at 0 µM  compare to 1 or 5 µM TMP (P= 
0.99 and 0.19, respectively). The virus titre at (10, 50 or 100 µM) was significantly different 
from virus titre that cultured in the absence of TMP (P=0.0131, 0.0003 or 0.0014, 
respectively). Virus titres increased approximately 2 fold when using 50 µM TMP compare 
to the titres of the virus that cultured in the absence of TMP (Figure 3. 44 and Table 3.8).  
Consistent with the more marked attenuated phenotype of pp28 from earlier characterization, 
the rescue of MCMV-pp28-F140P replication by TMP was dose dependent. While MCMV-
pp28-F140P failed to produce detectable virion progeny without TMP, its replication and titre 
increased with increasing concentration of TMP. Statistical analysis revealed that there were 
significant differences between the titres of the virus cultured in the absence and presence of 
(1, 5, 10, 50 or 100 µM) TMP (P= 0.004, 0.02, 0.03, 0.0001 or 0.0001, respectively; Figure 
3.45; Table 3.9).  
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This observation is in agreement with the low plaque numbers of virus at decreased 
concentration of TMP (Table 3.7). These data showed that there was significant difference 
between the virus titre that cultured in the different concentration of TMP it shows does 
dependent regulation of attenuation which is not observed for pp150.    
 
 
Figure 3.44 Dose-dependent regulation of the recombinant MCMV-pp150-F140P 
replication by ligand-TMP. MEF cells were infected with the MCMV-pp150-F140P virus at 
an MOI of 0.01 PFU/cell and cultivated in the presence of various concentration of TMP as 
indicated. At day four post infection the virus titres (log 10 PFU/cell) were determined in cell 
culture supernatants by TCID50. The TCID50 assay was performed on MEF cells maintained 
with 100 µM TMP. Virus titres were determined in triplicate. Statistical significance 
determined using a one way of variance (ANOVA) and Tukey`s multiple comparison test, 
*** P˂0.0003.  
 
               Table 3.8 TMP concentration (0, 1, 5, 10, 50, 100 μM) and P values of Tukey`s  
                               multiple comparison test of recombinant MCMV-pp150-F140P virus                                                         
Concentration of TMP        P value               Summary       Fold changes 
               (μM)                                                                           
            0 VS. 1                            0.999                     N.S.                  0.5 fold 
 
            0 VS. 5                            0.199                       N.S.                  1 fold 
            0 VS. 10                          0.0003                     *                       1 fold 
            0 VS. 50                          0.0131                     ***                   2 fold 
            0 VS. 100                        0.0014                     **                     1 fold 
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Figure 3.45 Dose-dependent regulation of the recombinant MCMV-pp28-F140P 
replication by ligand- TMP. MEF cells were infected with the MCMV-pp28-F140P virus at 
an MOI of 0.01 PFU/cell and cultivated in the presence of various concentration of TMP as 
indicated. At day four post infection the virus titres (log 10 PFU/cell) were determined in cell 
culture supernatants by TCID50. The TCID50 assay was performed on MEF cells maintained 
with 100 µM TMP. Virus titres were determined in triplicate. Statistical significance 
determined using a one way of variance (ANOVA) and Tukey`s multiple comparison test, 
**** P˂0.00001. Data values indicated below the threshold of detection arise from 
calculation of the average of values that vary across the threshold. 
 
             Table 3.9 TMP concentration (0, 1, 5, 10, 50, 100 μM) and P values of Tukey`s  
                          multiple comparison test of recombinant MCMV-pp28-F140P virus                                                         
Concentration of TMP        P value               Summary     Fold changes 
               (μM)                                                                           
            0 VS. 1                           0. 0041                     **                        1.5 fold 
  
            0 VS. 5                           0.02                          *                          3 fold 
            0 VS. 10                         0.03                          *                          3.5 fold 
            0 VS. 50                         0.0001                     ****                     4 fold 
            0 VS. 100                       ˂ 0.0001                  ****                     4.5  fold 
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3.2.4.1.1 Confirmation that F140P fused to MCMV-pp150/pp28 at the different 
concentration of TMP 
3.2.4.1.1.1 PCR analysis of recombinant MCMV-pp150/pp28-F140P vectors 
In order to test these viruses that released from the cells that cultured without TMP, were 
reverted into the wild type as a result of the insertion of ecDHFR mutant to the virus, we 
analysed those viruses by PCR and Sanger sequencing. Following infection of MEFs with the 
recombinant MCMV-pp150-F140P or MCMV-pp28-F140P and cultivation at the different 
concentrations of TMP, on day 4 post infection, infected cells were harvested and the DNA 
were extracted (Section 2.3.1.3). Purified DNA was then screened and analysed by PCR 
(Figures 3.46 and 3.47) to amplify the ecDHFR(F140P) from recombinant viruses at a 
different concentrations of TMP and also to confirm the absence of wild type sequence from 
recombinant viruses. PCR analyses were performed using the same primer pair used to 
confirm absence of wild type sequence from recombinant MCMV virus stocks (pp150Short-F 
and pp150Short-R as well as pp28Short-F and pp28Short-R) for recombinant MCMV-pp150 
and MCMV-pp28, respectively (Tables 2.6 and 2.7). Two independent PCR were performed 
from each recombinant virus that was cultured in a desired concentration of TMP (Section 
3.2.4.1). As shown in (Figures 3.46 and 3.47), the data revealed a band of the correct size to 
include the sequence for the F140P domain. The resulting PCR products gave one band about 
500 bp (lanes 1 and 2) while 1000 bp (lanes 3 to 14), the sizes of the PCR products indicated 
the presence of the F140P gene (~ 1000 bp) compare to the band that we observed from 
MCMV-WT genome (~ 500 bp) fragment which indicated the absence of F140P gene from 
the MCMV-WT. These data confirmed similar band fragment size that were previously 
amplified and observed from concentrated virus stock (Figures 3.38 and 3.39. 29). The data 
also indicated that we did not observe any reversion to the wild-type virus. In addition to this 
analysis, the sequencing of these amplified fragments will provide a more detailed genomic 
sequence examination to confirm any genetic rearrangements or mutations.  
218 
 
 
Figure 3.46 PCR screening of recombinant MCMV-pp150-F140P mutant virus 
maintained at different concentration of TMP. MEF cells were infected with the parental 
wild-type virus (1,2) or mutant MCMV-pp150-F140P virus at an MOI of 0.01 PFU/cell and 
cultivated in the presence of various concentrations of TMP; 0µM (3,4), 1µM (5,6), 5µM 
(7,8), 10µM (9,10), 50µM (11,12), 100µM (13,14) respectively. At day four post infection, 
supernatants were collected and the virus DNA were extracted and purified. PCR were 
performed using primers just outside the ecDHFR (F140P). PCR segment containing the 
F140P gives PCR products that are about 1 kbp (lanes 3 to 14) larger than the PCR products 
from the MCMV-WT genome which gave 500 bp (lanes 1 and 2) product . Molecular size 
marker (MW) in kbp is indicated. 
 
 
Figure 3.47 PCR screening of recombinant MCMV-pp28-F140P mutant virus 
maintained at different concentration of TMP. MEF cells were infected with the parental 
wild-type virus (1,2) or mutant MCMV-pp28-F140P virus at an MOI of 0.01 PFU/cell and 
cultivated in the presence of various concentrations of TMP; 0 µM (3,4), 1 µM (5,6), 5 µM 
(7,8), 10 µM (9,10), 50 µM (11,12), 100 µM (13,14) respectively. At day four post infection, 
supernatants were collected and the virus DNA were extracted and purified. PCR were 
performed using primers just outside the ecDHFR (F140P). PCR segment containing the 
F140P gives PCR products that are about 1 kbp (lanes 3 to 14) larger than the PCR products 
from the MCMV-WT genome which gave 500 bp (lanes 1 and 2) product. Molecular size 
marker (MW) in kbp is indicated. 
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3.2.4.1.1.2 Sequence confirmation of recombinant MCMV-pp150/pp28-F140P at a 
different concentration of TMP 
To provide additional proof that the culturing of recombinant virus at different concentrations 
of TMP did not cause any gross changes in the ecDHFR(F140P) domain, sequence analyses 
were performed. The PCR products prepared above (Section 3.2.4.2.1) were used for Sanger 
sequencing. Two clones of each recombinant MCMV-pp150/pp28-F140P virus cultured at (0, 
50 or 100) μM TMP were selected for screening by Sanger sequencing, using the 
pp150Short-F or pp28Short-F primer (Tables 2.6 and 2.7). As shown in Figures 3.38 and 3.39, 
the sequence data indicated that the full length sequence of the ecDHFR(F140P) domain was 
present and fused to the pp150/pp28 protein in recombinant virus cultured without TMP (A 
and B), with 50 µM (C and D) or with 100 µM of TMP (E and F), in the correct position and 
did not have any deletions or mutations which may impede the protein expression. Taken 
together these results confirmed that the MCMV-pp150-F140P and MCMV-pp28-F140P 
viruses which were cultivated at the different concentrations of TMP had a destabilization 
domain protein fused to the pp150 or pp28 protein and there was no alteration or mutation in 
the F140P domain sequences. 
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(A) 
  
GCCACACTCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCT
GGTAAAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTA
TCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACA
CCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAG
GACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAG
TCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGG
TCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAG
AAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGC
GAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGA
GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTT
CCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCG
GATATCGCTAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGG
TTTTTATTATTTTTTTATTATCATCACAGTAAAAAGAAAGACACTGTTCACACACTCTCTCG 
(B) 
TCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCTGGTAAAA
AAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATG
GAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAAT
AAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAA
AATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGA
TGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTT
ATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAA
GGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCAC
GATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCC
TATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCC
GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCGC
TAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGGTTTTTATT
ATTTTTTTATTATCATCACAGTAAAAAGAAAGACACTGTTCACACACTCTCTCG 
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(C) 
GCCACACTCTCCACAGTTCGCCGGCTCCCCATTCGCCGGTTCTGATGGGGACGGTGGCGGCCT
GGTAAAAAAATCGTCGTCGTCTCACATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTA
TCGGCATGGAAAACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACA
CCTTAAATAAACCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAG
GACGCAAAAATATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAG
TCGGTGGATGAAGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGG
TCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAG
AAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGC
GAACCCCACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGA
GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTT
CCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCG
GATATCGCTAATTCCCATGTCAGCCGTTAAGTACAAGATCGATGATCGCTCGCTCCTGGTTGG
TTTTTATTATTTTTTTATTATCATCACAGTAAAAAGAAAGACACTGTTCACACACTCTC 
Figure 3.48 Sequence conformation of recombinant MCMV-pp150-F140P vector 
cultured with the different concentration of TMP. (A) In the absence of TMP, (B) at 50 
μM or (C) 100 μM. PCR were performed on the recombinant viruses and two PCR reactions 
from each virus were sequenced. Black sequences: represent sequence homology to the 
pp150 protein; Green sequences: represent sequence homology to the ecDHFR (F140P); 
Orange sequences: homology to V5 tag; Blue sequences: represent sequence homology to the 
pOriFRT(wt)-ecDHFR(F140P) plasmid. 
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(A) 
 
AGGGAGGCGGAAGCGGACGTCGTCTTTGAAATCCGCCAAGAACGGCGCCGGCGTGAAGAAAA
AAGTCAGGGCCTTGATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAA
AACGCCATGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAA
CCCGTGATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAAT
ATTATCCTCAGCAGTCAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGA
AGCCATCGCTGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATG
AACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCACAAGTGGAAGGC
GACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGAT
GCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTAT
CCCTAACCCTCTCCTCGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAA
GTTCCTATTCTCTAGAAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCTCTAA
TTCCCATGTCAGCCGTTAAGTTATCTATCTATCGATCGACC 
 
(B) 
 
GGACGTCGTCTTTGAATCCGCCAAGAACGGCGCCGGCGTGAAGAAAAAAGTCAGGGCCTTGA
TCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAAAACGCCATGCCGTGG
AACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACCCGTGATTATGGGC
CGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATTATCCTCAGCAGT
CAACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAAGCCATCGCTGCGTG
TGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATGAACAGTTCTTGCCAA
AAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAAGGCGACACCCATTTCCCG
GATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGATGCTGATGCGCAGAA
CTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAAGTTCCTATTCTCTAG
AAAGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCGCTATTCCCATGTCAGCCGT
TAAGTTATCTATCTATCGATCGACCGTGAGGGTGGGAGAAAGGTAGAAAGAGTGGAGGAGAT
TGATTAAACAAACGACATGGTGTACGTATTTGTTTCTTCTCCACGGGTAAGTTTTTTTAAAA
GGCTCTCTCGACTCTTTCTCGCTTTCTCCCCCCTCACGTCGGATCG 
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(C) 
 
ACGTCGTCTTTGAATCCGCCAAGAACGGCGCCGGCGTGAAGAAAAAAGTCAGGGCCTTGATC
AGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAAAACGCCATGCCGTGGAA
CCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACCCGTGATTATGGGCCG
CCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATTATCCTCAGCAGTCA
ACCGAGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAAGCCATCGCTGCGTGTG
GTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTATGAACAGTTCTTGCCAAAA
GCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAAGGCGACACCCATTTCCCGGA
TTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAACCCCACGATGCTGATGCGCAGAACT
CTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGAGGTAAGCCTATCCCTAACCCTCTCCTCG
GTCTCGATTCTACGTAACCCGGGGATCTTGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAA
AGTATAGGAACTTCAGAGCGCTTTTGAAGCTGCGGATATCGCTATTCCCATGTCAGCCGTTA
AGTTATCTATCTATCGATCGACCGTGAGGGTGGGAGAAAGGTAGAAAGAGTGGAGGAGATTG
ATTAAACAAACGACATGGTGTACGTATTTGTTTCTTCTCCACGGGTAAGTTTTTTTAAAAGG
CTCTCTCGACTCTTTCTCGCTTTCT 
 
Figure 3.49 Sequence conformation of recombinant MCMV-pp28-F140P vector 
cultured with the different concentration of TMP. (A) In the absence of TMP, (B) at 50 
μM or (C) 100 μM. PCR were performed on the recombinant viruses and two PCR reactions 
from each virus were sequenced. Black sequences: represent sequence homology to the pp28 
protein; Green sequences: represent sequence homology to the ecDHFR (F140P); Orange 
sequences: homology to V5 tag; Blue sequences: represent sequence homology to the 
pOriFRT(wt)-ecDHFR(F140P) plasmid. 
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3.2.4.2 Dynamics of pp150 or pp28 stability impacting on virus replication were 
analysed during infection  
As we detailed above (Section 1.1.6.3), one advantage of using DD strategy is the ability of a 
ligand to stabilize the DD protein restoring their biological function in a rapid, reversible and 
dose dependent manner (Banaszynski et al., 2006; Iwamoto et al., 2010). It has been shown 
that DHFR systems are reversible (Glaß et al., 2009), to determine whether ecDHFR 
similarly has this characteristic, we tested reversibility of ecDHFR(F140P)-pp150/pp28 in 
response to TMP. We tested whether fused tegument proteins with ecDHFR could be 
reversed through withdrawal or adding of TMP. Although not the focus of this thesis, this 
would provide a tool for loss as well as gain of function experiments for pp150 and pp28 in 
future studies beyond the scope of this thesis.  
A schematic of the experiment is shown in Figures 3.50-3.51. Briefly, MEFs were infected 
with recombinant MCMV-pp150-F140P, MCMV-pp28-F140P or MCMV-WT each in four 
separate cultures: two were maintained in the presence of 50 or 100 μM TMP for MCMV-
pp150-F140P and MCMV-pp28-F140P, respectively; and the other two were maintained in 
the absence of TMP. All cells were then cultured for four days at 37C. On day four post-
infection the cells that were cultivated in the presence of TMP were then either maintained 
with TMP (by adding fresh TMP), or withdrew from TMP (by removal of TMP-containing 
media, washing monolayers with DPBS and then adding fresh DMEM media without TMP). 
All cells were then cultured for 6 hr at 37C (Figure 3.50). While the infected MEF cells 
cultivated in the absence of TMP where then either maintained in the absence of TMP by 
adding fresh media (as a positive control) or cultured in the presence of TMP (50 μM) for 6 
hr at 37C  (Figure 3.51).  
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To obtain a more quantitative assessment we examined the viral growth by titration of 
progeny virus before (harvesting supernatant only) and after adding of TMP for 6 hr 
(supernatant and cell associated virus were harvested). Infectious culture supernatants were 
collected at day 4 post infection and the titres of cell-free viruses were determined by TCID50 
assay in the presence of 50 µM or 100 µM TMP (for culture of recombinant MCMV-pp150 
or MCMV-pp28, respectively). As expected, the titres of the MCMV-WT virus were the 
same regardless to add/withdrawal of TMP for 6 h. No significant difference was seen 
(P0.05), (Figures 3.52 and 3.53A).  
When TMP was withdrawn from the cells infected with MCMV-pp150-F140P initially 
cultured with TMP for 4 days, the virus titre decreased compared to the virus that was 
continuously kept with TMP. Statistical analysis using Tukey`s multiple comparison test 
revealed a significant difference (P˂0.00308) between the titres (Figure 3.52 B). However, 
when the TMP was added to the cells kept initially without TMP, virus replication was 
increased compared to the viruses grown in the continuous absence of TMP. Statistical 
analysis revealed significant difference between them (P˂0.00417); (Figure 3.53 B).  
In contrast, when cells infected with MCMV-pp28-F140P for 4 days in the presence of TMP 
were studied, withdrawal of TMP from MCMV-pp28-F140P infected cells made the virus 
titre significantly decrease (P˂0.001) compared to the virus grown in the continuous presence 
of TMP (Figure 3.52 C) indicating rapid degradation of pp28. However, when we added 
TMP to infected cells kept initially without TMP, the virus titre increased significantly 
(P˂0.0018) compared to the virus grown in the continuous absence of TMP (Figure 3.53 C), 
indicating rapid stabilization of pp28 protein by TMP. 
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Figure 3.50 Schematic illustration of the pp150 or pp28 stability during infection in the 
presence of TMP. MEF cells were infected with MCMV-pp150-F140P or MCMV-pp28-
F140P viruses at MOI of 0.01 PFU/cell and cultivated in the presence of TMP. At day four 
post infection the supernatants were collected (0 hr) and infected cells cultured for 6 hours in 
the presence or absence of TMP (6 hr +/- TMP).   
 
 
 
 
Figure 3.51 Schematic illustration of the pp150 or pp28 stability during infection in the 
absence of TMP. MEF cells were infected with MCMV-pp150-F140P or MCMV-pp28-
F140P virus at MOI of 0.01 PFU/cell and cultivated in the absence of TMP. At day four post 
infection the supernatants were collected (0 hr) and infected cells cultured for 6 hours in the 
presence or absence of TMP (6 hr +/- TMP).    
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(C)MCMV-pp28-F140P 
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Figure 3.52 Dynamics of pp150 or pp28 stability were analysed during infection in the 
presence of TMP. MEF cells were infected with the (A) MCMV-WT, (B) MCMV-pp150-
F140P or (C) MCMV-pp28-F140P at MOI of 0.01 PFU/cell and cultivated in the presence of 
TMP for four days. At day four post infection the supernatants were collected (0 hr) and 
infected cells cultured for 6 hours in the presence or absence of TMP. Supernatants and cell 
associated virus were collected (6 hr +/-) and analysed for the presence of virus by TCID50 
assay on MEF cells kept with TMP. Virus titres were determined in triplicate. Statistical 
significance determined using a one way of variance (ANOVA) and Tukey`s multiple 
comparison test. 
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Figure 3.53 Dynamics of pp150 or pp28 stability were analysed during infection in the 
absence of TMP. MEF cells were infected with the (A) MCMV-WT (B) MCMV-pp150-
F140P or (C) MCMV-pp28-F140P at MOI of 0.01 PFU/cell and cultivated in the absence of 
TMP for four days. At day four post infection the supernatants were collected (0hr) and 
infected cells cultured for 6 hours in the presence or absence of TMP. Supernatants and cell 
associated virus (6 hr +/- TMP) were collected and analysed for the presence of virus by 
TCID50 assay on MEF cells kept with TMP. Virus titres were determined in triplicate. 
Statistical significance determined using a one way of variance (ANOVA) and Tukey`s 
multiple comparison test.  
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3.2.4.3 Characterisation of the recombinant MCMV-pp150/pp28-F140P viruses 
phenotypes  
The data shown in (Figures 3.44 and 3.45), revealed difference growth profiles between the 
viruses when cultured in relative to the concentration of TMP. These difference was most 
apparent at a concentration of 50 μM TMP for recombinant MCMV-pp150-F140P; Figure 
3.44) or at a concentration of 100 μM TMP for MCMV-pp28-F140P virus Figure 3.45). As 
virus progeny production was measured at only a single time point (day 4 pi), it is possible 
that this difference reflected only a kinetic delay in replication of the virus under restrictive (-
TMP) conditions. To determine whether destabilization of pp150 or pp28 influences virus 
growth, we compared the growth of two recombinant viruses (MCMV-pp150-F140P and 
MCMV-pp28-F140P) viruses with their parental wild-type (MCMV-WT). Time courses of 
production of extracellular infectious virions were examined in the presence or absence of 
TMP at low MOI (0.01PFU/cell; multi step growth curve). At low MOI, multiple rounds of 
replication of virus can take place, since not all cells are infected at the same time of 
inoculation. When cells are not exposed to large numbers of viral particles, this enables 
examination of virus dissemination in terms of features, such as plaque size or production of 
secondary plaques in an individual cell monolayar that gets infected. Using multi step growth 
curve amplifies effects of attenuation enabling more subtle effects to be seen the virus is 
moving through multiple replication cycles instead of just one. 
The growth rates of the constructed viruses as well as the wild-type virus were studied on 
MEF cells (Section 2.6.2.8). Monolayers of MEF cells were infected with the recombinant 
viruses or parental virus at MOI (0.01 PFU/cell) in triplicate in the presence or absence of 
TMP. In order to maintain the concentration of the TMP at a desired concentration in the 
infected monolayer, TMP was added every 24 hr (by adding TMP to the media). Following 
incubation of the MEFs with respective viral progeny for two hours, the supernatant was 
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harvested and fresh medium with the TMP was added. The supernatant that had been 
harvested after 2 hours of infection, represent day 0. The titres of the virus were determined 
on day (0, 1, 2, 3, 4, and day 5) post infection. Virus progeny in cell culture supernatants was 
quantified by the TCID50 assay on MEF cells (Section 2.6.2.6) in the presence of desired 
concentration of TMP. The growth rates of all viruses were performed and assayed in 
triplicate. 
  
3.2.4.3.1 Mutant MCMV-pp150F140P has wild-type properties in MEF fibroblast cells 
in the presence of TMP, but shows intermediate attenuated growth in the absence of 
TMP 
Wild-type MCMV was first tested with respect to growth on MEF cells in the presence of (50 
µM) or absence of TMP. As we expected (Figures 3.54-3.55 A) and consistent with previous 
data (Figures 3.52-3.53), the results demonstrate that the growth of MCMV-WT was similar 
regardless of whether TMP was present or absent. Replication kinetics of MCMV-WT were 
similar, virus (cultured with or without TMP) was first detected in cell culture supernatant on 
day 2 post infection and then reaching the maximum yield of  10
7
 PFU/cell on day 5 post 
infection. Statistical analysis using t-test showed that there were no significant differences 
between yield of the wild type virus that cultured in the presence or absence of TMP at any 
time point (P= 0.9928). No significant differences between the MCMV-WT yields in the 
presence or absence of TMP were identified from 2 to 5 days post infection (P0.05).    
Next, we compared the growth kinetics of recombinant MCMV-pp150-F140P to the MCMV-
WT in the presence of TMP (Figure 3.54 B). Virus yields were first detected on day 2 post 
infection (approximately 10
3 
PFU/cell), they then increased rapidly reaching the maximum 
level of (10
6 
PFU/cell) on day 5 post infection. Data demonstrated that the growth rate of 
mutant MCMV virus in the presence of TMP was similar to that of the parental MCMV-WT 
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viruses at most time points, only a difference in the range of one log unit compared to 
parental WT was detected. Although statistical analysis showed no significant different 
between yields of these two viruses from day 2 to 5 post infection (P=0.8442), the virus titre 
trended towards a decreased level. Thus the growth rate of recombinant virus on MEF cells in 
the presence of TMP was comparable to parental MCMV-WT confirming TMP-treatment 
restored the growth of mutant virus to wild-type level (Figure 3.54 B).  
Next we compared the growth kinetics of recombinant MCMV-pp150-F140P in the presence 
or absence of TMP. Replication of mutant virus that grew in MEF cells without TMP was 
similar to that of the virus that grew in the presence of TMP (Figure 3.54 C). Initially, the 
yield of the virus (kept without TMP) on day 2 was only slightly lower than that kept with 
TMP, yields reached maximum of  10
4
 PFU/cell on day 5 without TMP compared to the 
virus titre of 10
6 
PFU/cell on day 5 for the virus kept with TMP (Figure 3.54 C). A 
difference in the range of two log units between the presence and absence of TMP was 
detected. In the absence of TMP, virus replication was diminished compared to the virus that 
grew in the presence of TMP. Statistical analysis using t-test revealed that there were no 
significant difference between them (P=0.7804). As a complement to the studies described 
above, although the F140P domain enables regulated stability of pp150 ORF, the F140P 
domain tag inhibits some aspect of replication of mutant MCMV we saw a little effect of 
TMP, suggesting a level of destabilization of the pp150 in an intermediate attenuated 
replication phenotype of the virus. Taken together, these results showed that in the presence 
of ligand TMP, the growth of recombinant MCMV-pp150-F140P was comparable to the 
parental MCMV-WT; the mutant shows wild-type properties in MEF fibroblast cells. While 
in the absence of TMP, we saw some aspect of intermediate attenuation phenotype of the 
MCMV-pp150-F140P compare to the parental MCMV-WT virus.    
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Figure 3.54 Replication of recombinant MCMV-pp150-F140P viruses in the presence or 
absence of TMP. Compare the (A) MCMV-WT in the presence or absence of TMP, (B) 
MCMV-pp150-F140P to the MCMV-WT in the presence of TMP and (C) MCMV-pp150-
F140P in the presence and absence of TMP. MEF cells were infected with the MCMV-
pp150F140P mutant virus at an MOI of 0.01 PFU/cell and cultivated with 100 µM TMP or 
without TMP, at the time points indicated. Supernatants and cell associated virus were 
collected and analysed for the presence of virus by TCID50 assay on MEF cells kept with 
100 µl TMP. (+), cells infected in the presence of TMP; (-), cells infected in the absence of 
TMP. Results are the mean -/+ standard deviation (SD) of two experiments three replicates in 
each. Error bars representing the SD. Some of the SD are so small that the error bars are 
hidden behind the symbols representing the data points.   
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3.2.4.3.2 Recombinant MCMV-pp28-F140P growth properties in MEF fibroblast cells 
in the presence or absence of TMP 
As explained above (Section 3.2.5), multiple growth curves were performed to compare the 
growth kinetics of recombinant MCMV-pp28-F140P to the MCMV-WT in the presence (100 
µM) or absence of the TMP using TCID50 for the virus titration. As shown in (Figure 3.55 B) 
the data demonstrated that in the presence of TMP, the replication kinetics of recombinant 
MCMV-pp28-F140P was 2-logs down compare to that of MCMV-WT. Recombinant virus 
was first detected in cell culture supernatant on day 2 post infection and reached maximum 
levels on day 5 post infection. Maximum yields of the MCMV-pp28-F140P were 10
6 
PFU/cell compare to  10
7
 PFU/cell for MCMV-WT. Although the growth rate of the mutant 
was down 2 log compared to the parental virus, statistical analysis revealed that no significant 
difference was identified between yields of the two virus from day 2 to day 5 post infection 
(P0.05). Thus the growth rate of recombinant virus on MEF cells in the presence of TMP 
was comparable to parental MCMV-WT; there were no significant difference between them, 
confirming TMP-treatment restored the growth of mutant virus to wild-type level (Figure 3. 
55 B). 
Next, we examined the multi-step growth kinetics of MCMV-pp28-F140P in the absence of 
TMP compared to the titre of the virus that grew in the presence of TMP. It was noticed that 
at day 3 and later post infection, in the absence of TMP, MCMV-pp28-F140P started to 
produce a low level of virus in the absence of TMP. It appeared these viruses may not 
establish a second round of infection because their titre did not increased over time (Figure 
3.55 B). The titre of the virus reached maximum levels on day 5 post infection (less than 10
2
 
PFU/cell), while MCMV-pp-28-F140P in the presence of TMP reached maximum titres 10
5 
PFU/cell on day 5 post infection. Statistical analysis revealed that there were significant 
differences between the virus titre achieved in the presence or absence of TMP (P˂0.0001).   
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In addition to the TCID50, another way to quantify viral titre is by performing plaque assay. 
Both of these assays depend on the ability to detect visible CPE on the infected cells in vitro. 
However, plaque assay is one of the most accurate and sensitive methods for the direct 
quantification of a virus via counting of the number of plaques in cell culture (Baer & Kehn-
Hall, 2014; Dulbecco, 1952). In order to quantify the number of MCMV-pp28-F140P virus 
particles that grew in the absence of TMP in growth kinetics assay, plaques counts were 
determined by plaque assay to increase accuracy of the assay (see Section 2.6.2.7). 
As explained above (Section 3.2.5), multiple growth curves were performed to compare the 
growth kinetics of recombinant viruses to the MCMV-WT in the presence (100 µM) or 
absence of TMP using plaque assay for the virus titration. As shown in (Figure 3.55 A) and 
consistent with previous data (Figure 3.54 A), there is no significant difference between 
MCMV-WT cultured in the presence or absence of TMP (P= 0.99; Figure 3.56 A). When 
recombinant MCMV-pp28-F140P virus compared to MCMV-WT in the presence of TMP, 
again the replication kinetics of recombinant MCMV-pp28-F140P were such that 2-logs 
down compared to MCMV-WT. Recombinant virus was first detected in cell culture 
supernatant on day 2 post infections and reached maximum levels on day 5 post infections. 
Maximum yields of the MCMV-pp28-F140P were 10
6 
PFU/cell compare to the MCMV-WT 
which was  10
7
 PFU/cell. Although the growth rate of mutant were down 1 log compared to 
the parental virus, however statistical analysis revealed that no significant difference were 
identified between yields of the two virus from day 2 to day 5 post infection (P=0.393). Thus 
the growth rate of recombinant virus on MEF cells in the presence of TMP was comparable 
to parental MCMV-WT; there were no significant difference between them, confirming 
TMP-treatment restored the growth of mutant virus to wild-type level (Figure 3. 55 B). 
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Next, we compared the multi-step growth kinetics of MCMV-pp28-F140P in the absence of 
TMP compared to the titre of the virus that grew in the presence of TMP. It was noticed that 
at day 3 and later post infection, MCMV-pp28-F140P started to produce a low level of virus 
even in the absence of TMP (approximately 88.2 × 10
-1
 PFU/cell). These viruses appeared 
not to establish a second round of infection because there titre did not increased over time 
(Figure 3.55 C). The titre of the virus reached maximum levels on day 5 post infection (8.96 
× 10
+1
 PFU/cell), while MCMV-pp-28-F140P in the presence of TMP reached maximum 
titres 10
6 
PFU/cell on day 5 post infection. Statistical analysis revealed that there were 
significant differences between the virus titre achieved in the presence or absence of TMP 
(P˂0.0001).  The level of the virus that was detected by plaque assay was consistent with the 
results from the TCID50 assay (Figure 3.56). 
Taken together, these results revealed that the growth rate of MCMV-pp28-F140P virus in 
the absence of TMP was slower than of the recombinant virus that grew in the presence of 
TMP at most time points. Using TCID50 and plaque assay to assess virus titres, data indicated 
that there was a significant difference between the viruses when cultured in the presence or 
absence of TMP with respect to growth in MEF cells (Figures 3.55-3.56). As a complement 
to the studies described above, the F140P domain regulated stability of pp28 ORF, the F140P 
domain tag inhibits replication of recombinant MCMV-pp28, suggesting a complete 
destabilization of the PP28 and a complete attenuated replication phenotype of the virus.  
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(C) 
 
 
Figure 3.55 Replication of recombinant MCMV-pp28-F140P virus compared to its 
parental MCMV-WT virus in the presence or absence of TMP. MEF cells were infected 
with the MCMV-pp28F140P mutant or parental virus at an MOI of 0.01 PFU/cell and 
cultivated with 100 µM TMP (A) or without TMP (B), at the time points indicated. 
Supernatants were collected and analysed for the presence of virus by TCID50 assay on MEF 
cells kept with 100 µl TMP. (+), cells infected in the presence of TMP; (-), cells infected in 
the absence of TMP. Results are the mean -/+ standard deviation (SD) of two experiments 
three replicates in each. Error bars representing the SD. Some of the SDs are so small that the 
error bars are hidden behind the symbols representing the data points. Dashed lines mark the 
detection limit of the assay.  
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Figure 3.56 Replication of recombinant MCMV-pp28-F140P virus compared to its 
parental MCMV-WT virus in the presence or absence of TMP using standard plaque 
assay. MEF cells were infected with the MCMV-pp28-F140P mutant or parental virus at an 
MOI of 0.01 PFU/cell and cultivated with 100 µM TMP or without TMP, at the time points 
indicated. Supernatants were collected and analysed for the presence of virus by standard 
plaque assay on MEF cells kept with 100 µM TMP. (+), cells infected in the presence of 
TMP; (-), cells infected in the absence of TMP. Results are the mean -/+ standard deviation 
(SD) of two experiments three replicates in each. Error bars representing the SD. Some of the 
SD is so small that the error bars are hidden behind the symbols representing the data points. 
Dashed lines mark the detection limit of the assay.  
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3.2.4.4 Recombinant MCMV-pp28-F140P that grew in the MEF cells in the absence of 
TMP could not cause secondary infection 
After cultivation of the infected MEFs with recombinant MCMV-pp28-F140P virus without 
TMP a few minifoci became detectable, which did not develop into plaques as described in 
(Section 3.2.4.1; Figure 3.43). In the absence of TMP the recombinant MCMV-pp28-F140P 
virus produced almost no virus (approximately 10
1
 PFU/cell) by day four post infection and a 
very low level of progeny while in the presence of TMP the recombinant virus reached peak 
titre of (1.96 x 10
6 
PFU/cell) and restored the growth of the virus to wild-type level (Figure 
3.45) only (2-logs below). The next step was to examine the secondary infection of a few 
viruses that were detectable in the absence of TMP. To determine whether growth of virus 
was due to the leakiness of the TMP degradation or represented escape mutants (i.e. whether 
the virus had the ability to cause secondary infection in MEF cells or not). When infected 
MEFs were cultured with minimum amount of ligand (1 µM), we observed plaque formation 
at lowered levels by mutant MCMV-pp28 virus, consistent with stabilization of the MCMV-
Protein requiring 1 µM TMP (Figure 3.45).  
In contrast, when the mutant viruses were cultured in the absence of TMP for 5 days, almost 
no viral progeny were produced. Following the third passage of infection we were unable to 
detect any viral progeny even in the presence of minimal amount of TMP (Table 3.10). Taken 
together, these data indicate that those few viruses that grew in the absence of TMP, are 
unable to produce secondary infection and they grew only with TMP. These data suggested 
that these viruses were not escape mutants and TMP regulation allows for tight control of the 
pp28 function during the virus replication cycle.   
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Figure 3.50 Secondary infection of the recombinant MCMV-pp28-F140P in the absence 
of TMP. MEF cells were infected with the MCMV-pp28-F140P mutant virus at an MOI of 
0.01 PFU/cell and cultivated in the absence of TMP. At day four post infection the 
supernatants were collected and new MEFs were infected with 1 ml supernatant in the 
presence (1µM) or in the absence of TMP (0 µM). Images of infected cells were taken at day 
four and five post infection, depicting plaque formation by mutant MCMV under different 
concentration of TMP.  
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  Table 3.10 Mean plaque counts of mutant MCMV-pp28-F140P virus in the presence or   
absence of TMP. Summarizing total counts from two independent experiments 
MCMV-pp28-F140P virus                                       Plaque numbers 
                                                                          (1 µM TMP)             (0 µM TMP) 
    Passage one                                                          23                               0 
    Passage two                                                          15                              0                                                                             
    Passage three                                                         0                               0                                                               
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3.3 Discussion 
Vaccination is perhaps one of the most important innovations in medical science and public 
health in history, since it has the ability to substantially reduce morbidity and mortality 
caused by infectious diseases. All current vaccines rely on the ability to elicit a host immune 
response that protects against microbial disease. As we described previously (Section 1.1.6), 
vectored vaccines are comprised of a carrier virus which has been modified to carry gene 
from the microbe being targeted. When the vector is given to the recipient, the antigen will be 
expressed and protective immune responses will be generated. CMV-based vectors are a 
promising addition to our arsenal of existing vaccines against infectious diseases. They are 
unique in the associated high level of immunity they induce against their heterologous 
encoded pathogen target antigen, as well as the duration of the immunity and its immediate 
effector T cell function. Although still in their early developmental phase, CMV-based 
vaccines are starting to become an attractive vaccine vector against different microbial 
pathogens via inducing protective immunity against encoded antigens (Hansen et al., 2011; 
Jarvis et al., 2013; Karrer et al., 2004; Klyushnenkova et al., 2012; Marzi et al., 2016; 
Redwood et al., 2005; Tierney et al., 2012; Tsuda et al., 2011; Tsuda et al., 2015).   
A fundamental problem associated with the clinical application of CMV vaccine vectors is 
their replication-competent nature (Skenderi & Jonjić, 2012). CMV is generally benign and a 
symptomatic in immunocompetent individuals, but can cause severe disease in individuals 
whose immune systems are immature or weakened, including: neonates, patients with human 
immunodeficiency virus infection/Acquired Immunodeficiency Syndrome (HIV/AIDS), 
individuals receiving immunosuppressive therapy or chemotherapeutic agents, organ 
transplant and bone marrow transplant recipients and pregnant women (Corona-Nakamura et 
al., 2013).  
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Interestingly, previous studies have indicated that CMV replication is not required for 
induction of the characteristic immune response associated with CMV infection (Snyder et al., 
2011). Furthermore, replication-defective versions of CMV have been shown to maintain 
their immunogenicity at least in mouse studies (Mohr et al., 2010). Replication-defective 
CMV vectors may therefore provide a means to enhance the safety profile of the CMV 
platform without affecting immunogenicity.  
Replication-defective mutant viruses are specifically defective for one or more viral functions 
that are essential for viral genome replication or synthesis and assembly of progeny viral 
particles. The main advantages of the use of replication-defective viruses as vaccines are their 
high level of safety and ability to express viral antigens inside the infected cells. These 
antigens can be presented efficiently by MHC molecules with concomitant induction of 
immune responses, especially cell-mediated immunity (Nguyen et al.,1992; (Morrison & 
Knipe, 1996; Nguyen, Knipe & Finberg, 1992). Although CMV is associated with disease, 
disease is very context specific with the virus only being harmful in individuals with an 
immature immune system; otherwise the virus is generally asymptomatic in the general 
population. However, given the potential for CMV to spread from vaccines to non-vaccinated 
individuals, efforts for attenuation of the CMV-based vaccine platform will be critical in an 
attempt to prevent or reduce any vaccine-associated morbidity in any population prone to 
CMV disease.  
Although the high level of safety associated with replication-defective vaccines due to 
permanent deletion of essential genes is a main advantage of this method of attenuation, the 
requirement for cell lines expressing the missing viral gene product(s) to complement virus 
replication can prove problematic and, if not prohibitive, increases production costs. Cellular 
toxicity from expression of the trans-complementing viral gene can occur when expressed in 
isolation at levels necessary to fully complement virus replication. The production of stable 
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cell lines for viruses that require primary cells for growth and the requirement for expression 
at particular stages of the virus replication cycle may also be problematic for conventional 
complementation systems (Pan et al., 2016). Cell lines to complement replication-defective 
herpesviruses are particularly difficult to obtain especially for β- and γ- subfamilies, since 
only a few complementing cell lines have been established, mainly because many of these 
viruses can be propagated only on primary cells (Borst et al., 2008; Mocarski et al., 1996; 
Silva et al., 2003).  
The main aim of the work detailed in this thesis was to develop the protein-destabilization 
strategy towards production of a conditional replication-defective version of a MCMV 
vaccine vector by targeting essential tegument proteins (pp150 and pp28). The tegument 
proteins of CMV are known to be essential and play important roles in all stages of the viral 
life cycle including viral entry, gene expression, immune evasion, assembly and egress 
(Kalejta, 2008). Many reports have demonstrated a crucial role for both pp150 and pp28 
tegument proteins in virion assembly and morphogenesis. Pp150 plays an essential role in 
stabilizing nucleocapsid during virus maturation and directing their movement (AuCoin et al., 
2006; Tandon & Mocarski, 2008). Deletion of the pp150 leads to a complete loss of 
productive virus replication (Tandon & Mocarski, 2008). Pp28 is essential for virus 
replication due to its role in the secondary envelopment of virion in the cytoplasm (Britt et al., 
2004; Silva et al., 2003). In the absence of pp28 tegument proteins, non-enveloped capsids 
accumulate in the cytoplasm of infected cells, late in infection (Silva et al., 2003). 
Since expression of the targeted antigen by CMV at L times appears to bias towards antibody 
responses, these two tegument proteins were also selected based on their L time of expression, 
as this would enable expression of any target antigen regulated with L kinetics.  Use of a DD 
based on ecDHFR (Figure 3.1; (Banaszynski et al., 2006; Iwamoto et al., 2010) as opposed to 
FKBP made such a system suitable for development for use in LMICs due to the relative cost 
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of the TMP compared to Shield-1 stabilizing molecules. Importantly, the DD strategy was 
used for development of this complementation system for MCMV as it does not require the 
generation of complementing cell lines. In addition to L kinetics of expression, both pp150 
and pp28 belong to the group of tegument proteins not glycoproteins, the latter of which 
consists of major targets for the neutralizing antibody response of HCMV. Finally, M32 
encoding pp150 and M99 encoding pp28 of MCMV are the homologues of UL32 and UL99 
of HCMV, which allows for potential translation into the human CMV platform. The pp150 
and pp28 of MCMV were targeted and fused with DD separately in distinct MCMV vectors 
in parallel allowing for a direct parallel comparison. 
CMV is highly species-specific, thus, the generation of vaccine strategies are dependent on 
animal model system to provide significant insight of host-pathogen interactions like 
immunity, infection routes and immune modulation in vivo. The use of MCMV in mice 
shares many similarities with HCMV infection in human and therefore serves an important 
biological model for vaccine development experiments (Armas et al., 1996; Morello, Ye & 
Spector, 2002; Ye, Morello & Spector, 2002). Although analysis of immunogenicity induced 
by these conditionally attenuated MCMV vectors was not possible within this thesis, studies 
are ongoing in the Ebola virus mouse model using an identical strategy to the one developed 
in the current thesis.  The aim of the in vivo studies will be to compare T cell immunity and 
efficacy induced by the conditionally attenuated MCMV Ebola vectors against those induced 
by the fully replicating version. Earlier studies have shown replication-defective MCMV 
based on permanent deletion of essential genes induce immune responses against endogenous 
MCMV proteins comparable to wild type virus, but these future studies will be the first to test 
immunity against a heterologous target antigen induced by such a replication-defective 
MCMV platform. 
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This study has been facilitated by the advances in mutagenesis of CMV that cloned and 
maintained the virus gen as a bacterial artificial chromosome (BACs) in E. coli (Dunn et al., 
2003; Messerle et al., 1997; Wagner, Ruzsics & Koszinowski, 2002). This propagation of 
CMV as infectious BACs has made the genetics of the virus accessible to the tools of 
bacterial genetics (Messerle et al., 1997). Other cloning strategies have been developed to 
genetically manipulate large herpesvirus genomes, including: yeast artificial chromosomes 
(YACs; (Burke, Carle & Olson, 1987), mammalian artificial chromosomes (MACs; 
(Harrington et al., 1997), P1-derived artificial chromosomes (PACs; (Amemiya et al., 1994), 
and cosmids (Collins & Hohn, 1978; Ish-Horowicz & Burke, 1981). However, these methods 
all present with limitations for cloning the large DNA genome of herpesviruses. YACs are 
amenable to cloning large DNA fragments even up to 1000 kb, but since they are propagated 
in yeast they are more prone to genetic rearrangement and generation of chimeric clones 
(Burke, Carle & Olson, 1987; Green et al., 1991; Monaco & Larin, 1994). PACs and cosmids 
both have advantages of being bacterial based cloning vectors like BACs, but their ability for 
cloning large DNA genomes such as herpesviruses is limited with a carrying capacity of 100-
300 and 35-45 kb, respectively (Amemiya et al., 1994; Ish-Horowicz & Burke, 1981). Due to 
the unstable nature of repetitive sequence in herpesvirus genomes, BAC technology 
represented the best method of cloning. BACs are also able to maintain up to 300 kb of DNA 
stably in the bacterial host. In addition BAC encode an F-factor gene that maintain a single 
plasmid copy per bacterial cell so during propagation, limiting unprompted viral DNA 
recombination (Shizuya et al., 1992).  
Prior to the use of BAC-based technology, mutagenesis via homologous recombination of 
large CMV genomes within eukaryotic cells was a time-consuming task due to the slow 
replication of the virus in cell culture (Mocarski et al., 1996). The advent of BAC technology 
allowed for easier mutation of the viral genome and the subsequent development of various 
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mutants that have helped shed light on viral gene functions in the context of infection. In 
addition to maintaining the viral genome as a BAC, simple and straightforward methods to 
generate CMV mutants are vital to characterise the viral functions of CMV leading to 
therapeutic and vaccine developments. In the current study, mutagenesis (insertion of 
ecDHFR domain) was performed in the MCMV BAC using E/T homologous recombination 
in E. coli, which is derived from bacteriophage λ. This system utilizes dsDNA ends as a 
substrate for the recombination reaction. The E/T system is comprised of three components: 
(i) Gam protein that protects dsDNA ends from degradation in bacteria (Sakaki et al., 1973), 
(ii) Alpha protein, which is the 5`-3` exonuclease that generates 3` ssDNA overhangs (Kovall 
& Matthews, 1997), and (iii) Beta protein, which is the ssDNA binding protein that can bind 
and protect ssDNA from degradation (Wu et al., 2006). These components of the E/T 
recombination system can be provided via use of E. coli bacteria (DY380 and its FLP-
recombinase expressing derivative, EL250) containing a chromosomally encoded λ prophage. 
In this system, these three proteins are induced in a temperature-dependent manner (Lee et al., 
2001). 
In order to insert the ecDHFR domain into the pp150 and pp28 of MCMV via homologous 
recombination, these domains must be cloned into a suitable plasmid (Figures 3.4, 3.5 & 
3.12). To generate the recombinant viruses we constructed a plasmid vector where DD was 
cloned to the pOriFRT(wt) plasmid and placed next to Kan
R
 marker flanked by FRT-sites, to 
be able to select for transfer. The most widely used technique in molecular cloning is the use 
of restriction endonuclease enzymes. Cloning is a straightforward technique, whenever 
suitable restriction enzyme sites are available in sequence of both insert and vector DNA. 
PCR cloning has been widely used in biological engineering (Mead et al., 1991; Mitchell, 
Ruggli & Tratschin, 1992). The first part of the cloning process consisted of a PCR 
amplification step. The primers used for amplification of these fragments contained a V5 
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epitope tag and recognition sites for single cutter restriction enzymes (single cutters target 
one restriction site only within the DNA sequence), which at a later stage would allow 
cloning each of the fragments to the desired vector. Furthermore, we identified the same 
unique restriction sites within the pOriFRT(wt) vector. According to this strategy, following 
PCR amplification the resultant PCR product could be digested with the respective enzymes 
and then cloned into the vectors which were similarly prepared by using the same restriction 
enzymes. This method worked well for amplifying the (E134G, Y100I and F140P) domain. 
There are a number of reasons for using the pOriFRT(wt) vector for these studies. First, this 
vector is known to be a vector amenable to genetic manipulation. Second, the pOriFRT(wt) 
vector contained the Kan
R
 gene flanked by FRT sites enabling removal of the marker by 
arabinose induction of the FLP-recombinase in the EL250 bacteria. Finally this plasmid 
contains a R6Kγ origin of replication which only allows replication of plasmids that express 
the replication protein π, thereby avoiding false positive Kan
R
 BAC clones resulting from 
carry-over of the parental template used for generation of the recombination fragment by 
PCR. 
Large oligonucleotides with a priming region homologous to a desired template plasmid that 
contained ecDHFR, the kan
R
 marker flanked by FRT sites and viral homologies to the 
targeted MCMV gene were used to amplify the recombination PCR fragments (Figures 3.19-
3.21). Following amplification, the PCR fragment was then inserted by the flanking 60 bp 
viral homologies. This short homologous sequence required for the recombination is the 
major advantage of the R/T recombination system as it enables the homology targeting 
regions to be contained within a single DNA primer. In contrast, the other recombination 
system like the RecABCD require 2 kbp homologies on both sides for efficient homologous 
recombination, which requires preparatory cloning to assemble the necessary long homology 
domains within a single plasmid prior to use in recombination. 
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The Kan
R
 cassette was inserted to select for the relatively rare occurrence of double cross-
over between the recombination fragment and the corresponding homologous viral sequences. 
The Kan
R
 gene was flanked by short 34 bp FRT-sites, which then enables removal by 
induction of FLP recombinase in the EL250 cells to remove the resistance marker 
(Cherepanov & Wackernagel, 1995; Figures 3.30-3.33). In this study, primers with a length 
of 75 to 80 nt were used for targeting of the E/T recombination system. Primers larger than 
80 nt are costly and difficult to synthesise and also PCR amplification with long primers is 
difficult. Importantly, the primers used were HPLC purified as point mutations within the 
primer themselves resulting from inefficiency of the primer synthesis technology are a 
frequent source of inadvertent mutations during E/T recombination. Using this approach, the 
ecDHFR domain was fused into the viral genome, leaving a single FRT site along with 
flanking vector sequence for a total of 80 bp remaining after Kan
R
 marker excision. 
Previously, a similar strategy was used for fusion of the FKBP to other essential proteins of 
HCMV and MCMV (Glaß et al., 2009). This strategy allowed the successful fusion of 
ecDHFR domain to the C- terminus of both pp150 and pp28 viral proteins in our study. 
In order to confirm overall integrity of the mutated genome and the correct insertion of the 
ecDHFR domain sequence, The BAC DNA were analysed by restriction enzyme digestion 
(Figures 3.32-3.33) and Sanger sequencing (Figures 3.34-3.35). To analyse genomic integrity, 
the genomic pattern of the mutant BAC DNA was compared to the genomic pattern of the 
parental MCMV-WT. The most commonly used restriction digestion enzymes is EcoRI as 
upon agarose gel electrophoresis it produces evenly spaced fragments which are useful to 
detect any gross alteration of the viral genome (Paredes & Yu, 2012). The restriction enzyme 
method for confirmation of genomic integrity of the MCMV BAC DNA has been used 
widely by many studies. It is accepted as a definitive and reliable method for analysis of 
genomic integrity. Although comparison of the genomic integrity between the recombinant 
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virus and the parental MCMV BAC did not identify any gross genetic rearrangement, it is 
possible that more subtle genetic mutations could have occurred. As virus was able to be 
reconstituted from all BACs, any spontaneous small mutation is clearly in a region not 
critical for viral fitness. In this regard, NGS sequencing of the entire MCMV BAC genomes 
will need to be performed to determine whether any gene re-arrangements or deletions have 
occurred.  
The E/T homologous recombination has been shown to be very effective and we were able to 
produce all the mutant virus constructs. However, some difficulties were experienced during 
this project. Although removal of the Kan
R
 cassette from MCMV-PP150/PP28-F140 was a 
straightforward process, removal from MCMV-PP150-E134G/Y100I that fused to the N-
terminus, presented many challenges (Table 3.3). It is not clear why it was not possible to 
remove the selective marker from these MCMV BAC genomes, as many times many 
bacterial colonies presented the expected phenotype (Kan resistant) on the LB agar plate, but 
were negative when screened on LB plates and by PCR analysis. MCMV BAC 
recombination and the excision of the antibiotic resistance cassette are vastly used in the 
literature. The insertion of the ecDHFR domain to the MCMV BAC genome was quite 
simple and uncomplicated (Figure 3.22). Several independent attempts were tried to 
overcome this problem, but they all proved unsuccessful. Whether it was an unknown 
mutation or a reagent problem, we did not identify the source of the block preventing the 
excision of the Kan
R
 marker. 
Reconstitution of viruses with genetically inactivated essential genes is a powerful method of 
studying viral gene function, but requires a complementation system for the growth of 
recombinant viruses. However, such complementing cell line are frequently difficult to derive 
for a number of reasons: 1) The exogenous promoter used to regulate the viral gene may not 
enable appropriate timing and expression levels of the mutated gene; 2) The viral gene may 
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be toxic to the cell when expressed in isolation; 3) primary cells required for growth of CMV 
are not amenable for production of stable cell lines. Following recombination, recombinant 
MCMV BAC DNA must be transfected into eukaryotic cells to determine whether derivative 
viruses can be reconstituted into infectious virus in tissue culture. MCMV BAC DNA was 
delivered into murine embryonic fibroblasts by electroporation in the presence of TMP.  
Destabilization domain strategy is based on genetic fusion of essential genes to DD that can 
be stabilized by a small molecule known as ligand; in this project we used Trimethoprim 
(TMP; (Iwamoto et al., 2010). TMP is an inexpensive small molecule with excellent 
pharmacological characteristics, as it is widely used at lower concentrations than for DD 
stabilization to treat urinary tract infection (Schnell, Dyson & Wright, 2004). All the 
experiments performed with replication defective versions of MCMV-pp150/pp28-F140P in 
this study were grown and titered on MEF cells in the presence or absence of TMP. 
Transfection of recombinant viruses into MEFs in the presence or absence of TMP 
demonstrated the drastic difference in the ability of recombinant to grow in the presence 
versus absence of TMP (Figures 3.36-3.37). Although this system has been used to assess 
gene function, our work represents one of the few studies that take advantage of this powerful 
approach towards development of a conditionally-attenuated vaccine platform (Table 1.4). 
Strict specificity has prevented the study of HCMV in animals, and MCMV has been widely 
used as a model for studying CMV in an animal system (Krmpotic et al., 2003).  
Characteristics of the pp150 and pp28 MCMV recombinants were distinct. Compared to the 
pp150 destabilized virus, the pp28 virus showed a severely delayed reconstitution (between 8 
and 10 days) in the absence of TMP, which was associated with fewer plaques, smaller 
plaque size and lack of spread. This suggested that release of infectious particles after the 
virus reconstitution takes place with extremely low efficiency, similar to the pattern observed 
after deletion of the pp28 (Britt et al., 2004; Silva et al., 2003 & Seo & Britt, 2006).  
256 
 
In contrast, the mutant MCMVpp150-F140P has not shown delay in reconstitution (between 
day 4 and 5) in the absence of TMP, indicating that stabilization of the fusion protein was 
partial, and the degradation of pp150 protein in the absence of TMP ligand was not fully 
achieved. However in the presence of TMP both viruses grew almost the same as their 
parental MCMV-WT (Figures 3.36- 3.37). 
A live attenuated CMV-based vaccine vector should possess the following features. First, the 
virus vector should grow to high titres in cell culture for easy production. Second, the vector 
should be severely attenuated in vivo in both immunocompetent and immunocompromised 
individuals. Third, the vector should induce a strong immune response sufficient to protect 
against a challenge to the same level as or even better than that of natural infection with the 
wild-type CMV. Evaluation of the conditional system using DD protein revealed that the 
CMV mutants grew to titres that were comparable to those of the parental virus when the 
optimal concentration of ligand was added. For efficient complementation of the CMV 
mutants, different concentration of ligand were required and used. Thus, the amount of ligand 
needed for stabilization of the target protein differed for each fusion protein indicating that 
the optimal ligand concentration has to determine empirically (Glaß et al., 2009). To indicate 
the tenability of plaque formation and determine optimal concentration of TMP, we grew 
infected MEF cells with different amount of TMP (Figures 3.42-3.45). We observed effective 
plaque formation by MCMV-PP150-F140P at 50 μM TMP. Similarly, higher amounts (100 
μM) of TMP were needed for stabilization of PP28-F140P. This observation is in agreement 
with previous studies that proved that the concentration of ligand that stabilizing to each 
fusion protein should be determined individually (Banaszynski et al., 2006; Iwamoto et al., 
2010).  
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Moreover, conditional expression of genes using ecDHFR strategy is a promising tool in 
order to study function (s) of essential genes to develop antiviral compounds and vaccine 
vectors. TMP-dependent rapid degradation/stabilization of ecDHFR-tagged proteins 
(Banaszynski et al., 2006; Iwamoto et al., 2010) provides a means to control essential genes, 
taking advantage of the possibility to study the “off” and “on” situations with the same virus 
stock preparation. Treating MCMV-pp150/pp28-F140P infected cells with TMP for four days 
and then withdrawal of TMP for 6 hr decreased the titre of the viruses significantly compared 
to virus maintained with TMP continuously (P˂0.0308 and P˂0.0001, respectively) 
Withdrawal of TMP for short times, even 6 hr, partially degraded their growth (Figure 3.53 B 
& C). Whereas treating MCMV-pp150/pp28-F140P infected cells without TMP for four days 
and then culture for 6 hr with TMP, partially restored their growth via increasing the titre of 
the virus compared to virus maintained without TMP continuously (P˂0.0417 and P˂0.0018, 
respectively). Indicating partially restored growth (Figure 3. 54 B & C).     
 Based on the expression kinetics, both pp150 and pp28 are true L genes. Although there 
were significant differences between MEF cells infected with MCMV-pp150/pp28-F140P the 
titre of the virus regardless to add/withdrawal of TMP when cultured for 6 hr, probably if 
culture be followed for longer periods statistically significant difference may increase 
between them. Our results are consistent with previous studies that both pp150 and pp28 
tegument protein are essential for late stages of CMV virion assembly and aggress.    
To examine the growth kinetics of recombinant viruses (MCMV-pp150-F140P or MCMV-
pp28-F140P), we compared the virus growth in the presence or absence of ligand TMP in the 
different time points. Compared to the MCMV-WT parental virus and in the presence of 
TMP, the virus grew to titres comparable to those of the wild-type virus (Figure 3.55 B).  
However in the absence of TMP the MCMV-pp150-F140P virus showed almost similar 
growth kinetics to the virus kept with TMP (Figure 3.55 C). Consistent with the previous 
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results, that indicated the virus grew regardless of the presence or absence of TMP (Figure 
3.36). As a complement to the studies described above, although the F140P domain enables 
regulated stability of pp150 ORF, the F140P domain tag inhibits some aspect of replication of 
mutant MCMV we saw a little effect of TMP, suggesting a level of destabilization of the 
pp150 in an intermediate attenuated replication phenotype of the virus. 
In the presence of TMP, the MCMV- pp28-F140P grew to titres comparable to the parental 
MCMV-WT (only 2 log lower; Figure 3.56 B). Infected cells kept without TMP produced a 
few viruses in day 3 post infection and later however the titres of these viruses did not 
increased over time (Figure 3.56 C. The TMP restored the function of recombinant MCMV-
pp28-F140P virus through restoring the function of ecDHFR fused pp28. While in the 
absence of TMP only a few foci had developed and the titre did not increase over time 
(Figure 3.56). This provides evidence that the defective growth phenotype of the virus was 
due to degradation of the pp28 tegument protein.  
In conclusion, the results described in this chapter highlight the potential of the generation 
and characterisation of the replication defective version of recombinant MCMV vector with 
fusion of ecDHFR to tegument proteins of late kinetic class which can be used as a valuable 
tool for design and development of an effective and inexpensive vaccine for potential use in 
all individuals regardless of immune status. This new strategy will provide the necessary 
groundwork for future studies evaluating the utility of MCMV model in which to study 
HCMV vaccine development and also to develop a vaccine platform that is suitable for 
development to target emerging viruses in low income countries. Future studies will now be 
able to exploit the MCMV infection model in mice to explore the efficacy of these 
conditionally attenuated vaccines against a variety of significant infectious and non-infectious 
diseases taking advantage of existing mouse models. These include various mouse cancer 
models, as well as infectious disease models of Ebola and IA viruses and tetanus. 
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Chapter Four: 
CD8
+
 T cell targeting of conserved IA virus structural 
proteins using CMV-based vectors to elicits homo and 
heterosubtypic immunity 
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4.1 Introduction 
IA virus is one of the most common causes of respiratory tract infection in humans, being 
responsible for annual outbreaks of influenza disease within the human population as 
seasonal or epidemic flu. The virus can also periodically and unpredictably lead to pandemic 
influenza that results from introduction of a completely new IA virus into an 
immunologically naïve population to devastating effect on human health worldwide. Current 
seasonal vaccination induces protective antibodies against the HA and NA of the IA virus. 
These vaccines are aimed only at induction of antibodies against the surface HA and NA 
glycoproteins and are poor inducers of T cell responses. These vaccines are relatively 
effective against the current IA viruses circulating in the human population. However, 
seasonal vaccines are completely ineffective against pandemic IA viruses possessing new HA 
and NA genes for which the human population has no immunological memory.  
A universal vaccine that induces broad protection by targeting more conserved regions of the 
virus could be more effective, thereby inducing cross-protection against multiple IA virus 
subtypes (Altenburg, Rimmelzwaan & de Vries, 2015; Strutt et al., 2013). The internal 
proteins are highly conserved among different virus subtypes and are not exposed to the 
humoral immune system. Therefore these proteins do not change as frequently as HA and NA 
(Lee et al., 2014), and thereby may be able to induce a heterosubtypic immune response 
associated with  CTL responses (Suda et al., 2011). In our study we explored the use of fully 
replicating WT MCMV expressing conserved internal proteins of the IA virus (NP, PA and 
NS2) as a vaccine vector to induce heterosubtypic IA virus-specific CD8
+
 T cell immunity.  
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4.2 Results 
4.2.1 Cloning of MCMV-IA-based vectors 
As detailed in the introduction (Sections 1.7 and 4.1), the overall aim of this study was to 
establish at a proof-of-concept level in the mouse model that targeting T cell immune 
responses against more highly conserved regions of the IA virus for the development of a 
universal flu vaccine would yield a vaccine effective against all serotypes of IA virus. Not 
only would this protect against pandemic IA viruses, but it would also remove the need for 
vaccines to be reformulated annually. Given the accepted ability of CMV-based vaccines to 
induce high levels of T cell immunity, we explored a CMV-based approach using MCMV as 
a vaccine vector against IA virus expressing epitopes of conserved IA virus proteins. Three 
MCMV-based influenza vaccines (MCMV-IAV) were designed, each expressing a single 
H2
b
-restricted CD8
+
 T cell epitope of a conserved IA structural protein: NP represented by 
NP366-374 (ASNENMETM) (Andreansky et al., 2005), PA by PA224-233 (SSLENFRAYV) 
(Belz et al., 2000) and NS2 by NS2114-121 (RTFSFQLI) (Belz et al., 2000). These epitopes 
were fused in-frame to the carboxyl terminus of IE2, a non-essential protein of MCMV 
(Figure 4.1). MCMV-IA (NP, PA, and NS2) vectors were constructed by E/T linear 
recombination using the pSMfr BAC containing the MCMV (Smith strain) genome (Messerle 
et al., 1997), as described in Section 2.5.1. The m157 gene of MCMV was deleted from this 
BAC for these studies due to the NK activating effect of the m157 gene product on NK 
activity in the C57BL/6 mouse background, as discussed above. The E/T linear 
recombination strategy is outlined in the Chapter 3 (Figure 3.3.).  
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Figure 4.1 Schematic illustration of MCMV-IAV constructs expressing a single H2b-
restricted cytotoxic T cell (CTL) epitope. H2
b
-restricted T cell epitopes from IA conserved 
structural proteins NP (NP366-374; ASNENMETM), PA (PA224-233; SSLENFRAYV) or NS2 
(NS2114-121; RTFSFQLI) were fused in-frame to the carboxyl terminus of MCMV IE2 
generating the recombinant MCMV/IA-NP, MCMV/IA-PA and MCMV/IA-NS2 vaccine 
vectors. 
 
To construct the recombinant MCMV-IA vaccines, linear DNA fragments encoding the 
sequences of the IA epitopes and a Kan
R
 marker, flanked on either end by sequence 
homologous to the targeted IE2 insertion site were generated by PCR, as described in Section 
2.3.3. These recombinant PCR fragments were transformed by electroporation into 
electrocompetent, E/T recombinase-induced EL250 cells as described in Section 2.2.4. 
Recombinant clones were selected based on resistance to both Cam and Kan. Following 
genomic characterization, the Kan
R
 marker was removed by arabinose induction of the FLP 
recombinase system (Section 2.5.1.3). Recombinant viruses were reconstituted by 
transfection using electroporation of BAC DNA into MEFs as described in Section 2.6.2.1. 
Following virus reconstitution, virus was passaged to remove the BAC cassette (Section 
2.6.2.3) and seed and concentrated virus stocks of all three viruses were prepared (see Figure 
2.1 for schematic of construction process). 
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4.2.1.1 PCR fragments with flanking viral homologies to IE2 were generated 
Recombination fragments were amplified by PCR using the forward primer IE2-NP-F5-F, 
IE2-PA-F5-F or IE2-NS2-F5-F together with a common reverse primer, IE2-NP/PA/NS2-F5-
R (Table 2.2). The pOriFRT(F5) plasmid was used as a as a template for all reactions. This 
template plasmid contains the F5 mutant version of the FRT, which is necessary to prevent 
inadvertent recombination between the FRT (WT) ‘scar’ remaining from the m157 deletion. 
The 5` end of each primer contained 45 bp sequence with homology to the epitope insertion 
site at the immediate carboxyl terminus of the MCMV IE2 ORF with removal of the IE2 stop 
codon. This homology sequence was followed by sequence encoding the NP, PA or NS2 
epitopes and a 16 bp sequence necessary for primer binding to the pOriFRT(F5) template 
plasmid. Each recombination fragment was prepared in duplicate using 2 independent PCR 
reactions, which were then used in parallel for cloning of independent versions of each 
MCMV-IA recombinant, to avoid concerns with spurious PCR-associated mutations during 
production of recombination fragments. Gel electrophoresis confirmed amplification of PCR 
recombination fragments of the expected 1.5 kb size (Figure 4.2 A and B). Recombination 
PCR fragments were extracted from the gel (Section 2.3.6) and purified using a gel extraction 
kit (Section 2.3.7). Gel purified recombination fragments were confirmed to be of the correct 
size by electrophoresis (Figure 4.2 C).  
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 (A) 
 
(B) 
 
(C) 
 
Figure 4.2 Recombination PCR fragments used for construction of three MCMV-IA 
vaccine vectors. (A) Schematic showing PCR generated E/T recombination fragments used 
for construction of the three MCMV-IA vaccine vectors. (B) DNA gel showing recombinant 
PCR generated fragments containing NP, PA, and NS2 H2
b
 - restricted CD8
+
 T cell epitopes. 
The single DNA band at 1.5 kb shows amplification of the desired recombination fragments. 
Two independent PCR reactions were prepared for each clone. (C) Gel purified PCR products 
confirming the extraction procedure was successful and the correct sized bands purified. 
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4.2.1.2 Construction of recombinant MCMV-IA (NP, PA and NS2) based vector using 
E/T-based linear recombination 
PCR-derived recombination products prepared above were inserted at the extreme carboxyl 
terminus of the IE2 locus within the MCMV BAC genome using E/T recombination (Section 
2.5.1.2) to generate the respective MCMV-IA BAC recombinants. Following recombination, 
bacteria were plated on Kan/Cam plates to select for clones containing recombinant BACs. 
Bacterial colonies were counted (Table 4.1) and two clones from each recombination were 
selected for further characterization. For each MCMV/IA virus, recombination was 
performed twice, each using a different independently generated recombination fragments. 
This was a precautionary necessity as DNA sequences of recombinant viruses are analysed 
only at the recombinant BAC stage. Overnight cultures were prepared and recombinant 
BACs were purified by alkaline lysis (Sambrook et al., 2001) as described in Section 2.3.1.2. 
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Figure 4.3 Schematic illustrating the construction of MCMV-IAV vectors. The E/T-
based linear recombination strategy used for construction of the three MCMV-IAV vectors. 
Recombinant fragments carrying the Kan
R
 marker flanked by FRT sites and the sequence 
encoding the H2
b
 restricted epitopes from conserved IA structural proteins (NP, NS2 or PA) 
were amplified by PCR, and electroporated into EL250 bacteria containing the MCMV BAC. 
Following selection of recombinant BACs on the basis of Kan resistance, the Kan
R
 marker 
was removed using FLP mediated-recombination. Recombinant MCMV-IA BACs were 
electroporated into MEFs to reconstitute recombinant MCMV/IA virus. Frt, FRT FLP-
recombinase recognition site from the yeast Saccharomyces cerevisiae; Kan
R
, Kan resistance 
gene; IA epitope, conserved protein epitope (NP, NS2 or PA) of IA virus.  
 
               Table 4.1 Number of recombinant MCMV-IA (NP, PA or NS2)  
                             BAC clones following E/T recombination 
MCMV Construct                       PCR fragment       Number of colonies 
MCMV-IA-NP                                        1                             200-250 
                                                                 2                             200-250                                  
MCMV-IA-NS2                                      1                             200-250 
                                                                 2                             250-300 
MCMV-IA-PA                                        1                             100-150 
                                                                 2                             150-200 
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4.2.1.3 Restriction digestion analysis of recombinant BAC DNA  
Rearrangement of the BAC genome can occur during E/T based recombination. To ensure 
selected Kan-resistant clones had retained genomic integrity, restriction digest analysis was 
performed. A MCMV-WT BAC and three clones of each of the recombinant MCMV-IA (NP, 
PA, and NS2) BACs were digested using EcoRI and the resulting banding pattern was 
analysed by gel electrophoresis on a 1% gel (see Section 2.3.5). The results are shown in 
Figure 4.4. The banding patterns generated by the digested recombinant MCMV-IA BACs 
were consistent with the banding pattern of the digested MCMV-WT BAC control sample, 
indicating that there were no gross genomic rearrangements in the recombinant MCMV-IA 
(NP, PA and NS2) BAC DNAs following the recombination process (Figure 4.4).  
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Figure 4.4 Characterization of the recombinant MCMV-IA BAC genome using EcoRI 
restriction enzyme digestion. MCMV-WT BAC and three independent clones of each 
MCMV-IAV vector (NP, PA and NS2) BACs were digested with EcoRI and the resulting 
fragments were separated on a 1% agarose gel for 18-20 h at 45 V, followed by visualization 
with 0.5 µg/ml EtBr. Comparable restriction digestion pattern between the MCMV-IA clones 
and MCMV-WT(FRT F5) BAC shows the absence of any gross genomic rearrangements. 
Molecular size marker lane (MW) in kb is indicated.  
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4.2.1.4   Excision of the Kan
R
 cassette from recombinant MCMV-IA (NP, PA and NS2) 
BAC DNA  
Following confirmation that recombinant BAC genomes were genetically intact, the next step 
was to remove the FRT-flanked Kan
R
 marker by arabinose induction of the EL250 FLP 
recombinase (see Section 2.5.3). To confirm that Kan
R
 was removed from recombinant 
MCMV-IA (NP, PA and NS2) BACs, 25 colonies from each ‘FLPed’ recombinant MCMV-
IA BAC were replica-plated on Cam/Kan and Cam only plates (Section 2.5.3). Clones in 
which the FRT-flanked Kan
R
 marker had been excised were no longer able to grow in the 
presence of Kan, but retained the ability to grow in the presence of Cam (Table 4.2). 
To confirm that the absence of genetic rearrangements during Kan
R
 excision, DNA from 
‘FLPed’ BAC recombinants was again analysed by restriction digest with EcoRI (Figure 4.5), 
followed by electrophoresis on a 1% agarose gel. MCMV WT BAC DNA and MCMV-IA 
recombinant BAC DNA (pre-and post-FLP) were compared to confirm genomic integrity of 
the post FLP recombinant clones. The banding patterns generated by the EcoR1 digested 
recombinant MCMV-IA BACs showed the absence of genomic rearrangements in the 
recombinant MCMV-IA (NP, PA and NS2) BACs following FLP recombinase-mediated 
removal of the Kan
R
 gene. 
 
       Table 4.2 Analysis of recombinant MCMV BAC clones following excision of Kan
R
           
   MCMV Construct     Recombination    Clone   Selected colonies   Sensitive to Kan 
MCMV-IA-NP                      1                      3                   25                               All 
                                                     2                      5                   25                               All 
MCMV-IA-PA                      1                      1                  25                                All 
                                                      2                      1                 25                                All 
MCMV-IA-NS2                    1                       4                 25                               All 
                                                      2                       4                 25                               All 
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(A) 
 
(B) 
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(C) 
 
 
 
Figure 4.5 Characterization of recombinant post-FLP MCMV-IA BAC genomes using 
EcoRI restriction enzyme digestion. MCMV-WT and recombinant MCMV-IA pre-FLP and 
derivative post-FLP BACs were digested with EcoRI and the resulting fragments were 
separated on a 1% agarose gel for 18-20 h at 45 V and visualized by staining with 0.5 µg/ml 
EtBr. (A) MCMV-WT and recombinant MCMV-IA-NP pre-FLP (clones 3 and 6) and 
derivative post-FLP (clones 3-1, 3-3, 3-6, 3-9, 6-2, 6-4, 6-6 and 6-8) BACs. (B) MCMV-WT 
and recombinant MCMV-IA-PA pre-FLP (clones 1 and 2) and derivative post-FLP (clones 1-
1, 1-2, 1-4, 1-6, 2-3, 2-5, 2-7 and 2-9) BACs. (C) MCMV-WT and recombinant MCMV-IA-
NS pre-FLP (clones 4 and 5) and derivative post-FLP (clones 4-2, 4-4, 4-6, 4-8, 5-1, 5-3 and 
5-5) BACs. Comparable restriction banding patterns between the MCMV-IA-NP clones (both 
pre and post FLP- recombinase) and MCMV-WT demonstrate absence of any gross genomic 
rearrangments. Molecular size marker lane (MW) in kb is indicated.  
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To confirm excision of the Kan
R
 marker from the recombinant BAC genomes, PCR was 
performed using IE2-Flank primers that flank the IA insertion site within the IE2 locus (Table 
2.2). PCR was performed on recombinant BAC DNA (pre-and post-FLP), and on WT 
MCMV BAC DNA (included as a control; Figure 4.6). PCR of the WT MCMV BAC yielded 
a band of approximately 700 bp. In contrast, PCR of  the pre-FLP BAC clones PCRs yielded 
bands of approximately 1.5 kbp, which was consistent with presence of the Kan
R
 gene (and 
presumably the respective IA epitope sequence) at the desired location within the MCMV 
BAC genome. The post-FLP clones yielded bands of approximately 750 bp reflecting the loss 
of the Kan
R
 gene. 
To confirm sequence integrity of the IA epitopes, PCR using IE2-Flank-F and IE2-Flank-R 
primers was used to amplify the 3’ end of the IE2 ORF from each of the MCMV-IA 
recombinants using BAC DNA as the template. Two independent clones of each recombinant 
MCMV-IA (NP, PA and NS2) BAC were then sequenced. The sequence data indicated that 
the full-length sequences of the IA virus CTL epitopes were present, without any deletions or 
mutations (Figure 4.7). 
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(A) 
 
(B) 
 
(C) 
 
Figure 4.6 Confirmation of excision of the Kan
R
 marker from (A) MCMV-IA-NP, (B) 
MCMV-IA-PA, and (C) MCMV-IA-NS2 BACs genome by PCR. BAC DNA from 
MCMV-WT and four clones of each recombinant MCMV-IA (NP, PA and NS2) BAC (both 
pre and post-FLP) were screened by using PCR using primers flanking the IE2 site targeted 
by recombination. PCR products were separated on a 1% agarose gel for 60-90 min at 75 V, 
and visualized by staining with 0.5 µg/ml EtBr. PCR pre-FLP MCMV-IA (NP, PA, and NS2) 
and post-FLP MCMV-IA (NP, PA, and NS2) yielded PCR products of 1.5 kb and 750 bp, 
respectively. Molecular size marker (MW) in bp is indicated. 
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(A)  
  MCMV-IA-NP Clone (1-3) 
 
 
   MCMV-IA-NP Clone (3-3) 
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  (B) 
  MCMV-IA-PA Clone (2-1) 
 
 
  MCMV-IA-PA Clone (2-2) 
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  (C)  
 MCMV-IA-NS2 Clone (4-2)  
 
 
  MCMV-IA-NS2 Clone (4-4) 
 
Figure 4.7 Confirmation of IA epitope within MCMV-IA BACs via Sanger sequencing. 
PCR were performed on post-FLP BAC clones: (A) MCMV-AI-NP clones (3-1) and (3-3). 
(B) MCMV-AI-PA clones (2-1) and (2-2). (C) MCMV-AI-NS2 clones (4-2) and (4-4). Black 
text represents IE2 genome sequence, green represents represented IA epitope tag sequence 
and black text represents downstream MCMV genome sequence.  
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4.2.1.5   Reconstitution of recombinant MCMV-IA (NP, PA, and NS2) virus 
Herpesvirus genomic DNA is infectious. This means that the DNA genome of the virus in 
itself (in this case contained within the BAC) is sufficient to reconstitute de novo progeny 
virus when introduced into permissive eukaryotic cells. To reconstitute the recombinant 
MCMV-IA (NP, PA, and NS2) viruses, each BAC DNA was introduced into MEFs by 
electroporation; MEFs were also electroporated with WT-MCMV BAC DNA as a positive 
control (see Section 2.6.2.1). Two independent clones from each vector were selected for 
reconstitution (Table 4.3) to mitigate effects of any potential second site mutations. Cell 
monolayers were monitored daily for signs of virus-induced CPE such as swelling, rounding, 
aggregation, cell death and plaque development (Kim & Carp, 1971). All recombinant 
MCMV-IA viruses were successfully reconstituted. Virus plaques were visible in MEF 
monolayers beginning at 3 to 7 days post-infection. Numbers of plaques are shown in Table 
4.3. MCMV-IA (NP, PA, and NS2) plaques were picked as described in Section 2.6.2.1 and 
passaged as described in Section 2.6.2.3. 
 
        Table 4.3 Plaque numbers of recombinant MCMV-IA (NP, PA, and NS2)  
                        following reconstitution in MEFs          
MCMV-IA BAC vector plaques             Clones                     Plaque numbers           
     MCMV-WT                                            2443                               12 
     MCMV-IA-NP                                       3-1                                   7 
                                                                     3-6                                   8  
     MCMV-IA-PA                                       1-4                                   6 
                                                                    1-14                                 5 
    MCMV-IA-NS2                                     4-6                                   13 
                                                                    4-8                                   7 
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4.2.1.6 Removal of BAC cassette from recombinant MCMV-IA viruses 
Freshly reconstituted (passage 1) recombinant MCMV-IA viruses still contain the BAC 
cassette within their genome. The BAC cassette serves no function within the viral genome. 
However, the increased genome size, resulting from presence of the BAC cassette can  
interfere with packaging of the viral genome into the confined space of CMV capsid, which 
ultimately leads to in vivo attenuation of the recombinant viruses (Wagner et al., 1999). To 
resolve this issue, the pSMfr BAC cassette has been flanked by homologous directly repeated 
genomic sequence regions of 527 bp (Wagner et al., 1999). The presence of these 
homologous regions within the ‘oversized genome’ leads to targeted excision of the BAC 
cassette following serial passage in vitro (Wagner et al., 1999). MCMV-IA viruses were 
serially passaged 5 times in MEFs to remove the BAC cassette followed by preparation of 
virus seed stocks.  
 
Figure 4.8 Confirming excision of BAC cassette from reconstituted MCMV-IA-(NP, PA 
or NS2) genome by PCR. DNA was isolated from cells infected with reconstituted MCMV-
IA (NP, PA or NS2) virus after five passages using a QIAamp kit and PCR was carried out. 
PCR products were separated on a 1% agarose gel. The presence of a 750 bp band in 
recombinant MCMV-IA-PA (lanes 1 and 2), -NP (lanes 3 and 4) and -NS2 (lanes 5 and 6), 
respectively confirmed the excision of BAC cassette from the virus genome. 
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4.2.1.7   Preparation of recombinant MCMV-IA virus seed stocks 
Seed stocks of MCMV-IA-NP, MCMV-IA-PA and MCMV-IA-NS2 were prepared using 
supernatants from passage 5 virus stocks (P5; Section 2.6.2.4). A parental MCMV-WT seed 
stock was also prepared. Infected cell monolayers were incubated for four days, by which 
time approximately 95% of cells demonstrated substantial CPE. Cells and supernatant were 
harvested, freeze thawed at -80C, clarified at 3,800 rpm (4,600 × g) for 20 min at RT, 
aliquoted and stored at -80C. Following preparation of the virus seed stocks, the infectivity 
titre in PFU/cell of the frozen stocks was determined using TCID50, as described in Section 
2.6.2.6.  
 
4.2.1.8 Preparation of concentrated virus stocks from seed stock  
High titre virus stocks for use in in vitro characterization and in animal studies were prepared 
from seed stocks generated above, as described in Section 2.6.2.5. These stocks were fully 
characterized prior to use in animal experiments. It was particularly important to confirm that 
the sequence of the IA epitopes had remained intact in all of the MCMV-IA clones. Two 
clones of each recombinant MCMV-IA (NP, PA or NS2) virus were selected for 
characterization. Two independent PCR amplifications of viral DNA from each of these 
clones was then performed using IE2-Flank primers (Table 2.2) (see Section 2.3.3). Bands of 
the expected sizes of 700 bp and 750 bp were observed in the MCMV-WT lanes (1 & 2), and 
recombinant MCMV-IAV lanes (3-6), respectively (Figure 4.9). Sanger DNA sequencing of 
the PCR products showed that the respective full-length IA virus epitopes were located in the 
correct position at the carboxyl-terminus of the IE2 ORF and did not have any deletions or 
mutations which would possibly confound CTL recognition (Figure 4.10). These results 
confirm the presence of the IA epitopes, and also demonstrate the absence of MCMV-WT 
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contamination within recombinant MCMV-IA virus stocks. The presence of MCMV-WT 
contamination is due to the maintenance of BACs as low copy rather than single copy within 
bacteria. This is always a concern, but one which we have largely overcome by agarose 
overlay and plaque purification at the virus reconstitution stage. 
 
Table 4.4 Titres of MCMV-WT and the recombinant MCMV-IA virus vectors stocks.  
         Virus (MCMV)                                       Titre by TCID50 (PFU/cell) 
         MCMV-WT(F5)                                                                 8.71 ×10
7
 
         MCMV-IA-NP                                                                    8.48 ×10
7
 
         MCMV-IA-PA                                                                    2.50 ×10
7
 
        MCMV-IA-NS2                                                                   6.70 ×10
7
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(A)                                           
 
(B)   
 
(C) 
 
Figure 4.9 Confirming presence of IA epitopes in MCMV-IA viruses genome by PCR. 
DNA was isolated from MCMV-IA (NP, PA, and NS2) concentrated stocks using a QIAmp 
kit and PCR was performed using IE2-Flank primers. PCR products were separated on a 1% 
agarose gel. The presence of a 750 bp band in recombinant (A) MCMV-IA-NP, (B) MCMV-
IA-PA and (C) MCMV-IA-NS2 virus lanes (3-6) was consistent with presence of the desired 
epitope, which was then confirmed by DNA sequencing. Absence of the MCMV-WT sized 
band (700 bp) in the MCMV-IA (NP, PA and NS2) viruses lanes (1-2) confirmed the absence 
of WT contamination of recombinant stocks. 
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 (A)  
 MCMV-IA-NP PCR 1  
 
 
  MCMV-IA-NP PCR 2 
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(B)  
MCMV-IA-PA PCR 1 
 
 
   MCMV-IA-PA PCR 2 
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(C)  
  MCMV-IA-NS2 PCR 
 
 
  MCMV-IA-NS2 PCR 2 
 
Figure 4.10 Confirmation of IA epitope within MCMV-IA virus genome by Sanger 
DNA sequencing. PCR was performed on viral DNA isolated from concentrated viral stocks 
(show in Figure 4.9). The two independent PCR products were sequenced: (A) MCMV-IA-
NP PCR 1 and PCR 2. (B) MCMV-IA-PA PCR 1 and PCR 2. (C) MCMV-IA-NS2 PCR 1 
and PCR 2. IE2 genome sequence (blue), IA epitope tag sequence (green), downstream 
MCMV genome sequence (black). The stop codon is shown in red.  
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 4.2.1.9 Recombinant MCMV-IA viruses show comparable replication to MCMV-WT 
virus 
Virus stock titres were quantified by TCID50 assay as described in Section 2.6.1.6. Results 
showing comparable yields of virus in the MCMV-IAV and MCMV-WT stocks suggested 
that the recombinant viruses were WT in characteristic as regards in vitro replication (Table 
4.4). Multi-step growth curves were performed to confirm that the MCMV-IA viruses had in 
vitro replication kinetics comparable to MCMV-WT. MEFs were infected in triplicate at a 
multiplicity of infection (0.1 PFU/cell) with either MCMV-WT or the different MCMV-IA 
recombinant viruses. Supernatants were harvested at selected time-points (0, 1, 3, and day 5 
post-infection) and viral titres were quantified by TCID50 assay (see Section 2.6.1.6). As 
shown in Figure 4.11, levels of progeny virus production and kinetics of replication of the 
MCMV-IA recombinant viruses were comparable to MCMV-WT. Although all recombinant 
MCMV-IA viruses trended towards a slightly lower replication rate, this difference was not 
statistically significant (NP: P= 0.5052, PA: P= 0.3728 and NS2: P= 0.4224). These results 
indicated that insertion of influenza epitopes into the IE2 ORF does not negatively affect 
MCMV replication in vitro, which is consistent with other published studies (Karrer et al., 
2004; Tsuda et al., 2011).   
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Figure 4.11 Replication of recombinant MCMV-IA vectors compared to its parental 
MCMV-WT (FWT) virus. MEF cells were infected with: (A) MCMV-IA-NP, (B) MCMV-
IA-PA, (C) AMCMV-IA-NS2 or MCMV-WT at an MOI of 0.1 PFU/cell. At the time points 
indicated, supernatants were collected and virus levels were determined by TCID50 assay on 
MEF cells. Results are the mean of two separate experiments, with samples measured in 
triplicate. Error bars show the standard deviations (Note: each recombinant is compared to 
the same MCMV-WT titration).  
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4.2.2 Induction of CD8+ T cell responses using recombinant MCMV-IA virus vectors 
Recombinant MCMV-IA (NP, PA, or NS2) vectors were tested in a mouse model for their 
ability to induce specific CD8
+
T cell immune responses against the respective IA epitopes. 
Immunogenicity studies were performed in H2
b
-restricted mice (C57BL/6, 6-8 week old, 
female). Mice were inoculated intraperitoneally with a single dose of 1 × 10
5 
PFU of a 
mixture of the three recombinant MCMV-IA (NP, PA, and NS2) vectors combined as a 
single bolus for a total of 3 × 10
5 
PFU (1x10
5 
PFU of each virus). Control groups received 3 × 
10
5 
PFU of MCMV-WT, 1 × 10
5 
PFU of formalin-inactivated H5N1 IA virus or diluent 
(mock).  
After 7/8 and 12 weeks, splenocytes were harvested for analysis of T cell responses by using 
ICS (Section 2.8.1) with a 6 hr in vitro stimulation by incubation with the different IA and 
MCMV (control) peptides (Table 4.5). Importantly, peptides used for the in vitro stimulation 
were both those homologous to the PR8 (A/Puerto Rico/8/1934 H1N1) epitope present within 
the recombinant MCMV-IA viruses, as well as peptides representing the heterologous 
versions from an additional two different IA virus subtypes H3N1 
(A/Swine/Minnesota/00395/2004) and H5N1 (A/Vietnam/1194/2004). In some cases, (for 
example PA224-233) the epitope sequence is conserved across all three IA subtypes, such that 
measurement of T cell responses against a single peptide also represents the heterosubtypic 
response to this epitope for all three IA viruses. However, where sequences are divergent 
between different IA virus subtypes, this approach enables assessment of cross-reactive 
responses induced by the MCMV-IA virus encoding the PR8 epitope to the non-identical 
peptide of the heterologous virus. Together, this approach thereby enables both homo- as well 
as heterosubtypic IA virus T cell responses to be determined. A schematic of the vaccination 
and T cell characterization is shown in Figure 4.12. 
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Table 4.5 Influenza A and MCMV H2
b
- restricted peptides, used in ICS assay 
for induction of T cell responses. (Source: Influenza Research Database (IRD) 
H2
b
- Restricted Peptides                          Sequence               MHC specificity 
IA NP366-374 (PR8+X31)                              ASNENMETM             H-2D
b
 
IA NP366-374 (H5N1Viet)                             ASNENMEAM             H-2D
b
 
IA PA224-233 (PR8+ X31+ H5N1Viet)         SSLENFRAYV             H-2D
b
& H-2K
b
 
IA NS2114-121 (PR8+X31)                             RTFSFQLI                   H-2D
b
& H-2K
b
 
IA NS2114-121 (H5N1Viet)                             RAFSFQLI                  H-2D
b
& H-2K
b
 
IA PB1703-711 (PR8+ X31+ H5N1Viet)*       SSYRRPVGI               H-2K
b
 
MCMV M38**                                              HGIRNASFI               H-2K
b
 
MCMV M45***                                                      SSPPMFRV                H-2D
b
 
           * PB: Not present in MCMV-IAV vaccine construct 
         ** M38: Endogenous MCMV peptide-inflationary 
        ***M45: Endogenous MCMV peptide-non-inflationary 
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Figure 4.12 Schematic showing MCV-IA vaccinated mouse groups. C57BL/6 (H2
b
-
restricted, 6-8 weeks old female mice) were inoculated intraperitoneally with a single dose of 
1 × 10
5
 PFU of each of the three recombinant MCMV-IA-(NP, PA and NS2) vectors 
combined for a total of 3 × 10
5
 PFU (1x10
5
 PFU of each virus). Control groups received 3 × 
10
5
 PFU of MCMV-WT, 1 × 10
5
 PFU of diluent (Mock) or formalin-inactivated H5N1 IA. 
At weeks 8 and 12 splenocytes together with lungs for week 12 only were harvested for 
analysis of T cell responses. 
 
Results are shown in Figure 4.13 through Figure 4.18. By week 7/8 post-inoculation, IA-
specific T cell responses were observed against all homosubtypic IA epitopes in MCMV-IA 
vaccinated mice (Figures 4.13 - 4.14). Average homosubtypic responses against the PR8 
peptides were as follows (n=4 group): NP 0.09 (+/- 0.08), PA 0.11 (+/- 0.05) and NS2 0.03 
(+/- 0.01). We have determined a cut-off value for a positive response as 0.02 and above, 
which is based on the mean of all responses against the IA epitopes observed for MCMV-WT 
mice + 3 SD.  These responses were shown to be statistically significant (t-test, 2-tailed) 
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when compared against either Mock or MCMV-WT control mouse groups (n=4) for PA 
(0.003) and NS2 (0.002), and trending towards significance for NP (p=0.056) (p-values 
presented are those compared against MCMV-WT). Statistically significant cross-reactive 
heterosubtypic responses were observed against PA (where the epitope is completely 
conserved across the three IA subtypes, and therefore is identical to homosubtypic, PR8 
responses), as well as NP, which differs between IA subtypes by a single amino acid residue 
(see Table 4.5).  
In contrast to earlier published studies, responses directed against the IA epitopes were an 
order of 10-fold lower than had been seen using comparable recombinant MCMV viruses 
expressing the IA virus NP366 epitope (Karrer et al., 2004), as well as other H2b-restricted 
CTL epitopes from either Ebola virus or human prostate specific antigen (PSA) fused to the 
IE2 carboxyl-terminus (Tsuda et al., 2011; Tsuda et al., 2015); (Figures 4.13- 4.14). Immune 
responses against H2b-restricted epitopes from endogenous MCMV proteins (M38 and M45) 
were present in mouse groups receiving either the MCMV-IAV (M38 1.9 +/- 0.65) or 
MCMV-WT (2.4 +/- 1.004) viruses, where levels were high and comparable to those 
presented in previous published studies. M38 responses were statistically identical between 
MCMV-IAV and MCMV-WT groups. M45 responses although at levels comparable to those 
seen in studies were indicated to be significantly lower in the MCMV-IAV compared to 
MCMV-WT group. 
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Figure 4.13 T cells responses at week 7/8 following vaccination with MCMV-IA 
(NP+PA+NS2) vector. C57BL/6 (H2
b
-restricted, 6-8 weeks old) female mice were 
immunized using a single i.p. dose of 1x10
5
 PFU of the indicated MCMV-IA vector(s). Mice 
receiving the combination of the 3 MCMV IA vectors were inoculated with 1 × 10
5
 PFU of 
each vector as a single i.p. bolus for a total of 3 × 10
5
 PFU. Control groups received MCMV-
WT (3 × 10
5
 PFU), diluent (Mock) or formalin-inactivated H5N1. At weeks 7/8, splenocytes 
were harvested for analysis of T cell responses. T cells were analysed via using ICS with a 6 
hour incubation in the presence of BFA with peptides. All MCMV-IA-(NP+NS2+PA) 
immunised mice (n= 4) showed diminished T cell responses against flu target antigen when 
administrated as a mixture. Error bars show the s.d. 
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Figure 4.14 Kinetic analysis of T cells responses to MCMV-IA-(NP+PA+NS2) at week 
7/8.  C57BL/6 H2
b
-restricted mice (N=4) were immunized using a single i.p. dose of 1 × 10
5
 
PFU of the indicated MCMV-IAV vector(s). Mice receiving the combination of the 3 MCMV 
IA vectors were inoculated with 1 × 10
5
 PFU of each vector combined in a single i.p. bolus 
for a total of 3 × 10
5
 PFU. Control group received MCMV-WT (3 × 10
5
 PFU). At time 
indicated, splenocytes were harvested for analysis of T cell responses, ICS with a 6 hour 
incubation in the presence of BFA with the flu peptides. All MCMV-IA-(NP+NS2+PA) 
immunised mice (n= 4) showed diminished T cell responses against flu target antigen when 
administrated as a mixture. Error bars show the s.d. 
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Figure 4.15 MCMV-IA-(NP+PA+NS2) induce low level of IA-specific T cell response in 
C57BL/6 mice at week 7/8.  C57BL/6 H2
b
-restricted mice (N=4) were immunized i.p.using 
a combination of the 3 MCMV IA vectors (each 1 × 10
5
 PFU) for a total of 3 × 10
5
 PFU as a 
single bolus. Control group (MCMV-WT) received 3 × 10
5
 PFU. At time indicated, 
splenocytes were harvested for analysis of T cell responses, using ICS with a 6 hour 
incubation in the presence of BFA with the flu peptides. The average of all MCMV-IA-
(NP+NS2+PA) immunised mice showed diminished T cell responses against flu target 
antigen when administrated as a mixture. Error bars show the s.d. 
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At week 12, T cell responses were analyzed in the different mouse groups (n=6) in both 
spleen as well as lung.  Due to the lower level of T cells, lungs from groups of 3 mice were 
pooled for analysis of this organ site. The results are shown in Figures 4.16 through 4.18. IA-
specific T cell responses were observed against homosubtypic IA NP (0.05 +/- 0.02) and PA 
(0.08 +/- 0.02) epitopes in MCMV-IAV vaccinated mice (Figures 4.16 and 4.18).  Responses 
were no longer detected against the NS2 epitope, which had fallen below the detection cut-off 
(0.01 +/- 0.01). These responses were shown to be statistically significant (t-test, 2-tailed) 
when compared against either Mock or MCMV-WT control mouse groups (n=6) for PA 
(p<0.000001) and NS2 (0.01).  
Responses against NP were now shown to be statistically significant (p<0.0001) (p-values 
presented are those compared against MCMV-WT). Statistically significant cross-reactive 
heterosubtypic responses were observed against PA (where the epitope is completely 
conserved across the three IA subtypes, and therefore is identical to homosubtypic, PR8 
responses). However, the statistically significant responses against NP and NS2, which had 
been observed at week 7/8 were no longer present. It is important to note that although 
responses against H2
b 
restricted epitope from endogenous MCMV protein (M38) which had 
been observed at week 7/8 was high and comparable to the MCMV-WT, at week 12 these 
responses had fallen in MCMV-IAV immunized mice (0.51 +/- 0.2) compared to the 
MCMV-WT group (1.24 +/- 0.52). These responses were statistically significant (t-test, 2-tail; 
p˂0.01) when compared to the MCMV-WT control group (Figures 4.16 and 4.18). At week 
12, PB1 peptide (not present in MCMV-IA vaccine construct) was included as another 
control.  
At week 12 post-inoculation, in lung tissue, IA specific T-cell responses to IA PA (0.025 +/-
0.007) epitope in MCMV-IA vaccinated mice (Figure 4.18) were shown to be statistically 
significant when compared to the Mock or MCMV-WT control mouse group (P=0.03). 
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However T cell responses against both homo and heterosubtypic IA NP and NS2 were no 
longer detected against the NP and NS2 epitopes, all had fallen down below the detection cut-
off (0.01 +/- 0.01; Figure 4.18). 
 
 
Figure 4.16 T cells responses at week 12 following vaccination with MCMV-IA 
(NP+PA+NS2) vector. C57BL/6 (H2
b
-restricted, 6-8 weeks old) female mice were 
immunized using a single i.p. dose of 1 × 10
5
 PFU of the indicated MCMV-IA vector(s). 
Mice receiving the combination of the 3 MCMV IA vectors were inoculated with 1 × 10
5
 
PFU of each vector as a single i.p. bolus for a total of 3 × 10
5
 PFU. Control groups received 
MCMV-WT (3 × 10
5
 PFU), diluent (Mock) or formalin-inactivated H5N1. At weeks 12, 
splenocytes were harvested for analysis of T cell responses. T cells were analysed via using 
ICS with a 6 hour incubation in the presence of BFA with peptides. All MCMV-IA-
(NP+NS2+PA) immunised mice (n= 6) showed diminished T cell responses against flu target 
antigen when administrated as a mixture. Error bars show the s.d. 
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Figure 4.17 Kinetic analysis of T cells responses to MCMV-IA-(NP+PA+NS2) at week 
12.  C57BL/6 H2
b
-restricted mice (N=4) were immunized using a single i.p. dose of 1 × 10
5
 
PFU of the indicated MCMV-IA vector(s). Mice receiving the combination of the 3 MCMV 
IA vectors were inoculated with 1 × 10
5
 PFU of each vector as a single i.p. bolus for a total of 
3 × 10
5
 PFU. Control group received MCMV-WT (3 × 10
5
 PFU). At time indicated, 
splenocytes were harvested for analysis of T cell responses, ICS with a 6 hour incubation in 
the presence of BFA with the flu peptides. All MCMV-IA-(NP+NS2+PA) immunised mice 
(n= 6) showed diminished T cell responses against flu target antigen when administrated as a 
mixture. Error bars show the s.d. 
 
 
 
 
 
 
 
  
 
298 
 
               
 
 
 
Figure 4.18 T cells responses at week 12 following vaccination with MCMV-IA 
(NP+PA+NS2) vector. C57BL/6 (H2
b
-restricted, 6-8 weeks old) female mice were 
immunized using a single i.p. dose of 1 × 10
5
 PFU of the indicated MCMV-IA vector(s). 
Mice receiving the combination of the 3 MCMV IA vectors were inoculated with 1 × 10
5
 
PFU of each vector as a single i.p. bolus for a total of 3 × 10
5
 PFU. Control groups received 
MCMV-WT (3 × 10
5
 PFU), diluent (Mock) or formalin-inactivated H5N1. At week 12, lungs 
were harvested for analysis of T cell responses. T cells were analysed via using ICS with a 6 
hour incubation in the presence of BFA with peptides. All MCMV-IA-(NP+NS2+PA) 
immunised mice showed diminished T cell responses against flu target antigen when 
administrated as a mixture. Error bars show the s.d. 
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 4.2.3 Construction of recombinant MCMV-IA-NP within a different MCMV-WT 
background MCMV-WT (F5)  
There are two possibilities to account for the lowered T cell response observed during the 
present studies using the MCMV-IA viruses. The first is a biological explanation, wherein the 
presence of CTL epitopes for presentation by MHC-I molecules of a limited number of APCs 
would result in competition between the individual CTL epitopes thereby diminishing 
responses when used as a mixture for vaccination. Such a phenomenon has been observed 
previously for recombinant MCMV vaccines, whereby ‘inflationary’ responses against the 
major endogenous T cell epitopes are diminished by inclusion of a second heterologous 
competing CTL epitope in a recombinant virus (Dekhtiarenko et al., 2013; Farrington et al., 
2013). This is an extremely interesting biological phenomenon that also suggests that the 
APC involved in priming such responses are limiting when administered via the i.p. route. A 
second technical possibility, which would be less interesting from the biological context, is 
that an unexpected mutation in the MCMV genome may be responsible.  However, this may 
not be the case since we get normal immune response against M38 in MCMV-WT control. 
These immune responses have been diminished in MCMV-IA- (NP+PA+NS2) version. This 
indicates that the competition is the more obvious reason behind low T cell responses as both 
viruses have the same genetic background.    
To discriminate between these two hypotheses we constructed an additional recombinant 
MCMV-IAV vector that encodes the same NP epitope that we used for generation of the 
previous MCMV-IAV vectors with the exception of the parental genetic background. For 
generation of this vector we used the same genetic background as was used for development 
of recombinant MCMV-EBOV-NP (Tsuda et al., 2011). In order to address this hypothesis, 
an additional recombinant MCMV-IAV vector expressing the H2
b
-restricted T cell epitope 
from influenza A conserved structural proteins NP366-374 (ASNENMETM), was generated in 
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this study. As described previously, MCMV-IAV vectors were constructed using MCMV 
(Smith strain) BAC pSMfr3 in which the natural killer cell activating m157 MCM gene has 
been deleted (pSMfr3 m157).  
This MCMV-IA-NP (FWT) was constructed exactly as described above (Section 4.2.1), 
using E/T homologous recombination to insert the NP epitope to the carboxyl terminus of IE2 
locus of the MCMV-WT (FWT) BAC genome (Figure 4.19). The recombinant PCR fragment 
(containing the NP epitope and an FRT flanked Kan
R
 gene) was amplified from the pOriFRT 
(wt) plasmid using synthetic oligonucleotides IE2-NP-(FWT)-F and IE2-NP-(FWT)-R (Table 
2.2). PCR products were separated on a 1% agarose gel and as expected, yielded a band of 
1.5 kb in size. The PCR fragment was spin column purified (Section 2.3.7) to remove 
unwanted small molecular weight products. After purification, the PCR products were run on 
a 1% agarose gel again to confirm the small non-specific products had been removed (Figure 
4.20).  
 
 
Figure 4.19 Schematic illustration of MCMV-IA-NP (F5) constructs expressing a single 
cytotoxic T cell (CTL) epitope. An H2
b
-restricted T cell epitope from IA conserved 
structural proteins NP366-374 (ASNENMETM) was fused in frame to the carboxyl terminus of 
MCMV IE2 generating the recombinant MCMV-IA-NP (F5) vaccine vectors. 
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(A) 
 
 (B)  
 
Figure 4.20 Recombination PCR fragments used for construction of MCMV-IA-NP (F5) 
vaccine vector. (A) DNA gel showing recombinant PCR generated fragments containing NP 
H2
b
 -restricted CD8
+
 T cell epitope from IA virus. The single DNA band at 1.5 kb shows 
amplification of the desired recombinant fragments. Two independent PCR reactions were 
prepared for each clone. (B) Gel purified PCR products confirming the extraction procedure 
was successful and the correct sized bands were purified. MW= 1kp molecular weight marker; 
lanes 1-4 = MCMV-IA-NP (F5). 
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The recombinant PCR products generated above were inserted into the IE2 locus of the 
MCMV BAC genome using E/T recombination, exactly as described above (Section 4.2.1.2) 
to generate MCMV-IA-NP(F5) recombinant BACs (in this alternate MCMV-WT genetic 
background). After the recombination procedure, the bacteria were plated out onto Kan/Cam 
plates to select clones that contained recombinant BACs. The colonies were counted (Table 
4.6), and eight colonies were selected for further characterization by restriction digest (to 
confirm genomic integrity; Figure 4.21). After confirmation of genomic integrity, the Kan
R
 
marker was excised as described above (Section 2.5.1.3), genomic integrity was confirmed 
and the presence of the NP epitope by PCR (Figure 4.22). Sanger sequencing of the amplified 
PCR product was used to confirm presence of the desired NP epitope (Figure 4.23), as 
described above (Section 2.3.8). 
 
               
                   Table 4.6 Numbers of recombinat MCMV-IA-NP (F5) BAC clones                    
MCMV Construct                       PCR fragment       Number of colonies 
MCMV-IA-NP(F5)                                 1                                200-250 
                                                                 2                                250-300 
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Figure 4.21 Characterization of recombinant MCMV-IA-NP (F5) BAC genome using 
EcoRI restriction enzyme digestion. MCMV-WT and eight independent clones of 
recombinant MCMV-IA-NP (F5) BACs were digested with EcoRI and the resulting 
fragments were separated on a 1% agarose gel for 18-20 h at 45 V, followed by visualization 
with 0.5 µg/ml EtBr. Comparable restriction digestion pattern between the MCMV-IA clones 
and MCMV-WT (FRT F5) BAC shows the absence of any gross genomic rearrangments. 
Molecular size marker lane (MW) in kb is indicated.   
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         Table 4.7 Analysis of MCMV BAC clones following excision of Kan cassette. 
MCMV Construct         PCR       Clone       Selected colonies         Sensitivity to Kan 
MCMV-IA-NP (F5)        1             4                            25                                All 
                                           2            6                            25                                All 
 
 
 
 
 
Figure 4.22 Confirming excision of Kan
R
 marker from MCMV-IA-NP(F5) BAC genome 
by PCR. BAC DNA from MCMV-WT (FRT F5) and four clones of each recombinant 
MCMV-IA-NP(F5) BAC (both pre and post-FLP) were screened by using PCR, using 
primers positioned 5` and 3`of the IE2 site targeted by recombination. PCR products were 
separated on a 1% agarose gel for 60-90 min at 75 V, and visualized by staining with 0.5 
µg/ml EtBr. PCR of pre-FLP MCMV-IA-NP (F5), and post-FLP MCMV-IA-NP (F5) yield 
PCR products of 1.5 kb and 750bp, respectively. Molecular size marker (MW) in bp is 
indicated. 
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 (A) 
  MCMV-IA-NP (F5) BAC clone (2-4) 
 
  
 (B) 
 MCMV-IA-NP (F5) BAC clone(4-16) 
 
Figure 4.23 Confirmation of IA epitope within MCMV-IA-NP (F5) BACs via Sanger 
sequencing. PCR was performed on post-FLP BAC clones: (A) MCMV-AI-NP (F5) clone 
(2-4) and (B) MCMV-AI-NP (F5) clone (4-16). Blue text represents IE2 genome sequence, 
green represents represented NP epitope tag sequence and black text represents downstream 
MCMV genome sequence.  
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Two independent clones were selected for reconstitution. BAC DNA was electroporated into 
MEF cells as described above (Section 3.2.1.5 Table 3.5) and monolayers were monitored 
daily for signs of plaque development. Plaques were picked on day 5 post infection, and 
serially passaged five times in MEFs to allow excision of the BAC cassette from the viral 
genome (Section 2.6.2.3). Seed and concentrated high titre viral stocks were prepared as 
described above (Sections 2.6.2.4 and 2.6.2.5). PCR of viral DNA using IE2-Flank primers, 
was performed on recombinant viral DNA extracted from concentrated stocks (Section 
2.6.2.5), to ensure that the MCMV-IA-NP (FRT WT) virus still contained the intact NP 
epitope (Figure 4.24) followed by sequencing of the PCR products to confirm that there were 
no point mutations in the epitope sequence (Figure 4.25). The titre of the recombinant 
MCMV-IA-NP (FRT WT) was measured and compared to both of the parental wild-type 
(MCMV-WT) and recombinant MCMV-EBOV-NP (5A1) using TCID50 assay (Section 
2.6.2.6). Result indicated that the titre of the recombinant MCMV-IA-NP (FWT) virus was 
comparable to the parental wild-type virus and the recombinant MCMV-EBOV virus (Table 
4.8). 
 
 
     Table 4.8 Reconstitution of recombinant MCMV-IA -NP BAC clones in the MEFs 
      MCMV-IA BAC vector                        Clones                     Plaque numbers           
         MCMV-IA-NP (FWT)                          2-4                                     7 
                                                                         4-16                                    8  
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Figure 4.24 Confirming presence of NP epitope in MCMV-IA-NP (F5) virus genome by 
PCR. DNA was isolated from MCMV-IA-NP (F5) concentrated stock using a QIAmp kit and 
PCR was carried out using IE2-Flank-F and IE2-Flank-R primers. PCR products were 
separated on a 1% agarose gel. The presence of a 750 bp band in recombinant MCMV-IA-NP 
(F5) lanes (3-6) confirmed that the epitope was present, and the absence of the MCMV-WT 
sized band (700 bp) in the recombinant viruses lanes (1-2) confirmed the absence of WT 
contamination of recombinant stocks. 
 
 
 
Table 4.9 Titres of MCMV-WT and the recombinant MCMV-IA virus vectors stocks.  
  Virus (MCMV)                                       Titre by TCID50 (PFU/cell) 
     MCMV-WT (F5)                                                               1.22 × 10
8
 
     MCMV-EBOV-NP (5A1)                                                  1.10 × 10
8
 
     MCMV-IA-NP (4-16)                                                        1.08 × 10
8
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 (A) 
  MCMV-IA-NP (F5) PCR 1 
 
 (B) 
  MCMV-IA-NP (F5) PCR 2 
 
Figure 4.25 Confirmation of NP epitope within MCMV-IA-NP (F5) virus genome. PCR 
was performed on viral DNA isolated from concentrated viral stocks and two independent 
PCR products were Sanger sequenced. (A) PCR 1 and (B) PCR 2. Blue text represents IE2 
genome sequence, green represents represented IA epitope tag sequence and black text 
represents downstream MCMV genome sequence.  
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Multistep growth curves were performed in a similar way as was described above (Section 4. 
2.1.9), to determine whether the insertion of NP into this MCMV-WT (F5) genetic 
background had any deleterious effects on virus replication. As described above, MEF cells 
were infected in triplicate at a multicity of infection (0.1 PFU/cell) with MCMV-WT (F5), 
MCMV-IA-NP (F5) or MCMV-ZEBOV-NP (5A1) virus. Supernatants were harvested at 
selected time points (day 0, 1, 3, and 5 post infection) and viral titres were quantified by 
TCID50 (Section 2.6.2.6). MCMV-ZEBOV-NP (5A1) recombinant virus (Tsuda et al., 2011) 
was also included as an additional control. As observed previously, presence of IA-NP (F5) 
or ZEBOV-NP (5A1) did not affect virus replication in MEFs, with comparable levels of 
virus growth being observed for all strains at all time points (Figures 4.26 - 4.28). There were 
no significant differences in the growth of both recombinant MCMV-IA-NPs compared to the 
both parental wild type (MCMV-WT (FWT or F5) wild-type and recombinant MCMV-
EBOV with respect to growth on MEFs (P 0.05). Taken together, neither the introduction of 
NP epitope to the MCMV with the (F5), nor to the MCMV with the (FWT) impairs growth in 
fibroblast, as shown in Figure 4.28 and both mutants show both wild-type and recombinant 
MCMV-EBOV properties in MEF cells. 
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Figure 4.26 Replication of recombinant MCMV-IA-NP (F5) virus compared to its 
parental MCMV-WT (F5) virus. MEF cells were infected with the MCMV-IA-NP (F5) or 
MCMV-WT (F5) at an MOI of 0.1 PFU/cell. At the time points indicated, supernatants were 
collected and analysed for the presence of virus by TCID50 assay on MEF cells. Results are 
the mean of two separate experiments, each in triplicate. Error bars representing the standard 
deviations. Some of the standard deviations are so small that the error bars are hidden behind 
the symbols representing the data points.   
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Figure 4.27 Replication of recombinant MCMV-IA-NP (F5) virus compared to its 
parental MCMV-WT (F5) and MCMV-EBOV-NP (5A1) virus. MEF cells were infected 
with the desired MCMV-IA-NP (F5), MCMV-EBOV-NP (5A1) or MCMV-WT (F5) at an 
MOI of 0.1 PFU/cell. At the time points indicated, supernatants were collected and analysed 
for the presence of virus by TCID50 assay on MEF cells. Results are the mean of two separate 
experiments, each in triplicate. Error bars representing the standard deviations. Some of the 
standard deviations are so small that the error bars are hidden behind the symbols 
representing the data points. 
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Figure 4.28 Replication of recombinant MCMV-IA-NP (F5) virus compared to its 
parental MCMV-WT (F5), MCMV-EBOV-NP (5A1), MCMV-WT (FWT), and the 
MCMV-IA-NP (FWT) virus. MEF cells were infected with the desired viruses at an MOI of 
0.1 PFU/cell. At the time points indicated, supernatants were collected and analysed for the 
presence of virus by TCID50 assay on MEF cells. Results are the mean of two separate 
experiments, each in triplicate. Error bars representing the standard deviations. Some of the 
standard deviations are so small that the error bars are hidden behind the symbols 
representing the data points.   
 
4.2.3.1 Expression of IE2 protein in the recombinant MCMV-IAV vectors 
In order to explore and analyse the expression kinetics of the IE2 protein and whether fusion 
of the flu epitope affect the expression of the IE2 protein, MEF cells were infected with 
MCMV-IA-NP (F5), MCMV-IA-NP (FWT), MCMV-WT (F5), MCMV-WT (FWT) or 
MCMV-EBOV-NP (as a positive control). At various time post infection (8, 12, 24 and 36 
hours), western blot analysis was performed as described in (Section 2.7.2). As shown in 
(Figure 4.29), results indicated that the expression kinetics of IE2 fused epitope in 
recombinant MCMV-IA-NP (F5/FWT) were comparable to those of parental MCMV-
WT(F5/FWT) as well as recombinant MCMV-EBOV-NP virus. The IE2 protein with a 
molecular mass of 43 KDa, predominantly were produced between 0.5 and 3 hr post infection 
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(Messerle, Keil & Koszinowski, 1991). The 43KDa IE2 proteins were already highly 
expressed at 8 hr post infection and persistent throughout infection (Figure 4.29). The level of 
expression was monitored and no significant differences between viruses were found, 
indicating that the presence of the NP insertion did not affect the expression of the IE2 
protein. Therefore, these results provided additional evidence for the absence of genome 
rearrangements during construction of recombinant MCMV-IAV vectors. 
 
 
Figure 4.29 Analysis of IE2 expression of recombinant MCMV and parental wild-type 
via Western blot. MEF cells were infected with recombinant MCMV or wild-type viruses at 
MOI: 0.01. The infected cells were harvested at 8, 12, 24 and 36 hours post infection and 
processed for Western blotting analysis. The infected cell lysates showed that IE2 was 
expressed and that expression was stable over multiple time point. The number of the right 
panel represents the time point. While on the left hand panel represent the size of IE2 protein 
in kilo Daltons. Beta-actin served as a loading control.       
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An alternative approach to using the three MCMV/IA vectors in combination, will be to 
design an experiment to characterize MCMV-IA-NP (F5) immunogenicity and to determine 
protective efficacy against IA virus challenge. C57BL/6 mice (H2
b
-restricted, 6-8 week old 
female; ten mice per group) will be immunized i.p. with the indicated MCMV-IA-NP (F5) 
vector or controls: Mock, UV-inactivated H1N1, MCMV-WT and MCMV-IA (NP+NS2+PA 
combined). Vaccination will consist of a single i.p. dose of 1 × 10
5
 PFU of the indicated 
MCMV-IA-NP (F5) vector. Control groups will receive MCMV-WT (3 × 10
5
 PFU), diluent 
(Mock), 1 × 10
7 
PFU of UV- inactivated H1N1 (PR8) or a combination of the three 
MCMV/IA (NP+NS2+PA) vectors as a single i.p. bolus, giving a total of 3 × 10
5
 PFU (1x10
5
 
PFU of each vector). At weeks 7-8, one mouse per each group and at week 12, four mice will 
be chosen for analysis of T cell responses by harvesting splenocytes. At week 14, C57BL/6 
mice will be challenged with LD50 of H1N1(A/Puerto Rico/8/1934) given intranasally as a 30 
µl dose (Kashima et al., 2009). Following this challenge, the disease severity will be 
monitored on the basis of visual clinical signs (on a daily basis), as well as by rectal 
temperature and weight loss every other day post–IA challenge, followed by analysis of T 
cell responses  one month post IA challenge.  
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4.3 Discussion 
The unpredictable emergence of pandemic IA subtypes represents a constant major global 
health concern (Taubenberger & Morens, 2013; Zhang, Hirve & Kieny, 2017). One approach 
to prevent a pandemic IA strain is the development of vaccines that induce heterosubtypic 
immunity capable of protecting against all possible IA subtypes. Current seasonal inactivated 
vaccines work primarily by inducing antibodies that confer strain-specific immunity, rather 
than creating cross-protective (heterosubtypic) immunity against IA infection. When 
mismatched with circulating strains, these vaccines become less efficacious (Demicheli et al., 
2014). Thus, there is an urgent need to develop effective cross-protective vaccines. Evidence 
suggests that CD8
+
 cytotoxic T cells play a critical role in protective immunity against the 
influenza virus (Subbarao, Murphy & Fauci, 2006) and that a breadth of T cell immunity is 
essential for broad heterosubtypic protection (Gianfrani et al., 2000).  
An aim of the thesis was to provide initial studies in the mouse MCMV model towards 
development of a universal vaccine against all serotypes of IA by targeting internal structural 
proteins to enhance the strength of influenza virus specific ‘effector’ CD8+ T cell based 
immunity. The potential of CMV for development as such a vaccine against IA virus is 
supported by previous studies that have identified CMV-based vaccines as a unique vaccine 
platform capable of inducing high levels of ‘effector’ CD8
+
 T cells with immediate effector 
functions that accumulate at peripheral sites including the lungs (Hansen et al., 2011; Marzi 
et al., 2016; Tsuda et al., 2011). This characteristic makes the CMV vector platform ideal for 
inducing immunity against IA virus, which infects the lung and can spread rapidly within the 
host. 
We constructed a MCMV recombinant that expressed the epitope sequence of three 
conserved internal structural proteins (NP, NS2 and PA) of the IA virus that are less 
changeable than the surface glycoproteins hemagglutinin and neuraminidase (Townsend & 
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Skehel, 1984). The selection of conserved proteins is critical for dictating the breadth of 
immune response, through boosting cross-reactive immunity (Kwon et al., 2014). It has been 
shown that about 90% of T cell responses that recognize cytotoxic T cell epitopes derived 
from the conserved internal proteins of IA were directed towards an NP336 protein (Doherty et 
al., 2006); heterosubtypic protection which is mediated by T cells can only be achieved when 
challenge viruses share the internal protein (NP) epitope (Zhong et al., 2010). Therefore, to 
achieve heterosubtypic protection against distant strains of IA virus, the NP epitope was 
selected. 
MCMV was used as an in vivo model for the assessment of CMV-based IA vaccines. CMVs 
are highly host specific with each mammalian host carrying its own species-specific CMV 
(Kern, 2006). However, all CMVs share common characteristic of growth, cytopathology and 
capacity to establish persist and latent infection. These similarities have enabled the use of 
MCMV infection of mice to address questions relating to human CMV (HCMV; (Krmpotic 
et al., 2003). In addition, due to the extensive characterization of the mouse immune response, 
low cost of mice and the availability of reagents, the MCMV mouse model is the most 
extensively used in vivo model for HCMV. The mouse IA model is also extremely well 
characterized and enables extensive analysis of vaccine immunogenicity and efficacy against 
IA infection.  Since CMV possess large-sized genomes and replicate slowly in the cell culture, 
in the past mutagenesis by homologous recombination was difficult and time consuming 
(Mocarski et al., 1996). The propagation of CMV genomes as infectious BACs in E.coli has 
made the CMV genome accessible to manipulation (Messerle et al., 1997).   
MCMV-based IA vaccines (MCMV-IA) were designed, expressing a CD8
+ 
CTL epitope 
from IA conserved proteins; NP366-374 ASNENMETM (Andreansky et al., 2005), NS2114-121 
RTFSFQLI (Belz et al., 2000), and PA224-233  SSLENFRAYV (Belz et al., 2000), all of which 
were fused to the IE2  protein of MCMV in separate vectors (Figure 4.1). IE2 is a 
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nonessential protein that has been used in a number of previous studies as a site for fusion for 
a variety of defined T cell epitopes for induction of T cell responses (Karrer et al., 2004; 
Tsuda et al., 2011). MCMV-IA (NP, NS2, and PA) were constructed by lambda-based E/T 
linear recombination (Tierney et al., 2012; Tsuda et al., 2011) using the pSMfr3 BAC 
containing the MCMV (Smith strain) genome (Messerle et al., 1997). The strategy is outlined 
in (Figure 3.2). In order to avoid attenuation of MCMV replication by natural killer (NK) 
cells in the C57BL/6 mouse strain, the m157 gene of MCMV was deleted (pSMfr3m157). 
The deletion was necessary since the activation of NK cells is regulated by the cell surface 
receptor Ly49H, which encodes both activator and inhibitor receptors (Arase et al., 2002). 
The m157 gene which has MHC class I molecule structure, is recognized by the Ly49H 
activate receptor. Binding of m157 to host Ly49H NK receptors delivers an activating signal 
to NK cells as a result limiting viral replication (Pyzik et al., 2011). 
Following identification of recombinant MCMV BACs, restriction enzyme digestion of the 
BAC DNA which was carried out in order to determine successful recombination as well as 
to confirm genome integrity prior to the reconstitution of mutant viral progeny, showed no 
gross genomic rearrangement compared to the WT parental BAC (Figures 4.4 and 4.6). Next, 
the biological properties of the mutant MCMV were analysed upon the reconstitution of the 
virus into the MEF cells. The virus reconstitution was achieved through direct transfection of 
MEFs by invasive bacteria carrying BAC DNA via electroporation. Since the presence of the 
BAC sequence in the viral genome interferes with biological properties of MCMV in vitro 
and potentially causes unpredictable effects in vivo (Wagner et al., 1999) the BAC sequence 
was removed. The results of experiments performed to remove BAC sequence from the 
mutant MCMV-IA genome showed that removal of this sequence had no influence on the 
genomic integrity and stability of the recombinant viruses, with the continued stable 
expression of the IA epitope within mutant viral genome. Our data from the growth kinetics 
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assay in vitro indicated that this insertion of IA epitope has no effect on virus growth in vitro 
in MEF cells. Furthermore, recombinant MCMV-IA (NP, PA or NS2) vector showed similar 
growth kinetics to the MCMV-WT (FWT) in vitro (Figures 4.11 - 4.13).  
 Using this panel of MCMV-IAV viruses we then performed immunogenicity studies in 
C57BL/6 H2
b
-restricted mice. It has previously been shown that CMV-based vaccine vectors 
have the ability to induce significant levels of CD8
+
 CTL responses against target pathogens 
(Dekhtiarenko et al., 2013; Hansen et al., 2011; Tsuda et al., 2011). In addition, it has been 
shown in the case of C57BL/6 mice infected with the recombinant MCMV expressing the 
CD8
+
 T cell epitope from the nucleoprotein of the Zaire Ebola virus (fused into the IE2 
protein comparable to the IA epitopes), that the recombinant MCMV successfully induced 
considerable levels of CD8
+ 
T cells (1 to 2% of total CD8
+
 T cells); (Tsuda et al., 2011). 
However, this high level of CD8
+
 T cell was not observed in this present study (Figure 4. 14), 
which showed an order of magnitude lower levels.   
There are two possible explanations that would explain the low CD8
+
 T-cell responses in this 
present study. Firstly, there is possibility that the low responses may be due to unexpected 
mutation in the MCMV genome that then resulted in diminution of T cell response. The 
second possibility is associated with use of a combination of the three constructed vectors 
(MCMV-IA- NP, PA and NS2), which in the present study were used together as a mixture 
for the mice vaccination. In this model, the use of a mixture would result in competition 
between these three epitopes in terms of their presentation on the antigen presenting cells 
(APCs), consequently causing diminished CD8
+
 T cell responses as compared to responses 
when administered individually (Tsuda et al., 2011). This is in agreement with a recent study 
by Dekhtiarenko and colleagues who used an MCMV recombinant containing a single CD8
+
 
T cell epitope (gB) from HSV-1 (SSIEFARL, linked to the C terminus of either M45 or IE2 
gene), to examine the role of gene expression and antigen competition in CMV T cell 
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immunity. They revealed that the mice that were infected with either recombinant MCMV 
(M45 or IE2) resulted in strong CD8+ T cell responses when the peptide was expressed in 
each case, while in case of multiple target antigens, expressed by the same recombinant 
MCMV/HSV-1, suboptimal immune responses to the target antigens resulted. This may have 
been due to competition between T cells for recognition of antigens, potentially limiting its 
protective capacity (Dekhtiarenko et al., 2013).  
Similarly, Farrington et al. (2013) showed that a recombinant MCMV encoding an 
immunodominant heterologous SIINFEKL peptide fused to the C terminus of IE2 resulted in 
the SIINFEKL epitope being a completely immunodominant epitope, which was associated 
with high CD8+ T cell responses. However, responses against endogenous MCMV-derived 
epitopes that were normally inflationary for WT-MCMV no longer exhibited an inflationary 
phenotype. Importantly, suppression of these inflationary responses against the endogenous 
epitopes was observed only when SINNFEKL was co-expressed within the same MCMV 
recombinant. Inhibition was not observed when mice were co-infected with separate MCMV-
WT and recombinant MCMVs. This observation implies that when different cells in the same 
mice can present endogenous epitopes in the absence of the SIINFEKL epitope, the 
SIINFEKL epitope had no inhibitory influence on endogenous responses. Thus, MCMV-WT 
infected APCs have the ability to present MCMV epitopes which T cells can recognise and  
which are able to inflate with SIINFEKL response. However, when both SIINFEKL and 
endogenous epitopes were encoded by the same virus and therefore necessarily expressed on 
the same APC, induction of T cells to SIINFEKL out-competed induction of those against 
endogenous antigens. This may have been due to the cells possessing more available Ag or 
alternatively because they were able to access the Ag more efficiently (Farrington et al., 
2013).   
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Thus, this supports the hypothesis that competition between T cell clones for antigens at the 
level of the APC have a significant role in  inflationary responses during MCMV infection, 
based on the possibility that the combined MCMV-IA (NP+PA+ NS2) vector dose is giving 
far lower CD8
+
 T cell responses than have been observed previously with other CMV 
recombinant vectors when used singly (Tsuda et al., 2011).  
To address the possible technical issue that probably are responsible for diminish T cell 
responses that observed using the MCMV-IAV vectors, new recombinant MCMV-IAV 
encoding NP epitope of NP protein were constructed. However this may not be the case, 
since our results indicated the normal T cell responses against M38 of the MCMV-WT 
(Figure 4.14) and then this T cell responses were diminished using the MCMV-IAV vector. 
Decrease T cell responses against M38 in the MCMV-IA virus compare to the MCMV-WT 
indicates that the MCMV-WT background is fine (Figure 4.14 & Tables 4.6 - 4.7). The low T 
cell responses probably not due to a defective background may be due to the competition of 
epitopes on the surface of APC. 
In addition, binding peptides to the MHC molecules is important  for the T cell activation. 
Peptides that are more abundantly presented, due to the processing, expression or binding 
affinity are more likely to succeed to induce T cell response (Yewdell, 2006). So another 
evidence to explain the low T cell responses is due to the competition between the epitopes is 
that IA epitopes (PA and NS2)  and the MCMV-derived inflationary epitope (M38), all of 
which are presented by binding to H-2K
b
  alleli this probably caused the competition (Table 
4.5),   
To avoid the competing epitopes being recognized on the same APC (which may be caused 
by using three vectors combined in a single dose, administrating MCMV-IAV encoding NP 
epitope individually, since MHC binding affinity of NP366 and inflationary M38 peptides are 
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different (H-2D
b 
or
 
H-2K
b
, respectively; Table 4.5). May results in presentation of IA internal 
protein individually on the surface of APCs, thus avoiding presentation on the same APCs 
consequently will avoid competition between them.  
 As described previously, the m157 gene of the parental MCMV that was used in this study 
has been deleted by homologous recombination using FRT sites (FWT) and for construction 
of recombinant MCMV-IA-(NP, PA, or NS2) vectors (F5; a different version of FRT sites) 
has been used, since they were two different version of FRT they cannot combine with each 
other.  
For the generation of the new MCMV-IA-NP construct, we used a different genetic 
background using plasmid template that contain, (FRTWT) and from which the m157 has 
been deleted using FRT 5 (F5). This genetic background is the same that has been used for 
construction of recombinant MCMV-EBOV-NP (5A1) which was developed by other 
members of the Jarvis lab (Tsuda et al., 2011).  
The new MCMV-IA-NP was constructed as detailed in the generation of previous MCMV-
IAV vectors. Only the NP epitope was assayed, since the research to date has tended to focus 
on the NP protein rather than other internal conserved proteins. It has been shown that 
heterosubtypic protection which is mediated by T cell responses can only be achieved when 
inoculum and challenge viruses contain the NP366 epitope (Zhong et al., 2010). It has  also 
been shown that 90% of CD8
+
 T-cell responses are directed to an NP366 epitope (Kwon et al., 
2014). In addition, NP is predominant during primary and secondary influenza infection 
(Flynn et al., 1999). Moreover, as a result of using a recombinant MCMV expressing IA 
virus nucleoprotein (NP366-374) epitope that was fused to the IE2 gene in C terminus showed 
that this recombinant virus was able to induce T cell response to the NP epitope and that after 
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IA virus infection, NP specific CD8
+
 T cells rapidly increased in number and have capability 
to provide protection against influenza virus challenge (Karrer et al., 2004). 
 In order to assess the efficacy of recombinant MCMV-IAV vectors in vivo, an alternative 
approach to characterize immunogenicity and determine protective efficacy against IA virus 
challenge, by inoculation of C57BL/6 mice with the MCMV-IA-NP(F5) alone or controls 
Mock, UV-inactivated H1N1, MCMV-IA-(NP+PA+NS2) combined, MCMV-EBOV-NP and 
both parental MCMV-WT (F5 and FWT).  
In summary, a MCMV-based IA vaccine expressing a CD8
+
 CTL epitope from three 
conserved proteins (NP, PA and NS2) was designed by using lambda-based linear 
recombination with a BAC contained within the MCMV genome. Characterization of 
MCMV vectors in vitro for genomic stability and IA epitope sequence integrity showed 
stability of the IA epitope expression within MCMV genome. Although the CD8
+ 
T cell 
response were not as were expected, on the basis of the evidence presented above one can 
predict that low CD8
+
 T cell responses are likely to have occurred due to the competition 
between T cell clones for immune responses which would potentially limit their protective 
activity. Use of a single clone vector (MCMV-IA-NP) to present the NP epitope individually 
on the surface of APCs may avoid this competition.  
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Chapter Five 
Conclusions And Future Direction 
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5. Conclusion and Future Direction 
Vaccines are widely regarded as one of the most successful public health interventions to date. 
Many approaches have been used to design variant vaccines against pathogens, among them 
recombinant viral vectors. Various recombinant viral vectors were created and evaluated for 
vaccine and immunotherapeutic applications. Several studies have shown effectiveness of 
CMV vectors at inducing protective immunity against various pathogens. As such, 
recombinant MCMV vector has also been shown to induce protective immunity against 
various pathogens (i.e. express antigens from) like highly virulent Ebola virus and 
Mycobacterium tuberculosis (Tierney et al., 2012; Tsuda et al., 2011; Tsuda et al., 2015). In 
this dissertation, the MCMV mouse model is used for initial investigation into development 
of CMV as a vaccine platform. MCMV, a natural pathogen isolated from mice, is a 
Betaherpesvirus and constitutes the most widely used animal model for studying HCMV 
infection.  
 Studies described in Chapter three of this dissertation explored use of MCMV to examine the 
ability of a destabilization domain strategy to generate a conditionally replication-defective 
MCMV vaccine vector that can be produced in vitro, but will be attenuated in vivo.  Chapter 
four is concerned with the initial development of a MCMV-based vector expressing internal 
conserved proteins of IA virus towards development of a universal IA vaccine.    
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5.1   Development of a conditionally-attenuated CMV vaccine vector platform 
CMV, a beta-herpesvirus represents a widespread pathogen that causes morbidity and 
mortality in both immunocompromised and immunocompetent individuals, depending on age 
as well as location and socioeconomic status (Mocarski et al., 2013; Pass, 2001). Generally, 
HCMV infection in immunocompetent individuals is asymptomic. However, it can cause life-
threating disease in immunocompromised individuals. Several studies have shown CMV 
vectors to be an attractive vaccine platform. It is also an important source of knowledge that 
despite their attractive immunological characteristics, fully replicating CMV vector have 
disadvantages. The important one is that associated with safety profile in vivo in 
immunocompromised individuals (Corona-Nakamura et al., 2013). Several studies have 
revealed that replication of CMV is not required  for priming immune responses by CMV 
(Mohr et al., 2010; Snyder et al., 2011).  
There are several challenges that hamper the generation of an effective live attenuated virus 
as a vaccine vector. For instance, it is essential to have balance between safety and 
immunogenicity. Generation of a live HCMV vaccine based on the Towne strain, could not 
prevent infection in renal transplant individuals, but lowered severity of the CMV disease 
(Adler et al., 1998). Suggesting that this vaccine was probably over attenuated. Subsequently, 
there is a need to develop a CMV vaccine that presents an excellent safety profile and at the 
same time is capable of inducing an immune response like natural infection. To generate 
recombinant viruses with mutated essential genes requires the complementing cell lines that 
express the missing viral gene product(s). For herpesviruses, the complementing cells that 
support mutant herpesviruses are difficult to obtain especially for β- and γ- subfamilies, since 
only a few complementing cell lines have been established for virus mutants, and because 
many of these vaccines can be propagated on primary cultures only (Borst et al., 2008; 
Mocarski et al., 1996; Silva et al., 2003). An alternative approach to the use and development 
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of such cell lines, which is expensive, technically difficult and not suitable for use in low and 
middle-income countries, is using destabilization domain (DD) technology (Banaszynski et 
al., 2006; Glaß et al., 2009). DDs are conditionally unstable protein domains that genetically 
fuse to the protein of interest. The stability of fused proteins thus generated depends on the 
presence of a small molecule ligand (Banaszynski et al., 2006).   
In this regard, this work has aimed to propose that generation replication-defective version of 
MCMV vaccine vector targeting essential tegument proteins (pp150 and pp28) to determine 
whether is a suitable strategy for development of the conditional replication defective MCMV 
vaccine vector, for use in low and middle-income countries (LMICs). Although previous 
studies have shown the sufficient of the FKBP-based destabilization domain for targeting 
essential genes of CMV (Table 1.4) using shield-1 as a ligand, however the disadvantage is 
that the shield-1must be maintained in the infected cells to maintain growth and replication of 
the mutant virus, this may become cost-prohibitive because this ligand is relatively expensive. 
Fortunately, similar effective DD-system such as dihydrofolate reductase (ecDHFR)-based 
destabilization domain which is stabilized by trimethoprim (TMP), an inexpensive ligand 
(Matthews et al., 1985) has been developed. Characterization of the ecDHFR-based system is 
also revealed that this DD behave very similar to the FKBP-based system and both systems 
work orthogonally (Iwamoto et al., 2010) would allow modulation of protein of interest. 
Another important advantage of using the ecDHFR-domain is that the TMP is commercially 
available, inexpensive, with excellent pharmacological properties. In addition, using DD 
strategy for the development of vaccines, the essential gene (tegument proteins in this project) 
was not expressed by a complementing cell line in trans. Instead, adding TMP ligand into 
Murine fibroblast cells to enable restoring of function of missing gene. 
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The products of pp150 and pp28 function to regulate the replication of MCMV directly that 
plays a role in virus pathogenesis and in supporting production and late infection (Figure 
3.37). Mutation or deletion in these genes results in attenuation of virus replication in 
fibroblast cells in vitro. Our results indicated that reconstitution of recombinant MCMV-
pp28-F140P in MEFs cultured in the absence of TMP did not result in any detectable viral 
infection. However when TMP was added, the ligand restored the fused protein consequently 
growth of the virus to levels approaching wild-type. This suggests a direct effect of the DD 
domain on stability of the pp28 protein, which is then stabilized by TMP at least partially 
restoring function (Figure 3.37). Our results are consistent with prior reports that pp28 of 
MCMV is essential for late stage of virus assembly and egress.  
Notably, in the MCMV-pp28-F140P mutants analysed in vitro we did not observe any 
reversion to the wild type sequence this phenomenon is essential for development of 
replication defective vaccine vector. We did not see the similar behaviour of MCMV-pp150-
F140P virus as the reconstitution of the virus resulted in production of viral plaques 
regardless presence or absence of TMP (Figure 3.36), however it is partially attenuated.  
Although the DD system has been successfully applied to regulate other proteins of CMV 
(Table 1.4), however this strategy may not be applicable to all proteins. Fehr and his 
colleague showed that the DD technique was not successful and failed to regulate protein 
(Fehr & Yu, 2011).      
For future directions, it will be interesting to test these vectors in vivo in mice model. The 
DHFR-derived system may be a suitable strategy for in vivo regulation of proteins that are 
required for vaccine development. As another important advantage of using the ecDHFR-
derived DD system in vivo is that the TMP possesses good pharmacological properties is 
commercially available inexpensive. The TMP can be administered orally, a more convenient 
and less invasive method of drug administration than both i.p. injection or i.v. administration. 
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It has been shown that TMP concentration in rat in vivo has no adverse effects, like diarrhea 
or boy loss weight. TMP passes the placenta and the blood-brain barrier (Schulz, 1972; 
Barling & Selkont, 1978).   
 
5.2 An initial investigation into use of MCMV as a vaccine against pandemic IA virus   
IA virus is an infectious pathogen that causes significant respiratory illness in human 
populations worldwide (Duan & Thomas, 2016). From the Spanish flu in 1918 to the Asian 
flu 1957 and the Hong Kong flu 1963 to the Swine flu 2009, millions of people died from 
influenza pandemics (Li & Cao, 2016). IA viruses are a continuing threat to the humans due 
to their naturally high mutation rate and their ability to undergo antigenic drift or shift in their 
evolution (Gasper et al., 2016). IA virus with antigenic shift has distinct surface antigens 
when compared to the recently circulating seasonal virus.  
Currently, vaccinations are the most effective strategy used to prevent influenza infection 
(Schotsaert & García-Sastre, 2014). Since seasonal inactivated influenza vaccines work 
primarily by inducing antibodies that confer strain-specific immunity, rather than creating 
cross-protective (heterosubtypic) immunity against influenza infection, there has been a boost 
in research on vaccines that have ability for inducing heterosubtypic immunity against 
multiple subtypes of influenza A virus. In the past years, many strategies have been 
developed targeting conserved parts of IA virus. Generally, these strategies can be divided 
into T cell inducing and antibody-inducing vaccines. Potential T cell inducing vaccines often 
aim to induce T-cell responses directed towards more conserved parts of the internal proteins 
of IA virus such as NP, M1 and PB1 (Assarsson et al., 2008; Grant et al., 2013). On the other 
hand, antibody inducing vaccines often aim to induce antibodies directed to HA, NA or M2e 
epitopes (Fiers et al., 2004; Steel et al., 2010). Although virus spread can be limited by 
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antibodies, T cells are responsible for elimination of the virus by killing virus infected cells 
mainly by CD8
+ 
and CD4
+ 
T cells. Even though, T cell inducing vaccines cannot prevent 
infection, they are critical for inducing clearance of infection and limiting virus transmission 
and disease severity (Duan & Thomas, 2016).  
In this study, we attempted to develop a safe, inexpensive, single dose universal vaccine 
capable of inducing CD8
+ 
T cell responses against conserved proteins and thus potentially 
providing a broad protection against all serotypes of IA virus. We decided to use an MCMV-
based vaccine approach expressing epitopes of IA virus conserved proteins. In the first part of 
this study three MCMV-based influenza vaccines (MCMV-IAV) were generated and 
characterised in vitro, each expressing a single H2
b
 restricted CD8
+
 T cell epitope of a 
conserved IA structural protein; NP366-374, PA224-233 and NS2114-121 were designed. These 
epitopes were fused to the non-essential gene (IE2) of MCMV using BAC technology and 
homologous recombination.  
To assess the potential for development of MCMV as a vaccine vector against influenza A  
virus, we developed and characterised  MCMV-IAV expressing a CD8
+
 T cell epitope from  
conserved proteins of IA virus (NP, PA and NS2) both in vitro and in vivo. Epitopes were 
fused to the carboxyl terminus of a non-essential protein of MCMV (IE2; Figures 4.1 and 
4.17). Two independent clones from each vector were selected for in vitro characterization. 
Restriction enzyme digestion analysis followed by electrophoresis showed no gross genomic 
rearrangements compared to the parental wild-type BAC and also following the removal of 
Kan
R
 marker consistent with previous studies that used MCMV as a vaccine vector. We 
concluded that insertion of the NP, PA or NS2 epitope of influenza A virus in the selected 
locus (IE2) of MCMV was stable and did not change the level of expression of IE2 gene and 
did not change the replication of recombinant MCMV in vitro. The growth kinetics of 
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recombinant MCMV was comparable to those of the parental virus (Tierney et al., 2012; 
Tsuda et al., 2011). 
The main aim of construction of recombinant MCMV-IA vaccine vector was to induce flu 
specific CD8
+
 T cell responses, therefore, experiments were designed to find out whether 
these vectors were capable of inducing robust T cell responses. During influenza virus 
infection, CD8
+
 T cells have been shown to be involved in the reduction and control of viral 
load. The CD8
+
 precursor T cells mature into (CTL). Upon recognition of short peptides 
presented by MHC class I molecules on APCs they control virus replication by releasing high 
levels of cytokines such as IFNγ and TNF-α. Secondly, they can destroy infected cells 
through lytic action involving granzymes and perforin.  
Previous studies have shown that CMV-based vaccine vectors have the ability to induce high 
levels of CD8
+
 T cell responses, followed by robust protection against different pathogen 
challenge (Dekhtiarenko et al., 2013; Hansen et al., 2011; Tsuda et al., 2011). All of the 
vectors in the study here were able to induce CD8 T cells. However, this significant level of 
CD8
+
 T cell response was not observed in our study. Following vaccination, specific T cell 
responses were induced but were significantly lower than those previously repeated. There 
are two possibilities to explain this low T cell response: (i) there may be unexpected 
mutations in the MCMV genome that may cause immune responses to be diminished, (ii) The 
second possibility to explain the low level of  T cell responses and in agreement with a study 
by Dekhtiarenko and his colleagues (Dekhtiarenko et al., 2013), is that the three constructed 
vectors (MCMV-IA-NP, PA and NS2) were used together for the mice vaccination, this 
combination could have caused competition between the three epitopes in terms of their 
presentation on the antigen presenting cells (APCs), consequently causing diminished CD8
+
 
T cell responses as compared to the positive control (Tsuda et al., 2011).  
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To avoid the competing epitopes being recognized on the same APC, using single MCMV-
IAV vector is probably needed to obtain a protective response after vaccination. A 
recombinant MCMV-IAV encoding a single epitope from the NP protein was constructed to 
achieve presentation of an internal protein from the influenza virus individually on the 
surface of APCs, thus avoiding presentation on the same APCs. In future studies, since only 
low T cell responses were achieved, it will be of interest to repeat in vivo study. Comparing 
the single MCMV-IA-NP vector with the combine MCMV-IA-(NP+PA+NS2) vector despite 
of inducing robust CD8+ T cell responses. In order to avoid the competing epitopes being 
recognised on the same APC, using individual vector may result in presentation of influenza 
epitope individually on the surface of APCs. If successful, future and ongoing studies could 
be focused on the design of CMV vectors expressing IA epitopes using RhCMV-based 
vectors. To initially prove the ability of the IA epitopes to induce CD8
+
 T cell responses. A 
future study combining generation of replication defective MCMV model using DD system 
with epitope from internal influenza virus protein would be very interesting to generate safe 
and effective vaccine platform against pandemic IA virus in immunocompromised 
individuals. 
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APPENDIX I- Seeding densities, Staining and Fixative  
 
Cell Seeding Densities    
 Dish Type                    MEF cells 
  96 well plate                 1 x 10
5
 
  24 well plate                 2 x 10
5
 
   6 well plate                  4 x 10
5
 
    
 
 
Cell culture solutions 
2.5% Glutaraldehyde 
1.5 ml of 50% glutaraldehyde stock was added to 28.5 ml DPBS buffer. The solution was 
aliquoted and stored at RT.  
 
Freezing Solution 
FCS                         80 % 
DMSO                    20 % 
 
1.2 Seaplaque agar 
Sea Plaque agar                   0.6 g 
Sterile H2o                          50 ml  
Microwave for two min until boiled and then sterilized by autoclaving. 
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20 % Sorbitol Cushion 
 D- sorbitol                      100g                   
1M Tris pH 7.4               2.5 ml            
1M MgCl2                       1 ml                  
Distilled H2o to 500 ml     
                
1M MgCl2 
MgCl2*6H2O                   101.65 g  
Distilled  H2O to 500 ml     
     
              
2xDMEM 
DMEM powder               13.38 g   
NaHCO                            49.3 ml 
Distilled H2O to 500 ml. Mixed thoroughly and then added 10 ml PSG and 100 ml FBS. 
Mixed by shaking and then sterilized by filtration.        
 
           
10 × RBC buffer 
NH4Cl (0.155M)                          45 g 
KHCO3 (0.01M)                           5 g 
EDTA (0.1mM)                           185 ml 
Distilled H2O to 500 ml. 
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Trypsin Diluent   
Na2HPO4.7 H2O       245 g   
Dextrose        2.5 g   
KH2PO4        0.015 g   
KCl         1.0 g   
NaCl        20.0 g   
Phenol Red       0.05 g 
All the reagents were dissolved in 2 L of double distilled H2O. The pH was adjusted to 7.3 
with 1N HCl. The volume was gradually brought to 2.5 L with double distilled H2o.  
 
Neutral red stain solution 
Trypsin diluent                            50 ml 
Sodium bicarbonate (7.5%)          0.1 ml 
Neutral red stock                           4 ml 
 
1X Methylcellulose (MTC) 
4 g methylcellulose powder carefully weighed out and placed in 250 ml bottle. 110 ml 
molecular distilled H2o was placed in 250 ml bottle. Next, the MTC and H2O were autoclaved 
for 30 minutes. As soon as MTC and H2O were removed from autoclave, the hot H2O was 
poured into MTC in tissue culture hood. In a cold room the solution was continuously 
shacked for 20 minl. In a tissue culture hood, 100 ml of 2 × DME was added to 100 ml MTC 
solution and stored at 4 C.      
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APPENDIX II- PCR and Agarose Gel Electrophoresis 
 
PCR Reaction     
Ingredients                                            amount 
PCR Reaction Buffer (10 x)                     5 µl 
Forward primer (10 µM)                          1.25 µl 
Reverse primer (10 µM)                           1.25 µl 
Taq DNA polymerase (5 U)                      0.2 µl 
Distilled H2O                                             40.3 µl 
cDNA                                                        2  µl 
Total                                                           50 µl  
   
      
 Standard PCR Conditions     
                                            Temperature             Duration            Number of cycles 
Initial denaturation                    94C                      5 minutes                        1 cycle 
Denaturation                              94C                      30 seconds 
Annealing                                    58C                     30 seconds                      35 ×    cycles 
Extension                                     68C                    5 minutes 
Final extension                             68C                   10 minutes                       1 cycle 
 The annealing temperature depends on the melting temperatures ™ of the primers. 
 Extension time depends on the length of sequence to be amplified. 
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50 × Tris Acetate EDTA (TAE) Running Buffer 
Tris Base (Sigma)                                  242 g 
Glacial Acetic Acid (Sigma)                 57.2 ml 
0.5 M EDTA, pH 8                               100 ml 
Distilled H2O to 1000 ml  
50 × TAE stock solutions were diluted to 1 × concentration using distilled H2O. 
1 g agarose was added to 100 ml 1 × TAE buffer and microwaved until dissolved completely. 
The agarose was allowed to cool slightly and 5 µl ethidium bromide (EtBr) was added to the 
flask and gently swirled to ensure adequate mixing. The gel was poured and allowed to set at 
room temperature for 20 min prior to use. 
 
 
0.5 M EDTA 
186 g disodium ethylene was added to 1000 ml distilled H2O. The pH was adjusted to 8.0 
with NaOH. 
 
 
Molecular Ladder (1Kb) 
Kb DNA Extension Ladder (Invitrogene)                      80 µl 
Loading Dye (5 ×)                                                          133.2 µl 
 Distilled H2O                                                                 586.41 µl 
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           APPENDIX III- BAC Preparation Buffers and Reagents 
 
Buffer P1 
Tris base                              6.055 g             
EDTA                                  3.722 g   
 H2O                                    80 ml    
The pH was adjusted to 8.0 with HCl. 
 
Buffer P2 
 5M NaOH                       4 ml          
 10% SDS                        10 ml           
H2O                               86 ml     
 
Buffer P3 
KAc                         294.45  g   
H2O                             500 ml   
The pH was adjusted to 5.5 with glacial acetic acid.    
 
3M NaOAc   
NaOAc                        204.15 g 
 dH2o                           500 ml 
The pH was adjusted to 5.5 with glacial acetic acid   
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APPENDIX IV-Culture Media 
 
LB Broth 
Tryptone                           1 % (w/v)  
Yeast extract                    0.5 % (w/v)  
NaCl                                 1 % (w/v)  
5 g LB broth powder was added to 200 ml dH2O. Sterilized by autoclaving at 15 lbs/in
2
 for 
15 min. LB medium was used for bacterial culture. 
 
 
LB Agar Plates 
Tryptone                             1 % (w/v)  
Yeast extract                       0.5 % (w/v)  
NaCl                                    1 % (w/v)  
H2O dye was added to a final volume of 500 ml. Sterilised by autoclaving at 20 lbs/in
2
 for 15 
min.
  
LB plates were used for cultivation of bacteria. 
 
 
SOC medium 
Tryptane                             2.0g   
Yeast extract                      0.5g 
1M MgCl2                         1 ml  
1M MgSO4                       1 ml  
1M NaCl                           1ml  
1M KCl                             250µl 
20% Glucose                    1.8 µl  
In 100 ml  dH2O. 
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M9 Salts Medium (1×) for 1000 ml 
Na2HPO4                            3 g 
NH4Cl                                1 g  
NaCl                                  0.5 g 
The above ingredients were added to 1liter dH2O. Sterilized by autoclaving for 15 min at 121 
C. The M9 salt medium was used to wash transfected SW105 bacteria to remove any   
carbohydrates before plating on galactose or DOG selection plates. 
 
 
M63 Salts (5X) 
(NH4)2SO4                                     10 g 
KH2PO4                                         68 g  
Fe SO4.7H2O                                 2.5 g 
The above ingredients were added to 1liter dH2O. Adjust the pH to 7 with KOH. Sterilized by 
autoclaving for 15 min at 121 C. M63 salt solution was used for preparation of galactose and 
DOG selection plates 
 
Others 
d-biotin                                             0.2 mg/ml (1: 5000) 
Galactose                                          20%  in water (1:100) 
2-deoxy-galactose                            20%   in water (1:100) 
Glycerol                                             20%  in water (1:100) 
L-leucine                                           10 mg/ml (1%) 
MgSO4. 7H2O                                   1 M in water (1:1000) 
Chloramphenicol                              25 mg/ml in EtOH (1:2000) 
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M63-Agar plates for 300 ml/1000 ml 
Autoclave 4.5 g/15 g agar in 240/800 ml H2O and then let cool down a little. Add 60 ml/200 
ml of autoclaved 5 × M63 medium and 300 µl/ 1 ml MgSO4.. Adjust volume to 300 ml/ 1000 
ml with H2O. Let cool down to 50C then add 3.3 ml/ 10 ml of carbon source, 1.5 ml/ 5 ml 
Biotin, 1.4 ml/ 4.5 ml L-leucine, and 150 µl/ 500 µl Chloramphenicol.                                        
 
Galactose plates 
Agar                                   15 g 
dd H2O                               800 ml 
Sterilized by autoclaving and then let cool down to 50 C. Added sterile: 200 ml 5 × M63 
medium, 1 ml MgSO4. 10 ml 20% galactose, 5ml 0.2 mg/ml D-biotin, 4.5 ml/ 10mg/ ml L-
leucine, and 368 µl 34 µg/ml Chloramphenicol. Galactose plates were used for positive 
selection of SW105 bacterial colonies that encode the galactokinase K (galK) gene. 
 
 
MacConkey indicator plates 
MacConkey agar                       10 g  
Dd H2O                                     250 ml 
Sterilized by autoclaving and then let cool down to 50 C. 
Add sterile 2.5 ml 20% galactose and 91.911µl chloramphenicol (12.5 µg /ml). MacConkey 
plates were used as indicator plate to verify expression of galK gene. Galk+ bacteria colonies 
turn pink/red while galK- bacteria colonies stay white.  
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DOG plates 
Agar                                       15 g 
Dd H2O                                 250 ml 
Sterilized by autoclaving and then let cool down to 50 C. Added sterile: 200 ml 5 × M63 
medium, 1 ml MgSO4. 10 ml 20% glycerol, 10 ml 20% DOG, 5ml 0.2 mg/ml D-biotin, 4.5 
ml/ 10 mg/ ml L-leucine, and 368 µl  34 µg/ml Chloramphenicol. DOG plates were used for 
negative selection of galk- SW105 bacterial colonies. 
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APPENDIX V-SDS-PAGE Gel Electrophoresis  
 
 Sodium Dodecyl Sulphate (SDS- Solution 10 %) 
 SDS stock (10 %) made in 100 ml volumes and stored at room temperature.  
  
10 % Ammonium Persulphate (APS) 
0.1 g APS was weighed out and dissolved in 1 ml sterile distilled H2O immediately prior to 
use. 
 Resolving Gel 
10 ml was sufficient for 1 mini gel. 
                                           12%                   15% 
Sterile distilled H2O            3.3 ml              2.3 ml                      
30 % Acrylamide                4.0 ml              5.0 ml  
1.5 M Tris (pH 8.8)            2.5 ml               2.5 ml         
10 % SDS                          100 µl                100 µl     
10 % APS                          100 µl               100 µl      
TEMED                             8 µl                    8 µl                       
 
 
Stacking Gel 
 
4 ml of stacking gel was sufficient for 1 mini gel. 
                                         4 ml 5% stacking gel 
Sterile distilled H2O                            2.7 ml              
30 % Acrylamide                                670 µl               
1.5 M Tris (pH 6.8)                             500 µl              
10 % SDS                                            40 µl               
10 % APS                                            40 µl               
TEMED                                               4 µl              
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5 ×  Sample Buffer 
SDS Powder                                           2 g 
1 M Tris/HCl, (pH 6.8)                         6 ml               
Bromophenol Blue                               0.05 g                 
Glycerol                                               8 ml               
Sterile distilled H2O to 18.8 ml    
                             
10 × Running Buffer 
SDS Powder                                       20 g 
 Tris Base                                           30.3 g               
Glycine                                              144.2 g                 
Sterile distilled H2O to                      1 L 
The 10 × stock solution was diluted to 1 × concentration using distilled H2O prior to use. 
 
1 × Transfer Buffer (pH 8.3) 
SDS Powder                                   1 g 
Tris Base                                        3 g               
Glycine                                          14.42 g                 
Sterile distilled H2O                      800 ml 
Methanol                                      200 ml 
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APPENDIX VII- Western Blotting 
 
10 × Tris Buffered Saline (TBS) 
Tris Base                                 24.2 g 
NaCl                                       80 g 
Distilled H2O to 1 L  
The pH was adjusted to 7.6 with HCl. The 1× TBS was made by diluting 10 × with distilled 
H2o prior to use.  
 
1×  Tris Buffered Saline- Tween (TBS-T) 
10 × TBS                             100 ml 
Distilled H2O                      900 ml 
Tween 20                           100 µl 
Tween was added while on a magnetic stirrer at a medium setting. 
 
 
Blocking Solution 
Skimmed Milk Powder                   2.5 g 
1 × PBS-T or 1 × TBS                    50 ml 
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APPENDIX X-Animal Study 
 
Intracellular Cytokine Staining (ICS) 
   Reagents                                           Source                         Comment 
Brefeldin A Solution (BFA)                eBiosciences           Inhibit intracellular protein transport         
Intracellular Fixation and                   eBiosciences           Use in intracellular staining 
Permeabilization Buffer set                       
Comp Bead; Anti-rat and                   BD Biosciences       Use to optimise fluorescence-  
anti-hamster IgG kappa negative                                      compensation setting for multicolour 
control compensation particle set.                                     Flow cytometric analysis. 
 
 
Surface Staining Antibodies 
Antibody                             Clone                       Source 
CD3, APC-eFlour780           17A2                   eBiosciences 
CD4; Pacific Blue                  RM4-5                BD Biosciences 
CD8a; PerCP-Cy5.5              53-6.7                  BD Biosciences  
 
 
Intracellular Staining Antibodies 
Antibody                             Clone                       Source 
 TNFα; PE                             MP6-XT22              BD Biosciences 
  IFNγ; APC                           XMG1.2                  BD Biosciences  
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Peptides 
H2
b
- Restricted Peptides (Influenza A Peptides) 
Peptides                                                                                     Sequence 
 IA NP366-374 (PR8)                                                            ASNENMETM 
IA NP366-374 (H5N1 Viet)                                                  ASNENMEAM 
IA PA224-233 (PR8+ H5N1Viet )                                         SSLENFRAYV 
IA NS2 114-121 (PR8)                                                            RTFSFQLI 
IA NS2 114-121 (H5N1Viet)                                                   RAFSFQLI 
IA PB1703-711 (PR8+  H5N1Viet )                                         SSYRRPVGI 
Not present in MCMV/IA vaccine construct 
 
  
H2
b
- Restricted Peptides (Control Peptides) 
Antibody                                                                                              Sequence 
MCMV M38 (endogenous MCMV peptide-inflationary)                  HGIRNASFI 
MCMV M45 (endogenous MCMV peptide-non-inflationary)           SSPPMFRV 
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